{"title":"Angelini Products","description":"\u003cp data-start=\"379\" data-end=\"743\" class=\"\"\u003e Wide range of Angelini products for daily care and well-being: over-the-counter medicines for pain, inflammation, cough, reflux and intestinal disorders; supplements for immune defenses, menstrual cycle, sleep, joints and digestion; natural devices for children and adults. Certified quality and pharmaceutical safety. Fast shipping in 24\/48 hours.\u003c\/p\u003e","products":[{"product_id":"tachipirina-antidolorifico-500-mg-20-compresse","title":"Tachipirina Painkiller 500 mg 20 Tablets","description":"\u003cp\u003eTachipirina 500 mg is an over-the-counter drug based on \u003cstrong\u003eparacetamol with analgesic, antipyretic and anti-inflammatory action\u003c\/strong\u003e . Tachipirina 20 Tablets is an antipyretic indicated in the symptomatic treatment of febrile conditions such as \u003cstrong\u003einfluenza, exanthematous diseases, acute respiratory tract conditions\u003c\/strong\u003e or.\u003c\/p\u003e\n\n\u003cp\u003e Paracetamol is an antipyretic \u003cstrong\u003esuitable for treating fever in children\u003c\/strong\u003e , lowering temperature and controlling flu symptoms.\u003c\/p\u003e\n\n\u003cp\u003e Paracetamol is a painkiller and analgesic useful in cases of \u003cstrong\u003eheadaches, neuralgia, myalgia\u003c\/strong\u003e and other painful conditions of medium severity and of various origins.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Tachipirina Antidolorifico 500 mg 20 Tablets - What is the active ingredient of Tachipirina Antidolorifico 500 mg 20 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis medicine 500 mg tablets. Each tablet contains: paracetamol 500 mg. This medicine 500 mg effervescent granules. Each sachet contains: paracetamol 500 mg. This medicine 125 mg effervescent granules. Each sachet contains: paracetamol 125 mg. This medicine - newborns 62.5 mg suppositories. Each suppository contains: paracetamol 62.5 mg. This medicine - early childhood 125 mg suppositories. Each suppository contains: paracetamol 125 mg. This medicine - children 250 mg suppositories. Each suppository contains: paracetamol 250 mg. This medicine - children 500 mg suppositories. Each suppository contains: paracetamol 500 mg. This medicine - adults 1000 mg suppositories. Each suppository contains: paracetamol 1000 mg.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Tachipirina Antidolorifico 500 mg 20 Tablets - What does Tachipirina Antidolorifico 500 mg 20 Tablets contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eTablets: microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, croscarmellose sodium. Effervescent granules: maltitol, mannitol, sodium bicarbonate, anhydrous citric acid, citrus flavouring, aspartame, sodium docusate. Suppositories: solid semi-synthetic glycerides.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Tachipirina Antidolorifico 500 mg 20 Tablets - Why is Tachipirina Antidolorifico 500mg 20 Tablets used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eAs an antipyretic: symptomatic treatment of febrile conditions such as influenza, exanthematous diseases, acute respiratory tract conditions, etc. As an analgesic: headaches, neuralgia, myalgia and other moderately severe painful conditions of various origins.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Tachipirina Antidolorifico 500 mg 20 Tablets - When should Tachipirina Antidolorifico 500 mg 20 Tablets not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to paracetamol or to any of the excipients. Patients with severe haemolytic anaemia (this contraindication does not apply to the 500 mg oral formulations). Severe hepatocellular insufficiency (this contraindication does not apply to the 500 mg oral formulations).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Tachipirina Antidolorifico 500 mg 20 Tablets - How do you take Tachipirina Antidolorifico 500 mg 20 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor children, it is essential to respect the dosage defined according to their body weight, and therefore choose the appropriate formulation. The approximate ages according to body weight are given for information purposes only. In adults, the maximum oral dosage is 3000 mg and rectal dosage is 4000 mg of paracetamol per day. The doctor must evaluate the need for treatments for more than 3 consecutive days. The dosage schedule of this medicine in relation to body weight and administration route is as follows. 500 mg tablets. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 1\/2 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day (3 tablets). Children weighing between 26 and 40 kg (approximately 8 to 11 years): 1 tablet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 41 and 50 kg (approximately 12 to 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Adults: 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 tablets of 500 mg to be repeated if necessary after not less than 4 hours. Effervescent granules of 500 mg in sachets. Dissolve the effervescent granules in a glass of water. Children weighing between 26 and 40 kg (approximately 8 to 11 years): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 41 and 50 kg (approximately 12 to 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Adults: 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 sachets of 500 mg to be repeated if necessary after not less than 4 hours. Effervescent granules of 125 mg in sachets. Dissolve the effervescent granules in a glass of water. Children weighing between 7 and 10 kg (approximately between 6 and 19 months): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing between 13 and 20 kg (approximately between 30 months and less than 6.5 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Suppositories Neonates 62.5 mg. Children weighing between 3.2 and 5 kg (approximately between birth and 2 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Early Childhood 125 mg. Children weighing between 6 and 7 kg (approximately between 3 and 5 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 7 and 10 kg (approximately between 6 and 19 months): 1 suppository at a time, to be repeated if necessary after 4 - 6 hours, without exceeding 5 administrations per day. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Suppositories Children 250 mg. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing between 13 and 20 kg (approximately between 30 months and less than 6.5 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Children 500 mg. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing between 26 and 40 kg (approximately between 8 and 11 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Adults 1000 mg. Children weighing between 41 and 50 kg (approximately between 12 and 15 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Adults: 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Renal insufficiency. In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Tachipirina Antidolorifico 500 mg 20 Tablets - How is Tachipirina Antidolorifico 500 mg 20 Tablets stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTablets and effervescent granules: no special precautions for storage. Suppositories: store at a temperature not exceeding 25 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Tachipirina Antidolorifico 500 mg 20 Tablets - About Tachipirina Antidolorifico 500 mg 20 Tablets it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn rare cases of allergic reactions, administration should be suspended and appropriate treatment should be instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u0026gt;9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause alterations to the kidney and blood, even serious, therefore administration to subjects with renal insufficiency should be carried out only if really necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and renal function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other medicine. Important information about some of the excipients. This 125 mg effervescent granules medicine contains: aspartame, which is a source of phenylalanine. It may be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. Maltitol: use with caution in patients with rare hereditary problems of fructose intolerance. 70.6 mg of sodium per sachet equivalent to 3.53% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult: to be taken into consideration by people with reduced kidney function or who follow a low-sodium diet. This 500 mg effervescent granules medicinal product contains: aspartame, a source of phenylalanine. It may be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. Maltitol: use with caution in patients with rare hereditary problems of fructose intolerance. 283 mg of sodium per sachet is equivalent to 14.1% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The maximum dose for this product is equivalent to 84.6% of the WHO recommended maximum daily intake of sodium: to be taken into consideration by patients with reduced kidney function or who follow a low-sodium diet.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Tachipirina Antidolorifico 500 mg 20 Tablets - Which medicines or foods can modify the effect of Tachipirina Antidolorifico 500 mg 20 Tablets?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe oral absorption of paracetamol depends on the rate of gastric emptying. Therefore, the concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may determine a decrease or increase respectively in the bioavailability of the product. The concomitant administration of cholestyramine reduces the absorption of paracetamol. The simultaneous intake of paracetamol and chloramphenicol may induce an increase in the half-life of chloramphenicol, with the risk of increasing toxicity. Concomitant use of paracetamol (4 g daily for at least 4 days) with oral anticoagulants may cause slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its interruption. Use with extreme caution and under close supervision during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol may interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Tachipirina Antidolorifico 500 mg 20 Tablets can cause side effects - What are the side effects of Tachipirina Antidolorifico 500 mg 20 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following are the adverse reactions of paracetamol organised according to the MedDRA system organ classification. There are insufficient data to establish the frequency of the individual effects listed. Blood and lymphatic system disorders: thrombocytopenia, leukopenia, anaemia, agranulocytosis. Immune system disorders: hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock). Nervous system disorders: dizziness. Gastrointestinal disorders: gastrointestinal reaction. Hepatobiliary disorders: abnormal liver function, hepatitis. Skin and subcutaneous tissue disorders: erythema multiforme, Stevens Johnson syndrome, epidermal necrolysis, rash. Renal and urinary disorders: acute renal failure, interstitial nephritis, haematuria, anuria. Very rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina Antidolorifico 500 mg 20 Tablets.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePregnancy: A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to administer the product only in cases of real need and under the direct supervision of a doctor.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207822356595,"sku":"012745093","price":5.89,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-spa-tachipirina-antidolorifico-500-mg-20-compresse-farmacia-dottor-tili-1213792780.jpg?v=1767112250"},{"product_id":"moment-200mg-analgesico-36-compresse-rivestite","title":"Moment 200mg Analgesic 36 Coated Tablets","description":"\u003cp\u003eMoment 200 mg 36 Coated Tablets is an over-the-counter drug without a prescription based on ibuprofen, \u003cstrong\u003ean analgesic, anti-inflammatory and antipyretic molecule\u003c\/strong\u003e . Moment 36 Tablets is indicated for the treatment of \u003cstrong\u003epain of various origins and natures\u003c\/strong\u003e such as: \u003cstrong\u003eheadache, toothache\u003c\/strong\u003e , \u003cstrong\u003eneuralgia\u003c\/strong\u003e , \u003cstrong\u003eosteoarticular and muscular pain, menstrual pain\u003c\/strong\u003e .\u003c\/p\u003e\n\n\u003cp\u003e The \u003cstrong\u003eantipyretic action\u003c\/strong\u003e of ibuprofen in Moment 36 Tablets \u003cstrong\u003elowers temperature\u003c\/strong\u003e and contributes to the symptomatic treatment of feverish and flu-like conditions.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Moment 200mg Analgesic 36 Coated Tablets - What is the active ingredient in Moment 200mg Analgesic 36 Coated Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEach coated tablet contains active substance: ibuprofen 200 mg. Excipients with known effect: sucrose, sodium. For a full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Moment 200mg Analgesic 36 Coated Tablets - What does Moment 200mg Analgesic 36 Coated Tablets contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEach tablet contains: maize starch, sodium starch glycolate, povidone, colloidal anhydrous silica, talc, hydroxypropylcellulose, gum arabic, sucrose, macrogol 6000, light magnesium carbonate, titanium dioxide.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Moment 200 Mg Ibuprofen 12 Coated Tablets - Why is Moment 200mg Analgesic 36 Coated Tablets used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePain of various origins and natures (headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain). Adjuvant in the symptomatic treatment of feverish and flu states.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eContraindications Moment 200mg Analgesic 36 Coated Tablets - When should Moment 200mg Analgesic 36 Coated Tablets not be used?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substance, to other antirheumatics (acetylsalicylic acid, etc.) or to any of the excipients listed in section 6.1; children under 12 years of age; third trimester of pregnancy and breastfeeding (see section 4.6); active or severe gastroduodenal ulcer or other gastropathies; history of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding); severe hepatic or renal insufficiency; severe cardiac insufficiency (NYHA class IV); severe dehydration (caused by vomiting, diarrhoea or insufficient fluid intake).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Moment 200mg Analgesic 36 Coated Tablets - How to take Moment 200 Mg Ibuprofen 12 Coated Tablets?\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage, adults and adolescents over 12 years: 1-2 tablets, 2-3 times a day. Do not exceed the dose of 1200 mg (6 tablets) per day. If the use of the medicinal product is necessary for more than 3 days in adolescents aged 12 years and over, or in case of worsening of symptoms, a doctor should be consulted. Do not exceed the recommended doses. Elderly patients should adhere to the minimum dosages indicated above (see section 4.4). Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). Renal impairment: in patients with mild or moderate reduction of renal function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and renal function should be monitored. Hepatic impairment: In patients with mild or moderate reduction of liver function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and liver function should be monitored. Moment is contraindicated in patients with severe hepatic impairment (see section 4.3). Paediatric population: Moment is contraindicated in children under 12 years of age (see section 4.3). Method of administration: Moment can be taken on an empty stomach. In subjects with gastric tolerability problems, it is preferable to take the medicine on a full stomach.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Moment 200mg Analgesic 36 Coated Tablets - How to store Moment 200mg Analgesic 36 Coated Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicine does not require any special storage temperatures.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Moment 200mg Analgesic 36 Coated Tablets - About Moment 200mg Analgesic 36 Coated Tablets it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn asthmatic patients the product should be used with caution, following medical evaluation. The use of Moment, as with any drug inhibiting the synthesis of prostaglandins and cyclooxygenase is not recommended in women who intend to become pregnant. The administration of Moment should be suspended in women who have fertility problems or who are undergoing investigation of fertility. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). Elderly: elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2). Cardiovascular and cerebrovascular effects Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a modest increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low doses of ibuprofen (e.g. \u0026lt;= 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration should also be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses (2400 mg\/day) of ibuprofen are required. Caution is advised before initiating treatment in patients with a history of hypertension and\/or heart failure since fluid retention, hypertension and oedema have been reported in association with NSAID therapy. NSAIDs may reduce the effect of diuretics, unlike other antihypertensive agents (see section 4.5). Gastrointestinal bleeding, ulceration and perforation: the use of Moment should be avoided in combination with NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors due to an increased risk of ulceration and bleeding (see section 4.5). Gastrointestinal bleeding, ulceration and perforation, which may be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest dose available. Concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients taking low dose aspirin or other drugs likely to increase GI risk (see below and section 4.5). Patients with a history of GI toxicity, particularly when elderly, should report any unusual GI symptoms (especially GI bleeding) particularly in the initial stages of treatment. Carefully monitor patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as aspirin (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients receiving Moment, the treatment should be withdrawn. NSAIDs should be given with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Renal effects: Caution should be exercised in patients with considerable dehydration when initiating treatment with ibuprofen. Ibuprofen may cause water, sodium and potassium retention in patients with no history of renal disease due to its effects on renal perfusion. This may lead to oedema or cardiac failure or hypertension in predisposed patients. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other pathological renal changes. In general, the habitual use of analgesics, especially combinations of several analgesic active ingredients, can lead to permanent renal damage, with risk of onset of renal failure (analgesic nephropathy). Renal toxicity has been observed in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. The administration of NSAIDs in these patients may lead to a dose-dependent reduction in prostaglandin formation and, as a secondary effect, renal blood flow which can quickly lead to renal failure. Patients most at risk of these reactions are those with reduced renal function, heart failure, liver dysfunction, the elderly and all those patients taking diuretics and ACE inhibitors. Discontinuation of NSAID therapy is usually followed by recovery to the pre-treatment state. There is a risk of impaired renal function in dehydrated adolescents. In case of prolonged use, renal function should be monitored, particularly in cases of diffuse lupus erythematosus. Severe skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Acute generalized exanthematous pustulosis (AGEP) has been reported in relation to medicinal products containing ibuprofen.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Moment 200mg Analgesic 36 Coated Tablets - Which medicines or foods can modify the effect of Moment 200mg Analgesic 36 Coated Tablets?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIbuprofen (like other NSAIDs) should be used with caution in combination with the substances listed below. Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4). Anticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin or heparin (see section 4.4). In case of concomitant treatment, monitoring of the coagulation status is recommended. Acetylsalicylic acid: concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit platelet aggregation with low dose acetylsalicylic acid when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1). Cyclooxygenase-2 (COX-2) inhibitors and other NSAIDs: These substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). However, it is advisable not to combine ibuprofen with acetylsalicylic acid or other NSAIDs, including selective COX-2 inhibitors, due to the potential additive effect (see section 4.4). Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): Increased risk of gastrointestinal bleeding (see section 4.4). Diuretics, ACE inhibitors (such as captopril), beta blockers and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of nephrotoxicity associated with NSAIDs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit cyclooxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Moment concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and thereafter. Phenytoin and lithium: Concomitant administration of ibuprofen and phenytoin or lithium preparations may result in reduced elimination of these drugs with consequent increase in their plasma levels with the possibility of reaching the toxic threshold. If this combination is deemed necessary, monitoring of plasma levels of phenytoin and lithium is recommended in order to adapt the dosage during concomitant treatment with ibuprofen. Methotrexate: NSAIDs may inhibit the tubular secretion of methotrexate and some metabolic interactions may occur resulting in reduced methotrexate clearance and increased risk of toxicity. Moclobemide: increases ibuprofen. Aminoglycosides: NSAIDs may decrease the excretion of aminoglycosides increasing toxicity. Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides. Monitoring of serum glycoside levels is recommended. Cholestyramine: Concomitant administration of ibuprofen and cholestyramine may reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is unknown. Ciclosporin: Concomitant administration of ciclosporin and some NSAIDs causes an increased risk of renal damage. This effect cannot be excluded for the combination of ciclosporin and ibuprofen. Plant extracts: Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs. Mifepristone: Due to the anti-prostaglandin properties of NSAIDs, their use after mifepristone administration may result in a reduction of mifepristone. Limited evidence suggests that co-administration of NSAIDs and prostaglandins on the same day does not adversely affect the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination. Quinolone antibiotics: Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions. Sulfonylureas: NSAIDs may increase the hypoglycaemic effect of sulfonylureas. Monitoring of blood glucose levels is recommended in the case of simultaneous treatment. Tacrolimus: Co-administration of NSAIDs and tacrolimus may increase the risk of nephrotoxicity. Zidovudine: There is evidence of an increased risk of haemarthrosis and haematoma in HIV-positive haemophiliac patients receiving concomitant treatment with zidovudine and other NSAIDs. A blood test is recommended 1-2 weeks after starting treatment. Ritonavir: may cause an increase in plasma concentrations of NSAIDs. Probenecid: slows the excretion of ibuprofen, with possible increase in its plasma concentrations. CYP2C9 inhibitors: Concomitant administration of ibuprofen with CYP2C9 inhibitors may slow the elimination of ibuprofen (CYP2C9 substrate) resulting in increased exposure to ibuprofen. In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)-ibuprofen of approximately 80% to 100% was observed. Consideration should be given to reducing the dose of ibuprofen when co-administered with strong CYP2C9 inhibitors, particularly when high doses of ibuprofen are administered with voriconazole or fluconazole. Alcohol, bisphosphonates and oxpentifylline (pentoxifylline): may enhance gastrointestinal side effects and the risk of bleeding and ulceration. Baclofen: high toxicity of baclofen.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Moment 200mg Analgesic 36 Coated Tablets can cause side effects - What are the side effects of Moment 200mg Analgesic 36 Coated Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe undesirable effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and are reported below using the following convention: very common (\u0026gt;=1\/10); common (\u0026gt;=1\/100, \u0026lt; 1\/10); uncommon (\u0026gt;= 1\/ 1,000, \u0026lt; 1\/100); rare (\u0026gt;=1\/10,000, \u0026lt; 1\/1,000); very rare (\u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data). The most commonly observed adverse events are gastrointestinal in nature. Gastrointestinal disorders: peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Gastrointestinal perforation with the use of ibuprofen has been observed rarely. After administration of Moment the following have been reported: feeling of heaviness in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, epigastric pain, heartburn, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Uncommon: gastritis; very rare: pancreatitis. Immune system disorders: following treatment with NSAIDs the following undesirable effects have been reported: non-specific allergic reaction and anaphylaxis; uncommon: hypersensitivity reactions such as various types of skin rash, urticaria, pruritus, purpura, angioedema, exanthema, respiratory tract reactions including bronchospasm, dyspnoea, asthmatic attack (sometimes with hypotension); rare: lupus erythematosus syndrome; very rare: severe hypersensitivity reactions. Symptoms may include: severe asthma, facial oedema, tongue oedema, laryngeal oedema, airway oedema with bronchospasm, dyspnoea, tachycardia, anaphylaxis, exfoliative and bullous dermatitis. Cardiac and vascular disorders: Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Very rare: palpitations, heart failure, myocardial infarction, acute pulmonary oedema, hypertension. Other adverse events for which causality has not necessarily been established include: Blood and lymphatic system disorders: Rare: leucopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia, inhibition of platelet aggregation. Psychiatric disorders. Uncommon: insomnia, anxiety; rare: depression, confusional state, hallucinations. Nervous system disorders. Common: dizziness; uncommon: paraesthesia, somnolence, rare: optic neuritis. Infections and infestations. Uncommon: rhinitis; rare: aseptic meningitis. Rhinitis and aseptic meningitis have been observed especially in patients with pre-existing autoimmune disorders (such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). Exacerbation of infection-related inflammation (e.g. development of necrotising fasciitis) has been described. Respiratory, thoracic and mediastinal disorders. Uncommon: bronchospasm, dyspnoea, apnoea. Eye disorders. Uncommon: visual disturbances; rare: ocular impairment resulting in visual disturbances, toxic optic neuropathy. Ear and labyrinth disorders. Uncommon: impaired hearing, tinnitus, vertigo. Hepatobiliary disorders. Uncommon: abnormal liver function, hepatitis and jaundice; very rare: liver failure. Skin and subcutaneous tissue disorders. Allergic skin rashes (erythema, pruritus, urticaria) may occasionally occur. Uncommon: photosensitivity reactions; very rare: bullous dermatitis including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme. In exceptional cases, serious skin infections and soft tissue disorders may occur during chickenpox infection (see \"Infections and infestations\"). Not known: drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), acute generalized exanthematous pustulosis (AGEP). Renal and urinary disorders. Uncommon: impaired renal function and toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure; rare: azotaemia. General disorders and administration site conditions. Common: malaise, fatigue; rare: oedema. Diagnostic tests. Rare: increased transaminases, increased alkaline phosphatase, decreased haemoglobin, decreased haematocrit, prolonged bleeding time, decreased blood calcium, increased blood uric acid. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Moment 200mg Analgesic 36 Coated Tablets.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. From the twentieth week of pregnancy onwards, the use of Moment may cause oligohydramnios resulting from fetal renal dysfunction. This may occur soon after initiation of treatment and is usually reversible upon discontinuation. In addition, cases of constriction of the ductus arteriosus have been reported after treatment in the second trimester, most of which resolved upon discontinuation of treatment. Therefore, during the first and second trimester of pregnancy, Moment should not be given unless clearly necessary. If Moment is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. Following exposure to Moment for several days from gestational week 20 onwards, antenatal monitoring for oligohydramnios and constriction of the ductus arteriosus should be considered. Moment should be discontinued if oligohydramnios or constriction of the ductus arteriosus is observed. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (premature constriction\/closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction (see above); the mother and the neonate, at the end of pregnancy, to: possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, Moment is contraindicated during the third trimester of pregnancy (see and sections 4.3 and 5.3). Breast-feeding: Ibuprofen is excreted in breast milk, but at therapeutic doses during short-term treatment, the risk of influence on the neonate seems unlikely. If, however, treatment is longer term, early weaning should be considered. NSAIDs should be avoided during breast-feeding. Fertility: The use of Ibuprofen may impair female fertility and is not recommended in women attempting to conceive. This effect is reversible upon discontinuation of treatment. In women who have difficulties conceiving or who are undergoing investigation of infertility, discontinuation of ibuprofen should be considered.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207823011955,"sku":"025669185","price":14.42,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-moment-200mg-analgesico-36-compresse-rivestite-farmacia-dottor-tili-1213792749.jpg?v=1767125589"},{"product_id":"thermacare-menstrual-3-pezzi","title":"Thermacare Menstrual 3 Pieces","description":"\u003cp\u003e \u003cstrong\u003eThermacare Menstrual\u003c\/strong\u003e is a medical device designed to relieve menstrual pain through therapeutic heat. These patches are designed to provide up to 8 hours of constant heat, aimed at relieving menstrual cramps and relaxing abdominal muscles. Thermacare Menstrual is a non-pharmacological solution to reduce menstrual pain and improve well-being during the cycle. The patches are discreet, comfortable to wear under clothing and allow you to carry out normal daily activities without discomfort.\u003c\/p\u003e\n\n\n\u003ch2\u003e How to use\u003c\/h2\u003e\n\n\u003ch3\u003e How to use Thermacare Menstrual?\u003c\/h3\u003e\n\n         \u003cp\u003e1. \u003cstrong\u003eApplication\u003c\/strong\u003e : Remove the patch from the packaging and place it directly on the skin of the abdominal area or lower back. The patch begins to warm up within a few minutes.\u003c\/p\u003e\n\n\u003cp\u003e 2. \u003cstrong\u003eDuration\u003c\/strong\u003e : Use the patch for up to 8 consecutive hours. If necessary, it can also be used more than once a day, but always with at least 24 hours of pause between one application and another.\u003c\/p\u003e\n\n\u003cp\u003e 3. \u003cstrong\u003eRemoval\u003c\/strong\u003e : After use, remove the patch and dispose of it safely.\u003c\/p\u003e\n\n\n\u003ch2\u003e Package Contents\u003c\/h2\u003e\n\n\u003ch3\u003e What's in the Thermacare Menstrual package?\u003c\/h3\u003e\n\n\u003cp\u003e The package contains \u003cstrong\u003e3 disposable heating patches\u003c\/strong\u003e for the treatment of menstrual pain. Each patch is individually packaged to ensure freshness and safety of use.\u003c\/p\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings for Thermacare Menstrual?\u003c\/h3\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\n\u003cli\u003e Do not use on damaged or irritated skin.\u003c\/li\u003e\n\n         \u003cli\u003eDiscontinue use if irritation or burning occurs.\u003c\/li\u003e\n\n\u003cli\u003e Do not use while sleeping.\u003c\/li\u003e\n\n\u003cli\u003e Avoid applying excessive pressure to the patch during use.\u003c\/li\u003e\n\n\u003cli\u003e Keep out of reach of children.\u003c\/li\u003e\n\n\u003cli\u003e Consult your doctor before use if you are pregnant or have diabetes, circulation problems or skin conditions.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of Thermacare Menstrual?\u003c\/h3\u003e\n\n\u003cp\u003e Store \u003cstrong\u003eThermacare Menstrual\u003c\/strong\u003e in a cool, dry place. Do not use after the expiry date printed on the package.\u003c\/p\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e Thermacare Menstrual is available in a pack of \u003cstrong\u003e3 disposable, ready-to-use heating patches\u003c\/strong\u003e .\u003c\/p\u003e\n\n","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207823110259,"sku":"981076134","price":11.31,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-thermacare-menstrual-3-pezzi-farmacia-dottor-tili-1213792761.jpg?v=1767125652"},{"product_id":"tachipirina-sciroppo-bambini-paracetamolo-120-mg-5-ml","title":"Tachipirina Syrup Children Paracetamol 120 mg\/5 ml","description":"\u003cp\u003eTachipirina Sciroppo 120 mg\/5 ml is an over-the-counter medicine based \u003cstrong\u003eon low-dose Paracetamol\u003c\/strong\u003e for children (from 7.2 kg and up). \u003cstrong\u003eParacetamol is preferable in children\u003c\/strong\u003e as an antipyretic to lower temperature and in the symptomatic treatment of febrile conditions such as \u003cstrong\u003einfluenza, exanthematous diseases, acute respiratory tract conditions\u003c\/strong\u003e , etc.\u003c\/p\u003e\n\n\u003cp\u003e Tachipirina Syrup 120 mg\/5 also has \u003cstrong\u003ean analgesic action\u003c\/strong\u003e in cases of \u003cstrong\u003eheadache\u003c\/strong\u003e , \u003cstrong\u003eneuralgia\u003c\/strong\u003e , \u003cstrong\u003emyalgia\u003c\/strong\u003e and other painful manifestations of medium severity and of various origins.\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - What is the active ingredient of Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eTACHIPIRINA 120 mg\/5 ml syrup, 5 ml of syrup contain; active ingredient: paracetamol 120 mg. Excipients with known effects: sucrose, methyl parahydroxybenzoate, sodium. TACHIPIRINA 100 mg\/ml oral drops solution, 1 ml of solution contains; active ingredient: paracetamol 100 mg. Excipients with known effects: sorbitol, propylene glycol.For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - What does Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eSyrup: sucrose, sodium citrate, sodium saccharin, methyl parahydroxybenzoate, potassium sorbate, macrogol 6000, citric acid monohydrate, strawberry flavouring, mandarin flavouring, purified water. Oral drops: propylene glycol, macrogol 6000, sorbitol, sodium saccharin, citrus-vanilla flavouring, propyl gallate, caramel (E150a), sodium edetate, purified water.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eTherapeutic indications Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - Why is Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml used? What is it used for?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eAs an antipyretic: symptomatic treatment of febrile conditions such as influenza, exanthematous diseases, acute respiratory tract conditions, etc. As an analgesic: headaches, neuralgia, myalgia and other moderately severe painful conditions of various origins.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - When should Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with severe haemolytic anaemia (this contraindication does not apply to the 500 mg oral formulations). Severe hepatocellular insufficiency (this contraindication does not apply to the 500 mg oral formulations).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - How do you take Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn children up to 10 years of age, it is essential to respect the dosage defined based on body weight and not on age, which is approximate and indicated for information purposes only. If the age of the child does not correspond to the weight shown in the table, always refer to body weight when choosing the dosage. In children weighing up to 7.2 kg, it is recommended to use the formulation in drops, between 7.2 and 11 kg it is possible to use drops or syrup as the dosage for each weight group is identical, between 12 and 32 kg it is recommended to use syrup. In the case of jaundice in children under three months, it is advisable to reduce the single dose. In children over 10 years of age, the relationship between weight and age becomes no longer homogeneous due to pubertal development which, at the same age, has a different impact on body weight depending on the sex and individual characteristics of the child. Therefore, above 10 years of age, the dosage of the syrup is indicated in terms of weight and age ranges, as follows. Children weighing between 33 and 40 kg (over 10 years and under 12 years of age): 20 ml of syrup at a time (corresponding to 480 mg), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Adolescents weighing more than 40 kg (aged 12 years or over) and adults: 20 ml of syrup at a time (corresponding to 480 mg), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. The doctor must evaluate the need for treatments for more than 3 consecutive days. Method of administration The package contains a dosing syringe with level marks corresponding to 1 ml, 2 ml, 3 ml, 4 ml, 4.5 ml and 5 ml and a dosing cup with level marks corresponding to 5.5 ml, 6 ml, 6.5 ml, 7.5 ml, 8.5 ml, 10 ml, 11 ml, 12.5 ml, 13.5 ml, 15.5 ml, 17.5 ml, 19 ml Syrup The syrup contains 24 mg of paracetamol per ml of product. To open the bottle, push the cap downwards and at the same time turn to the left. To use the syringe, insert the tip of the syringe fully into the hole in the undercap, turn the bottle upside down, holding the syringe firmly, gently pull the plunger downwards filling the syringe up to the mark corresponding to the desired dose; Return the bottle to an upright position, remove the syringe by gently rotating it, insert the tip of the syringe into the child's mouth and apply gentle pressure to the plunger to release the solution. The product must be used immediately after taking it from the bottle. Any residual product in the syringe must be discarded. For doses greater than 5 ml, take the required amount with the syringe and pour the contents into the cup. Repeat the procedure until the mark corresponding to the indicated dosage is reached, and administer to the child, inviting him to drink. For doses in children over 10 years of age and in adults, equal to 20 ml, use the cup, filling it twice up to the 10 ml mark. The product must be used immediately after taking it from the bottle. Any residual product in the syringe or cup must be discarded. After use, close the bottle by screwing the cap tightly and wash the syringe and cup with hot water. Leave them to dry, keeping them out of the reach and sight of children. Drops Each drop contains 4 mg of paracetamol. Turn the bottle upside down and pour the number of drops corresponding to the dosage to be used in 25-50 ml of water, and give the child to drink. Renal insufficiency In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - How is Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicinal product does not require any special storage conditions.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - About Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn rare cases of allergic reactions, administration should be suspended and appropriate treatment should be instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u0026gt;9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause alterations to the kidney and blood, even serious, therefore administration to subjects with renal insufficiency should be carried out only if really necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and renal function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other medicine (see section 4.5). Important information about some of the excipients. Tachipirina drops, solution contains, sorbitol: patients with rare hereditary problems of fructose intolerance, should not take this medicine; propylene glycol: may cause symptoms similar to those caused by alcohol. The container of Tachipirina drops, solution is made of latex rubber. May cause serious allergic reactions. Tachipirina syrup contains, sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency, should not take this medicine. For the 15 ml dose this medicinal product contains 5.25 g sucrose, for the 16.5 ml dose it contains 5.78 g sucrose, for the 18.5 ml dose it contains 6.48 g sucrose and for the 20 ml dose it contains 7 g sucrose. To be taken into consideration by people with diabetes mellitus. Methyl parahydroxybenzoate: may cause allergic reactions (possibly delayed). Sodium: this medicinal product contains 1.2 mmol (or 27.6 mg) sodium per 20 ml equivalent to 1.38% of the WHO recommended maximum daily intake of 2 g sodium for an adult. To be taken into consideration by people on a controlled sodium diet.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml - Which medicines or foods can modify the effect of Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe oral absorption of paracetamol depends on the rate of gastric emptying. Therefore, the concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may determine a decrease or increase respectively in the bioavailability of the product. The concomitant administration of cholestyramine reduces the absorption of paracetamol. The simultaneous intake of paracetamol and chloramphenicol may induce an increase in the half-life of chloramphenicol, with the risk of increasing toxicity. Concomitant use of paracetamol (4 g daily for at least 4 days) with oral anticoagulants may cause slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its interruption. Use with extreme caution and under close supervision during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol may interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml can cause side effects - What are the side effects of Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following are the adverse reactions of paracetamol organised according to the MedDRA system organ classification. There are insufficient data to establish the frequency of the individual effects listed. Blood and lymphatic system disorders: thrombocytopenia, leukopenia, anaemia, agranulocytosis. Immune system disorders: hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock). Nervous system disorders: dizziness. Gastrointestinal disorders: gastrointestinal reaction. Hepatobiliary disorders: abnormal liver function, hepatitis. Skin and subcutaneous tissue disorders: erythema multiforme, Stevens Johnson syndrome, epidermal necrolysis, rash. Renal and urinary disorders: acute renal failure, interstitial nephritis, haematuria, anuria. Very rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina Sciroppo Bambini Paracetamol 120 mg\/5 ml\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePregnancy: A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to take\/administer this medicine only in cases of real need and under direct medical supervision.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207823241331,"sku":"012745016","price":7.25,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachipirina-sciroppo-bambini-paracetamolo-120-mg-5-ml-farmacia-dottor-tili-1213792758.png?v=1767125710"},{"product_id":"tachipirina-bambini-10-supposte-250-mg","title":"Tachipirina Children 10 Suppositories 250 mg","description":"\u003cp\u003e\u003cstrong\u003eTachipirina Bambini Suppositories\u003c\/strong\u003e 250 mg is an analgesic and antipyretic drug indicated for the treatment of fever and mild to moderate pain in children. The active ingredient, \u003cstrong\u003eparacetamol\u003c\/strong\u003e , is widely used for its effect in reducing fever and relieving pain associated with flu-like conditions, sore throat, toothache or muscle pain. Thanks to the suppository formulation, Tachipirina offers a convenient administration method for children, particularly useful in cases where oral administration is difficult.\u003c\/p\u003e\n\n\u003cp\u003e Tachipirina Bambini is indicated for:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eTreatment of fever\u003c\/strong\u003e caused by infections or vaccinations.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eRelieve mild to moderate pain\u003c\/strong\u003e associated with toothache, headache, sore throat, muscle and joint pain.\u003c\/li\u003e\n\n\u003cli\u003e Also used for the management of post-vaccination fever.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eActive ingredients contained in Tachipirina Bambini 10 Suppositories 250 mg - What is the active ingredient of Tachipirina Bambini 10 Suppositories 250 mg?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicine 500 mg tablets. Each tablet contains: paracetamol 500 mg. This medicine 500 mg effervescent granules. Each sachet contains: paracetamol 500 mg. This medicine 125 mg effervescent granules. Each sachet contains: paracetamol 125 mg. This medicine - newborns 62.5 mg suppositories. Each suppository contains: paracetamol 62.5 mg. This medicine - early childhood 125 mg suppositories. Each suppository contains: paracetamol 125 mg. This medicine - children 250 mg suppositories. Each suppository contains: paracetamol 250 mg. This medicine - children 500 mg suppositories. Each suppository contains: paracetamol 500 mg. This medicine - adults 1000 mg suppositories. Each suppository contains: paracetamol 1000 mg.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eComposition of Tachipirina Bambini 10 Suppositories 250 mg - What does Tachipirina Bambini 10 Suppositories 250 mg contain?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTablets: microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, croscarmellose sodium. Effervescent granules: maltitol, mannitol, sodium bicarbonate, anhydrous citric acid, citrus flavouring, aspartame, sodium docusate. Suppositories: solid semi-synthetic glycerides.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Tachipirina Children 10 Suppositories 250 mg - Why is Tachipirina Painkiller 500mg 20 Tablets used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eAs an antipyretic: symptomatic treatment of febrile conditions such as influenza, exanthematous diseases, acute respiratory tract conditions, etc. As an analgesic: headaches, neuralgia, myalgia and other moderately severe painful conditions of various origins.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eContraindications Tachipirina Bambini 10 Suppositories 250 mg - When should Tachipirina Bambini 10 Suppositories 250 mg not be used?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to paracetamol or to any of the excipients. Patients with severe haemolytic anaemia (this contraindication does not apply to the 500 mg oral formulations). Severe hepatocellular insufficiency (this contraindication does not apply to the 500 mg oral formulations).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Tachipirina Bambini 10 Suppositories 250 mg - How to take Tachipirina Bambini 10 Suppositories 250 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor children, it is essential to respect the dosage defined according to their body weight, and therefore choose the appropriate formulation. The approximate ages according to body weight are given for information purposes only. In adults, the maximum oral dosage is 3000 mg and rectal dosage is 4000 mg of paracetamol per day. The doctor must evaluate the need for treatments for more than 3 consecutive days. The dosage schedule of this medicine in relation to body weight and administration route is as follows. 500 mg tablets. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 1\/2 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day (3 tablets). Children weighing between 26 and 40 kg (approximately 8 to 11 years): 1 tablet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 41 and 50 kg (approximately 12 to 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Adults: 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 tablets of 500 mg to be repeated if necessary after not less than 4 hours. Effervescent granules of 500 mg in sachets. Dissolve the effervescent granules in a glass of water. Children weighing between 26 and 40 kg (approximately 8 to 11 years): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 41 and 50 kg (approximately 12 to 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Adults: 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 sachets of 500 mg to be repeated if necessary after not less than 4 hours. Effervescent granules of 125 mg in sachets. Dissolve the effervescent granules in a glass of water. Children weighing between 7 and 10 kg (approximately between 6 and 19 months): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing between 13 and 20 kg (approximately between 30 months and less than 6.5 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Suppositories Neonates 62.5 mg. Children weighing between 3.2 and 5 kg (approximately between birth and 2 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Early Childhood 125 mg. Children weighing between 6 and 7 kg (approximately between 3 and 5 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 7 and 10 kg (approximately between 6 and 19 months): 1 suppository at a time, to be repeated if necessary after 4 - 6 hours, without exceeding 5 administrations per day. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Suppositories Children 250 mg. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing between 13 and 20 kg (approximately between 30 months and less than 6.5 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Children 500 mg. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing between 26 and 40 kg (approximately between 8 and 11 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Adults 1000 mg. Children weighing between 41 and 50 kg (approximately between 12 and 15 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Adults: 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Renal insufficiency. In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Tachipirina Bambini 10 Suppositories 250 mg - How is Tachipirina Bambini 10 Suppositories 250 mg stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTablets and effervescent granules: no special precautions for storage. Suppositories: store at a temperature not exceeding 25 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Tachipirina Bambini 10 Suppositories 250 mg - About Tachipirina Bambini 10 Suppositories 250 mg it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn rare cases of allergic reactions, administration should be suspended and appropriate treatment should be instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u0026gt;9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause alterations to the kidney and blood, even serious, therefore administration to subjects with renal insufficiency should be carried out only if really necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and renal function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other medicine. Important information about some of the excipients. This 125 mg effervescent granules medicine contains: aspartame, which is a source of phenylalanine. It may be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. Maltitol: use with caution in patients with rare hereditary problems of fructose intolerance. 70.6 mg of sodium per sachet equivalent to 3.53% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult: to be taken into consideration by people with reduced kidney function or who follow a low-sodium diet. This 500 mg effervescent granules medicinal product contains: aspartame, a source of phenylalanine. It may be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. Maltitol: use with caution in patients with rare hereditary problems of fructose intolerance. 283 mg of sodium per sachet is equivalent to 14.1% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The maximum dose for this product is equivalent to 84.6% of the WHO recommended maximum daily intake of sodium: to be taken into consideration by patients with reduced kidney function or who follow a low-sodium diet.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Tachipirina Bambini 10 Suppositories 250 mg - Which medicines or foods can modify the effect of Tachipirina Bambini 10 Suppositories 250 mg?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eOral absorption of paracetamol depends on the rate of gastric emptying. Therefore, concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may lead to a decrease or increase in the bioavailability of the product, respectively. Concomitant administration of cholestyramine reduces the absorption of paracetamol. Concomitant intake of paracetamol and chloramphenicol may lead to an increase in the half-life of chloramphenicol, with the risk of increasing toxicity. Concomitant use of paracetamol (4 g daily for at least 4 days) with oral anticoagulants may induce slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its interruption. Use with extreme caution and under close supervision during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol may interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Tachipirina Bambini 10 Suppositories 250 mg can cause side effects - What are the side effects of Tachipirina Bambini 10 Suppositories 250 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following are the adverse reactions of paracetamol organised according to the MedDRA system organ classification. There are insufficient data to establish the frequency of the individual effects listed. Blood and lymphatic system disorders: thrombocytopenia, leukopenia, anaemia, agranulocytosis. Immune system disorders: hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock). Nervous system disorders: dizziness. Gastrointestinal disorders: gastrointestinal reaction. Hepatobiliary disorders: abnormal liver function, hepatitis. Skin and subcutaneous tissue disorders: erythema multiforme, Stevens Johnson syndrome, epidermal necrolysis, rash. Renal and urinary disorders: acute renal failure, interstitial nephritis, haematuria, anuria. Very rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina Bambini 10 Suppositories 250 mg\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePregnancy: A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to administer the product only in cases of real need and under the direct supervision of a doctor.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207823994995,"sku":"012745042","price":6.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachipirina-bambini-10-supposte-250-mg-farmacia-dottor-tili-1213792739.jpg?v=1767126699"},{"product_id":"verolax-ad-rettale-6-clismi-6-75g","title":"Verolax AD Rectal 6 Enemas 6.75g","description":"\u003cp\u003e\u003cstrong\u003eVerolax AD\u003c\/strong\u003e is a drug used to treat occasional constipation. Thanks to its \u003cstrong\u003eglycerol\u003c\/strong\u003e -based formulation, Verolax works by softening the stool and facilitating its expulsion. This rectal enema is indicated for a rapid and delicate action, with local effects that help stimulate intestinal transit without causing irritation or cramps. The package contains \u003cstrong\u003e6 ready-to-use enemas\u003c\/strong\u003e , 6.75g, for rapid and safe relief.\u003c\/p\u003e\n\n\u003cp\u003e Verolax AD is indicated for the treatment of \u003cstrong\u003eoccasional constipation\u003c\/strong\u003e in adults. It is particularly useful in situations where rapid evacuation is necessary, such as before medical or surgical examinations. It can also be used in case of temporary constipation caused by changes in diet, stress or a sedentary lifestyle.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eActive ingredients contained in Verolax AD Rettale 6 Clismi 6 - What is the active ingredient of Verolax AD Rettale 6 Clismi 6?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eAdults Rectal Solution. 6 single-dose containers 9G: glycerin 6.75 g. Children Rectal Solution. 6 Single-dose Containers 3 G: glycerin 2.25 g. Adults Suppositories: glycerin 2.25 g. Children Suppositories: glycerin 1.375 g. Infants Suppositories: glycerin 0.675 g.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Verolax AD Rectal 6 Enemas 6 - What does Verolax AD Rectal 6 Enemas 6 contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eRectal solution. Adults and Children: mallow fluid extract; chamomile fluid extract; wheat starch; purified water. Suppositories Adults, Children, Infants: sodium stearate, sodium carbonate.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Verolax AD Rectal 6 Enemas 6 - Why is Verolax AD Rectal 6 Enemas 6 used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eConstipation.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eContraindications Verolax AD Rectal 6 Enemas 6 - When should Verolax AD Rectal 6 Enemas 6 not be used?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eKnown individual hypersensitivity to the product. Anorectal affections, hemorrhagic rectocolitis and inflammation of hemorrhoids.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Verolax AD Rectal 6 Enemas 6 - How do you take Verolax AD Rectal 6 Enemas 6?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eRectal solution: 1 or 2 single-dose containers in 24 hours. In case of obstinate constipation, no more than 2 doses can be introduced into the rectum at the same time. Suppositories: 1 suppository as needed. Do not exceed the recommended doses.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Verolax AD Rectal 6 Enemas 6 - How do you store Verolax AD Rectal 6 Enemas 6?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eNo special storage precautions.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWarnings Verolax AD Rectal 6 Enemas 6 - About Verolax AD Rectal 6 Enemas 6 it is important to know that:\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eContinuous use of laxatives can cause addiction or harm of various kinds. Do not use laxatives if you have abdominal pain, nausea and vomiting. If constipation is persistent, consult your doctor.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Verolax AD Rettale 6 Clismi 6 - Which medicines or foods can modify the effect of Verolax AD Rettale 6 Clismi 6?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eNo interactions with other drugs have been found.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Verolax AD Rettale 6 Clismi 6 can cause side effects - What are the side effects of Verolax AD Rettale 6 Clismi 6?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThe only effects that may be encountered are of an irritative nature, at the level of the rectal area. These are usually mild forms, which do not require medical intervention.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Verolax AD Rettale 6 Clismi 6\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eBased on its chemical-physical properties, rectal glycerin can be usefully used during pregnancy or the puerperium.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207824453747,"sku":"026525055","price":5.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-verolax-ad-rettale-6-clismi-6-75g-farmacia-dottor-tili-1213792736.jpg?v=1767126868"},{"product_id":"tachifludec-limone-polvere-10-bustine","title":"Tachifludec Lemon Powder 10 Sachets","description":"\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eTachifludec Lemon Powder 10 Sachets is an\u003c\/span\u003e \u003cb\u003eover-the-counter analgesic and antipyretic\u003c\/b\u003e \u003cspan style=\"font-weight: 400;\"\u003epowder based on Paracetamol, Ascorbic Acid and Phenylephrine hydrochloride. Tachifludec Lemon Powder is indicated for the\u003c\/span\u003e \u003cb\u003esymptomatic treatment of influenza, colds and feverish and painful conditions\u003c\/b\u003e \u003cspan style=\"font-weight: 400;\"\u003erelated to them. The decongestant action of Tachifludec on the upper airways\u003c\/span\u003e \u003cb\u003efluidifies and frees from mucus and phlegm\u003c\/b\u003e \u003cspan style=\"font-weight: 400;\"\u003ein case of cough and cold.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp\u003e Tachifludec Lemon Flavor 10 Sachets is a preparation formulated with:\u003c\/p\u003e\n\n\u003cp\u003e • \u003cstrong\u003eParacetamol\u003c\/strong\u003e : active ingredient with antipyretic and analgesic action which makes the medicine particularly suitable in cases of: pain and spasms in the stomach and intestines, pain caused by obstacles in the flow of the urinary tract and biliary tract and menstrual pain.\u003c\/p\u003e\n\n \u003cp\u003e• \u003cstrong\u003eVitamin C\u003c\/strong\u003e (Ascorbic Acid): active ingredient that participates in the body's defense system.\u003c\/p\u003e\n\n\u003cp\u003e • \u003cstrong\u003ePhenylephrine Hydrochloride\u003c\/strong\u003e : sympathomimetic active ingredient that acts by causing vasoconstriction of the local vascular bed, improving the symptoms of nasal obstruction.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Tachifludec Lemon Powder 10 Sachets - What is the active ingredient of Tachifludec Lemon Powder 10 Sachets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEach sachet contains active ingredients: paracetamol 600 mg, ascorbic acid 40 mg and phenylephrine hydrochloride 10 mg (equivalent to phenylephrine 8.2 mg). Excipients with known effects: Tachifludec lemon flavour contains: 1.817 g of sucrose, 112.86 mg of sodium, 6.65 mg of glucose. Tachifludec lemon and honey flavour contains: 1.892 g of sucrose, 135.79 mg of sodium. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eComposition of Tachifludec Lemon Powder 10 Sachets - What does Tachifludec Lemon Powder 10 Sachets contain?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTachifludec powder for oral solution lemon flavour: sucrose, anhydrous citric acid, sodium citrate, corn starch, sodium cyclamate, sodium saccharin, anhydrous colloidal silica, lemon flavouring, curcumin (E100), dried glucose syrup. Tachifludec powder for oral solution lemon and honey flavour: sucrose, anhydrous citric acid, sodium citrate, corn starch, sodium cyclamate, sodium saccharin, lemon flavouring, honey flavouring, caramel (E150), anhydrous colloidal silica.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Tachifludec Lemon Powder 10 Sachets - Why is Tachifludec Lemon Powder 10 Sachets used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eShort-term treatment of cold and flu symptoms, including mild to moderate pain and fever, when associated with nasal congestion.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Tachifludec Lemon Powder 10 Sachets - When should Tachifludec Lemon Powder 10 Sachets not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eChildren under 12 years of age; hypersensitivity to the active substances or to any of the excipients (listed in section 6.1); patients taking beta-blockers; patients taking tricyclic antidepressants and those taking or who have taken in the last 2 weeks monoamine oxidase inhibitors; patients with bronchial asthma, pheochromocytoma, narrow-angle glaucoma, or who are taking other sympathomimetic medicinal products (such as decongestants, appetite suppressants and amphetamine-like psychostimulants); patients with hepatic or renal insufficiency, diabetes, hyperthyroidism, hypertension and cardiovascular disease; paracetamol-based products are contraindicated in patients with manifest glucose-6-phosphate dehydrogenase insufficiency and in those with severe haemolytic anaemia; severe hepatocellular insufficiency.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Tachifludec Lemon Powder 10 Sachets - How to take Tachifludec Lemon Powder 10 Sachets?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eDosage. Adults and children over 12 years: 1 sachet every 4-6 hours and up to a maximum of 3 sachets in 24 hours. The medicine should not be used for more than 3 consecutive days without consulting your doctor. Paediatric population. Children under 12 years: Tachifludec lemon, lemon and honey flavour is contraindicated in children under 12 years of age (see section 4.3). Method of administration: dissolve the contents of 1 sachet in half a glass of very hot water and, if desired, dilute with cold water to cool and sweeten as desired.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Tachifludec Lemon Powder 10 Sachets - How do you store Tachifludec Lemon Powder 10 Sachets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eStore below 25 degrees C. Store in the original container in order to protect from moisture and light.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Tachifludec Lemon Powder 10 Sachets - About Tachifludec Lemon Powder 10 Sachets it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePatients should be advised not to take other paracetamol-containing medicinal products while taking Tachifludec as high doses of paracetamol may cause serious adverse reactions. Avoid alcohol consumption during treatment with Tachifludec. The risk of overdose is greater in patients with liver problems. Invite the patient to contact the doctor before combining warfarin or any other drug (see also section 4.5). The use of the product is not recommended if the patient is being treated with anti-inflammatory drugs. Caution is advised if paracetamol is administered concomitantly with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism), as well as in those using maximum daily doses of paracetamol. Careful monitoring is recommended, including measurement of urinary 5-oxoproline. Consult your doctor before using the product in patients with enlarged prostate gland or occlusive vascular diseases (e.g. Raynaud's syndrome). Do not exceed the recommended dose and do not administer for more than 3 consecutive days. Tachifludec lemon flavor contains; sodium: this medicine contains 112.86 mg of sodium per sachet equivalent to 5.64% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult, to be taken into consideration in patients with reduced kidney function or who follow a low-sodium diet; sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Patients with diabetes should take into account the sucrose content within Tachifludec when taking more than 2 sachets per day (sucrose\u0026gt; 5g); glucose: patients with rare glucose-galactose malabsorption problems should not take this medicine. Tachifludec lemon and honey flavour contains: sodium: 135.79 mg of sodium per sachet equivalent to 6.79% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult, to be taken into consideration in patients with reduced renal function or who follow a low-sodium diet; sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. The sucrose content in Tachifludec should be taken into consideration in people with diabetes mellitus in case of taking more than 2 sachets per day (sucrose\u0026gt; 5g).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTachifludec Lemon Powder 10 Sachets Interactions - Which medicines or foods can modify the effect of Tachifludec Lemon Powder 10 Sachets?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eParacetamol: hepatotoxicity of paracetamol can be enhanced by the intake of other drugs active on the liver such as zidovudine and isoniazid which can produce an inhibition of the metabolism of paracetamol. The administration of probenecid before paracetamol decreases the clearance of paracetamol and the urinary elimination of paracetamol sulphate and paracetamol-glucuronide, and increases the half-life of paracetamol itself. Use with extreme caution and under strict control during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). Paracetamol increases the half-life of chloramphenicol. The product taken in high doses can enhance coumarin anticoagulants (warfarin). Metoclopramide and domperidone may increase the absorption of paracetamol, while it is reduced or delayed by cholestyramine and anticholinergics, respectively. Caution should be exercised when paracetamol is used concomitantly with flucloxacillin since concomitant intake has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4). Phenylephrine: phenylephrine may antagonise beta-blocking and antihypertensive drugs (including debrisoquine, guanethidine, reserpine and methyldopa) and may potentiate the action of monoamine oxidase inhibitors (see section 4.3). Concomitant use of phenylephrine with tricyclic antidepressants or sympathomimetic amines may increase the risk of cardiovascular effects. Phenylephrine may interact with digoxin and cardiac glycosides, increasing the risk of arrhythmia or infarction, and with alkaloids (ergotamine and methylsergide), increasing the risk of ergotism. Ascorbic acid: Ascorbic acid may increase the absorption of iron and estrogens. Ascorbic acid is metabolized to oxalate, and may potentially cause hyperoxaluria and kidney stones in patients through the crystallization of calcium oxalate in patients who tend to form calcium stones. Interference with some laboratory tests: Paracetamol administration may interfere with the determination of uric acid (by the phosphotungstic acid method) and blood glucose (by the glucose-oxidase-peroxidase method). Ascorbic acid may interfere with the measurement of blood and urine parameters (e.g. urate, glucose, bilirubin, hemoglobin).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Tachifludec Lemon Powder 10 Sachets can cause side effects - What are the side effects of Tachifludec Lemon Powder 10 Sachets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following adverse reactions are listed below, organised according to the MedDRA System Organ Class. Frequency is defined as follows: very common (\u0026gt;=1\/10), common (from \u0026gt;=1\/100 to \u0026lt;1\/10), uncommon (from \u0026gt;=1\/1000 to \u0026lt;1\/100), rare (from \u0026gt;=1\/10,000 to \u0026lt;1\/1000), very rare (\u0026lt;1\/10,000), not known (frequency cannot be estimated from the available data). Blood and lymphatic system disorders. Rare: agranulocytosis1, leucopenia1, thrombocytopenia1; not known: anaemia1. Immune system disorders. Rare: allergic reactions1,2, hypersensitivity reactions1,2, anaphylaxis1,2; not known: anaphylactic shock1,2. Metabolism and nutrition disorders. Common: anorexia2. Psychiatric disorders. Very rare: insomnia2, nervousness2, anxiety2, restlessness2, confusion2, irritability2. Nervous system disorders. Very rare: tremor2, dizziness2, headache2. Eye disorders. Not known: mydriasis2, acute angle-closure glaucoma2. Cardiac disorders. Rare: tachycardia2, palpitations2. Vascular disorders. Not known: hypertension2. Respiratory, thoracic and mediastinal disorders. Rare: bronchospasm1,2; not known: laryngeal oedema1. Gastrointestinal disorders. Common: nausea2, vomiting2; not known: diarrhoea1, gastrointestinal disorder1. Hepatobiliary disorders. Rare: liver function abnormal1; not known: liver disorder1, hepatitis1. Skin and subcutaneous tissue disorders. Rare: rash1,2, angioedema2; not known: toxic epidermal necrolysis1, Steven Johnson syndrome1, erythema multiforme or polymorphic1. Renal and urinary disorders. Very rare: tubulointerstitial nephritis (after prolonged use of paracetamol at high doses)1; not known: aggravated renal failure1, haematuria1, anuria1 urinary retention2. Very rare cases of serious skin reactions have been reported. ^1 Undesirable effects associated with paracetamol. ^2 Undesirable effects associated with phenylephrine. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachifludec Lemon Powder 10 Sachets.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy; paracetamol: a large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible duration and with the lowest possible frequency. Epidemiological studies in pregnant women have shown that there are no contraindications to the use of paracetamol when used in the recommended doses, but the administration of the preparation during pregnancy and breastfeeding should take place under the direct supervision of a doctor. Phenylephrine: data on the use of phenylephrine during pregnancy are limited. Vasoconstriction of the uterine vessels and reduction of blood flow to the uterus associated with the use of phenylephrine may result in fetal hypoxia. The use of phenylephrine during pregnancy should be avoided as further information is needed. Ascorbic acid: There are no controlled data on use during pregnancy. The use of ascorbic acid during pregnancy is recommended only when the benefit outweighs the risk. Breastfeeding; paracetamol: Paracetamol is excreted in breast milk but in clinically insignificant quantities. Available published data do not contraindicate its use during breastfeeding. Phenylephrine: There are no data on the excretion of phenylephrine in breast milk nor are there any information on the effects of phenylephrine on breast-fed children. In the absence of available data, the use of phenylephrine should be avoided during breastfeeding. Ascorbic acid: Ascorbic acid is excreted in breast milk. The effects on breast-fed children are unknown. In summary, the use of Tachifludec is not recommended during pregnancy and breastfeeding. Fertility: There is no evidence in non-clinical studies to indicate effects of paracetamol on male and female fertility at doses commonly used in clinic. Phenylephrine has not been studied on male and female fertility. There is sufficient evidence to indicate the importance of ascorbic acid at different levels in the reproductive process. However, no definitive data in humans are available on the clinical potential of vitamin C.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207824814195,"sku":"034358010","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachifludec-limone-polvere-10-bustine-farmacia-dottor-tili-1213792728.webp?v=1767127487"},{"product_id":"tachifludec-limone-e-miele-polvere-10-bustine","title":"Tachifludec Lemon and Honey Powder 10 Sachets","description":"\u003cp\u003eTachifludec Lemon and Honey Powder 10 Sachets is an \u003cstrong\u003eover-the-counter analgesic and antipyretic\u003c\/strong\u003e powder based on Paracetamol, Ascorbic Acid and Phenylephrine hydrochloride. Tachifludec Lemon and Honey Powder is indicated for the \u003cstrong\u003esymptomatic treatment of influenza, colds and feverish and painful conditions\u003c\/strong\u003e related to them. The decongestant action of Tachifludec on the upper airways \u003cstrong\u003efluidifies and frees from mucus and phlegm\u003c\/strong\u003e in case of cough and cold.\u003c\/p\u003e\n\n\u003cp\u003e Tachifludec Lemon and Honey Flavor 10 Sachets is a preparation formulated with:\u003c\/p\u003e\n\n\u003cp\u003e •\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eParacetamol\u003c\/strong\u003e : active ingredient with antipyretic and analgesic action which makes the medicine particularly suitable in cases of: pain and spasms in the stomach and intestines, pain caused by obstacles in the flow of the urinary tract and biliary tract and menstrual pain.\u003c\/p\u003e\n\n \u003cp\u003e•\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eVitamin C\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e(Ascorbic Acid): active ingredient that participates in the body's defense system.\u003c\/p\u003e\n\n\u003cp\u003e •\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003ePhenylephrine Hydrochloride\u003c\/strong\u003e : sympathomimetic active ingredient that acts by causing vasoconstriction of the local vascular bed, improving the symptoms of nasal obstruction.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Tachifludec Lemon and Honey Powder 10 Sachets - What is the active ingredient in Tachifludec Lemon and Honey Powder 10 Sachets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEach sachet contains active ingredients: paracetamol 600 mg, ascorbic acid 40 mg and phenylephrine hydrochloride 10 mg (equivalent to phenylephrine 8.2 mg). Excipients with known effects: Tachifludec lemon flavour contains: 1.817 g of sucrose, 112.86 mg of sodium, 6.65 mg of glucose. Tachifludec lemon and honey flavour contains: 1.892 g of sucrose, 135.79 mg of sodium. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eComposition of Tachifludec Lemon and Honey Powder 10 Sachets - What does Tachifludec Lemon and Honey Powder 10 Sachets contain?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTachifludec powder for oral solution lemon flavour: sucrose, anhydrous citric acid, sodium citrate, corn starch, sodium cyclamate, sodium saccharin, anhydrous colloidal silica, lemon flavouring, curcumin (E100), dried glucose syrup. Tachifludec powder for oral solution lemon and honey flavour: sucrose, anhydrous citric acid, sodium citrate, corn starch, sodium cyclamate, sodium saccharin, lemon flavouring, honey flavouring, caramel (E150), anhydrous colloidal silica.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Tachifludec Lemon and Honey Powder 10 Sachets - Why is Tachifludec Lemon and Honey Powder 10 Sachets used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eShort-term treatment of cold and flu symptoms, including mild to moderate pain and fever, when associated with nasal congestion.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Tachifludec Lemon and Honey Powder 10 Sachets - When should Tachifludec Lemon and Honey Powder 10 Sachets not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eChildren under 12 years of age; hypersensitivity to the active substances or to any of the excipients (listed in section 6.1); patients taking beta-blockers; patients taking tricyclic antidepressants and those taking or who have taken in the last 2 weeks monoamine oxidase inhibitors; patients with bronchial asthma, pheochromocytoma, narrow-angle glaucoma, or who are taking other sympathomimetic medicinal products (such as decongestants, appetite suppressants and amphetamine-like psychostimulants); patients with hepatic or renal insufficiency, diabetes, hyperthyroidism, hypertension and cardiovascular disease; paracetamol-based products are contraindicated in patients with manifest glucose-6-phosphate dehydrogenase insufficiency and in those with severe haemolytic anaemia; severe hepatocellular insufficiency.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Tachifludec Lemon and Honey Powder 10 Sachets - How do you take Tachifludec Lemon and Honey Powder 10 Sachets?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eDosage. Adults and children over 12 years: 1 sachet every 4-6 hours and up to a maximum of 3 sachets in 24 hours. The medicine should not be used for more than 3 consecutive days without consulting your doctor. Paediatric population. Children under 12 years: Tachifludec lemon, lemon and honey flavour is contraindicated in children under 12 years of age (see section 4.3). Method of administration: dissolve the contents of 1 sachet in half a glass of very hot water and, if desired, dilute with cold water to cool and sweeten as desired.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Tachifludec Lemon and Honey Powder 10 Sachets - How do you store Tachifludec Lemon and Honey Powder 10 Sachets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eStore below 25 degrees C. Store in the original container in order to protect from moisture and light.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Tachifludec Lemon and Honey Powder 10 Sachets - About Tachifludec Lemon and Honey Powder 10 Sachets it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePatients should be advised not to take other paracetamol-containing medicinal products while taking Tachifludec as high doses of paracetamol may cause serious adverse reactions. Avoid alcohol consumption during treatment with Tachifludec. The risk of overdose is greater in patients with liver problems. Invite the patient to contact the doctor before combining warfarin or any other drug (see also section 4.5). The use of the product is not recommended if the patient is being treated with anti-inflammatory drugs. Caution is advised if paracetamol is administered concomitantly with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism), as well as in those using maximum daily doses of paracetamol. Careful monitoring is recommended, including measurement of urinary 5-oxoproline. Consult your doctor before using the product in patients with enlarged prostate gland or occlusive vascular diseases (e.g. Raynaud's syndrome). Do not exceed the recommended dose and do not administer for more than 3 consecutive days. Tachifludec lemon flavor contains; sodium: this medicine contains 112.86 mg of sodium per sachet equivalent to 5.64% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult, to be taken into consideration in patients with reduced kidney function or who follow a low-sodium diet; sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Patients with diabetes should take into account the sucrose content within Tachifludec when taking more than 2 sachets per day (sucrose\u0026gt; 5g); glucose: patients with rare glucose-galactose malabsorption problems should not take this medicine. Tachifludec lemon and honey flavour contains: sodium: 135.79 mg of sodium per sachet equivalent to 6.79% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult, to be taken into consideration in patients with reduced renal function or who follow a low-sodium diet; sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. The sucrose content in Tachifludec should be taken into consideration in people with diabetes mellitus in case of taking more than 2 sachets per day (sucrose\u0026gt; 5g).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Tachifludec Lemon and Honey Powder 10 Sachets - Which medicines or foods can modify the effect of Tachifludec Lemon and Honey Powder 10 Sachets?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eParacetamol: hepatotoxicity of paracetamol can be enhanced by the intake of other drugs active on the liver such as zidovudine and isoniazid which can produce an inhibition of the metabolism of paracetamol. The administration of probenecid before paracetamol decreases the clearance of paracetamol and the urinary elimination of paracetamol sulphate and paracetamol-glucuronide, and increases the half-life of paracetamol itself. Use with extreme caution and under strict control during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). Paracetamol increases the half-life of chloramphenicol. The product taken in high doses can enhance coumarin anticoagulants (warfarin). Metoclopramide and domperidone may increase the absorption of paracetamol, while it is reduced or delayed by cholestyramine and anticholinergics, respectively. Caution should be exercised when paracetamol is used concomitantly with flucloxacillin since concomitant intake has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4). Phenylephrine: phenylephrine may antagonise beta-blocking and antihypertensive drugs (including debrisoquine, guanethidine, reserpine and methyldopa) and may potentiate the action of monoamine oxidase inhibitors (see section 4.3). Concomitant use of phenylephrine with tricyclic antidepressants or sympathomimetic amines may increase the risk of cardiovascular effects. Phenylephrine may interact with digoxin and cardiac glycosides, increasing the risk of arrhythmia or infarction, and with alkaloids (ergotamine and methylsergide), increasing the risk of ergotism. Ascorbic acid: Ascorbic acid may increase the absorption of iron and estrogens. Ascorbic acid is metabolized to oxalate, and may potentially cause hyperoxaluria and kidney stones in patients through the crystallization of calcium oxalate in patients who tend to form calcium stones. Interference with some laboratory tests: Paracetamol administration may interfere with the determination of uric acid (by the phosphotungstic acid method) and blood glucose (by the glucose-oxidase-peroxidase method). Ascorbic acid may interfere with the measurement of blood and urine parameters (e.g. urate, glucose, bilirubin, hemoglobin).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Tachifludec Lemon and Honey Powder 10 Sachets can cause side effects - What are the side effects of Tachifludec Lemon and Honey Powder 10 Sachets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following adverse reactions are listed below, organised according to the MedDRA System Organ Class. Frequency is defined as follows: very common (\u0026gt;=1\/10), common (from \u0026gt;=1\/100 to \u0026lt;1\/10), uncommon (from \u0026gt;=1\/1000 to \u0026lt;1\/100), rare (from \u0026gt;=1\/10,000 to \u0026lt;1\/1000), very rare (\u0026lt;1\/10,000), not known (frequency cannot be estimated from the available data). Blood and lymphatic system disorders. Rare: agranulocytosis1, leucopenia1, thrombocytopenia1; not known: anaemia1. Immune system disorders. Rare: allergic reactions1,2, hypersensitivity reactions1,2, anaphylaxis1,2; not known: anaphylactic shock1,2. Metabolism and nutrition disorders. Common: anorexia2. Psychiatric disorders. Very rare: insomnia2, nervousness2, anxiety2, restlessness2, confusion2, irritability2. Nervous system disorders. Very rare: tremor2, dizziness2, headache2. Eye disorders. Not known: mydriasis2, acute angle-closure glaucoma2. Cardiac disorders. Rare: tachycardia2, palpitations2. Vascular disorders. Not known: hypertension2. Respiratory, thoracic and mediastinal disorders. Rare: bronchospasm1,2; not known: laryngeal oedema1. Gastrointestinal disorders. Common: nausea2, vomiting2; not known: diarrhoea1, gastrointestinal disorder1. Hepatobiliary disorders. Rare: liver function abnormal1; not known: liver disorder1, hepatitis1. Skin and subcutaneous tissue disorders. Rare: rash1,2, angioedema2; not known: toxic epidermal necrolysis1, Steven Johnson syndrome1, erythema multiforme or polymorphic1. Renal and urinary disorders. Very rare: tubulointerstitial nephritis (after prolonged use of paracetamol at high doses)1; not known: aggravated renal failure1, haematuria1, anuria1 urinary retention2. Very rare cases of serious skin reactions have been reported. ^1 Undesirable effects associated with paracetamol. ^2 Undesirable effects associated with phenylephrine. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachifludec Lemon and Honey Powder 10 Sachets.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy; paracetamol: a large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible duration and with the lowest possible frequency. Epidemiological studies in pregnant women have shown that there are no contraindications to the use of paracetamol when used in the recommended doses, but the administration of the preparation during pregnancy and breastfeeding should take place under the direct supervision of a doctor. Phenylephrine: data on the use of phenylephrine during pregnancy are limited. Vasoconstriction of the uterine vessels and reduction of blood flow to the uterus associated with the use of phenylephrine may result in fetal hypoxia. The use of phenylephrine during pregnancy should be avoided as further information is needed. Ascorbic acid: There are no controlled data on use during pregnancy. The use of ascorbic acid during pregnancy is recommended only when the benefit outweighs the risk. Breastfeeding; paracetamol: Paracetamol is excreted in breast milk but in clinically insignificant quantities. Available published data do not contraindicate its use during breastfeeding. Phenylephrine: There are no data on the excretion of phenylephrine in breast milk nor are there any information on the effects of phenylephrine on breast-fed children. In the absence of available data, the use of phenylephrine should be avoided during breastfeeding. Ascorbic acid: Ascorbic acid is excreted in breast milk. The effects on breast-fed children are unknown. In summary, the use of Tachifludec is not recommended during pregnancy and breastfeeding. Fertility: There is no evidence in non-clinical studies to indicate effects of paracetamol on male and female fertility at doses commonly used in clinic. Phenylephrine has not been studied on male and female fertility. There is sufficient evidence to indicate the importance of ascorbic acid at different levels in the reproductive process. However, no definitive data in humans are available on the clinical potential of vitamin C.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207824879731,"sku":"034358022","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachifludec-limone-e-miele-polvere-10-bustine-farmacia-dottor-tili-1213792714.jpg?v=1767127548"},{"product_id":"tachifludec-arancia-polvere-10-bustine","title":"Tachifludec Orange Powder 10 Sachets","description":"\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eTachifludec Orange Powder 10 Sachets is an\u003c\/span\u003e \u003cb\u003eover-the-counter analgesic and antipyretic\u003c\/b\u003e \u003cspan style=\"font-weight: 400;\"\u003epowder based on Paracetamol, Ascorbic Acid and Phenylephrine hydrochloride. Tachifludec Orange Powder is indicated for the\u003c\/span\u003e \u003cb\u003esymptomatic treatment of influenza, colds and feverish and painful conditions\u003c\/b\u003e \u003cspan style=\"font-weight: 400;\"\u003erelated to them. The decongestant action of Tachifludec on the upper airways\u003c\/span\u003e \u003cb\u003efluidifies and frees from mucus and phlegm\u003c\/b\u003e \u003cspan style=\"font-weight: 400;\"\u003ein case of cough and cold.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp\u003e Tachifludec Orange Flavor 10 Sachets is a preparation formulated with:\u003c\/p\u003e\n\n\u003cp\u003e •\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eParacetamol\u003c\/strong\u003e : active ingredient with antipyretic and analgesic action which makes the medicine particularly suitable in cases of: pain and spasms in the stomach and intestines, pain caused by obstacles in the flow of the urinary tract and biliary tract and menstrual pain.\u003c\/p\u003e\n\n \u003cp\u003e•\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eVitamin C\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e(Ascorbic Acid): active ingredient that participates in the body's defense system.\u003c\/p\u003e\n\n\u003cp\u003e •\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003ePhenylephrine Hydrochloride\u003c\/strong\u003e : sympathomimetic active ingredient that acts by causing vasoconstriction of the local vascular bed, improving the symptoms of nasal obstruction.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Tachifludec Orange Powder 10 Sachets - What is the active ingredient of Tachifludec Orange Powder 10 Sachets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEach sachet contains active ingredients: paracetamol 600 mg, ascorbic acid 40 mg and phenylephrine hydrochloride 10 mg (equivalent to phenylephrine 8.2 mg). Excipients with known effect: 2 g of sucrose; 135.82 mg of sodium; 33.25 mg of glucose. For the full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Tachifludec Orange Powder 10 Sachets - What does Tachifludec Orange Powder 10 Sachets contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eSucrose, anhydrous citric acid, sodium citrate, corn starch, sodium cyclamate, sodium saccharin, colloidal anhydrous silica, red orange flavouring, curcumin (E100), dried glucose syrup.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Tachifludec Orange Powder 10 Sachets - Why is Tachifludec Orange Powder 10 Sachets used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eShort-term treatment of cold and flu symptoms, including mild to moderate pain and fever, when associated with nasal congestion.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Tachifludec Orange Powder 10 Sachets - When should Tachifludec Orange Powder 10 Sachets not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eChildren under 12 years of age; hypersensitivity to the active substances or to any of the excipients (listed in section 6.1); patients taking beta-blockers; patients taking tricyclic antidepressants and those taking or who have taken in the last 2 weeks monoamine oxidase inhibitors; patients with bronchial asthma, pheochromocytoma, narrow-angle glaucoma, or who are taking other sympathomimetic medicinal products (such as decongestants, appetite suppressants and amphetamine-like psychostimulants); patients with hepatic or renal insufficiency, diabetes, hyperthyroidism, hypertension and cardiovascular disease. Paracetamol-based products are contraindicated in patients with manifest glucose-6-phosphate dehydrogenase insufficiency and in those with severe haemolytic anaemia; severe hepatocellular insufficiency.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Tachifludec Orange Powder 10 Sachets - How to take Tachifludec Orange Powder 10 Sachets?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eDosage; adults and children over 12 years: 1 sachet every 4-6 hours and up to a maximum of 3 sachets in 24 hours. The medicine should not be used for more than 3 consecutive days without consulting your doctor. Paediatric population; children under 12 years: Tachifludec orange flavour is contraindicated in children under 12 years of age (see section 4.3). Method of administration: dissolve the contents of one sachet in a glass of hot or cold water and sweeten to taste. Once dissolved, the medicine gives rise to a yellow opalescent solution, free of foreign particles and with an orange flavour.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Tachifludec Orange Powder 10 Sachets - How do you store Tachifludec Orange Powder 10 Sachets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eStore below 25 degrees C. Store in the original container in order to protect from moisture and light.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Tachifludec Orange Powder 10 Sachets - About Tachifludec Orange Powder 10 Sachets it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePatients should be advised not to take other paracetamol-containing medicinal products while taking Tachifludec as high doses of paracetamol may cause serious adverse reactions. Avoid alcohol consumption during treatment with Tachifludec. The risk of overdose is greater in patients with liver problems. Instruct the patient to contact the doctor before combining warfarin or any other drug (see also section 4.5). The use of the product is not recommended if the patient is being treated with anti-inflammatory drugs. Caution is advised if paracetamol is administered concomitantly with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism), as well as in those using maximum daily doses of paracetamol. Careful monitoring is recommended, including measurement of urinary 5-oxoproline. Consult your doctor before using the product in patients with enlarged prostate gland or occlusive vascular diseases (e.g. Raynaud's syndrome). Do not exceed the recommended dose and do not administer for more than 3 consecutive days. Tachifludec orange flavor contains, sodium: this medicine contains 135.82 mg of sodium per sachet, equivalent to 6.79% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult, to be taken into consideration in patients with reduced kidney function or who follow a low-sodium diet. Sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Patients with diabetes should take into account the sucrose content within Tachifludec when taking more than 2 sachets per day (sucrose\u0026gt; 5g). Glucose: Patients with rare glucose-galactose malabsorption problems should not take this medicine.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTachifludec Orange Powder 10 Sachets Interactions - Which medicines or foods can modify the effect of Tachifludec Orange Powder 10 Sachets?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eParacetamol: hepatotoxicity of paracetamol can be enhanced by the intake of other drugs active on the liver, such as zidovudine and isoniazid which can produce an inhibition of the metabolism of paracetamol. The administration of probenecid before paracetamol decreases the clearance of paracetamol and the urinary elimination of paracetamol sulphate and paracetamol-glucuronide, and increases the half-life of paracetamol itself. Use with extreme caution and under strict control during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). Paracetamol increases the half-life of chloramphenicol. The product taken in high doses can enhance coumarin anticoagulants (warfarin). Metoclopramide and domperidone may increase the absorption of paracetamol, while it is reduced or delayed by cholestyramine and anticholinergics, respectively. Caution should be exercised when paracetamol is used concomitantly with flucloxacillin since concomitant intake has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4). Phenylephrine: phenylephrine may antagonise beta-blocking and antihypertensive drugs (including debrisoquine, guanethidine, reserpine and methyldopa) and may potentiate the action of monoamine oxidase inhibitors (see section 4.3). Concomitant use of phenylephrine with tricyclic antidepressants or sympathomimetic amines may increase the risk of cardiovascular effects. Phenylephrine may interact with digoxin and cardiac glycosides, increasing the risk of arrhythmia or heart attack, and with alkaloids (ergotamine and methylsergide), increasing the risk of ergotism. Ascorbic Acid: Ascorbic acid may increase the absorption of iron and estrogens. Ascorbic acid is metabolized to oxalate, and may potentially cause hyperoxaluria and kidney stones in patients through the crystallization of calcium oxalate in patients who tend to form calcium stones. Interference with some laboratory tests: Paracetamol administration may interfere with the determination of uric acid (by the phosphotungstic acid method) and blood sugar (by the glucose-oxidase-peroxidase method). Ascorbic acid may interfere with the measurement of blood and urine parameters (e.g. urate, glucose, bilirubin, hemoglobin).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Tachifludec Orange Powder 10 Sachets can cause side effects - What are the side effects of Tachifludec Orange Powder 10 Sachets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following adverse reactions are listed below, organised according to the MedDRA System Organ Class. Frequency is defined as follows: very common (\u0026gt;=1\/10), common (\u0026gt;=1\/100 to \u0026lt;1\/10), uncommon (\u0026gt;=1\/1000 to \u0026lt;1\/100), rare (\u0026gt;=1\/10,000 to \u0026lt;1\/1000), very rare (\u0026lt;1\/10,000), not known (frequency cannot be estimated from the available data). Blood and lymphatic system disorders. Rare: agranulocytosis1, leukopenia1, thrombocytopenia1; not known: anaemia1. Immune system disorders. Rare: allergic reactions1,2, hypersensitivity reactions1,2, anaphylaxis1,2; not known: anaphylactic shock1, 2. Metabolism and nutrition disorders. Common: anorexia2. Psychiatric disorders very rare: insomnia2, nervousness2, anxiety2, restlessness2, confusion2, irritability2. Nervous system disorders. Very rare: tremor2, dizziness2, headache2. Eye disorders. Not known: mydriasis2, acute angle-closure glaucoma2. Cardiac disorders. Rare: tachycardia2, palpitations2. Vascular disorders. Not known: hypertension2. Respiratory, thoracic and mediastinal disorders. Rare: bronchospasm1,2; not known: laryngeal oedema1. Gastrointestinal disorders. Common: nausea2, vomiting2; not known: diarrhoea1, gastrointestinal disorder1. Hepatobiliary disorders. Rare: liver function abnormal1; not known: liver disorder1, hepatitis1. Skin and subcutaneous tissue disorders. Rare: rash1,2, angioedema2; not known: toxic epidermal necrolysis1, Steven Johnson syndrome1, erythema multiforme or polymorphic1. Renal and urinary disorders. Very rare: tubulointerstitial nephritis (after prolonged use of paracetamol at high doses)1; not known: aggravated renal failure1, haematuria1, anuria1 urinary retention2. Very rare cases of serious skin reactions have been reported. ^1 Undesirable effects associated with paracetamol ^2 Undesirable effects associated with phenylephrine. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachifludec Orange Powder 10 Sachets.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy; paracetamol: a large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible duration and with the lowest possible frequency. Epidemiological studies in pregnant women have shown that there are no contraindications to the use of paracetamol when used in the recommended doses, but the administration of the preparation during pregnancy and breastfeeding should take place under the direct supervision of a doctor. Phenylephrine: data on the use of phenylephrine during pregnancy are limited. Vasoconstriction of the uterine vessels and reduction of blood flow to the uterus associated with the use of phenylephrine may result in fetal hypoxia. The use of phenylephrine during pregnancy should be avoided as further information is needed. Ascorbic acid: There are no controlled data on use during pregnancy. The use of ascorbic acid during pregnancy is recommended only when the benefit outweighs the risk. Breastfeeding; paracetamol: Paracetamol is excreted in breast milk but in clinically insignificant quantities. Available published data do not contraindicate its use during breastfeeding. Phenylephrine: There are no data on the excretion of phenylephrine in breast milk nor are there any information on the effects of phenylephrine on breast-fed children. In the absence of available data, the use of phenylephrine should be avoided during breastfeeding. Ascorbic acid: Ascorbic acid is excreted in breast milk. The effects on breast-fed children are unknown. In summary, the use of Tachifludec is not recommended during pregnancy and breastfeeding. Fertility: There is no evidence in non-clinical studies to indicate effects of paracetamol on male and female fertility at doses commonly used in clinic. Phenylephrine has not been studied on male and female fertility. There is sufficient evidence to indicate the importance of ascorbic acid at different levels in the reproductive process. However, no definitive data in humans are available on the clinical potential of vitamin C.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207824912499,"sku":"034358034","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachifludec-arancia-polvere-10-bustine-farmacia-dottor-tili-1213792726.jpg?v=1767127528"},{"product_id":"tachipirina-orosolubile-12-bustine-500-mg","title":"Tachipirina Orosolubile 12 Sachets 500 mg","description":"\u003cp\u003e\u003cstrong\u003eTachipirina Orosolubile\u003c\/strong\u003e is a paracetamol-based medicine, indicated for the symptomatic treatment of mild to moderate pain, such as headache, toothache, muscle and joint pain, and to reduce fever. Thanks to the orosoluble sachet format, the product can be taken without water, dissolving directly in the mouth, which makes it particularly convenient to use even outside the home.\u003c\/p\u003e\n\n\u003cp\u003e \u003cstrong\u003eTachipirina Orosolubile\u003c\/strong\u003e is indicated for:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e Treatment of fever.\u003c\/li\u003e\n\n\u003cli\u003e Treatment of mild to moderate pain, such as headache, muscle pain, toothache, joint pain, back pain, neuralgia.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Tachipirina Orosolubile 12 Sachets 500 mg - What is the active ingredient of Tachipirina Orosolubile 12 Sachets 500 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis medicine 500 mg tablets. Each tablet contains: paracetamol 500 mg. This medicine 500 mg effervescent granules. Each sachet contains: paracetamol 500 mg. This medicine 125 mg effervescent granules. Each sachet contains: paracetamol 125 mg. This medicine - newborns 62.5 mg suppositories. Each suppository contains: paracetamol 62.5 mg. This medicine - early childhood 125 mg suppositories. Each suppository contains: paracetamol 125 mg. This medicine - children 250 mg suppositories. Each suppository contains: paracetamol 250 mg. This medicine - children 500 mg suppositories. Each suppository contains: paracetamol 500 mg. This medicine - adults 1000 mg suppositories. Each suppository contains: paracetamol 1000 mg.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Tachipirina Orosolubile 12 Sachets 500 mg - What does Tachipirina Orosolubile 12 Sachets 500 mg contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eTablets: microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, croscarmellose sodium. Effervescent granules: maltitol, mannitol, sodium bicarbonate, anhydrous citric acid, citrus flavouring, aspartame, sodium docusate. Suppositories: solid semi-synthetic glycerides.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Tachipirina Orosolubile 12 Sachets 500 mg - Why is Tachipirina Antidolorifico 500mg 20 Tablets used? What is it for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eAs an antipyretic: symptomatic treatment of febrile conditions such as influenza, exanthematous diseases, acute respiratory tract conditions, etc. As an analgesic: headaches, neuralgia, myalgia and other moderately severe painful conditions of various origins.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eContraindications Tachipirina Orosolubile 12 Sachets 500 mg - When should Tachipirina Orosolubile 12 Sachets 500 mg not be used?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to paracetamol or to any of the excipients. Patients with severe haemolytic anaemia (this contraindication does not apply to the 500 mg oral formulations). Severe hepatocellular insufficiency (this contraindication does not apply to the 500 mg oral formulations).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Tachipirina Orosolubile 12 Sachets 500 mg - How do you take Tachipirina Orosolubile 12 Sachets 500 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor children, it is essential to respect the dosage defined according to their body weight, and therefore choose the appropriate formulation. The approximate ages according to body weight are given for information purposes only. In adults, the maximum oral dosage is 3000 mg and rectal dosage is 4000 mg of paracetamol per day. The doctor must evaluate the need for treatments for more than 3 consecutive days. The dosage schedule of this medicine in relation to body weight and administration route is as follows. 500 mg tablets. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 1\/2 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day (3 tablets). Children weighing between 26 and 40 kg (approximately 8 to 11 years): 1 tablet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 41 and 50 kg (approximately 12 to 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Adults: 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 tablets of 500 mg to be repeated if necessary after not less than 4 hours. Effervescent granules of 500 mg in sachets. Dissolve the effervescent granules in a glass of water. Children weighing between 26 and 40 kg (approximately 8 to 11 years): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 41 and 50 kg (approximately 12 to 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Adults: 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 sachets of 500 mg to be repeated if necessary after not less than 4 hours. Effervescent granules of 125 mg in sachets. Dissolve the effervescent granules in a glass of water. Children weighing between 7 and 10 kg (approximately between 6 and 19 months): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Children weighing between 13 and 20 kg (approximately between 30 months and less than 6.5 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Suppositories Neonates 62.5 mg. Children weighing between 3.2 and 5 kg (approximately between birth and 2 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Early Childhood 125 mg. Children weighing between 6 and 7 kg (approximately between 3 and 5 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Children weighing between 7 and 10 kg (approximately between 6 and 19 months): 1 suppository at a time, to be repeated if necessary after 4 - 6 hours, without exceeding 5 administrations per day. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. Suppositories Children 250 mg. Children weighing between 11 and 12 kg (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing between 13 and 20 kg (approximately between 30 months and less than 6.5 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Children 500 mg. Children weighing between 21 and 25 kg (approximately between 6.5 and less than 8 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing between 26 and 40 kg (approximately between 8 and 11 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Suppositories Adults 1000 mg. Children weighing between 41 and 50 kg (approximately between 12 and 15 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. Children weighing more than 50 kg (approximately over 15 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Adults: 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Renal insufficiency. In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Tachipirina Orosolubile 12 Sachets 500 mg - How is Tachipirina Orosolubile 12 Sachets 500 mg stored?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTablets and effervescent granules: no special precautions for storage. Suppositories: store at a temperature not exceeding 25 degrees C.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Tachipirina Orosolubile 12 Sachets 500 mg - About Tachipirina Orosolubile 12 Sachets 500 mg it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIn rare cases of allergic reactions, administration should be suspended and appropriate treatment should be instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u0026gt;9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause alterations to the kidney and blood, even serious, therefore administration to subjects with renal insufficiency should be carried out only if really necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and renal function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other medicine. Important information about some of the excipients. This 125 mg effervescent granules medicine contains: aspartame, which is a source of phenylalanine. It may be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. Maltitol: use with caution in patients with rare hereditary problems of fructose intolerance. 70.6 mg of sodium per sachet equivalent to 3.53% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult: to be taken into consideration by people with reduced kidney function or who follow a low-sodium diet. This 500 mg effervescent granules medicinal product contains: aspartame, a source of phenylalanine. It may be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. Maltitol: use with caution in patients with rare hereditary problems of fructose intolerance. 283 mg of sodium per sachet is equivalent to 14.1% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The maximum dose for this product is equivalent to 84.6% of the WHO recommended maximum daily intake of sodium: to be taken into consideration by patients with reduced kidney function or who follow a low-sodium diet.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Tachipirina Orosolubile 12 Sachets 500 mg - Which medicines or foods can modify the effect of Tachipirina Orosolubile 12 Sachets 500 mg?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe oral absorption of paracetamol depends on the rate of gastric emptying. Therefore, the concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may determine a decrease or increase respectively in the bioavailability of the product. The concomitant administration of cholestyramine reduces the absorption of paracetamol. The simultaneous intake of paracetamol and chloramphenicol may induce an increase in the half-life of chloramphenicol, with the risk of increasing toxicity. Concomitant use of paracetamol (4 g daily for at least 4 days) with oral anticoagulants may cause slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its interruption. Use with extreme caution and under close supervision during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol may interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Tachipirina Orosolubile 12 Bustine 500 mg can cause side effects - What are the side effects of Tachipirina Orosolubile 12 Bustine 500 mg?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following are the adverse reactions of paracetamol organised according to the MedDRA system organ classification. There are insufficient data to establish the frequency of the individual effects listed. Blood and lymphatic system disorders: thrombocytopenia, leukopenia, anaemia, agranulocytosis. Immune system disorders: hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock). Nervous system disorders: dizziness. Gastrointestinal disorders: gastrointestinal reaction. Hepatobiliary disorders: abnormal liver function, hepatitis. Skin and subcutaneous tissue disorders: erythema multiforme, Stevens Johnson syndrome, epidermal necrolysis, rash. Renal and urinary disorders: acute renal failure, interstitial nephritis, haematuria, anuria. Very rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina Orosolubile 12 Sachets 500 mg\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePregnancy: A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to administer the product only in cases of real need and under the direct supervision of a doctor.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207824945267,"sku":"040313049","price":8.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachipirina-orosolubile-12-bustine-500-mg-farmacia-dottor-tili-1213793094.jpg?v=1767127510"},{"product_id":"fascia-thermacare-versatile-6-pezzi","title":"Thermacare Versatile Band 6 Pieces","description":"\u003cp\u003eThe \u003cstrong\u003eThermacare Versatile Band\u003c\/strong\u003e is a medical device designed to provide long-lasting relief from muscle and joint pain, thanks to its ability to emit constant therapeutic heat for up to 8 hours. Ideal for use on different parts of the body such as the back, neck, shoulders and joints, this versatile band helps to relax tense muscles, improve circulation and relieve pain related to muscle contractures and fatigue. Thanks to its flexible and comfortable design, it can be worn under clothing and allows freedom of movement during use.\u003c\/p\u003e\n\n\n\u003ch2\u003e How to use\u003c\/h2\u003e\n\n\u003ch3\u003e How to use Fascia Thermacare Versatile?\u003c\/h3\u003e\n\n\u003col\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eOpening and application\u003c\/strong\u003e : Remove the band from the packaging and place it on the affected area, making sure that the heating pads are in direct contact with the skin.\u003c\/li\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eHeat Activation\u003c\/strong\u003e : The band begins to gradually heat up within 30 minutes of opening and provides constant heat for up to 8 hours.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eTreatment duration\u003c\/strong\u003e : Wear the band for at least 8 hours to obtain maximum therapeutic benefit. The band is comfortable to wear and can be used during daily activities.\u003c\/li\u003e\n\n\n\u003c\/ol\u003e\n\n\n\u003ch2\u003e Box contents\u003c\/h2\u003e\n\n\u003ch3\u003e What does the Thermacare Versatile Band contain?\u003c\/h3\u003e\n\n\u003cp\u003e The package contains:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003e6 disposable self-heating bands\u003c\/strong\u003e , designed to adapt to different areas of the body such as the back, neck and joints.\u003c\/li\u003e\n\n\u003cli\u003e Each band is individually packaged to ensure hygiene and freshness until use.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings for Fascia Thermacare Versatile?\u003c\/h3\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDo not use on damaged or irritated skin\u003c\/strong\u003e : Avoid use on open wounds, cuts or irritation.\u003c\/li\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eDo not use on people insensitive to heat\u003c\/strong\u003e : This product is not suitable for people with reduced thermal sensitivity or conditions that limit the perception of heat.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDisposable\u003c\/strong\u003e : The bands are designed for a single use and should not be reused.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eConsult a doctor\u003c\/strong\u003e : If you have any pre-existing medical conditions such as diabetes, pregnancy or circulatory problems, consult a doctor before use.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDo not apply on recent swelling or bruises\u003c\/strong\u003e : Applying heat may worsen the condition.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of Fascia Thermacare Versatile?\u003c\/h3\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eExpiry\u003c\/strong\u003e : The expiry date is indicated on the package. Do not use the product beyond the expiry date.\u003c\/li\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eStorage\u003c\/strong\u003e : Store the product in a cool, dry place, away from heat and direct light. Do not open the package until use.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e The \u003cstrong\u003eThermacare Versatile Band\u003c\/strong\u003e is available in packs of \u003cstrong\u003e6 disposable bands\u003c\/strong\u003e , ideal for long-lasting relief from muscle and joint pain.\u003c\/p\u003e\n\n","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207825961075,"sku":"981076110","price":20.37,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-spa-fascia-thermacare-versatile-6-pezzi-farmacia-dottor-tili-1213793087.jpg?v=1767127690"},{"product_id":"fasce-autoriscaldanti-a-calore-terapeutico-thermacare-collo-spalla-polso-6-pezzi","title":"Thermacare Therapeutic Heat Self-Heating Bands Neck Shoulder Wrist 6 Pieces","description":"\u003cp\u003e\u003cstrong\u003eThermacare Self-Heating Therapeutic Heat Wraps Neck Shoulder Wrist\u003c\/strong\u003e are a medical device designed to provide long-lasting relief from muscle and joint pain localized in specific areas such as the neck, shoulders and wrist. Thanks to their self-heating technology, these wraps emit constant therapeutic heat for up to 8 hours, helping to relax tense muscles and reduce pain associated with tension, contractures and muscle fatigue. The wraps are disposable and discreet, allowing for comfortable use during daily activities.\u003c\/p\u003e\n\n\n\u003ch2\u003e How to use\u003c\/h2\u003e\n\n\u003ch3\u003e How to use Thermacare Therapeutic Heat Self-Heating Wraps Neck Shoulder Wrist?\u003c\/h3\u003e\n\n\u003col\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eOpening and application\u003c\/strong\u003e : Remove the band from the packaging and place it on the affected area, making sure that the heating pads are in direct contact with the skin.\u003c\/li\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eDuration of treatment\u003c\/strong\u003e : Wear the band for at least 8 hours to obtain maximum benefit. The heat activates gradually within 30 minutes of opening.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eComfort\u003c\/strong\u003e : The bands are designed to be worn under clothing, allowing you to continue your daily activities without hindrance.\u003c\/li\u003e\n\n\n\u003c\/ol\u003e\n\n\n\u003ch2\u003e Box contents\u003c\/h2\u003e\n\n\u003ch3\u003e What's in the Thermacare Therapeutic Heat Self-Heating Bandages Neck Shoulder Wrist package?\u003c\/h3\u003e\n\n\u003cp\u003e The package contains:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003e6 disposable self-heating bands\u003c\/strong\u003e , designed to fit different areas of the body such as the neck, shoulders and wrist.\u003c\/li\u003e\n\n\u003cli\u003e Each band is individually packaged to ensure maximum hygiene and protection until use.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings of Thermacare Therapeutic Heat Self-Heating Bands Neck Shoulder Wrist?\u003c\/h3\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDo not use on damaged skin\u003c\/strong\u003e : Avoid use on open wounds, burns or skin irritations.\u003c\/li\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eDo not use on people insensitive to heat\u003c\/strong\u003e : This device is not suitable for people with reduced thermal sensitivity or other medical conditions that limit the perception of heat.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eSingle-use\u003c\/strong\u003e : The bands are single-use and should not be reused.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eConsult a doctor\u003c\/strong\u003e : If you have any pre-existing medical conditions such as diabetes, pregnancy or circulation problems, it is recommended that you consult a doctor before use.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDo not apply on recent swelling or bruises\u003c\/strong\u003e : Heat may aggravate the condition.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eKeep out of reach of children\u003c\/strong\u003e .\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of Thermacare Therapeutic Heat Self-Heating Bandages Neck Shoulder Wrist?\u003c\/h3\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eExpiry\u003c\/strong\u003e : The expiry date is indicated on the package. Do not use the product after this date.\u003c\/li\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eStorage\u003c\/strong\u003e : Store the bands in a cool, dry place, away from heat sources and direct sunlight. Open the package only when ready to use.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e \u003cstrong\u003eThermacare Therapeutic Heat Self-Heating Wraps for Neck, Shoulder and Wrist\u003c\/strong\u003e are available in packs of \u003cstrong\u003e6 disposable wraps\u003c\/strong\u003e , ideal for long-lasting relief.\u003c\/p\u003e\n\n","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207825993843,"sku":"981076096","price":20.37,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-spa-fasce-autoriscaldanti-a-calore-terapeutico-thermacare-collo-spalla-polso-6-pezzi-farmacia-dottor-tili-1213793088.jpg?v=1767127786"},{"product_id":"fascia-autoriscaldante-a-calore-terapeutico-thermacare-schiena-4-pezzi","title":"Thermacare Therapeutic Heat Self-Heating Band Back 4 Pieces","description":"\u003cp\u003eThe \u003cstrong\u003eThermacare Back Therapeutic Heat Self-Heating Band\u003c\/strong\u003e is a medical device designed to provide long-lasting relief from muscle and joint pain in the lower back and lumbar region. Thanks to its advanced thermal technology, the band provides constant, therapeutic heat for up to 8 hours, allowing muscles to relax and relieving tension. It is ideal for treating chronic or acute pain, as well as pain caused by fatigue or poor posture.\u003c\/p\u003e\n\n\n\u003ch2\u003e How to use\u003c\/h2\u003e\n\n\u003ch3\u003e How to use Thermacare Therapeutic Heat Self-Heating Band for Back?\u003c\/h3\u003e\n\n\u003col\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eOpening and application\u003c\/strong\u003e : Remove the band from the packaging and place it directly on your lower back, with the heat pads facing your skin. Adjust the band around your waist using the adhesive tabs for a comfortable fit.\u003c\/li\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eTreatment duration\u003c\/strong\u003e : Wear the band for at least 8 hours to obtain maximum therapeutic benefit. The heat gradually activates within 30 minutes of application and provides a continuous effect throughout the entire treatment.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eSafety and Comfort\u003c\/strong\u003e : The band is designed to be worn under clothing, allowing you to continue your daily activities without discomfort. Do not exceed 8 hours of consecutive use in a 24-hour period.\u003c\/li\u003e\n\n\n\u003c\/ol\u003e\n\n\n\u003ch2\u003e Box contents\u003c\/h2\u003e\n\n\u003ch3\u003e What does the Thermacare Therapeutic Heat Self-Heating Back Band contain?\u003c\/h3\u003e\n\n\u003cp\u003e The package contains:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003e4 disposable self-heating bands\u003c\/strong\u003e , specific for the lumbar and lower back area.\u003c\/li\u003e\n\n\u003cli\u003e Each band is individually packaged to preserve the effectiveness and freshness of the product until use.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings of Thermacare Self-Heating Therapeutic Heat Back Wrap?\u003c\/h3\u003e\n\n\u003cul\u003e \n\u003cli\u003e\n\n\u003cstrong\u003eDo not use on damaged or irritated skin\u003c\/strong\u003e : Avoid use on wounds, cuts, burns or skin irritations.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDo not apply on recent swelling or bruising\u003c\/strong\u003e : Heat may aggravate the condition.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDo not use on people insensitive to heat\u003c\/strong\u003e : This device is not indicated for people with reduced thermal sensitivity or conditions that limit the perception of heat.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eSingle Use\u003c\/strong\u003e : The bands are designed for single use. Do not reuse.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eConsult a doctor\u003c\/strong\u003e : If you are pregnant, have diabetes, poor circulation or have any pre-existing medical conditions, consult a doctor before use.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eKeep out of reach of children\u003c\/strong\u003e .\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of the Thermacare Back Therapeutic Heat Wrap?\u003c\/h3\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eExpiry\u003c\/strong\u003e : The expiry date is indicated on the package. Do not use the product after the expiry date.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eStorage\u003c\/strong\u003e : Store the product in a cool, dry place, away from heat sources and direct sunlight. Do not open the package until ready to use.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e The \u003cstrong\u003eThermacare Self-Heating Therapeutic Heat Back Wrap\u003c\/strong\u003e is available in packs of \u003cstrong\u003e4 disposable wraps\u003c\/strong\u003e , each designed to fit the lower back area.\u003c\/p\u003e\n\n","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207826026611,"sku":"981042649","price":20.37,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-spa-fascia-autoriscaldante-a-calore-terapeutico-thermacare-schiena-4-pezzi-farmacia-dottor-tili-1213793056.jpg?v=1767127769"},{"product_id":"fascia-autoriscaldante-versatile-thermacare-xl-2-pezzi","title":"Thermacare XL 2 Piece Versatile Self-Heating Band","description":"\u003cp\u003eThe \u003cstrong\u003eThermacare XL Versatile Self-Heating Wrap\u003c\/strong\u003e is a medical device that provides long-lasting relief from muscle and joint pain. Using heat-releasing technology, the wrap emits constant therapeutic heat for 8 hours, penetrating deep into muscles and tissues to relieve pain. It is ideal for localized muscle and joint pain over large areas such as the back, shoulders and neck. The wrap is designed to be comfortable and discreet, allowing it to be worn under clothing during everyday activities.\u003c\/p\u003e\n\n\n\u003ch2\u003e How to use\u003c\/h2\u003e\n\n\u003ch3\u003e How to use Thermacare XL Versatile Self-Heating Band?\u003c\/h3\u003e\n\n\u003col\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eOpen the package\u003c\/strong\u003e : Remove the band from the package and place it directly on the skin, in the affected area.\u003c\/li\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eApplication\u003c\/strong\u003e : Place the wrap so that it covers the painful area. The wrap begins to gradually warm within 30 minutes of opening, providing constant heat for up to 8 hours.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDuration of treatment\u003c\/strong\u003e : Use the band for at least 8 hours to obtain maximum benefit. Do not exceed continuous use beyond 8 hours in a 24 hour period.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eSafety\u003c\/strong\u003e : Do not use the band on damaged or irritated skin, and do not apply over bruises or swelling. Consult a doctor if you have any pre-existing medical conditions.\u003c\/li\u003e\n\n\n\u003c\/ol\u003e\n\n\n\u003ch2\u003e Box contents\u003c\/h2\u003e\n\n\u003ch3\u003e What's in the Thermacare XL Versatile Self-Heating Band package?\u003c\/h3\u003e\n\n\u003cp\u003e The package contains:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003e2 disposable self-heating bands\u003c\/strong\u003e designed to fit different areas of the body.\u003c\/li\u003e\n\n\u003cli\u003e Each band is individually packaged to ensure maximum hygiene and preservation of the product until use.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n     \u003ch3\u003eWhat are the warnings for Thermacare XL Versatile Self-Heating Band?\u003c\/h3\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDo not use on damaged skin\u003c\/strong\u003e : Avoid use on open wounds, bruises or swelling.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDo not use on people sensitive to heat\u003c\/strong\u003e : This device is not suitable for people with reduced thermal sensitivity or other conditions that may limit the perception of heat.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDo not reuse\u003c\/strong\u003e : This product is single use only and should not be reused.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eConsult a doctor\u003c\/strong\u003e : If you are pregnant, have diabetes or circulatory problems, consult a doctor before use.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eKeep out of reach of children\u003c\/strong\u003e .\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of the Thermacare XL Versatile Self-Heating Wrap?\u003c\/h3\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eExpiry\u003c\/strong\u003e : The expiry date is indicated on the package. Do not use the product after the date indicated.\u003c\/li\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eStorage\u003c\/strong\u003e : Store the product in a cool, dry place, away from direct sunlight and heat sources. Do not open the package until ready to use.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Format\u003c\/h2\u003e\n\n\u003cp\u003e The \u003cstrong\u003eThermacare XL Versatile Self-Heating Band\u003c\/strong\u003e is available in packs of \u003cstrong\u003e2 disposable bands\u003c\/strong\u003e .\u003c\/p\u003e\n\n","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207826059379,"sku":"981076122","price":11.31,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-spa-fascia-autoriscaldante-versatile-thermacare-xl-2-pezzi-farmacia-dottor-tili-1213793086.jpg?v=1767127750"},{"product_id":"momentact-400-mg-analgesico-20-compresse","title":"Momentact 400 mg Analgesic 20 Tablets","description":"\u003cp\u003eMomentact Tablets is an over-the-counter analgesic medicine based on ibuprofen for the \u003cstrong\u003etreatment of pain of various origins and natures\u003c\/strong\u003e such as: headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain.\u003c\/p\u003e\n\n\u003cp\u003e The 400 mg of ibuprofen in Momentact Tablets are a valid aid in the symptomatic treatment of feverish states, to \u003cstrong\u003elower the temperature and fight flu symptoms\u003c\/strong\u003e .\u003c\/p\u003e\n\n\u003cp\u003e Momentact 400 mg is indicated in adults and adolescents over 12 years of age.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Momentact 400 mg Analgesic 20 Tablets - What is the active ingredient of Momentact 400 mg Analgesic 20 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEach film-coated tablet contains; active substance: ibuprofen 400 mg. Excipients with known effect: lactose, sodium. For a full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eComposition of Momentact 400 mg Analgesic 20 Tablets - What does Momentact 400 mg Analgesic 20 Tablets contain?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePregelatinized starch, sodium starch glycolate, sodium carmellose, povidone, microcrystalline cellulose, precipitated silica, talc, sodium lauryl sulphate, lactose monohydrate, hypromellose, titanium dioxide, macrogol 4000.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Momentact 400 mg Analgesic 20 Tablets - Why is Momentact 400 mg Analgesic 20 Tablets used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eMomentact is indicated in adults and adolescents over 12 years of age. Pain of various origins and nature (headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain). Adjuvant in the symptomatic treatment of feverish and flu states.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eContraindications Momentact 400 mg Analgesic 20 Tablets - When should Momentact 400 mg Analgesic 20 Tablets not be used?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substance, to other antirheumatics (acetylsalicylic acid, etc.) or to any of the excipients listed in section 6.1; do not administer to children under 12 years of age; ibuprofen is contraindicated during the third trimester of pregnancy and during breastfeeding (see section 4.6); active or severe gastroduodenal ulcer or other gastropathies; history of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding); severe hepatic or renal insufficiency; severe cardiac insufficiency (NYHA class IV); severe dehydration (caused by vomiting, diarrhoea or insufficient fluid intake).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Momentact 400 mg Analgesic 20 Tablets - How to take Momentact 400 mg Analgesic 20 Tablets?\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage. Adults and adolescents over 12 years: 1 tablet 2-3 times a day. Do not exceed 3 tablets per day. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). If use of the medicinal product is necessary for more than 3 days in adolescents, or in case of worsening of symptoms, a doctor should be consulted. Do not exceed the recommended doses: in particular, elderly patients should adhere to the minimum dosages indicated above. Elderly: NSAIDs should be used with particular caution in elderly patients who are more prone to adverse events and are at increased risk of potentially fatal gastrointestinal bleeding, ulceration or perforation (see section 4.4). If treatment is considered necessary, the lowest dose for the shortest duration necessary to control symptoms should be used (see section 4.4). Renal impairment: In patients with mild or moderate reduction of renal function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and renal function should be monitored. Hepatic impairment: In patients with mild or moderate reduction of liver function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and liver function should be monitored. Momentact is contraindicated in patients with severe hepatic impairment (see section 4.3). Paediatric population: Momentact is contraindicated in children under 12 years of age (see section 4.3). Method of administration: Momentact can be taken on an empty stomach. In subjects with gastric tolerability problems, it is preferable to take the medicine on a full stomach.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Momentact 400 mg Analgesic 20 Tablets - How to store Momentact 400 mg Analgesic 20 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicine does not require any special storage temperatures.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Momentact 400 mg Analgesic 20 Tablets - About Momentact 400 mg Analgesic 20 Tablets it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe use of Moment Act, as with any drug inhibiting the synthesis of prostaglandins and cyclooxygenase, is not recommended in women attempting to conceive. The administration of Moment Act should be suspended in women who have fertility problems or who are undergoing investigation of fertility. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). Elderly: elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2). Cardiovascular and cerebrovascular effects: caution is required before initiating treatment in patients with a history of hypertension and\/or heart failure since fluid retention, hypertension and oedema have been reported in association with NSAID therapy. NSAIDs may reduce the effect of diuretics and other antihypertensive drugs (see section 4.5). Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low doses of ibuprofen (e.g. \u0026lt;= 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration should also be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses (2400 mg\/day) of ibuprofen are required. Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration. Similar consideration should be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking). Gastrointestinal bleeding, ulceration and perforation: the use of Momentact should be avoided in combination with NSAIDs, including cyclooxygenase-2 (COX-2) selective inhibitors due to the increased risk of ulceration or bleeding (see section 4.5). In particular, gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest dose available. Concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant acetylsalicylic acid or other drugs likely to increase GI risk (see below and section 4.5). Patients with a history of GI toxicity, particularly when elderly, should report any unusual GI symptoms (especially GI bleeding) particularly in the initial stages of treatment. Carefully monitor patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients receiving Momentact, the treatment should be withdrawn. NSAIDs should be given with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Severe skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk early in the course of therapy: the onset of the reaction occurs in the majority of cases within the first month of treatment. Acute generalized exanthematous pustulosis (AGEP) has been reported in relation to medicinal products containing ibuprofen. Ibuprofen should be discontinued at the first appearance of signs and symptoms of severe skin reactions, such as rash, mucosal lesions or any other sign of hypersensitivity as well as if visual disturbances or persistent signs of liver dysfunction occur. Renal effects: Caution should be exercised when initiating treatment with ibuprofen in patients with considerable dehydration. Ibuprofen may cause water and sodium and potassium retention in patients with no history of renal disease due to its effects on renal perfusion. This may cause oedema or cardiac failure or hypertension in predisposed patients. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other pathological renal changes. In general, the habitual use of analgesics, especially combinations of several analgesic active ingredients, can lead to permanent renal damage, with the risk of onset of renal failure (analgesic nephropathy). Renal toxicity has been observed in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. The administration of NSAIDs in these patients may lead to a dose-dependent reduction in prostaglandin formation and, as a secondary effect, renal blood flow, which can quickly lead to renal failure.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Momentact 400 mg Analgesic 20 Tablets - Which medicines or foods can modify the effect of Momentact 400 mg Analgesic 20 Tablets?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIt is advisable to seek medical advice in case of any concomitant therapy before administering the product. Ibuprofen (like other NSAIDs) should be taken with caution in combination with the substances listed below. Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4). Anticoagulants: NSAIDs may enhance the effects of anticoagulants, such as warfarin or heparin (see section 4.4). In case of concomitant treatment, monitoring of the coagulation status is recommended. Cyclooxygenase-2 (COX-2) inhibitors and other NSAIDs: these substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). It is advisable not to combine ibuprofen with other NSAIDs, including selective COX-2 inhibitors, due to the potential additive effect (see section 4.4). Acetylsalicylic acid: Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit platelet aggregation with low dose acetylsalicylic acid when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1). Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4). Diuretics, ACE inhibitors (such as captopril), beta blockers and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of neurotoxicity associated with NSAIDs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit cyclooxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Momentact concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and thereafter. Phenytoin and lithium: Concomitant administration of ibuprofen and phenytoin or lithium preparations may result in reduced elimination of these drugs with consequent increase in their plasma levels with the possibility of reaching the toxic threshold. If this combination is deemed necessary, monitoring of plasma levels of phenytoin and lithium is recommended in order to adapt the appropriate dosage during concomitant treatment with ibuprofen. Methotrexate: NSAIDs may inhibit the tubular secretion of methotrexate and some metabolic interactions may occur resulting in reduced clearance of methotrexate and consequent increase in the risk of toxicity. Moclobemide: increases ibuprofen. Aminoglycosides: NSAIDs may decrease the excretion of aminoglycosides increasing toxicity. Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides. Monitoring of serum glycoside levels is recommended. Cholestyramine: Concomitant administration of ibuprofen and cholestyramine may reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is unknown. Ciclosporin: Concomitant administration of ciclosporin and some NSAIDs causes an increased risk of renal damage. This effect cannot be excluded for the combination of ciclosporin and ibuprofen. Plant extracts: Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs. Mifepristone: Due to the anti-prostaglandin properties of NSAIDs, their use after mifepristone administration may result in a reduction of mifepristone. Limited evidence suggests that co-administration of NSAIDs and prostaglandins on the same day does not adversely affect the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination. Quinolone antibiotics: Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions. Sulfonylureas: NSAIDs may increase the hypoglycaemic effect of sulfonylureas. Monitoring of blood glucose levels is recommended in the case of simultaneous treatment. Tacrolimus: Co-administration of NSAIDs and tacrolimus may increase the risk of nephrotoxicity. Zidovudine: There is evidence of an increased risk of haemarthrosis and haematoma in HIV-positive haemophiliac patients receiving concomitant treatment with zidovudine and other NSAIDs. A blood test is recommended 1-2 weeks after starting treatment. Ritonavir: may cause an increase in plasma concentrations of NSAIDs. Probenecid: slows the excretion of ibuprofen, with possible increase in their plasma concentrations. CYP2C9 inhibitors: Concomitant administration of ibuprofen and CYP2C9 inhibitors may slow the elimination of ibuprofen (CYP2C9 substrate) resulting in increased exposure to ibuprofen. In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)-ibuprofen of approximately 80% to 100% was observed. Consideration should be given to reducing the dose of ibuprofen when co-administered with strong CYP2C9 inhibitors, particularly when high doses of ibuprofen are administered with voriconazole or fluconazole. Alcohol, bisphosphonates and oxypentifylline (pentoxifylline): may enhance gastrointestinal side effects and the risk of bleeding and ulceration. Baclofen: high toxicity of baclofen.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Momentact 400 mg Analgesic 20 Tablets can cause side effects - What are the side effects of Momentact 400 mg Analgesic 20 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe undesirable effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and are reported below using the following convention: very common (\u0026gt;=1\/10); common (\u0026gt;=1\/100, \u0026lt; 1\/10); uncommon (\u0026gt;= 1\/ 1,000, \u0026lt; 1\/100); rare (\u0026gt;=1\/10,000, \u0026lt; 1\/1,000); very rare (\u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data). The most commonly observed adverse events are gastrointestinal in nature. Clinical trial and epidemiological data suggest that the use of ibuprofen (particularly at high doses 2400 mg\/day) and in long-term treatment may be associated with a modest increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Gastrointestinal disorders: Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Gastrointestinal perforation with the use of ibuprofen has been observed rarely. Following administration of ibuprofen, the following have been reported: feeling of heaviness in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Uncommon: gastritis; very rare: pancreatitis. Immune system disorders. The following undesirable effects have been reported following treatment with NSAIDs: non-specific allergic reaction and anaphylaxis; uncommon: hypersensitivity reactions such as rash of various types, urticaria, pruritus, purpura, angioedema, exanthema, respiratory tract reactions including asthma, including severe asthma, bronchospasm or dyspnoea, asthmatic attack (sometimes with hypotension); rare: lupus erythematosus syndrome; very rare: severe hypersensitivity reactions. Symptoms may include: facial oedema, tongue oedema, laryngeal oedema, airway oedema with constriction, dyspnoea, tachycardia, anaphylaxis, exfoliative and bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). Cardiac and vascular disorders: oedema, fatigue, hypertension and cardiac failure have been reported in association with NSAID treatment. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Very rare: palpitations, heart failure, myocardial infarction, acute pulmonary oedema, oedema, hypertension. These phenomena generally tend to regress on discontinuation of treatment. Other adverse events reported less frequently and for which causality has not necessarily been established include: Blood and lymphatic system disorders: Rare: leucopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia. Psychiatric disorders: Uncommon: insomnia, anxiety; rare: depression, confusional state, hallucinations. Nervous system disorders: Common: dizziness; uncommon: paraesthesia, somnolence; rare: optic neuritis. Infections and infestations. Uncommon: rhinitis; rare: aseptic meningitis. Rhinitis and aseptic meningitis (especially in patients with pre-existing autoimmune disorders, such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). Exacerbation of infection-related inflammation (e.g. development of necrotising fasciitis) has been described. Respiratory, thoracic and mediastinal disorders. Uncommon: bronchospasm, dyspnoea, apnoea. Eye disorders. Uncommon: visual disturbances; rare: ocular impairment resulting in visual disturbances, toxic optic neuropathy. Ear and labyrinth disorders. Uncommon: hearing impaired, tinnitus, vertigo. Hepatobiliary disorders. Uncommon: abnormal liver function, hepatitis and jaundice; very rare: liver failure. Skin and subcutaneous tissue disorders: Allergic skin rashes (erythema, pruritus, urticaria) may occasionally occur. Uncommon: photosensitivity reactions; very rare: bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. In exceptional cases, serious skin infections and soft tissue disorders may occur during varicella infection (see \"\"infections and infestations\"\"). Not known: drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), acute generalized exanthematous pustulosis (AGEP). Renal and urinary disorders: Uncommon: renal function impairment and toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure. General disorders and administration site conditions: Common: malaise, fatigue; rare: oedema. Reporting of suspected adverse reactions Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Momentact 400 mg Analgesic 20 Tablets.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. From the twentieth week of pregnancy onwards, the use of Momentact may cause oligohydramnios resulting from fetal renal dysfunction. This may occur soon after initiation of treatment and is usually reversible upon discontinuation. In addition, cases of constriction of the ductus arteriosus have been reported following treatment in the second trimester, most of which resolved upon discontinuation of treatment. Therefore, during the first and second trimester of pregnancy, Momentact should not be administered unless clearly necessary. If Momentact is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. Antenatal monitoring for oligohydramnios and constriction of the ductus arteriosus should be considered following exposure to Moment Act for several days of gestational week 20 onwards. Momentact should be discontinued if oligohydramnios or constriction of the ductus arteriosus is observed. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (premature constriction\/closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction (see above); at the end of pregnancy, all prostaglandin synthesis inhibitors may expose the mother and the neonate to: possible prolongation of bleeding time, and anti-aggregating effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, Momentact is contraindicated during the third trimester of pregnancy (see sections 4.3 and 5.3). Breast-feeding: ibuprofen is excreted in breast milk, but at therapeutic doses during short-term treatment, the risk of influence on the neonate seems unlikely. If, however, treatment is longer term, early weaning should be considered. NSAIDs should be avoided during breast-feeding. Fertility: The use of Ibuprofen may impair female fertility and is not recommended in women attempting to conceive. This effect is reversible upon discontinuation of treatment. In women who have difficulties conceiving or who are undergoing investigation of infertility, discontinuation of ibuprofen should be considered.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":40207837298803,"sku":"035618053","price":13.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-momentact-400-mg-analgesico-20-compresse-farmacia-dottor-tili-1213793024.webp?v=1767129047"},{"product_id":"momentact-400-mg-analgesico-12-compresse","title":"Momentact 400 mg Analgesic 12 Tablets","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMomentact Tablets is an over-the-counter analgesic medicine based on ibuprofen for the\u003c\/span\u003e \u003cstrong\u003etreatment of pain of various origins and natures\u003c\/strong\u003e \u003cspan\u003esuch as: headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThe 400 mg of ibuprofen in Momentact Tablets are a valid aid in the symptomatic treatment of feverish states, to\u003c\/span\u003e \u003cspan\u003elower the temperature and fight flu symptoms\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eMomentact 400 mg is indicated in adults and adolescents over 12 years of age.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Momentact 400 mg Analgesic 12 Tablets - What is the active ingredient of Momentact 400 mg Analgesic 12 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEach film-coated tablet contains; active substance: ibuprofen 400 mg. Excipients with known effect: lactose, sodium. For a full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eComposition of Momentact 400 mg Analgesic 12 Tablets - What does Momentact 400 mg Analgesic 12 Tablets contain?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePregelatinized starch, sodium starch glycolate, sodium carmellose, povidone, microcrystalline cellulose, precipitated silica, talc, sodium lauryl sulphate, lactose monohydrate, hypromellose, titanium dioxide, macrogol 4000.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Momentact 400 mg Analgesic 12 Tablets - Why is Momentact 400 mg Analgesic 12 Tablets used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eMomentact is indicated in adults and adolescents over 12 years of age. Pain of various origins and nature (headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain). Adjuvant in the symptomatic treatment of feverish and flu states.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eContraindications Momentact 400 mg Analgesic 12 Tablets - When should Momentact 400 mg Analgesic 12 Tablets not be used?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substance, to other antirheumatics (acetylsalicylic acid, etc.) or to any of the excipients listed in section 6.1; do not administer to children under 12 years of age; ibuprofen is contraindicated during the third trimester of pregnancy and during breastfeeding (see section 4.6); active or severe gastroduodenal ulcer or other gastropathies; history of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding); severe hepatic or renal insufficiency; severe cardiac insufficiency (NYHA class IV); severe dehydration (caused by vomiting, diarrhoea or insufficient fluid intake).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Momentact 400 mg Analgesic 12 Tablets - How to take Momentact 400 mg Analgesic 12 Tablets?\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage. Adults and adolescents over 12 years: 1 tablet 2-3 times a day. Do not exceed 3 tablets per day. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). If use of the medicinal product is necessary for more than 3 days in adolescents, or in case of worsening of symptoms, a doctor should be consulted. Do not exceed the recommended doses: in particular, elderly patients should adhere to the minimum dosages indicated above. Elderly: NSAIDs should be used with particular caution in elderly patients who are more prone to adverse events and are at increased risk of potentially fatal gastrointestinal bleeding, ulceration or perforation (see section 4.4). If treatment is considered necessary, the lowest dose for the shortest duration necessary to control symptoms should be used (see section 4.4). Renal impairment: In patients with mild or moderate reduction of renal function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and renal function should be monitored. Hepatic impairment: In patients with mild or moderate reduction of liver function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and liver function should be monitored. Momentact is contraindicated in patients with severe hepatic impairment (see section 4.3). Paediatric population: Momentact is contraindicated in children under 12 years of age (see section 4.3). Method of administration: Momentact can be taken on an empty stomach. In subjects with gastric tolerability problems, it is preferable to take the medicine on a full stomach.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Momentact 400 mg Analgesic 12 Tablets - How to store Momentact 400 mg Analgesic 12 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicine does not require any special storage temperatures.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Momentact 400 mg Analgesic 12 Tablets - About Momentact 400 mg Analgesic 12 Tablets it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe use of Moment Act, as with any drug inhibiting the synthesis of prostaglandins and cyclooxygenase, is not recommended in women attempting to conceive. The administration of Moment Act should be suspended in women who have fertility problems or who are undergoing investigation of fertility. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). Elderly: elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2). Cardiovascular and cerebrovascular effects: caution is required before initiating treatment in patients with a history of hypertension and\/or heart failure since fluid retention, hypertension and oedema have been reported in association with NSAID therapy. NSAIDs may reduce the effect of diuretics and other antihypertensive drugs (see section 4.5). Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low dose ibuprofen (e.g. \u0026lt;= 1200 mg\/day) is associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration should also be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses (2400 mg\/day) of ibuprofen are required. Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration. Similar consideration should be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking). Gastrointestinal bleeding, ulceration and perforation: the use of Momentact should be avoided in combination with NSAIDs, including cyclooxygenase-2 (COX-2) selective inhibitors due to the increased risk of ulceration or bleeding (see section 4.5). In particular, gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest dose available. Concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant acetylsalicylic acid or other drugs likely to increase GI risk (see below and section 4.5). Patients with a history of GI toxicity, particularly when elderly, should report any unusual GI symptoms (especially GI bleeding) particularly in the initial stages of treatment. Carefully monitor patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients receiving Momentact, the treatment should be withdrawn. NSAIDs should be given with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Severe skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk early in the course of therapy: the onset of the reaction occurs in the majority of cases within the first month of treatment. Acute generalized exanthematous pustulosis (AGEP) has been reported in relation to medicinal products containing ibuprofen. Ibuprofen should be discontinued at the first appearance of signs and symptoms of severe skin reactions, such as rash, mucosal lesions or any other sign of hypersensitivity as well as if visual disturbances or persistent signs of liver dysfunction occur. Renal effects: Caution should be exercised when initiating treatment with ibuprofen in patients with considerable dehydration. Ibuprofen may cause water and sodium, potassium retention in patients with no history of renal disease due to its effects on renal perfusion. This may cause oedema or cardiac failure or hypertension in predisposed patients. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other pathological renal changes. In general, the habitual use of analgesics, especially combinations of several analgesic active ingredients, can lead to permanent renal damage, with risk of renal failure (analgesic nephropathy). Renal toxicity has been observed in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. The administration of NSAIDs in these patients may lead to a dose-dependent reduction in prostaglandin formation and, as a secondary effect, renal blood flow, which can quickly lead to renal failure.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Momentact 400 mg Analgesic 12 Tablets - Which medicines or foods can modify the effect of Momentact 400 mg Analgesic 12 Tablets?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIt is advisable to seek medical advice in case of any concomitant therapy before administering the product. Ibuprofen (like other NSAIDs) should be taken with caution in combination with the substances listed below. Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4). Anticoagulants: NSAIDs may enhance the effects of anticoagulants, such as warfarin or heparin (see section 4.4). In case of concomitant treatment, monitoring of the coagulation status is recommended. Cyclooxygenase-2 (COX-2) inhibitors and other NSAIDs: these substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). It is advisable not to combine ibuprofen with other NSAIDs, including selective COX-2 inhibitors, due to the potential additive effect (see section 4.4). Acetylsalicylic acid: Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit platelet aggregation with low dose acetylsalicylic acid when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1). Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4). Diuretics, ACE inhibitors (such as captopril), beta blockers and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of neurotoxicity associated with NSAIDs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit cyclooxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Momentact concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and thereafter. Phenytoin and lithium: Concomitant administration of ibuprofen and phenytoin or lithium preparations may result in reduced elimination of these drugs with consequent increase in their plasma levels with the possibility of reaching the toxic threshold. If this combination is deemed necessary, monitoring of plasma levels of phenytoin and lithium is recommended in order to adapt the appropriate dosage during concomitant treatment with ibuprofen. Methotrexate: NSAIDs may inhibit the tubular secretion of methotrexate and some metabolic interactions may occur resulting in reduced clearance of methotrexate and consequent increase in the risk of toxicity. Moclobemide: increases ibuprofen. Aminoglycosides: NSAIDs may decrease the excretion of aminoglycosides increasing toxicity. Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides. Monitoring of serum glycoside levels is recommended. Cholestyramine: Concomitant administration of ibuprofen and cholestyramine may reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is unknown. Ciclosporin: Concomitant administration of ciclosporin and some NSAIDs causes an increased risk of renal damage. This effect cannot be excluded for the combination of ciclosporin and ibuprofen. Plant extracts: Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs. Mifepristone: Due to the anti-prostaglandin properties of NSAIDs, their use after mifepristone administration may result in a reduction of mifepristone. Limited evidence suggests that co-administration of NSAIDs and prostaglandins on the same day does not adversely affect the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination. Quinolone antibiotics: Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions. Sulfonylureas: NSAIDs may increase the hypoglycaemic effect of sulfonylureas. Monitoring of blood glucose levels is recommended in the case of simultaneous treatment. Tacrolimus: Co-administration of NSAIDs and tacrolimus may increase the risk of nephrotoxicity. Zidovudine: There is evidence of an increased risk of haemarthrosis and haematoma in HIV-positive haemophiliac patients receiving concomitant treatment with zidovudine and other NSAIDs. A blood test is recommended 1-2 weeks after starting treatment. Ritonavir: may cause an increase in plasma concentrations of NSAIDs. Probenecid: slows the excretion of ibuprofen, with possible increase in their plasma concentrations. CYP2C9 inhibitors: Concomitant administration of ibuprofen and CYP2C9 inhibitors may slow the elimination of ibuprofen (CYP2C9 substrate) resulting in increased exposure to ibuprofen. In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)-ibuprofen of approximately 80% to 100% was observed. Consideration should be given to reducing the dose of ibuprofen when co-administered with strong CYP2C9 inhibitors, particularly when high doses of ibuprofen are administered with voriconazole or fluconazole. Alcohol, bisphosphonates and oxypentifylline (pentoxifylline): may enhance gastrointestinal side effects and the risk of bleeding and ulceration. Baclofen: high toxicity of baclofen.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Momentact 400 mg Analgesic 12 Tablets can cause side effects - What are the side effects of Momentact 400 mg Analgesic 12 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe undesirable effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and are reported below using the following convention: very common (\u0026gt;=1\/10); common (\u0026gt;=1\/100, \u0026lt; 1\/10); uncommon (\u0026gt;= 1\/ 1,000, \u0026lt; 1\/100); rare (\u0026gt;=1\/10,000, \u0026lt; 1\/1,000); very rare (\u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data). The most commonly observed adverse events are gastrointestinal in nature. Clinical trial and epidemiological data suggest that the use of ibuprofen (particularly at high doses 2400 mg\/day) and in long-term treatment may be associated with a modest increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Gastrointestinal disorders: Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Gastrointestinal perforation with the use of ibuprofen has been observed rarely. Following administration of ibuprofen, the following have been reported: feeling of heaviness in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Uncommon: gastritis; very rare: pancreatitis. Immune system disorders. The following undesirable effects have been reported following treatment with NSAIDs: non-specific allergic reaction and anaphylaxis; uncommon: hypersensitivity reactions such as rash of various types, urticaria, pruritus, purpura, angioedema, exanthema, respiratory tract reactions including asthma, including severe asthma, bronchospasm or dyspnoea, asthmatic attack (sometimes with hypotension); rare: lupus erythematosus syndrome; very rare: severe hypersensitivity reactions. Symptoms may include: facial oedema, tongue oedema, laryngeal oedema, airway oedema with constriction, dyspnoea, tachycardia, anaphylaxis, exfoliative and bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). Cardiac and vascular disorders: oedema, fatigue, hypertension and cardiac failure have been reported in association with NSAID treatment. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Very rare: palpitations, heart failure, myocardial infarction, acute pulmonary oedema, oedema, hypertension. These phenomena generally tend to regress on discontinuation of treatment. Other adverse events reported less frequently and for which causality has not necessarily been established include: Blood and lymphatic system disorders: Rare: leucopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia. Psychiatric disorders: Uncommon: insomnia, anxiety; rare: depression, confusional state, hallucinations. Nervous system disorders: Common: dizziness; uncommon: paraesthesia, somnolence; rare: optic neuritis. Infections and infestations. Uncommon: rhinitis; rare: aseptic meningitis. Rhinitis and aseptic meningitis (especially in patients with pre-existing autoimmune disorders, such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). Exacerbation of infection-related inflammation (e.g. development of necrotising fasciitis) has been described. Respiratory, thoracic and mediastinal disorders. Uncommon: bronchospasm, dyspnoea, apnoea. Eye disorders. Uncommon: visual disturbances; rare: ocular impairment resulting in visual disturbances, toxic optic neuropathy. Ear and labyrinth disorders. Uncommon: hearing impaired, tinnitus, vertigo. Hepatobiliary disorders. Uncommon: abnormal liver function, hepatitis and jaundice; very rare: liver failure. Skin and subcutaneous tissue disorders: Allergic skin rashes (erythema, pruritus, urticaria) may occasionally occur. Uncommon: photosensitivity reactions; very rare: bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. In exceptional cases, serious skin infections and soft tissue disorders may occur during varicella infection (see \"\"infections and infestations\"\"). Not known: drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), acute generalized exanthematous pustulosis (AGEP). Renal and urinary disorders: Uncommon: renal function impairment and toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure. General disorders and administration site conditions: Common: malaise, fatigue; rare: oedema. Reporting of suspected adverse reactions Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Momentact 400 mg Analgesic 12 Tablets.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. From the twentieth week of pregnancy onwards, the use of Momentact may cause oligohydramnios resulting from fetal renal dysfunction. This may occur soon after initiation of treatment and is usually reversible upon discontinuation. In addition, cases of constriction of the ductus arteriosus have been reported following treatment in the second trimester, most of which resolved upon discontinuation of treatment. Therefore, during the first and second trimester of pregnancy, Momentact should not be administered unless clearly necessary. If Momentact is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. Antenatal monitoring for oligohydramnios and constriction of the ductus arteriosus should be considered following exposure to Moment Act for several days of gestational week 20 onwards. Momentact should be discontinued if oligohydramnios or constriction of the ductus arteriosus is observed. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (premature constriction\/closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction (see above); at the end of pregnancy, all prostaglandin synthesis inhibitors may expose the mother and the neonate to: possible prolongation of bleeding time, and anti-aggregating effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, Momentact is contraindicated during the third trimester of pregnancy (see sections 4.3 and 5.3). Breast-feeding: ibuprofen is excreted in breast milk, but at therapeutic doses during short-term treatment, the risk of influence on the neonate seems unlikely. If, however, treatment is longer term, early weaning should be considered. NSAIDs should be avoided during breast-feeding. Fertility: The use of Ibuprofen may impair female fertility and is not recommended in women attempting to conceive. This effect is reversible upon discontinuation of treatment. In women who have difficulties conceiving or who are undergoing investigation of infertility, discontinuation of ibuprofen should be considered.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":46374894371143,"sku":"035618026","price":10.7,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-momentact-400-mg-analgesico-12-compresse-farmacia-dottor-tili-1213792494.webp?v=1767112308"},{"product_id":"momendol-200mg-antinfiammatorio-24-compresse-rivestite","title":"Momendol 200mg Anti-inflammatory 24 Coated Tablets","description":"\u003cp\u003eMomendol Tablets is an over-the-counter medicine based on Naproxen which is used in the short-term symptomatic treatment of \u003cstrong\u003emild to moderate pain\u003c\/strong\u003e and in the \u003cstrong\u003etreatment of fever\u003c\/strong\u003e .\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp\u003e Momendol is an anti-inflammatory useful for treating \u003cstrong\u003emuscle and joint pain, headache, toothache and menstrual pain\u003c\/strong\u003e . Momendol Naproxen 200mg Anti-inflammatory 24 Tablets also has \u003cstrong\u003eantipyretic action\u003c\/strong\u003e , useful for \u003cstrong\u003econtrolling temperature and treating flu symptoms\u003c\/strong\u003e .\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Momendol 200mg Anti-inflammatory 24 Coated Tablets - What is the active ingredient of Momendol 200mg Anti-inflammatory 24 Coated Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eNaproxen 200 mg (corresponding to naproxen sodium 220 mg).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eComposition of Momendol 200mg Anti-inflammatory 24 Coated Tablets - What does Momendol 200mg Anti-inflammatory 24 Coated Tablets contain?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTablet core: lactose monohydrate, maize starch, microcrystalline cellulose, povidone (K25), sodium starch glycolate, colloidal anhydrous silica, magnesium stearate. Film-coating: hypromellose, macrogol 400, titanium dioxide (E171), talc.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Momendol 200mg Anti-inflammatory 24 Coated Tablets - Why is Momendol 200mg Anti-inflammatory 24 Coated Tablets used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eIt is indicated in adults and adolescents over 16 years of age for the short-term symptomatic treatment of mild to moderate pain such as muscle and joint pain, headache, toothache and menstrual pain. It can also be used in the treatment of fever.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eContraindications Momendol 200mg Anti-inflammatory 24 Coated Tablets - When should Momendol 200mg Anti-inflammatory 24 Coated Tablets not be used?\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients or to other active substances closely related to naproxen from a chemical point of view. Naproxen is contraindicated in patients with allergic manifestations, such as asthma, urticaria, rhinitis, nasal polyps, angioedema, and anaphylactic or anaphylactoid reactions induced by acetylsalicylic acid, analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs) and\/or antirheumatics, due to possible cross-sensitivity. Naproxen is contraindicated in patients with gastrointestinal bleeding or perforation related to previous treatment with nonsteroidal anti-inflammatory drugs, active or previous recurrent peptic ulcer\/hemorrhage, chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease), severe hepatic insufficiency, severe cardiac insufficiency, severe renal insufficiency (creatinine clearance \u0026lt; 30 ml\/min), angioedema, during intensive therapy with diuretics, and in subjects with active hemorrhage and at risk of hemorrhage during therapy with anticoagulants. - Third trimester of pregnancy and breastfeeding. Contraindicated in children under 12 years.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Momendol 200mg Anti-inflammatory 24 Coated Tablets - How to take Momendol 200mg Anti-inflammatory 24 Coated Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eAdults and adolescents over 16 years: 1 film-coated tablet every 8-12 hours. If necessary, a better effect can be obtained by starting, on the first day, with 2 film-coated tablets followed by 1 film-coated tablet after 8-12 hours. Do not exceed 3 film-coated tablets in 24 hours. Elderly\/Renal impairment. Elderly patients and patients with mild or moderate renal impairment should not exceed 2 film-coated tablets in 24 hours. Paediatric population. The drug is contraindicated in children under 12 years. Method of administration. The drug should preferably be taken after a meal. Swallow the tablets whole with water. Do not use for more than 7 days for pain and for more than 3 days for fever. Patients should be advised to consult a doctor if pain and fever persist or worsen.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eStorage Momendol 200mg Anti-inflammatory 12 Coated Tablets - How to store Momendol 200mg Anti-inflammatory 24 Coated Tablets?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eStore in the original package in order to protect from light and moisture.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Momendol 200mg Anti-inflammatory 24 Coated Tablets - About Momendol 200mg Anti-inflammatory 24 Coated Tablets it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eUndesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see gastrointestinal and cardiovascular risks below). Clinical trial and epidemiological data suggest that use of coxibs and some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Although some data suggest that use of naproxen (1000 mg\/day) may be associated with a lower risk, some risks cannot be excluded. There are insufficient data on the effects of naproxen at low doses (600 mg\/day) to draw definitive conclusions on possible thrombotic risks. There is a close correlation between dosage and the occurrence of severe gastrointestinal undesirable effects. Therefore, the lowest effective dosage should always be used. Caution is required (discuss with your doctor or pharmacist) before starting treatment in patients with a history of hypertension and\/or heart failure since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Diuresis and renal function must be carefully monitored, particularly in the elderly, in patients with chronic congestive heart failure or chronic renal failure, in patients treated with diuretics, or following major surgery involving hypovolemia. In patients with severe heart failure, worsening of conditions may occur. Particular caution is advised in patients with a history of gastrointestinal disease or liver failure and in patients with current or previous allergic manifestations, as in these subjects the product may cause bronchospasm, asthma, or other allergic phenomena. If visual disturbances occur, treatment with Momendol must be suspended. In association with the use of NSAIDs, serious skin reactions, some of them fatal, such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely. Patients appear to be at highest risk early in the course of therapy: the onset of the reaction occurs in the majority of cases within the first month of treatment. Momendol should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Naproxen, like any other NSAID, may mask the symptoms of concomitant infectious diseases. In isolated cases, exacerbation of infectious-based inflammation has been reported in temporal connection with the use of NSAIDs (e.g. development of necrotizing fasciitis). Gastrointestinal bleeding, ulceration and perforation, which may be fatal, have been reported at any time during treatment with all NSAIDs, with or without warning symptoms or a previous history of serious gastrointestinal events. The risk of GI bleeding, ulceration or perforation is higher with increasing doses of NSAIDs, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation. These patients should start treatment on the lowest dose available. The possible concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients taking low dose aspirin or other drugs likely to increase gastrointestinal risk. Patients with a history of GI toxicity, particularly when elderly, should report any unusual GI symptoms (especially GI bleeding) particularly in the initial stages of treatment. Caution should be exercised in patients taking concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as aspirin. In patients receiving the drug, treatment should be discontinued if gastrointestinal bleeding or ulceration occurs. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be aggravated. Use should be avoided in combination with NSAIDs, including selective COX-2 inhibitors. Elderly patients, who generally have some degree of renal, hepatic and cardiac function impairment, are more exposed to the risk of developing adverse effects related to the use of NSAIDs, especially gastrointestinal bleeding and perforation which may be fatal. Prolonged use of NSAIDs in the elderly is not recommended. Naproxen inhibits platelet aggregation and may prolong bleeding time. Patients with coagulation disorders or on therapy with medicinal products that interfere with haemostasis should be carefully monitored while taking Momendol. Caution is advised in habitual consumers of high daily doses of alcohol, due to the risk of gastric bleeding. The use of the product should be avoided in cases of pain of gastrointestinal origin. This medicinal product contains: - Lactose: patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Sodium: this medicinal product contains 23 mg sodium per tablet equivalent to 1.15% of the WHO recommended maximum daily intake of 2 g sodium for an adult.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Momendol 200mg Anti-inflammatory 24 Coated Tablets - Which medicines or foods can modify the effect of Momendol 200mg Anti-inflammatory 24 Coated Tablets?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eAdministration of naproxen with other NSAIDs or corticosteroids is not recommended as it increases the risk of ulcers and gastro-duodenal bleeding. Acetylsalicylic acid. Clinical pharmacodynamic data show that concomitant use of naproxen for more than one consecutive day may inhibit low-dose acetylsalicylic acid on platelet activity and this inhibition may persist for several days after discontinuation of treatment with naproxen. The clinical relevance of this interaction is unknown. Naproxen may increase anticoagulants, such as coumarin-type anticoagulants (e.g. warfarin, dicoumarol) because it prolongs prothrombin time and reduces platelet aggregation, increasing the risk of gastrointestinal bleeding. The combination of naproxen and lithium should be avoided; when necessary, closer monitoring of lithium plasma levels and dosage adjustment are recommended. Combinations to be used with caution. Due to the high binding of naproxen to plasma proteins, caution is advised in concomitant treatment with hydantoins or sulphonamides. Particular caution should also be exercised in patients treated with ciclosporin, tacrolimus, sulfonylureas, loop diuretics, methotrexate, beta-blockers, ACE inhibitors, probenecid, thiazide diuretics and digoxin. Naproxen may alter bleeding time (which may be increased up to 4 days after discontinuation of therapy), creatinine clearance (may decrease), azotemia and blood levels of creatinine and potassium (may increase), liver function tests (an increase in transaminases may be observed). Naproxen may induce false positives in the determination of urinary values ​​of 17-ketosteroid and may interfere with urinary determinations of 5-hydroxy-indoleacetic acid. Naproxen therapy should be discontinued at least 72 hours before performing adrenal function tests.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Momendol 200mg Anti-inflammatory 24 Coated Tablets can cause side effects - What are the side effects of Momendol 200mg Anti-inflammatory 24 Coated Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following undesirable effects have been reported with NSAIDs and naproxen. The most commonly observed undesirable effects are gastrointestinal in nature. Clinical trial and epidemiological data suggest that use of coxibs and some NSAIDs (particularly at high doses and in long-term treatment) may be associated with a modest increased risk of arterial thrombotic events (for example myocardial infarction or stroke). The undesirable effects are listed below, organised according to MedDRA system organ class. The following rating scales have been used: very common (\u0026gt;1\/10); common (\u0026gt;1\/100, \u0026lt;1\/10); uncommon (\u0026gt;1\/1,000, \u0026lt;1\/100); rare (\u0026gt;1\/10,000, \u0026lt;1\/1,000); very rare (\u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data). Blood and lymphatic system disorders Very rare: aplastic or haemolytic anaemia, thrombocytopenia, granulocytopenia. Immune system disorders. Uncommon: allergic reaction (including facial oedema and angioedema). Psychiatric disorders. Uncommon: sleep disturbances, excitation. Nervous system disorders. Common: headache, somnolence, dizziness; very rare: meningitis-like reaction. Eye disorders. Uncommon: visual disturbances. Ear and labyrinth disorders. Uncommon: tinnitus, hearing impairment. Cardiac disorders. Very rare: tachycardia, oedema, hypertension and cardiac failure have been observed in association with NSAID treatment. Vascular disorders. Uncommon: contusion. Respiratory, thoracic and mediastinal disorders. Very rare: dyspnoea, asthma. Gastrointestinal disorders. Common: nausea, dyspepsia, vomiting, heartburn, gastralgia, flatulence; uncommon: diarrhoea, constipation; rare: peptic ulcer, perforation or gastrointestinal bleeding, sometimes fatal, may occur especially in the elderly (see section 4.4), haematemesis, ulcerative stomatitis, aggravated colitis, aggravated Crohn's disease; very rare: colitis, stomatitis. Less frequently, gastritis has been observed. Hepatobiliary disorders. Very rare: jaundice, hepatitis, decreased liver function. Skin and subcutaneous tissue disorders. Uncommon: rash\/pruritus; very rare: photosensitivity, alopecia, bullous disorder including Stevens-Johnson syndrome and toxic epidermal necrolysis. Renal and urinary disorders. Uncommon: abnormal renal function. General disorders and administration site conditions. Uncommon: chills, oedema (including peripheral oedema). Investigations. Very rare: blood pressure increased. As with other NSAIDs, allergic reactions of anaphylactic or anaphylactoid type may occur in patients with or without previous exposure to drugs belonging to this class. The characteristic symptoms of an anaphylactic reaction are: severe and sudden hypotension, acceleration or slowing of the heartbeat, unusual tiredness or weakness, anxiety, agitation, loss of consciousness, difficulty in breathing or swallowing, itching, urticaria with or without angioedema, redness of the skin, nausea, vomiting, crampy abdominal pain, diarrhoea. Report any suspected adverse reactions via the national reporting system.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Momendol 200mg Anti-inflammatory 24 Coated Tablets.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eInhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or embryo\/fetal development. Results of epidemiological studies report an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The risk is believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss, and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, naproxen should not be administered unless clearly necessary. If naproxen is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the neonate, at the end of pregnancy, to: possible prolongation of bleeding time, and antiaggregant effect which may appear even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Therefore, naproxen is contraindicated during the third trimester of pregnancy. Since NSAIDs are excreted in breast milk, as a precautionary measure their use is contraindicated during breastfeeding. There is some evidence that drugs that inhibit the synthesis of prostaglandins and cyclooxygenase may cause problems with female fertility, through an effect on ovulation. This effect is reversible upon discontinuation of treatment.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":46656124649799,"sku":"025829185","price":13.3,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-momendol-200mg-antinfiammatorio-24-compresse-rivestite-farmacia-dottor-tili-1213792489.jpg?v=1767112598"},{"product_id":"momendol-200mg-antinfiammatorio-12-compresse-rivestite","title":"Momendol 200mg Anti-inflammatory 12 Coated Tablets","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMomendol Tablets is an over-the-counter medicine based on Naproxen which is used in the short-term symptomatic treatment of\u003c\/span\u003e \u003cspan\u003emild to moderate pain\u003c\/span\u003e \u003cspan\u003eand in the\u003c\/span\u003e \u003cspan\u003etreatment of fever\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eMomendol is an anti-inflammatory useful for treating\u003c\/span\u003e \u003cspan\u003emuscle and joint pain, headache, toothache and menstrual pain\u003c\/span\u003e \u003cspan\u003e. Momendol Naproxen 200 mg Anti-inflammatory 12 Tablets also has\u003c\/span\u003e \u003cspan\u003eantipyretic action\u003c\/span\u003e \u003cspan\u003e, useful for\u003c\/span\u003e \u003cspan\u003econtrolling temperature and treating flu symptoms\u003c\/span\u003e \u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Momendol 200 mg Anti-inflammatory 12 Coated Tablets - What is the active ingredient of Momendol 200 mg Anti-inflammatory 12 Coated Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eNaproxen 200 mg (corresponding to naproxen sodium 220 mg).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eComposition of Momendol 200 mg Anti-inflammatory 12 Coated Tablets - What does Momendol 200 mg Anti-inflammatory 12 Coated Tablets contain?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eTablet core: lactose monohydrate, maize starch, microcrystalline cellulose, povidone (K25), sodium starch glycolate, colloidal anhydrous silica, magnesium stearate. Film-coating: hypromellose, macrogol 400, titanium dioxide (E171), talc.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Momendol 200 mg Anti-inflammatory 12 Coated Tablets - Why is Momendol 200 mg Anti-inflammatory 12 Coated Tablets used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eIt is indicated in adults and adolescents over 16 years of age for the short-term symptomatic treatment of mild to moderate pain such as muscle and joint pain, headache, toothache and menstrual pain. It can also be used in the treatment of fever.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eContraindications Momendol 200 mg Anti-inflammatory 12 Coated Tablets - When should Momendol 200 mg Anti-inflammatory 12 Coated Tablets not be used?\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eHypersensitivity to the active substance or to any of the excipients or to other active substances closely related to naproxen from a chemical point of view. Naproxen is contraindicated in patients with allergic manifestations, such as asthma, urticaria, rhinitis, nasal polyps, angioedema, and anaphylactic or anaphylactoid reactions induced by acetylsalicylic acid, analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs) and\/or antirheumatics, due to possible cross-sensitivity. Naproxen is contraindicated in patients with gastrointestinal bleeding or perforation related to previous treatment with nonsteroidal anti-inflammatory drugs, active or previous recurrent peptic ulcer\/hemorrhage, chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease), severe hepatic insufficiency, severe cardiac insufficiency, severe renal insufficiency (creatinine clearance \u0026lt; 30 ml\/min), angioedema, during intensive therapy with diuretics, and in subjects with active hemorrhage and at risk of hemorrhage during therapy with anticoagulants. - Third trimester of pregnancy and breastfeeding. Contraindicated in children under 12 years.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eQuantity and method of taking Momendol 200 mg Anti-inflammatory 12 Coated Tablets - How to take Momendol 200 mg Anti-inflammatory 12 Coated Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eAdults and adolescents over 16 years: 1 film-coated tablet every 8-12 hours. If necessary, a better effect can be obtained by starting, on the first day, with 2 film-coated tablets followed by 1 film-coated tablet after 8-12 hours. Do not exceed 3 film-coated tablets in 24 hours. Elderly\/Renal impairment. Elderly patients and patients with mild or moderate renal impairment should not exceed 2 film-coated tablets in 24 hours. Paediatric population. The drug is contraindicated in children under 12 years. Method of administration. The drug should preferably be taken after a meal. Swallow the tablets whole with water. Do not use for more than 7 days for pain and for more than 3 days for fever. Patients should be advised to consult a doctor if pain and fever persist or worsen.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eStorage Momendol 200mg Anti-inflammatory 12 Coated Tablets - How to store Momendol 200 mg Anti-inflammatory 12 Coated Tablets?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eStore in the original package in order to protect from light and moisture.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Momendol 200 mg Anti-inflammatory 12 Coated Tablets - About Momendol 200 mg Anti-inflammatory 12 Coated Tablets it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eUndesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see gastrointestinal and cardiovascular risks below). Clinical trial and epidemiological data suggest that use of coxibs and some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Although some data suggest that use of naproxen (1000 mg\/day) may be associated with a lower risk, some risks cannot be excluded. There are insufficient data on the effects of naproxen at low doses (600 mg\/day) to draw definitive conclusions on possible thrombotic risks. There is a close correlation between dosage and the occurrence of severe gastrointestinal undesirable effects. Therefore, the lowest effective dosage should always be used. Caution is required (discuss with your doctor or pharmacist) before starting treatment in patients with a history of hypertension and\/or heart failure since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Diuresis and renal function must be carefully monitored, particularly in the elderly, in patients with chronic congestive heart failure or chronic renal failure, in patients treated with diuretics, or following major surgery involving hypovolemia. In patients with severe heart failure, worsening of conditions may occur. Particular caution is advised in patients with a history of gastrointestinal disease or liver failure and in patients with current or previous allergic manifestations, as in these subjects the product may cause bronchospasm, asthma, or other allergic phenomena. If visual disturbances occur, treatment with Momendol must be suspended. In association with the use of NSAIDs, serious skin reactions, some of them fatal, such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely. Patients appear to be at highest risk early in the course of therapy: the onset of the reaction occurs in the majority of cases within the first month of treatment. Momendol should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Naproxen, like any other NSAID, may mask the symptoms of concomitant infectious diseases. In isolated cases, exacerbation of infectious-based inflammation has been reported in temporal connection with the use of NSAIDs (e.g. development of necrotizing fasciitis). Gastrointestinal bleeding, ulceration and perforation, which may be fatal, have been reported at any time during treatment with all NSAIDs, with or without warning symptoms or a previous history of serious gastrointestinal events. The risk of GI bleeding, ulceration or perforation is higher with increasing doses of NSAIDs, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation. These patients should start treatment on the lowest dose available. The possible concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients taking low dose aspirin or other drugs likely to increase gastrointestinal risk. Patients with a history of GI toxicity, particularly when elderly, should report any unusual GI symptoms (especially GI bleeding) particularly in the initial stages of treatment. Caution should be exercised in patients taking concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as aspirin. In patients receiving the drug, treatment should be discontinued if gastrointestinal bleeding or ulceration occurs. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be aggravated. Use should be avoided in combination with NSAIDs, including selective COX-2 inhibitors. Elderly patients, who generally have some degree of renal, hepatic and cardiac function impairment, are more exposed to the risk of developing adverse effects related to the use of NSAIDs, especially gastrointestinal bleeding and perforation which may be fatal. Prolonged use of NSAIDs in the elderly is not recommended. Naproxen inhibits platelet aggregation and may prolong bleeding time. Patients with coagulation disorders or on therapy with medicinal products that interfere with haemostasis should be carefully monitored while taking Momendol. Caution is advised in habitual consumers of high daily doses of alcohol, due to the risk of gastric bleeding. The use of the product should be avoided in cases of pain of gastrointestinal origin. This medicinal product contains: - Lactose: patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Sodium: this medicinal product contains 23 mg sodium per tablet equivalent to 1.15% of the WHO recommended maximum daily intake of 2 g sodium for an adult.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Momendol 200 mg Anti-inflammatory 12 Coated Tablets - Which medicines or foods can modify the effect of Momendol 200 mg Anti-inflammatory 12 Coated Tablets?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eAdministration of naproxen with other NSAIDs or corticosteroids is not recommended as it increases the risk of ulcers and gastro-duodenal bleeding. Acetylsalicylic acid. Clinical pharmacodynamic data show that concomitant use of naproxen for more than one consecutive day may inhibit low-dose acetylsalicylic acid on platelet activity and this inhibition may persist for several days after discontinuation of treatment with naproxen. The clinical relevance of this interaction is unknown. Naproxen may increase anticoagulants, such as coumarin-type anticoagulants (e.g. warfarin, dicoumarol) because it prolongs prothrombin time and reduces platelet aggregation, increasing the risk of gastrointestinal bleeding. The combination of naproxen and lithium should be avoided; when necessary, closer monitoring of lithium plasma levels and dosage adjustment are recommended. Combinations to be used with caution. Due to the high binding of naproxen to plasma proteins, caution is advised in concomitant treatment with hydantoins or sulphonamides. Particular caution should also be exercised in patients treated with ciclosporin, tacrolimus, sulfonylureas, loop diuretics, methotrexate, beta-blockers, ACE inhibitors, probenecid, thiazide diuretics and digoxin. Naproxen may alter bleeding time (which may be increased up to 4 days after discontinuation of therapy), creatinine clearance (may decrease), azotemia and blood levels of creatinine and potassium (may increase), liver function tests (an increase in transaminases may be observed). Naproxen may induce false positives in the determination of urinary values ​​of 17-ketosteroid and may interfere with urinary determinations of 5-hydroxy-indoleacetic acid. Naproxen therapy should be discontinued at least 72 hours before performing adrenal function tests.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Momendol 200 mg Anti-inflammatory 12 Coated Tablets can cause side effects - What are the side effects of Momendol 200 mg Anti-inflammatory 12 Coated Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe following undesirable effects have been reported with NSAIDs and naproxen. The most commonly observed undesirable effects are gastrointestinal in nature. Clinical trial and epidemiological data suggest that use of coxibs and some NSAIDs (particularly at high doses and in long-term treatment) may be associated with a modest increased risk of arterial thrombotic events (for example myocardial infarction or stroke). The undesirable effects are listed below, organised according to MedDRA system organ class. The following rating scales have been used: very common (\u0026gt;1\/10); common (\u0026gt;1\/100, \u0026lt;1\/10); uncommon (\u0026gt;1\/1,000, \u0026lt;1\/100); rare (\u0026gt;1\/10,000, \u0026lt;1\/1,000); very rare (\u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data). Blood and lymphatic system disorders Very rare: aplastic or haemolytic anaemia, thrombocytopenia, granulocytopenia. Immune system disorders. Uncommon: allergic reaction (including facial oedema and angioedema). Psychiatric disorders. Uncommon: sleep disturbances, excitation. Nervous system disorders. Common: headache, somnolence, dizziness; very rare: meningitis-like reaction. Eye disorders. Uncommon: visual disturbances. Ear and labyrinth disorders. Uncommon: tinnitus, hearing impairment. Cardiac disorders. Very rare: tachycardia, oedema, hypertension and cardiac failure have been observed in association with NSAID treatment. Vascular disorders. Uncommon: contusion. Respiratory, thoracic and mediastinal disorders. Very rare: dyspnoea, asthma. Gastrointestinal disorders. Common: nausea, dyspepsia, vomiting, heartburn, gastralgia, flatulence; uncommon: diarrhoea, constipation; rare: peptic ulcer, perforation or gastrointestinal bleeding, sometimes fatal, may occur especially in the elderly (see section 4.4), haematemesis, ulcerative stomatitis, aggravated colitis, aggravated Crohn's disease; very rare: colitis, stomatitis. Less frequently, gastritis has been observed. Hepatobiliary disorders. Very rare: jaundice, hepatitis, decreased liver function. Skin and subcutaneous tissue disorders. Uncommon: rash\/pruritus; very rare: photosensitivity, alopecia, bullous disorder including Stevens-Johnson syndrome and toxic epidermal necrolysis. Renal and urinary disorders. Uncommon: abnormal renal function. General disorders and administration site conditions. Uncommon: chills, oedema (including peripheral oedema). Investigations. Very rare: blood pressure increased. As with other NSAIDs, allergic reactions of anaphylactic or anaphylactoid type may occur in patients with or without previous exposure to drugs belonging to this class. The characteristic symptoms of an anaphylactic reaction are: severe and sudden hypotension, acceleration or slowing of the heartbeat, unusual tiredness or weakness, anxiety, agitation, loss of consciousness, difficulty in breathing or swallowing, itching, urticaria with or without angioedema, redness of the skin, nausea, vomiting, crampy abdominal pain, diarrhoea. Report any suspected adverse reactions via the national reporting system.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Momendol 200 mg Anti-inflammatory 12 Coated Tablets.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eInhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or embryo\/fetal development. Results of epidemiological studies report an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The risk is believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss, and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, naproxen should not be administered unless clearly necessary. If naproxen is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the neonate, at the end of pregnancy, to: possible prolongation of bleeding time, and antiaggregant effect which may appear even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Therefore, naproxen is contraindicated during the third trimester of pregnancy. Since NSAIDs are excreted in breast milk, as a precautionary measure their use is contraindicated during breastfeeding. There is some evidence that drugs that inhibit the synthesis of prostaglandins and cyclooxygenase may cause problems with female fertility, through an effect on ovulation. This effect is reversible upon discontinuation of treatment.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI SpA","offers":[{"title":"Default Title","offer_id":46656185565511,"sku":"025829084","price":9.58,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-momendol-200mg-antinfiammatorio-12-compresse-rivestite-farmacia-dottor-tili-1213792488.jpg?v=1767112584"},{"product_id":"momentact-400mg-10-capsule-molli","title":"Momentact 400mg 10 soft capsules","description":"\u003cp\u003eMomentact 400mg 10 soft capsules is a medicine based on \u003cstrong\u003eibuprofen\u003c\/strong\u003e , an active ingredient belonging to the class of nonsteroidal anti-inflammatory drugs (NSAIDs). Each capsule contains 400 mg of ibuprofen, formulated to provide rapid relief from \u003cstrong\u003epain of various origins and natures\u003c\/strong\u003e , such as headache, toothache, neuralgia, osteoarticular and muscular pain, as well as menstrual pain. It is also indicated as an adjuvant in the symptomatic treatment of feverish and flu states. The soft capsules are designed for easy and fast intake, ensuring effective analgesic and anti-inflammatory action. Momentact is intended for use in adults and adolescents over 12 years of age.\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Active ingredients contained in Momentact 400mg 10 soft capsules - What is the active ingredient in Momentact 400mg 10 soft capsules?\u003c\/h3\u003e\n\n \u003cp\u003eEach capsule contains: \u003cu\u003eActive substance\u003c\/u\u003e : ibuprofen 400 mg \u003cu\u003eExcipients with known effect\u003c\/u\u003e : sorbitol, Ponceau 4R (E124)For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Composition of Momentact 400mg 10 soft capsules - What does Momentact 400mg 10 soft capsules contain?\u003c\/h3\u003e\n\n\u003cp\u003e Macrogol 600, potassium hydroxide, gelatin, partially dehydrated liquid \u003cb\u003esorbitol\u003c\/b\u003e , purified water, \u003cb\u003eponceau 4R (E124)\u003c\/b\u003e , lecithin, fractionated coconut oil.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Therapeutic indications Momentact 400mg 10 soft capsules - Why is Momentact 400mg 10 soft capsules used? What is it used for?\u003c\/h3\u003e\n\n\u003cp\u003e Momentact is indicated in adults and adolescents over 12 years of age. Pain of various origins and nature (headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain). Adjuvant in the symptomatic treatment of feverish and flu states.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\n \u003ch3\u003eContraindications Momentact 400mg 10 soft capsules - When should Momentact 400mg 10 soft capsules not be used?\u003c\/h3\u003e\n\n\u003cp\u003e • Hypersensitivity to the active substance, to other antirheumatics (acetylsalicylic acid, etc.) or to any of the excipients listed in section 6.1. • Do not administer to children under 12 years of age. • Ibuprofen is contraindicated during the third trimester of pregnancy and during breastfeeding. • Active or severe gastroduodenal ulcer or other gastropathies. • History of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). • Severe hepatic or renal insufficiency. • Severe cardiac insufficiency (NYHA class IV). • Severe dehydration (caused by vomiting, diarrhoea or insufficient fluid intake).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\n \u003ch3\u003eQuantity and method of taking Momentact 400mg 10 softgels - How to take Momentact 400mg 10 softgels?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cb\u003e\u003cu\u003eDosage\u003c\/u\u003e\u003c\/b\u003e \u003cb\u003eAdults and adolescents over 12 years\u003c\/b\u003e : 1 capsule 2-3 times a day. Do not exceed 3 capsules a day. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). If use of the medicinal product is necessary for more than 3 days in adolescents, or in case of worsening of symptoms, a doctor should be consulted. Do not exceed the recommended doses: in particular, elderly patients should adhere to the minimum dosages indicated above. \u003ci\u003eElderly\u003c\/i\u003e : NSAIDs should be used with particular caution in elderly patients who are more prone to adverse events and are at increased risk of potentially fatal gastrointestinal bleeding, ulceration or perforation (see section 4.4). If treatment is considered necessary, the lowest dose for the shortest duration necessary to control symptoms should be used (see section 4.4). \u003ci\u003eRenal impairment\u003c\/i\u003e : In patients with mild or moderate reduction of renal function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and renal function should be monitored. \u003ci\u003eHepatic impairment\u003c\/i\u003e : In patients with mild or moderate reduction of liver function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and liver function should be monitored. Momentact is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePaediatric population\u003c\/i\u003e Momentact is contraindicated in children under 12 years of age (see section 4.3). \u003cb\u003e\u003cu\u003eMethod of administration\u003c\/u\u003e\u003c\/b\u003e Momentact can be taken on an empty stomach. In subjects with gastric tolerability problems, it is preferable to take the medicine on a full stomach.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\n\u003ch3\u003e Storage Momentact 400mg 10 softgels - How to store Momentact 400mg 10 softgels?\u003c\/h3\u003e\n\n\u003cp\u003e Store below 25°C.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\n\u003ch3\u003e Warnings Momentact 400mg 10 soft capsules - About Momentact 400mg 10 soft capsules it is important to know that:\u003c\/h3\u003e\n\n \u003cp\u003e• The use of Momentact, as with any drug inhibiting the synthesis of prostaglandins and cyclooxygenase, is not recommended in women attempting to conceive. • Administration of Momentact should be suspended in women who have problems conceiving or who are undergoing investigation of infertility. • Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). • Elderly: elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2). \u003cb\u003e• Cardiovascular and cerebrovascular effects\u003c\/b\u003e Caution is required before initiating treatment in patients with a history of hypertension and\/or heart failure since fluid retention, hypertension and oedema have been reported in association with NSAID therapy. NSAIDs may reduce the effect of diuretics, and other antihypertensive drugs (see section 4.5). Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low dose ibuprofen (e.g. ≤ 1200 mg\/day) is associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration should also be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses (2400 mg\/day) of ibuprofen are required. Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration. Similar consideration should be made before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking). \u003cb\u003e• Gastrointestinal bleeding, ulceration and perforation\u003c\/b\u003e The use of Momentact should be avoided in combination with NSAIDs, including cyclooxygenase-2 (COX-2) selective inhibitors, due to an increased risk of ulceration or bleeding (see section 4.5). In particular, gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest dose available. Concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant acetylsalicylic acid or other drugs likely to increase GI risk (see below and section 4.5). Patients with a history of GI toxicity, particularly when elderly, should report any unusual GI symptoms (especially GI bleeding) particularly in the initial stages of treatment. Carefully monitor patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors (SSRIs) or anti-platelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients receiving Momentact, the treatment should be withdrawn. NSAIDs should be given with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). \u003cb\u003e• Dermatological effects\u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at higher risk in the early stages of therapy: the onset of the reaction occurs in most cases within the first month of treatment. Momentact should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity as well as if visual disturbances or persistent signs of liver dysfunction occur. \u003cb\u003e• Renal effects\u003c\/b\u003e When initiating treatment with ibuprofen, caution should be exercised in patients with considerable dehydration. Ibuprofen may cause water, sodium and potassium retention in patients with no history of renal disease due to its effects on renal perfusion. This may cause oedema or cardiac failure or hypertension in predisposed patients. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other pathological renal changes. In general, the habitual use of analgesics, especially combinations of several analgesic active ingredients, can lead to permanent renal damage, with the risk of renal failure (analgesic nephropathy). Renal toxicity has been observed in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. The administration of NSAIDs in these patients may lead to a dose-dependent reduction in prostaglandin formation and, as a secondary effect, renal blood flow, which can quickly lead to renal failure. Patients most at risk of these reactions are those with reduced renal function, heart failure, liver dysfunction, the elderly and all those patients taking diuretics and ACE inhibitors. Discontinuation of NSAID therapy is usually followed by recovery to the pre-treatment state. There is a risk of impaired renal function in dehydrated adolescents. In case of prolonged use, monitor renal function, particularly in cases of diffuse lupus erythematosus.• \u003ci\u003e\u003cu\u003eRespiratory disorders\u003c\/u\u003e\u003c\/i\u003e Momentact must be prescribed with caution in patients with bronchial asthma, chronic rhinitis, nasal polyps, sinusitis or current or previous allergic diseases because bronchospasm, urticaria and angioedema may occur. The same applies to those subjects who have experienced bronchospasm after the use of acetylsalicylic acid or other NSAIDs.• \u003ci\u003e\u003cu\u003eHypersensitivity reactions\u003c\/u\u003e\u003c\/i\u003e Analgesics, antipyretics, NSAIDs, can cause hypersensitivity reactions, potentially serious (anaphylactoid reactions), even in subjects not previously exposed to this type of drug. The risk of hypersensitivity reactions after taking ibuprofen is higher in subjects who have shown such reactions after the use of other analgesics, antipyretics, NSAIDs and in subjects with bronchial hyperreactivity (asthma), hay fever, nasal polyposis or chronic obstructive respiratory diseases or previous episodes of angioedema (see sections 4.3 and 4.8). Hypersensitivity reactions may present themselves in the form of asthma attacks (so-called analgesic asthma), Quincke's edema or urticaria. Serious hypersensitivity reactions (e.g. anaphylactic shock) have been observed rarely. At the first signs of a hypersensitivity reaction after administration of ibuprofen, treatment must be stopped. Medically assisted measures must be initiated by specialized medical personnel, in line with the symptoms. \u003cb\u003e• Reduced cardiac, renal and hepatic function\u003c\/b\u003e Particular caution must be adopted in the treatment of patients with reduced cardiac, hepatic or renal function since the use of NSAIDs may cause a deterioration of renal function. Habitual concomitant use of several painkillers may further increase this risk. In patients with impaired cardiac, hepatic or renal function, the lowest effective dose for the shortest duration of treatment should be used and periodic monitoring of clinical and laboratory parameters should be carried out, especially in case of prolonged treatment. \u003cb\u003e• Haematological effects\u003c\/b\u003e Ibuprofen, like other NSAIDs, can inhibit platelet aggregation and has been shown to prolong bleeding time in healthy subjects. Therefore, patients with coagulation defects or on anticoagulant therapy should be carefully observed. \u003cb\u003e• Aseptic meningitis\u003c\/b\u003e On rare occasions, symptoms of aseptic meningitis have been observed in patients receiving ibuprofen. Although this is more likely to occur in patients with systemic lupus erythematosus and related connective tissue diseases, it has also been observed in patients without concomitant chronic disease (see section 4.8). • Since ocular alterations have been observed in animal studies with NSAIDs, it is recommended that in case of prolonged treatment, periodic ophthalmological checks be carried out. • Alcohol consumption should be avoided as it can intensify the side effects of NSAIDs, especially those affecting the gastrointestinal tract or the central nervous system. • Ibuprofen may mask the signs or symptoms of infection (fever, pain and swelling). \u003cb\u003eImportant information about some of the excipients\u003c\/b\u003e Momentact capsules contain: - \u003cb\u003eSorbitol (E420\u003c\/b\u003e ): this medicine contains 23.46 mg of sorbitol per dose, equivalent to 23.46 mg\/1180 mg. The additive effect of co-administration of medicinal products containing sorbitol (or fructose) and the daily intake of sorbitol (or fructose) with the diet should be taken into account. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products; - \u003cb\u003ePonceau 4R (E124)\u003c\/b\u003e : may cause allergic reactions.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Interactions Momentact 400mg 10 soft capsules - Which medicines or foods can modify the effect of Momentact 400mg 10 soft capsules?\u003c\/h3\u003e\n\n \u003cp\u003eIt is advisable to seek medical advice in case of any concomitant therapy before administering the product. Ibuprofen (like other NSAIDs) should be taken with caution in combination with the substances listed below. • Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4). • Anticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin or heparin (see section 4.4). In case of concomitant treatment, monitoring of the coagulation status is recommended. • Cyclooxygenase-2 (COX-2) inhibitors and other NSAIDs: these substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). It is advisable not to combine ibuprofen with other NSAIDs, including selective COX-2 inhibitors, due to the potential additive effect (see section 4.4). • Acetylsalicylic acid: Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1). • Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4). • Diuretics, ACE inhibitors (such as captopril), beta blockers and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of nephrotoxicity associated with NSAIDs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Momentact concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and thereafter. • Phenytoin and lithium: concomitant administration of ibuprofen and phenytoin or lithium preparations may result in reduced elimination of these drugs with consequent increase in their plasma levels with the possibility of reaching the toxic threshold. If this combination is deemed necessary, monitoring of the plasma levels of phenytoin and lithium is recommended in order to adapt the appropriate dosage during concomitant treatment with ibuprofen. • Methotrexate: NSAIDs may inhibit the tubular secretion of methotrexate and some metabolic interactions may occur with consequent reduction in the clearance of methotrexate and increased risk of toxicity. • Moclobemide: increases the effect of ibuprofen. • Aminoglycosides: NSAIDs may decrease the excretion of aminoglycosides increasing their toxicity. • Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides. Monitoring of serum glycoside levels is recommended. • Cholestyramine: Concomitant administration of ibuprofen and cholestyramine may prolong and reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is unknown. • Ciclosporins: Concomitant administration of ciclosporin and some NSAIDs causes an increased risk of renal damage. This effect cannot be excluded for the combination of ciclosporin and ibuprofen. • Plant extracts: Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs. • Mifepristone: Due to the anti-prostaglandin properties of NSAIDs, their use after mifepristone administration may result in a reduction of the effect of mifepristone. Limited evidence suggests that co-administration of NSAIDs and prostaglandins on the same day does not adversely affect the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination. • Quinolone antibiotics: patients taking NSAIDs and quinolones may have an increased risk of developing convulsions. • Sulfonylureas: NSAIDs may enhance the hypoglycaemic effect of sulfonylureas. In case of simultaneous treatment, monitoring of blood glucose levels is recommended. • Tacrolimus: co-administration of NSAIDs and tacrolimus may lead to an increased risk of nephrotoxicity. • Zidovudine: there is evidence of an increased risk of haemarthrosis and haematoma in HIV-positive haemophiliac patients receiving concomitant treatment with zidovudine and other NSAIDs. A blood test is recommended 1-2 weeks after starting treatment. • Ritonavir: may cause an increase in plasma concentrations of NSAIDs. • Probenecid: slows the excretion of ibuprofen, with possible increase in their plasma concentrations. • CYP2C9 inhibitors: concomitant administration of ibuprofen and CYP2C9 inhibitors may slow the elimination of ibuprofen (CYP2C9 substrate) resulting in increased exposure to ibuprofen. In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)-ibuprofen of approximately 80% to 100% was observed. A reduction of the ibuprofen dose should be considered in cases of co-administration with strong CYP2C9 inhibitors, particularly when high doses of ibuprofen are administered with voriconazole or fluconazole. • Alcohol, bisphosphonates and oxypentifylline (pentoxifylline): may enhance gastrointestinal side effects and the risk of bleeding and ulceration. • Baclofen: high toxicity of baclofen.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Like all medicines, Momentact 400mg 10 soft capsules can cause side effects - What are the side effects of Momentact 400mg 10 soft capsules?\u003c\/h3\u003e\n\n \u003cp\u003eThe undesirable effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and are reported below using the following convention: Very common (≥1\/10) Common (≥1\/100, \u0026lt; 1\/10) Uncommon (≥ 1\/ 1,000, \u0026lt; 1\/100) Rare (≥1\/10,000, \u0026lt; 1\/1,000). Very rare (\u0026lt;1\/10,000) Not known (frequency cannot be estimated from the available data) The most commonly observed adverse events are gastrointestinal in nature. Clinical trial and epidemiological data suggest that use of ibuprofen (particularly at high doses (2400 mg\/day) and in long-term treatment may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Gastrointestinal perforation with ibuprofen has been observed rarely. After administration of Momentact the following have been reported: feeling of heaviness in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Uncommon: gastritis. Very rare: pancreatitis. \u003cb\u003eImmune system disorders\u003c\/b\u003e The following undesirable effects have been reported following treatment with NSAIDs: non-specific allergic reaction and anaphylaxis; uncommon: hypersensitivity reactions such as various types of skin rash, urticaria, pruritus, purpura, angioedema, exanthema, respiratory tract reactions including asthma, including severe asthma, bronchospasm or dyspnoea, asthmatic attack (sometimes with hypotension); rare: lupus erythematosus syndrome; very rare: severe hypersensitivity reactions. Symptoms may include: facial oedema, tongue oedema, laryngeal oedema, airway oedema with constriction, dyspnoea, tachycardia, anaphylaxis, exfoliative and bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). \u003cb\u003eCardiac and vascular disorders\u003c\/b\u003e Oedema, fatigue, hypertension and cardiac failure have been reported in association with treatment with NSAIDs. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Very rare: palpitations, cardiac failure, myocardial infarction, acute pulmonary oedema, oedema, hypertension. Other adverse events reported less frequently and for which causality has not necessarily been established include: \u003cb\u003eBlood and lymphatic system disorders\u003c\/b\u003e Rare: leucopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia. \u003cb\u003ePsychiatric disorders\u003c\/b\u003e Uncommon: insomnia, anxiety. Rare: depression, confusional state, hallucinations. \u003cb\u003eNervous system disorders\u003c\/b\u003e Common: dizziness. Uncommon: paraesthesia, somnolence. Rare: optic neuritis. \u003cb\u003eInfections and infestations\u003c\/b\u003e Uncommon: rhinitis. Rare: aseptic meningitis Rhinitis and aseptic meningitis (especially in patients with pre-existing autoimmune disorders, such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). Exacerbation of infection-related inflammations (e.g. development of necrotising fasciitis) has been described. \u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e Uncommon: bronchospasm, dyspnoea, apnoea. \u003cb\u003eEye disorders\u003c\/b\u003e Uncommon: visual disturbances. Rare: ocular impairment resulting in visual disturbances, toxic optic neuropathy. \u003cb\u003eEar and labyrinth disorders\u003c\/b\u003e Uncommon: hearing impaired, tinnitus, vertigo. \u003cb\u003eHepatobiliary disorders\u003c\/b\u003e Uncommon: abnormal liver function, hepatitis and jaundice. Very rare: liver failure. \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e Allergic skin rashes (erythema, pruritus, urticaria) may occasionally occur. Uncommon: photosensitivity reactions. Very rare: bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. In exceptional cases, serious skin infections and soft tissue disorders may occur during varicella infection (see \"Infections and infestations\"). Not known: drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). \u003cb\u003eRenal and urinary disorders\u003c\/b\u003e Uncommon: renal function impairment and toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure. \u003cb\u003eGeneral disorders and administration site conditions\u003c\/b\u003e Common: malaise, fatigue. Rare: oedema. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ehttp:\/\/www.agenziafarmaco.gov.it\/content\/comesegnalare-una-sospetta-reazione-avversa\u003c\/u\u003e .\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eOVERDOSE\u003c\/h2\u003e\n\n\u003ch3\u003e Momentact 400mg 10 Softgels Overdose - What are the risks of Momentact 400mg 10 Softgels in case of overdose?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cb\u003eToxicity\u003c\/b\u003e Signs and symptoms of toxicity have not generally been observed at doses below 100 mg\/kg in children or adults. However, supportive treatment may be necessary in some cases. Children have been observed to exhibit signs and symptoms of toxicity following ingestion of ibuprofen at doses of 400 mg\/kg or greater. \u003cb\u003eSymptoms\u003c\/b\u003e Most patients who have ingested significant amounts of ibuprofen will exhibit symptoms within 4 to 6 hours. The most commonly reported symptoms of overdose include nausea, vomiting, abdominal pain, lethargy, and somnolence. Central nervous system (CNS) effects include headache, tinnitus, dizziness, convulsions, and loss of consciousness. Nystagmus, metabolic acidosis, hypothermia, renal effects, gastrointestinal bleeding, coma, apnoea, diarrhoea, and CNS and respiratory depression have also been reported rarely. Disorientation, excitement, fainting and cardiovascular toxicity including hypotension, bradycardia and tachycardia have been reported. Renal failure and liver damage are possible in cases of significant overdose. In cases of severe poisoning, metabolic acidosis may occur. \u003cb\u003eTreatment\u003c\/b\u003e There is no specific antidote for ibuprofen overdose. Symptomatic and supportive treatment is indicated in the event of overdose. Particular attention should be paid to monitoring blood pressure, acid-base balance and gastrointestinal bleeding. Administration of activated charcoal should be considered within one hour of ingestion of a potentially toxic amount. Alternatively, gastric lavage should be considered within one hour of ingestion of a potentially life-threatening overdose in adults. Adequate diuresis should be ensured and renal and hepatic function should be closely monitored. The patient should remain under observation for at least four hours following ingestion of a potentially toxic amount. If frequent or prolonged convulsions occur, they should be treated with intravenous diazepam. Other supportive measures may be necessary depending on the patient's clinical condition. Contact your local poison control center for more information.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Momentact 400mg 10 soft capsules.\u003c\/h3\u003e\n\n \u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or the embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformation increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, Momentact should not be administered unless clearly necessary. If Momentact is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. \u003cu\u003eDuring the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to\u003c\/u\u003e : - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; \u003cu\u003eAt the end of pregnancy, all prostaglandin synthesis inhibitors may expose the mother and the neonate to\u003c\/u\u003e : - possible prolongation of bleeding time, and anti-aggregating effect which may occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, Momentact is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Ibuprofen is excreted in breast milk, but at therapeutic doses during short-term treatment, the risk of influence on the neonate seems unlikely. If, however, treatment is longer term, early weaning should be considered. NSAIDs should be avoided during breastfeeding. \u003cb\u003eFertility\u003c\/b\u003e The use of Ibuprofen may impair female fertility and is not recommended in women attempting to conceive. This effect is reversible upon discontinuation of treatment. In women who have difficulties conceiving or who are undergoing investigation of infertility, discontinuation of ibuprofen treatment should be considered.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\n\u003ch3\u003e Taking Momentact 400mg 10 softgels before driving or using machines - Does Momentact 400mg 10 softgels affect driving or using machines?\u003c\/h3\u003e\n\n\u003cp\u003e The use of ibuprofen does not usually affect the ability to drive or use machines. However, those patients whose activities require alertness should exercise caution if they experience drowsiness, dizziness or depression during therapy with ibuprofen.\u003c\/p\u003e","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51131203158343,"sku":"035618038","price":11.07,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-momentact-400mg-10-capsule-molli-farmacia-dottor-tili-1213792378.jpg?v=1767132947"},{"product_id":"tachipirina-flashtab-500mg-16-compresse-orodispersibili","title":"Tachipirina Flashtab 500mg 16 orodispersible tablets","description":"\u003cstrong\u003eTachipirina Flashtab 500mg 16 orodispersible tablets\u003c\/strong\u003e is a medicine designed for the \u003cstrong\u003esymptomatic treatment of mild to moderate pain\u003c\/strong\u003e and \u003cstrong\u003efever\u003c\/strong\u003e . Each tablet contains \u003cstrong\u003eparacetamol 500 mg\u003c\/strong\u003e , an active ingredient known for its analgesic and antipyretic properties. Orodispersible tablets are easy to take, as they dissolve quickly in the mouth without the need for water, offering a practical option for those who have difficulty swallowing traditional tablets. This format is particularly useful for rapid relief from symptoms, making Tachipirina Flashtab an effective choice for managing pain and fever.\n\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e  \u003ch3\u003eActive ingredients contained in Tachipirina Flashtab 500mg 16 orodispersible tablets - What is the active ingredient of Tachipirina Flashtab 500mg 16 orodispersible tablets?\u003c\/h3\u003e Each orodispersible tablet contains paracetamol 500 mg (as coated paracetamol crystals). Excipients with known effect: Each tablet also contains 40 mg aspartame (E951). For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tachipirina Flashtab 500mg 16 orodispersible tablets - What does Tachipirina Flashtab 500mg 16 orodispersible tablets contain?\u003c\/h3\u003e \u003ci\u003eCoated paracetamol crystals:\u003c\/i\u003e Basic butylated methacrylate copolymer, 30% polyacrylate dispersion, Silica, colloidal hydrophobic. \u003ci\u003eTablet\u003c\/i\u003e : Mannitol (granules, powder), crospovidone, aspartame (E951), blackcurrant flavour, magnesium stearate.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e  \u003ch3\u003eTherapeutic indications Tachipirina Flashtab 500mg 16 orodispersible tablets - Why is Tachipirina Flashtab 500mg 16 orodispersible tablets used? What is it used for?\u003c\/h3\u003e Symptomatic treatment of mild to moderate pain and\/or fever.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Tachipirina Flashtab 500mg 16 orodispersible tablets - When should Tachipirina Flashtab 500mg 16 orodispersible tablets not be used?\u003c\/h3\u003e - Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Phenylketonuria (due to the presence of aspartame). - Severe hepatocellular insufficiency.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Tachipirina Flashtab 500mg 16 orodispersible tablets - How do you take Tachipirina Flashtab 500mg 16 orodispersible tablets? \u003c\/h3\u003e\n\u003cb\u003e\u003ci\u003eDosage\u003c\/i\u003e\u003c\/b\u003e This medicine is FOR ADULTS ONLY. The maximum recommended dosage is 3000 mg of paracetamol per day, corresponding to 6 tablets per day. The usual dosage is 1 tablet of 500 mg, to be repeated if necessary after not less than four hours. In case of severe pain or high fever, 2 tablets of 500 mg to be repeated if necessary after not less than four hours. Do not exceed 6 tablets of 500 mg in 24 hours. \u003ci\u003eMaximum recommended dosage\u003c\/i\u003e : the total dose of paracetamol must not exceed 3 g per day for adults (see section 4.9 “Overdose”). \u003ci\u003eFrequency of administration\u003c\/i\u003e - In adults, administration should be performed at intervals of at least 4 hours. \u003ci\u003eRenal insufficiency\u003c\/i\u003e In case of severe renal insufficiency, the interval between 2 administrations must be at least \u003cu\u003e8 hours\u003c\/u\u003e . \u003cb\u003e\u003ci\u003eMethod of administration\u003c\/i\u003e\u003c\/b\u003e . Oral route. The tablet should be sucked and not chewed. It can be dispersed in half a glass of water.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Tachipirina Flashtab 500mg 16 orodispersible tablets - How is Tachipirina Flashtab 500mg 16 orodispersible tablets stored?\u003c\/h3\u003e This medicinal product does not require any special storage conditions.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tachipirina Flashtab 500mg 16 orodispersible tablets - About Tachipirina Flashtab 500mg 16 orodispersible tablets it is important to know that: \u003c\/h3\u003e\n\u003cb\u003e\u003ci\u003eWarnings\u003c\/i\u003e\u003c\/b\u003e Do not exceed the recommended dose. Prolonged use of the product, outside of medical supervision, may be harmful. This product should be used only if strictly necessary. Doses higher than those recommended carry a risk of very serious liver damage. Treatment with an antidote should be administered as soon as possible. See section 4.9. To avoid the risk of overdose, patients should be advised to avoid the concomitant use of other medicinal products containing paracetamol. This medicinal product contains aspartame, a source of phenylalanine, equivalent to 0.2 mg per tablet and, therefore, is contraindicated in subjects with phenylketonuria (see section 4.3). There are no non-clinical or clinical studies available on the use of aspartame in children under 12 weeks of age. \u003cb\u003e\u003ci\u003ePrecautions for use\u003c\/i\u003e\u003c\/b\u003e Paracetamol should be used with caution in case of: - Adults weighing less than 50 kg - Mild to moderate hepatocellular insufficiency (note: paracetamol is contraindicated in cases of severe hepatocellular insufficiency) - Chronic alcoholism - Chronic malnutrition (low reserves of hepatic glutathione) - Dehydration - Severe renal insufficiency (creatinine clearance ≤ 10 ml\/min - see paragraph 4.2). In case of high fever, or signs of secondary infection, or persistence of symptoms beyond 3 days, a reassessment of the treatment should be carried out. During prolonged treatment with analgesic drugs, carried out with doses higher than those indicated in the package leaflet, headache may occur which should not be treated with higher doses of the medicine. In general, the habitual use of analgesics, especially the combination of different analgesic drugs, may lead to permanent kidney damage with the risk of renal failure (analgesic nephropathy). If this situation occurs or is suspected, a doctor should be consulted and treatment should be discontinued. The diagnosis of “analgesic overuse headache” should be considered in patients who suffer from frequent or daily headaches despite (or because of) the regular use of headache medications. Caution is advised if paracetamol is administered concomitantly with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism), as well as in those using maximum daily doses of paracetamol. Careful monitoring, including measurement of urinary 5-oxoproline, is recommended.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Tachipirina Flashtab 500mg 16 orodispersible tablets - Which medicines or foods can modify the effect of Tachipirina Flashtab 500mg 16 orodispersible tablets? \u003c\/h3\u003e• Probenecid causes a reduction of at least 2-fold in the clearance of paracetamol by inhibiting its conjugation with glucuronic acid. In case of concomitant treatment with probenecid, a reduction in the dosage of paracetamol should be considered. • Salicylamide may prolong the elimination half-life of paracetamol. • Paracetamol should be used with caution in case of concomitant intake of enzyme inducers (such as carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. John's Wort or St. John's Wort) or potentially hepatotoxic substances (see section 4.9). • Metoclopramide and domperidone: accelerate the absorption of paracetamol • Cholestyramine: reduces the absorption of paracetamol. • Concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants may induce slight variations in INR values ​​with consequent increase in the risk of bleeding. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its discontinuation. • Caution should be exercised when paracetamol is used concomitantly with flucloxacillin since concomitant intake has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4). \u003ci\u003eInteractions with clinical tests\u003c\/i\u003e : The administration of paracetamol may alter the measurement of uric acid in the blood, obtained with the phosphotungstic acid method, and the measurement of blood glucose obtained with the glucose oxidase-peroxidase method.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tachipirina Flashtab 500mg 16 orodispersible tablets can cause side effects - What are the side effects of Tachipirina Flashtab 500mg 16 orodispersible tablets?\u003c\/h3\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eSystemic organic classification\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eRare (≥1\/10,000 to \u0026lt;1\/1,000)\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eVery rare (\u0026lt;1\/10,000), not known (frequency cannot be estimated from the available data)\u003c\/b\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eHepatobiliary pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e - increased levels of liver transaminases\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eImmune system disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e - hypersensitivity reaction (ranging from simple skin rash or urticaria to anaphylactic shock requiring discontinuation of treatment)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003ePathologies of the haemolymphopoietic system\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e - thrombocytopenia, leukopenia, neutropenia (sporadic reports)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e Very rare cases of serious skin reactions have been reported.\u003c\/td\u003e\n\u003c\/tr\u003e  \u003c\/table\u003eReporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.aifa.gov.it\/content\/ segnalazioni-reazioni-avverse\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Tachipirina Flashtab 500mg 16 orodispersible tablets - What are the risks of Tachipirina Flashtab 500mg 16 orodispersible tablets in case of overdose? \u003c\/h3\u003eThere is a risk of liver damage (including fulminant hepatitis, hepatic failure, cholestatic hepatitis, hepatic cytolysis), particularly in elderly subjects, in young children, in patients with liver disease, in chronic alcoholism, in patients with chronic malnutrition and in patients receiving enzyme inducers. In these cases, overdose can be fatal. Symptoms generally appear in the first 24 hours and include: nausea, vomiting, anorexia, pallor and abdominal pain. Overdose, 7.5 g or more of paracetamol in a single administration in adults or 140 mg\/kg of body weight in a single administration in children, causes necrosis of hepatocytes which makes it likely to induce complete and irreversible necrosis, resulting in hepatocellular failure, metabolic acidosis and encephalopathy which may lead to coma and death. Concomitantly, an increase in the levels of hepatic transaminases (AST, ALT), lactate dehydrogenase and bilirubin is observed, together with an increase in prothrombin time which may appear 12 to 48 hours after administration. Clinical symptoms of liver damage usually appear after two days and reach a maximum after 4 to 6 days. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Other non-hepatic symptoms that have been reported following paracetamol overdose include myocardial abnormalities and pancreatitis. \u003ci\u003eEmergency treatment\u003c\/i\u003e • immediate transfer to hospital even if there are no significant early symptoms • collection of a blood sample for initial measurement of plasma paracetamol concentration • gastric lavage • intravenous (or oral if possible) administration of the antidote N-acetylcysteine ​​if possible \u003cu\u003ewithin\u003c\/u\u003e ten hours of ingestion. N-acetylcysteine ​​can, however, provide a certain degree of protection even after 10 hours, and up to 48 hours, but in these cases prolonged treatment is performed. • symptomatic treatment must be performed. • oral methionine can be used as an alternative to N-acetylcysteine ​​provided that it is administered as soon as possible after the overdose and, in any case, within 10 hours of the overdose.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina Flashtab 500mg 16 orodispersible tablets. \u003c\/h3\u003e\n\u003cb\u003e\u003ci\u003ePregnancy\u003c\/i\u003e\u003c\/b\u003e A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically needed, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible duration and with the lowest possible frequency. \u003cb\u003e\u003ci\u003eBreastfeeding\u003c\/i\u003e\u003c\/b\u003e After oral administration, paracetamol is excreted in breast milk in small quantities. No undesirable effects on breast-fed children have been reported. Therapeutic doses of this medicinal product can be taken during breastfeeding.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e  \u003ch3\u003eTaking Tachipirina Flashtab 500mg 16 orodispersible tablets before driving or using machines - Does Tachipirina Flashtab 500mg 16 orodispersible tablets affect driving or using machines?\u003c\/h3\u003e Not relevant.","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51131261190471,"sku":"034329058","price":8.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-tachipirina-flashtab-500mg-16-compresse-orodispersibili-farmacia-dottor-tili-1213792290.jpg?v=1767143989"},{"product_id":"moment-200mg-12-bustine-granulato-per-soluzione-orale","title":"Moment 200mg 12 sachets granules for oral solution","description":"\u003cp\u003e\u003cstrong\u003eMoment 200mg\u003c\/strong\u003e is a drug based on \u003cstrong\u003eibuprofen\u003c\/strong\u003e , indicated for the treatment of \u003cstrong\u003emild and moderate pain\u003c\/strong\u003e and feverish states. Thanks to its formulation in \u003cstrong\u003egranules for oral solution\u003c\/strong\u003e , it guarantees a rapid and effective action against \u003cstrong\u003eheadaches, menstrual pain, toothache, muscle pain and fever\u003c\/strong\u003e .\u003c\/p\u003e\n\n\u003cp\u003e The sachet format allows for quick and easy intake, making it an ideal solution for those who have difficulty swallowing tablets. Simply dissolve the contents of a sachet in water to obtain an \u003cstrong\u003eanalgesic and anti-inflammatory effect\u003c\/strong\u003e in a short time. The \u003cstrong\u003e12-sachet\u003c\/strong\u003e pack is perfect for occasional use or to always have an effective remedy on hand.\u003c\/p\u003e\n\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Active ingredients contained in Moment 200mg 12 sachets granules for oral solution - What is the active ingredient in Moment 200mg 12 sachets granules for oral solution?\u003c\/h3\u003e\n\n \u003cp\u003eOne sachet contains: \u003cu\u003eActive ingredient:\u003c\/u\u003e ibuprofen 200 mg (as sodium salt dihydrate 256 mg). \u003cu\u003eExcipients with known effects:\u003c\/u\u003e sucrose, potassium, aspartame (E 951). For the full list of excipients, see section 6.1\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Composition of Moment 200mg 12 sachets granules for oral solution - What does Moment 200mg 12 sachets granules for oral solution contain?\u003c\/h3\u003e\n\n\u003cp\u003e Each sachet contains: \u003cb\u003eSucrose, potassium\u003c\/b\u003e bicarbonate, orange flavouring, acesulfame potassium, \u003cb\u003easpartame (E 951).\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Therapeutic indications Moment 200mg 12 sachets granules for oral solution - Why is Moment 200mg 12 sachets granules for oral solution used? What is it used for?\u003c\/h3\u003e\n\n\u003cp\u003e Pain of various origins and natures (menstrual pain, headache, toothache, neuralgia, osteo-articular and muscular pain).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Contraindications Moment 200mg 12 sachets granules for oral solution - When should Moment 200mg 12 sachets granules for oral solution not be used?\u003c\/h3\u003e\n\n \u003cp\u003e• Hypersensitivity to the active substance, to other antirheumatics (acetylsalicylic acid, etc.) or to any of the excipients listed in section 6.1. • Children under 12 years of age. • Third trimester of pregnancy and breastfeeding (see section 4.6). • Active or severe gastroduodenal ulcer or other gastropathies. • History of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). • Severe hepatic or renal insufficiency. • Severe cardiac insufficiency (NYHA class IV). • Phenylketonuria (see section 4.4). • Severe dehydration (caused by vomiting, diarrhoea or insufficient fluid intake).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\n\u003ch3\u003e Quantity and method of taking Moment 200mg 12 sachets granules for oral solution - How do you take Moment 200mg 12 sachets granules for oral solution?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cb\u003eAdults and adolescents over 12 years: 1-2\u003c\/b\u003e sachets, 2-3 times a day. Dissolve the contents of the sachet in a glass of water, stirring with a teaspoon until dissolved and drink the solution immediately. Do not exceed the dose of 1200 mg (6 sachets) per day. If the use of the medicine is necessary for more than 3 days in adolescents aged 12 years and over or in case of worsening of symptoms, a doctor should be consulted. Do not exceed the recommended doses. \u003cb\u003eElderly patients\u003c\/b\u003e should adhere to the minimum dosages indicated above (see section 4.4). Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). \u003cb\u003e\u003cu\u003eRenal impairment:\u003c\/u\u003e\u003c\/b\u003e in patients with mild or moderate reduction of renal function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and renal function should be monitored. \u003cb\u003e\u003cu\u003eHepatic impairment:\u003c\/u\u003e\u003c\/b\u003e In patients with mild or moderate reduction of liver function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and liver function should be monitored. Moment is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePaediatric population\u003c\/i\u003e Moment is contraindicated in children under 12 years of age (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e Dissolve the contents of the sachet in a glass of water, stirring with a teaspoon until dissolved and drink the solution immediately. Moment can be taken on an empty stomach. In subjects with gastric tolerability problems, it is preferable to take the medicine on a full stomach.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\n\u003ch3\u003e Storage Moment 200mg 12 sachets granules for oral solution - How do you store Moment 200mg 12 sachets granules for oral solution?\u003c\/h3\u003e\n\n\u003cp\u003e This medicinal product does not require any special storage conditions.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\n\u003ch3\u003e Warnings Moment 200mg 12 sachets granules for oral solution - About Moment 200mg 12 sachets granules for oral solution it is important to know that:\u003c\/h3\u003e\n\n \u003cp\u003e• In asthmatic patients the product should be used with caution, following medical evaluation. • The use of Moment, as of any drug inhibiting the synthesis of prostaglandins and cyclooxygenase is not recommended in women intending to become pregnant. • The administration of Moment should be suspended in women who have fertility problems or who are undergoing investigation of fertility. • Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). • Elderly: elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see paragraph 4.2). • \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a modest increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration should also be exercised before initiating long-term treatment in patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses (2400 mg\/day) of ibuprofen are required. Caution is advised before initiating treatment in patients with a history of hypertension and\/or heart failure since fluid retention, hypertension and oedema have been reported in association with NSAID therapy. NSAIDs may reduce the effect of diuretics and other antihypertensive drugs (see section 4.5) • \u003cu\u003eGastrointestinal bleeding, ulceration and perforation\u003c\/u\u003e The use of Moment should be avoided in combination with NSAIDs, including COX-2 selective inhibitors due to an increased risk of ulceration or bleeding (see section 4.5). Gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest dose available. Concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients taking low dose aspirin or other drugs likely to increase GI risk (see below and section 4.5). Patients with a history of GI toxicity, particularly when elderly, should report any unusual GI symptoms (especially GI bleeding) particularly in the initial stages of treatment. Carefully monitor patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as aspirin (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients receiving Moment the treatment should be withdrawn. NSAIDs should be given with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). • \u003cu\u003eRenal effects\u003c\/u\u003e When initiating treatment with ibuprofen, caution should be exercised in patients with considerable dehydration. Ibuprofen may cause water and sodium, potassium retention in patients with no history of renal disease due to its effects on renal perfusion. This may cause oedema or cardiac failure or hypertension in predisposed patients. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other pathological renal changes. In general, the habitual use of analgesics, especially combinations of several analgesic active ingredients, may lead to permanent renal damage, with risk of onset of renal failure (analgesic nephropathy). Renal toxicity has been observed in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. Administration of NSAIDs in these patients may result in a dose-dependent reduction in prostaglandin formation and, as a secondary effect, renal blood flow, which may rapidly lead to renal failure. Patients most at risk of these reactions are those with reduced renal function, heart failure, liver dysfunction, the elderly and all those patients taking diuretics and ACE inhibitors. Discontinuation of NSAID therapy is usually followed by recovery to the pre-treatment state. There is a risk of impaired renal function in dehydrated adolescents. In case of prolonged use, renal function should be monitored, particularly in cases of diffuse lupus erythematosus. - \u003cu\u003eSevere skin reactions\u003c\/u\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Acute generalised exanthematous pustulosis (AGEP) has been reported in connection with medicinal products containing ibuprofen. Ibuprofen should be discontinued at the first appearance of signs and symptoms of severe skin reactions, such as rash, mucosal lesions or any other sign of hypersensitivity, as well as if visual disturbances or persistent signs of liver dysfunction occur. • \u003cu\u003eRespiratory disorders\u003c\/u\u003e Moment should be prescribed with caution in patients with bronchial asthma, chronic rhinitis, nasal polyps, sinusitis or allergic diseases in progress or in history because bronchospasm, urticaria and angioedema may occur. The same applies to those subjects who have experienced bronchospasm after the use of acetylsalicylic acid or other NSAIDs. • \u003cu\u003eHypersensitivity reactions\u003c\/u\u003e Analgesics, antipyretics, NSAIDs, can cause hypersensitivity reactions, potentially serious (anaphylactoid reactions), even in subjects not previously exposed to this type of drug. The risk of hypersensitivity reactions after taking ibuprofen is greater in subjects who have shown such reactions after the use of other analgesics, antipyretics, NSAIDs and in subjects with bronchial hyperreactivity (asthma), hay fever, nasal polyposis or chronic obstructive respiratory diseases or previous episodes of angioedema (see paragraphs 4.3 and 4.8). Hypersensitivity reactions may present as asthma attacks (so-called analgesic asthma), Quincke's edema or urticaria. Severe hypersensitivity reactions (e.g. anaphylactic shock) have been observed rarely. At the first signs of a hypersensitivity reaction after administration of ibuprofen, treatment should be discontinued. Medically assisted measures should be initiated by specialized medical personnel, in line with the symptoms. • \u003cu\u003eReduced cardiac, renal and hepatic function\u003c\/u\u003e Particular caution should be exercised when treating patients with reduced cardiac, hepatic or renal function since the use of NSAIDs may lead to a deterioration of renal function. The habitual concomitant use of several painkillers may further increase this risk. In patients with reduced cardiac, hepatic or renal function, it is advisable to use the lowest effective dose for the shortest period of treatment and to periodically monitor clinical and laboratory parameters, especially in the case of prolonged treatment. • \u003cu\u003eHaematological effects\u003c\/u\u003e Ibuprofen, like other NSAIDs, may inhibit platelet aggregation and has been shown to prolong bleeding time in healthy subjects. Therefore, patients with coagulation defects or on anticoagulant therapy should be carefully observed. • \u003cu\u003eAseptic meningitis\u003c\/u\u003e On rare occasions, symptoms of aseptic meningitis have been observed in patients receiving ibuprofen. Although this is more likely to occur in patients with systemic lupus erythematosus and related connective tissue diseases, it has also been observed in patients without concomitant chronic disease (see section 4.8). Since ocular changes have been observed in animal studies with NSAIDs, periodic ophthalmological checks are recommended in case of prolonged treatment. Alcohol consumption should be avoided as it may intensify the side effects of NSAIDs, especially those affecting the gastrointestinal tract or the central nervous system. Masking of symptoms of underlying infections Moment may mask the symptoms of infection, which may delay the initiation of adequate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When Moment is administered for the relief of infection-related fever or pain, monitoring for infection is advised. In non-hospital settings, the patient should seek medical advice if symptoms persist or worsen. \u003cu\u003eImportant information about some of the ingredients\u003c\/u\u003e Moment 200 mg granules for oral solution contains: • \u003cb\u003ePotassium\u003c\/b\u003e : This medicine contains 2.25 mmol of potassium per sachet. To be taken into consideration by patients with reduced kidney function or by patients on a controlled potassium diet. • \u003cb\u003eAspartame\u003c\/b\u003e : This medicine contains 20 mg of aspartame per sachet equivalent to 20 mg\/3000 mg. Aspartame ingested orally is hydrolysed in the gastrointestinal tract. Phenylalanine is the main product of its hydrolysis, therefore it is contraindicated in subjects with phenylketonuria. • \u003cb\u003eSucrose\u003c\/b\u003e : patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Interactions Moment 200mg 12 sachets granules for oral solution - Which medicines or foods can modify the effect of Moment 200mg 12 sachets granules for oral solution?\u003c\/h3\u003e\n\n \u003cp\u003eIbuprofen (like other NSAIDs) should be used with caution in combination with the substances listed below. • Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4). • Anticoagulants: NSAIDs may enhance the effects of anticoagulants, such as warfarin or heparin (see section 4.4). In case of concomitant treatment, monitoring of the coagulation status is recommended. • Acetylsalicylic acid. The concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1). • Cyclooxygenase-2 (COX-2) inhibitors and other NSAIDs: these substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). However, it is advisable not to combine ibuprofen with acetylsalicylic acid or other NSAIDs, including selective COX-2 inhibitors, due to the potential additive effect (see section 4.4). • Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4). • Diuretics, ACE inhibitors (such as captopril), beta blockers and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of nephrotoxicity associated with NSAIDs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Moment concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and thereafter. • Phenytoin and lithium: concomitant administration of ibuprofen and phenytoin or lithium preparations may result in reduced elimination of these drugs with consequent increase in their plasma levels with the possibility of reaching the toxic threshold. If this combination is deemed necessary, monitoring of the plasma levels of phenytoin and lithium is recommended in order to adapt the appropriate dosage during concomitant treatment with ibuprofen. • Methotrexate: NSAIDs may inhibit the tubular secretion of methotrexate and some metabolic interactions may occur with consequent reduction in the clearance of methotrexate and increased risk of toxicity. • Moclobemide: increases the effect of ibuprofen. • Aminoglycosides: NSAIDs may decrease the excretion of aminoglycosides increasing their toxicity. • Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides. Monitoring of serum glycoside levels is recommended. • Cholestyramine: Concomitant administration of ibuprofen and cholestyramine may reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is unknown. • Ciclosporin: Concomitant administration of ciclosporin and some NSAIDs causes an increased risk of renal damage. This effect cannot be excluded for the combination of ciclosporin and ibuprofen. • Plant extracts: Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs. • Mifepristone: Due to the anti-prostaglandin properties of NSAIDs, their use after mifepristone administration may result in a reduction of the effect of mifepristone. Limited evidence suggests that co-administration of NSAIDs and prostaglandins on the same day does not adversely affect the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination. • Quinolone antibiotics: patients taking NSAIDs and quinolones may have an increased risk of developing convulsions. • Sulfonylureas: NSAIDs may enhance the hypoglycaemic effect of sulfonylureas. In case of simultaneous treatment, monitoring of blood glucose levels is recommended. • Tacrolimus: co-administration of NSAIDs and tacrolimus may lead to an increased risk of nephrotoxicity. • Zidovudine: there is evidence of an increased risk of haemarthrosis and haematoma in HIV-positive haemophiliac patients receiving concomitant treatment with zidovudine and other NSAIDs. A blood test is recommended 1-2 weeks after starting treatment. • Ritonavir: may cause an increase in plasma concentrations of NSAIDs. • Probenecid: slows the excretion of ibuprofen, with possible increase in its plasma concentrations. • CYP2C9 inhibitors: concomitant administration of ibuprofen and CYP2C9 inhibitors may slow the elimination of ibuprofen (CYP2C9 substrate) resulting in increased exposure to ibuprofen. In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)-ibuprofen of approximately 80% to 100% was observed. A reduction of the ibuprofen dose should be considered in cases of co-administration with strong CYP2C9 inhibitors, particularly when high doses of ibuprofen are administered with voriconazole or fluconazole. • Alcohol, bisphosphonates and oxpentifylline (pentoxifylline): may enhance gastrointestinal side effects and the risk of bleeding and ulceration. • Baclofen: high toxicity of baclofen.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Like all medicines, Moment 200mg 12 sachets granules for oral solution can cause side effects - What are the side effects of Moment 200mg 12 sachets granules for oral solution?\u003c\/h3\u003e\n\n \u003cp\u003eThe undesirable effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and are reported below using the following convention: Very common (≥1\/10); Common (≥1\/100, \u0026lt; 1\/10); Uncommon (≥ 1\/ 1,000, \u0026lt; 1\/100); Rare (≥1\/10,000, \u0026lt; 1\/1,000); Very rare (\u0026lt;1\/10,000); Not known (frequency cannot be estimated from the available data). The most commonly observed adverse events are gastrointestinal in nature. \u003cu\u003eGastrointestinal disorders:\u003c\/u\u003e Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Gastrointestinal perforation with the use of ibuprofen has been observed rarely. After administration of Moment the following have been reported: feeling of heaviness in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, epigastric pain, heartburn, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Uncommon: gastritis; Very rare: pancreatitis. \u003cu\u003eImmune system disorders\u003c\/u\u003e . The following undesirable effects have been reported following treatment with NSAIDs: non-specific allergic reaction and anaphylaxis. Uncommon: hypersensitivity reactions such as various types of skin rash, urticaria, pruritus, purpura, angioedema, exanthema, respiratory tract reactions including bronchospasm, dyspnoea, asthmatic attack (sometimes with hypotension); Rare: lupus erythematosus syndrome; Very rare: severe hypersensitivity reactions. Symptoms may include: severe asthma, facial oedema, tongue oedema, laryngeal oedema, airway oedema with bronchospasm, dyspnoea, tachycardia, anaphylaxis, exfoliative and bullous dermatitis. \u003cu\u003eCardiac and vascular disorders\u003c\/u\u003e : Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Very rare: palpitations, heart failure, myocardial infarction, acute pulmonary oedema, hypertension. Other adverse events for which causality has not necessarily been established include: \u003cu\u003eBlood and lymphatic system disorders:\u003c\/u\u003e Rare: leucopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia, inhibition of platelet aggregation. \u003cu\u003ePsychiatric disorders\u003c\/u\u003e . Uncommon: insomnia, anxiety; Rare: depression, confusional state, hallucinations. \u003cu\u003eNervous system disorders .\u003c\/u\u003e Common: dizziness; Uncommon: paraesthesia, somnolence; Rare: optic neuritis. \u003cu\u003eInfections and infestations .\u003c\/u\u003e Uncommon: rhinitis; Rare: aseptic meningitis. Rhinitis and aseptic meningitis have been observed especially in patients with pre-existing autoimmune disorders (such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). Exacerbation of infection-related inflammation (e.g. development of necrotising fasciitis) has been described. \u003cu\u003eRespiratory, thoracic and mediastinal disorders .\u003c\/u\u003e Uncommon: bronchospasm, dyspnoea, apnoea. \u003cu\u003eEye disorders\u003c\/u\u003e . Uncommon: visual disturbances; Rare: ocular alteration resulting in visual disturbances, toxic optic neuropathy. \u003cu\u003eEar and labyrinth disorders.\u003c\/u\u003e Uncommon: impaired hearing, tinnitus, vertigo. \u003cu\u003eHepatobiliary disorders\u003c\/u\u003e . Uncommon: abnormal liver function, hepatitis and jaundice; Very rare: liver failure. \u003cu\u003eSkin and subcutaneous tissue disorders\u003c\/u\u003e . Allergic skin rashes (erythema, pruritus, urticaria) may occasionally occur. Uncommon: photosensitivity reactions; Very rare: bullous dermatitis, including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme. In exceptional cases, serious skin infections and soft tissue disorders may occur during varicella infection (see “infections and infestations”). Not known: drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), acute generalised exanthematous pustulosis (AGEP). \u003cu\u003eRenal and urinary disorders.\u003c\/u\u003e Uncommon: impaired renal function and toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure; Rare: azotaemia. \u003cu\u003eGeneral disorders and administration site conditions.\u003c\/u\u003e Common: malaise, fatigue; Rare: oedema. \u003cu\u003eDiagnostic tests\u003c\/u\u003e . Rare: increased transaminases, increased alkaline phosphatase, decreased haemoglobin, decreased haematocrit, prolonged bleeding time, decreased blood calcium, increased blood uric acid. \u003ci\u003eReporting of suspected adverse reactions\u003c\/i\u003e Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eOVERDOSE\u003c\/h2\u003e\n\n\u003ch3\u003e Overdose Moment 200mg 12 sachets granules for oral solution - What are the risks of Moment 200mg 12 sachets granules for oral solution in case of overdose?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003eToxicity\u003c\/u\u003e Signs and symptoms of toxicity have not generally been observed at doses below 100 mg\/kg in children or adults. However, in some cases supportive treatment may be necessary. Children have been observed to exhibit signs and symptoms of toxicity following ingestion of ibuprofen at doses of 400 mg\/kg or greater. \u003cu\u003eSymptoms\u003c\/u\u003e Most patients who have ingested significant quantities of ibuprofen will exhibit symptoms within 4 to 6 hours. The most commonly reported symptoms of overdose include nausea, vomiting, abdominal pain, lethargy and somnolence. Central nervous system (CNS) effects include headache, tinnitus, dizziness, convulsions and loss of consciousness. Nystagmus, hypothermia, renal effects, gastrointestinal bleeding, coma, apnoea, diarrhoea and CNS and respiratory depression have also been reported rarely. Disorientation, excitement, fainting and cardiovascular toxicity including hypotension, bradycardia and tachycardia have been reported. Renal failure and liver damage are possible in cases of significant overdose. In cases of severe poisoning, metabolic acidosis may occur. \u003cu\u003eTreatment\u003c\/u\u003e There is no specific antidote for ibuprofen overdose. Symptomatic and supportive treatment is indicated in cases of overdose. Particular attention should be paid to monitoring blood pressure, acid-base balance and gastrointestinal bleeding. Administration of activated charcoal should be considered within one hour of ingestion of a potentially toxic amount. Alternatively, gastric lavage should be considered within one hour of ingestion of a potentially life-threatening overdose in adults. Adequate diuresis should be ensured and renal and hepatic function should be closely monitored. The patient should remain under observation for at least four hours following ingestion of a potentially toxic amount. If frequent or prolonged convulsions occur, they should be treated with intravenous diazepam. Other supportive measures may be necessary depending on the patient's clinical condition. Contact your local poison control center for more information.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Moment 200mg 12 sachets granules for oral solution.\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or the embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformation increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-foetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, Moment should not be administered unless clearly necessary. If Moment is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose \u003cu\u003ethe fetus to\u003c\/u\u003e : - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; \u003cu\u003ethe mother and the neonate, at the end of pregnancy, to\u003c\/u\u003e : - possible prolongation of bleeding time, and anti-aggregating effect which may occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, Moment is contraindicated during the third trimester of pregnancy \u003cu\u003eBreastfeeding\u003c\/u\u003e Ibuprofen is excreted in breast milk, but at therapeutic doses during short-term treatment, the risk of influence on the neonate seems unlikely. If, however, treatment is longer term, early weaning should be considered. NSAIDs should be avoided during breastfeeding. \u003cu\u003eFertility\u003c\/u\u003e The use of Ibuprofen may impair female fertility and is not recommended in women attempting to conceive. This effect is reversible upon discontinuation of treatment. In women who have difficulties conceiving or who are undergoing investigation of infertility, discontinuation of ibuprofen treatment should be considered.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\n\u003ch3\u003e Taking Moment 200mg 12 sachets granules for oral solution before driving or using machines - Does Moment 200mg 12 sachets granules for oral solution affect driving or using machines?\u003c\/h3\u003e\n\n\u003cp\u003e The use of ibuprofen does not usually affect the ability to drive or use machines. However, those patients whose activities require alertness should exercise caution if they experience drowsiness, dizziness or depression during therapy with ibuprofen.\u003c\/p\u003e","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51131271512391,"sku":"025669211","price":7.79,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-moment-200mg-12-bustine-granulato-per-soluzione-orale-farmacia-dottor-tili-1213792273.jpg?v=1767133228"},{"product_id":"momendol-220mg-12-capsule-molli","title":"Momendol 220mg 12 soft capsules","description":"\u003cp\u003eMomendol 220mg 12 softgels is a nonsteroidal anti-inflammatory drug (NSAID) designed for the \u003cstrong\u003eshort-term symptomatic treatment\u003c\/strong\u003e of mild to moderate pain. Each capsule contains \u003cstrong\u003enaproxen sodium 220 mg\u003c\/strong\u003e , equivalent to 200 mg of naproxen, an active ingredient known for its analgesic and anti-inflammatory properties. This medicine is indicated for the relief of \u003cstrong\u003emuscle and joint pain\u003c\/strong\u003e , \u003cstrong\u003eheadache\u003c\/strong\u003e , \u003cstrong\u003etoothache\u003c\/strong\u003e and \u003cstrong\u003emenstrual pain\u003c\/strong\u003e . In addition, Momendol can be used in the treatment of \u003cstrong\u003efever\u003c\/strong\u003e . The softgels are formulated for rapid absorption, ensuring effective and timely relief. Thanks to its composition, Momendol represents a practical solution for those who need rapid intervention against pain.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\n \u003ch3\u003eActive ingredients contained in Momendol 220mg 12 soft capsules - What is the active ingredient of Momendol 220mg 12 soft capsules?\u003c\/h3\u003e\n\n\u003cp\u003e Each soft capsule contains: \u003cu\u003eActive ingredient:\u003c\/u\u003e Naproxen sodium 220 mg (equivalent to naproxen 200 mg) \u003cu\u003eExcipients with known effect: sorbitol and sodium.\u003c\/u\u003e For a full list of excipients, see section 6.1\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Composition of Momendol 220mg 12 soft capsules - What does Momendol 220mg 12 soft capsules contain?\u003c\/h3\u003e\n\n\u003cp\u003e \u003cu\u003eCapsule content\u003c\/u\u003e : Macrogol 600, Lactic acid, Purified water. \u003cu\u003eCapsule coating\u003c\/u\u003e : Gelatin, Sorbitol\/Glycerol special (50:50), Brilliant blue (E133), Lecithin, Medium chain triglycerides.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Therapeutic indications Momendol 220mg 12 soft capsules - Why is Momendol 220mg 12 soft capsules used? What is it used for?\u003c\/h3\u003e\n\n \u003cp\u003eShort-term symptomatic treatment of mild to moderate pain such as muscle and joint pain, headache, toothache and menstrual pain. Momendol can also be used in the treatment of fever.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Contraindications Momendol 220mg 12 soft capsules - When should Momendol 220mg 12 soft capsules not be used?\u003c\/h3\u003e\n\n \u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1 or to other closely related substances from a chemical point of view, • patients with allergic manifestations, such as asthma, urticaria, rhinitis, nasal polyps, angioedema, and anaphylactic or anaphylactoid reactions induced by acetylsalicylic acid, analgesics, non-steroidal anti-inflammatory drugs (NSAIDs) and\/or antirheumatics, due to possible cross-sensitivity, • patients with gastrointestinal or other bleeding, e.g. cerebrovascular, • patients with gastrointestinal bleeding or perforation related to previous treatment with non-steroidal anti-inflammatory drugs, ongoing treatment with potentially gastro-injurious drugs or history of recurrent peptic haemorrhage\/ulcer (two or more distinct episodes of proven ulceration or bleeding), • active stomach and duodenal ulcer, • congestive gastropathy, atrophic gastritis, • chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease), • severe hepatic insufficiency, • severe cardiac insufficiency, • severe renal insufficiency (creatinine clearance \u0026lt; 30 ml\/min), • during full-dose treatment with diuretics, • in subjects with active bleeding and at risk of bleeding during anticoagulant therapy, • pregnancy and breastfeeding (See section 4.6 \u003ci\u003e)\u003c\/i\u003e . • children and adolescents under 16 years of age.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\n\u003ch3\u003e Quantity and method of taking Momendol 220mg 12 soft capsules - How to take Momendol 220mg 12 soft capsules?\u003c\/h3\u003e\n\n\u003cp\u003e \u003cb\u003eDosage\u003c\/b\u003e \u003cu\u003eAdults and adolescents over 16 years\u003c\/u\u003e 1 soft capsule every 8-12 hours. If necessary, a better effect can be obtained by starting, on the first day, with 2 soft capsules followed by 1 soft capsule after 8-12 hours. Do not exceed 3 soft capsules in 24 hours. \u003ci\u003e\u003cu\u003eElderly and patients with renal insufficiency\u003c\/u\u003e\u003c\/i\u003e Elderly patients and patients with mild or moderate renal insufficiency should not exceed 2 soft capsules in 24 hours. (See section 4.3, and section 4.4). Do not use for more than 7 days for pain and for more than 3 days for fever. Patients should be advised to consult a doctor if pain and fever persist or worsen. \u003cb\u003eMethod of administration\u003c\/b\u003e Momendol should be taken with a glass of water preferably after a meal.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONSERVATION\u003c\/h2\u003e\n\n \u003ch3\u003eStorage Momendol 220mg 12 soft capsules - How do you store Momendol 220mg 12 soft capsules?\u003c\/h3\u003e\n\n\u003cp\u003e Do not store above 25°C. Store in the original container to protect from moisture.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\n\u003ch3\u003e Warnings Momendol 220mg 12 soft capsules - About Momendol 220mg 12 soft capsules it is important to know that:\u003c\/h3\u003e\n\n \u003cp\u003eUndesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see gastrointestinal and cardiovascular risks below). Clinical trial and epidemiological data suggest that use of coxibs and some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Although some data suggest that use of naproxen (1000 mg\/day) may be associated with a lower risk, some risk cannot be excluded. There are insufficient data on the effects of naproxen doses of 220 to 660 mg\/day to draw firm conclusions on possible thrombotic risks. There is a close correlation between dosage and the occurrence of serious gastrointestinal undesirable effects. Therefore, the lowest effective dosage should always be used. Elderly patients, who generally have some degree of renal, hepatic and cardiac function impairment, are at increased risk of developing adverse effects related to the use of NSAIDs, especially gastrointestinal bleeding and perforation which may be fatal. These patients should start treatment with the lowest available dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients. Prolonged use of NSAIDs in the elderly is not recommended. \u003cb\u003eBefore starting treatment with Momendol\u003c\/b\u003e Caution is required before starting treatment in patients with a history of hypertension and\/or non-severe heart failure since fluid retention, hypertension and edema have been reported in association with NSAID treatment. Diuresis and renal function should be well monitored, particularly in the elderly, in patients treated with diuretics, or following major surgery involving hypovolaemia. Particular caution is advised in patients with a history of gastrointestinal disease or non-severe hepatic insufficiency, especially in the elderly. The use of the medicinal product should be avoided in cases of pain of gastrointestinal origin. The concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered in elderly patients, in patients with non-severe gastrointestinal disease and for patients taking low dose aspirin or other drugs that may increase the risk of gastrointestinal events (see below and section 4.5). Caution is advised when treating habitual consumers of high doses of alcohol, as they are at risk of gastric bleeding. The use of Momendol should be avoided in conjunction with NSAIDs including selective COX-2 inhibitors. \u003cb\u003eDuring treatment with Momendol\u003c\/b\u003e If visual disturbances occur, treatment with Momendol should be discontinued. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk in the early stages of therapy: the onset of the reaction occurs in most cases within the first month of treatment. Momendol should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Naproxen, like any other NSAID, may mask the symptoms of concomitant infectious diseases. In isolated cases, an exacerbation of infectious-based inflammation (e.g. development of necrotizing fasciitis) has been reported in temporal connection with the use of NSAIDs. Gastrointestinal bleeding, ulceration and perforation, which may be fatal, have been reported with all NSAIDs at any time \u003cu\u003eduring\u003c\/u\u003e treatment, with or without warning symptoms or a previous history of serious gastrointestinal events. Patients with gastric tolerance problems, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment. Caution should be exercised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as aspirin (see section 4.5). If gastrointestinal bleeding or ulceration occurs in patients receiving Momendol, the treatment should be withdrawn. Naproxen inhibits platelet aggregation and may prolong bleeding time. Patients with coagulation disorders or on therapy with medicinal products that interfere with haemostasis should be carefully monitored while taking Momendol. Regarding combinations with other medicinal products requiring caution, see section 4.5 \u003ci\u003e“Interaction with other medicinal products and other forms of interaction”\u003c\/i\u003e . Momendol soft capsules contain: • \u003cb\u003eSorbitol:\u003c\/b\u003e sorbitol is a source of fructose. If your doctor has told you that you (or your child) have an intolerance to some sugars, or if you have been diagnosed with hereditary fructose intolerance, a rare genetic disorder in which patients cannot break down fructose, talk to your doctor before you (or your child) take this medicine.• \u003cb\u003eSodium:\u003c\/b\u003e This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 'sodium-free'.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Interactions Momendol 220mg 12 soft capsules - Which medicines or foods can modify the effect of Momendol 220mg 12 soft capsules?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003eContraindicated combinations\u003c\/u\u003e \u003ci\u003eAnticoagulants\u003c\/i\u003e Naproxen may increase the effect of anticoagulants, such as coumarin-type anticoagulants (e.g. warfarin, dicoumarol) because it prolongs prothrombin time and reduces platelet aggregation, increasing the risk of gastrointestinal bleeding (see sections 4.3 and 4.4). \u003cu\u003eNot recommended combinations\u003c\/u\u003e \u003ci\u003eNonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids\u003c\/i\u003e The administration of naproxen with other nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids is not recommended as it increases the risk of ulcers and gastro-duodenal bleeding (see section 4.4). \u003ci\u003eLithium\u003c\/i\u003e The combination of naproxen and lithium should be avoided; when necessary, close monitoring of lithium plasma levels and dosage adjustment are recommended. Increased lithium levels may induce nausea, polydipsia, polyuria, tremor and confusion. \u003ci\u003eAntiplatelet agents and selective serotonin reuptake inhibitors (SSRIs)\u003c\/i\u003e Concomitant use of antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs) increases the risk of gastrointestinal bleeding (see section 4.4). \u003ci\u003eAcetylsalicylic acid\u003c\/i\u003e Clinical pharmacodynamic data show that concomitant use of naproxen for more than one consecutive day may inhibit the effect of low-dose acetylsalicylic acid on platelet activity and this inhibition may persist for several days after cessation of treatment with naproxen. The clinical relevance of this interaction is unknown. \u003ci\u003eCiclosporin\u003c\/i\u003e Inhibitors of prostaglandin synthesis such as naproxen, due to their effect on renal prostaglandins, may cause an increase in the nephrotoxicity of ciclosporin. \u003ci\u003eTacrolimus\u003c\/i\u003e Concomitant intake of nonsteroidal anti-inflammatory drugs and tacrolimus may lead to acute renal failure. \u003ci\u003eMethotrexate\u003c\/i\u003e A serious increase in methotrexate toxicity has also been observed in case of combined therapy with naproxen. The mechanism of this interaction is unclear, which may be due to a reduction in the renal clearance of methotrexate. \u003cu\u003eCombinations to be used with caution\u003c\/u\u003e \u003ci\u003eHydantoin and sulphonamide derivatives\u003c\/i\u003e Due to the high binding of naproxen to plasma proteins, caution is advised in concomitant treatment with hydantoin or sulphonamide derivatives. \u003ci\u003e\u003cu\u003eSulphonylureas\u003c\/u\u003e\u003c\/i\u003e It is important to take into account the possibility of an increase in the binding effects of sulphonylureas (oral antidiabetics) due to inhibition of plasma proteins. \u003ci\u003eFurosemide and loop diuretics\u003c\/i\u003e Concomitant use with furosemide may lead to a reduction in the natriuretic effect of the diuretic. \u003ci\u003eBeta-blockers\u003c\/i\u003e The association of Momendol with beta-blockers may reduce their antihypertensive effect. \u003ci\u003eProbenecid\u003c\/i\u003e Concomitant administration of probenecid increases plasma levels of naproxen and significantly prolongs the plasma half-life. \u003ci\u003eThiazide diuretics, ACE inhibitors and Angiotensin II antagonists\u003c\/i\u003e NSAIDs may reduce the effect of thiazide diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, especially in elderly patients. \u003ci\u003eDigoxin\u003c\/i\u003e Concomitant administration of Momendol with digoxin may alter the serum levels of the latter. \u003cu\u003eLaboratory Tests\u003c\/u\u003e Naproxen may affect bleeding time (which may be increased up to 4 days after discontinuation of therapy), creatinine clearance (may decrease), blood urea nitrogen, creatinine and potassium levels (may increase), and liver function tests (transaminase elevations may occur). Naproxen may induce false-positive urinary 17-ketosteroid determinations and may interfere with urinary 5-hydroxyindoleacetic acid determinations. Naproxen therapy should be discontinued at least 72 hours before adrenal function tests.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Like all medicines, Momendol 220mg 12 soft capsules can cause side effects - What are the side effects of Momendol 220mg 12 soft capsules?\u003c\/h3\u003e\n\n \u003cp\u003eLike other NSAIDs, naproxen may induce the following undesirable effects. The most commonly observed undesirable effects are gastrointestinal in nature. Clinical trial and epidemiological data suggest that use of coxibs and some NSAIDs (particularly at high doses and in long-term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease have been reported after administration of Momendol (see section 4.4). Less frequently, gastritis has been observed. Bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (very rare). Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment. As with other NSAIDs, allergic reactions of anaphylactic or anaphylactoid type may occur in patients with or without previous exposure to drugs belonging to this class. The characteristic symptoms of an anaphylactic reaction are: sudden severe hypotension, rapid or slow heartbeat, unusual tiredness or weakness, anxiety, agitation, loss of consciousness, difficulty breathing or swallowing, itching, urticaria with or without angioedema, redness of the skin, nausea, vomiting, crampy abdominal pain, diarrhoea. The following table lists the undesirable effects using the following frequency scales: very common (\u0026gt;1\/10); common (\u0026gt;1\/100, \u0026lt;1\/10); uncommon (\u0026gt;1\/1000, \u0026lt;1\/100); rare (\u0026gt; 1\/10,000, \u0026lt; 1\/1,000); very rare (\u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data). \u003c\/p\u003e\n\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\n\u003ctbody\u003e\n\n\u003ctr\u003e\n\n \u003ctd\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e\u003c\/td\u003e\n\n\u003ctd\u003e \u003cb\u003eFrequency category\u003c\/b\u003e\n\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003ePathologies of the haemolymphopoietic system\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e aplastic or haemolytic anaemia, eosinophilia, thrombocytopenia, leukopenia, granulocytopenia such as agranulocytosis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eImmune system disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eUncommon:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e allergic reactions (including facial oedema and angioedema).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e \u003cb\u003ePsychiatric disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eUncommon:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e sleep disturbance, excitement\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e depression, difficulty concentrating\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eMetabolism and nutrition disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eRare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e hyperglycaemia, hypoglycaemia\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"3\"\u003e \u003cb\u003eNervous system disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eCommon:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e headache, drowsiness, dizziness, lightheadedness\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003eUncommon\u003c\/i\u003e :\u003c\/b\u003e drowsiness, insomnia\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e meningitis-like reaction, aseptic meningitis in patients with autoimmune diseases, cognitive disorders, convulsions\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e \u003cb\u003eEye pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e \n\u003cb\u003e\u003ci\u003e\u003cu\u003eUncommon:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e vision disturbances\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e corneal opacity, papillitis, retrobulbar optic neuritis, papilledema\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e \u003cb\u003eEar and labyrinth pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eUncommon:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e tinnitus, hearing impairment\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e hearing loss\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eHeart disease\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e Tachycardia, edema, hypertension and cardiac failure have been observed in association with treatment with NSAIDs.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e \u003cb\u003eVascular pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eUncommon:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e ecchymosis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e \u003ci\u003evasculitis\u003c\/i\u003e\n\n\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eRespiratory, thoracic and mediastinal pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e dyspnoea, asthma, eosinophilic pneumonia, alveolitis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"5\"\u003e \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eCommon:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e nausea, dyspepsia, vomiting, heartburn, gastralgia, flatulence\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eUncommon:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e diarrhoea, constipation\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \n\u003cb\u003e\u003ci\u003e\u003cu\u003eRare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e peptic ulcer, perforation or gastrointestinal bleeding, sometimes fatal; haematemesis, ulcerative stomatitis, worsening of colitis and Crohn's disease may occur, especially in the elderly (see section 4.4).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e colitis, stomatitis, pancreatitis, aphthous ulcers, esophagitis. Less frequently, it has been observed\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eNot known:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e gastritis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eHepatobiliary pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e jaundice, hepatitis (including fatal cases), decreased liver function\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eUncommon:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e skin rash\/pruritus\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \n\u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e photosensitivity including porphyria cutanea tarda (“pseudoporphyria”) or epidermolysis bullosa, alopecia, vesicular eczema including Stevens-Johnson syndrome and toxic epidermal necrolysis, erythema multiforme, erythema nodosa, fixed erythema, lichen planus, pustules, systemic lupus erythematosus, purpura, sweating\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eMusculoskeletal and connective tissue disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eRare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e myalgia, muscle weakness\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"3\"\u003e \u003cb\u003eKidney and urinary disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eUncommon:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e decreased renal function\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eRare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e glomerulonephritis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e interstitial nephritis, papillary necrosis, nephrotic syndrome, nephritic syndrome, renal failure, nephropathy, haematuria, proteinuria\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"3\"\u003e \u003cb\u003eSystemic disorders and conditions related to the administration site\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eUncommon:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e chills, oedema (including peripheral oedema)\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eRare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e pyrexia\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \n\u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e thirst, malaise\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eDiagnostic tests\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e\n\n \u003cb\u003e\u003ci\u003e\u003cu\u003eVery rare:\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e increased blood pressure, increased serum creatinine, abnormal liver function tests, hyperkalaemia\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\n\u003c\/tbody\u003e\n\n\n\u003c\/table\u003e\n\n\u003cp\u003e \u003cb\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\n\u003ch3\u003e Momendol 220mg 12 softgels Overdose - What are the risks of Momendol 220mg 12 softgels in case of overdose?\u003c\/h3\u003e\n\n \u003cp\u003eSigns of overdose may include drowsiness, heartburn, diarrhea, nausea, vomiting, abdominal pain, dizziness, disorientation, gastric bleeding, drowsiness, increased blood sodium levels, metabolic acidosis, convulsions, changes in liver function, hypoprothrombinemia, renal dysfunction, apnea. In case of accidental or voluntary ingestion\/administration of a large amount of the product, the physician must implement the normal measures required in these cases. Emptying the stomach and the usual supportive measures are recommended. Prompt administration of an adequate amount of activated charcoal may reduce the absorption of the medicine.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e PREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Momendol 220mg 12 soft capsules.\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or the embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: • cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); • renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the neonate, at the end of pregnancy, to: • possible prolongation of bleeding time, and anti-aggregating effect which may occur even at very low doses; • inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, Momendol is contraindicated during pregnancy (see section 4.3). \u003cu\u003eBreast-feeding\u003c\/u\u003e Since NSAIDs are excreted in breast milk, the medicinal product is contraindicated during breast-feeding (see section 4.3). \u003cu\u003eFertility\u003c\/u\u003e There is some evidence that drugs which inhibit the synthesis of prostaglandins and cyclooxygenase may cause problems for female fertility by an effect on ovulation. This is reversible if treatment is stopped. \u003cu\u003eThe use of Momendol, as with any drug that inhibits the synthesis of prostaglandins and cyclooxygenase, is not recommended in women who intend to become pregnant.\u003c\/u\u003e \u003cb\u003eThe administration of Momendol should be suspended in women who have fertility problems or who are undergoing investigations of fertility.\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\n\u003ch3\u003e Taking Momendol 220mg 12 softgels before driving or using machines - Does Momendol 220mg 12 softgels affect driving or using machines?\u003c\/h3\u003e\n\n\u003cp\u003e Due to the possible occurrence of drowsiness, dizziness, vertigo or insomnia Momendol may compromise the ability to drive and use machinery. In this case, avoid these activities or others that require particular vigilance.\u003c\/p\u003e","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51131277869383,"sku":"025829223","price":10.14,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-momendol-220mg-12-capsule-molli-farmacia-dottor-tili-1213792251.jpg?v=1767133609"},{"product_id":"momentact-400mg-8-bustine-sospensione-orale-10ml","title":"Momentact 400mg 8 sachets oral suspension 10ml","description":"\u003cp\u003e\u003cstrong\u003eMomentact 400mg\u003c\/strong\u003e is a drug based on \u003cstrong\u003eibuprofen\u003c\/strong\u003e , an active ingredient belonging to the class of NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), known for its \u003cstrong\u003eanalgesic, anti-inflammatory and antipyretic action\u003c\/strong\u003e . It is indicated for the treatment of \u003cstrong\u003emild and moderate pain\u003c\/strong\u003e , as well as for the control of fever. Thanks to its oral suspension formulation, Momentact 400mg guarantees \u003cstrong\u003erapid absorption\u003c\/strong\u003e and effective action, proving particularly useful for those who have difficulty swallowing tablets and need immediate relief.\u003c\/p\u003e\n\n\u003ch2\u003e Directions\u003c\/h2\u003e\n\n\u003ch3\u003e When is Momentact 400mg indicated?\u003c\/h3\u003e\n\n\u003cp\u003e Momentact 400mg is indicated for the treatment of:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eHeadache and migraine\u003c\/strong\u003e , including migraine episodes.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eMuscle and joint pain\u003c\/strong\u003e , even those resulting from trauma or inflammation.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eMenstrual cramps\u003c\/strong\u003e , helping to reduce cramps and abdominal tension.\u003c\/li\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eToothache\u003c\/strong\u003e and post-tooth extraction pain.\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eFever and flu symptoms\u003c\/strong\u003e , helping to lower body temperature and alleviate general malaise.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Active ingredients contained in Momentact 400mg 8 sachets oral suspension 10ml - What is the active ingredient in Momentact 400mg 8 sachets oral suspension 10ml?\u003c\/h3\u003e\n\n\u003cp\u003e Each sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e : ibuprofen 400 mg. \u003cu\u003eExcipients with known effects\u003c\/u\u003e : \u003cb\u003esucrose\u003c\/b\u003e , \u003cb\u003esucrose\u003c\/b\u003e monopalmitate, \u003cb\u003esodium\u003c\/b\u003e edetate dihydrate, \u003cb\u003emethyl parahydroxybenzoate\u003c\/b\u003e , \u003cb\u003epropyl parahydroxybenzoate\u003c\/b\u003e . For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Composition of Momentact 400mg 8 sachets oral suspension 10ml - What does Momentact 400mg 8 sachets oral suspension 10ml contain?\u003c\/h3\u003e\n\n \u003cp\u003eCetyl alcohol, \u003cb\u003esucrose\u003c\/b\u003e , xanthan gum, \u003cb\u003esucrose\u003c\/b\u003e monopalmitate, colloidal anhydrous silica, citric acid monohydrate, disodium edetate dihydrate, \u003cb\u003emethyl parahydroxybenzoate\u003c\/b\u003e , simethicone emulsion, \u003cb\u003e\u003cu\u003epropyl\u003c\/u\u003e parahydroxybenzoate\u003c\/b\u003e , red orange flavouring, purified water.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Therapeutic indications Momentact 400mg 8 sachets oral suspension 10ml - Why is Momentact 400mg 8 sachets oral suspension 10ml used? What is it used for?\u003c\/h3\u003e\n\n\u003cp\u003e Momentact is indicated in adults and adolescents over 12 years of age. Pain of various origins and nature (headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain). Adjuvant in the symptomatic treatment of feverish and flu states.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Contraindications Momentact 400mg 8 sachets oral suspension 10ml - When should Momentact 400mg 8 sachets oral suspension 10ml not be used?\u003c\/h3\u003e\n\n \u003cp\u003e• Hypersensitivity to the active substance (ibuprofen), to acetylsalicylic acid, to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients listed in section 6.1. • Children under 12 years of age. • Third trimester of pregnancy and breast-feeding (see section 4.6). • Active or severe gastroduodenal ulcer or other gastropathies. • History of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). • Severe hepatic or renal insufficiency. • Severe cardiac insufficiency (NYHA class IV). • Severe dehydration (caused by vomiting, diarrhoea or insufficient fluid intake).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\n\u003ch3\u003e Quantity and method of taking Momentact 400mg 8 sachets oral suspension 10ml - How to take Momentact 400mg 8 sachets oral suspension 10ml?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cb\u003eAdults and adolescents\u003c\/b\u003e aged \u003cb\u003e12 years and over:\u003c\/b\u003e 1 sachet 2-3 times a day. Do not exceed the dose of 1200 mg (3 single-dose sachets) per day. If the use of the medicinal product is necessary for more than 3 days in adolescents aged 12 years and over, or in case of worsening of symptoms, a doctor should be consulted. Do not exceed the recommended doses. Elderly patients should adhere to the minimum dosages indicated above (see section 4.4). Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). \u003ci\u003eRenal impairment\u003c\/i\u003e : in patients with mild or moderate reduction of renal function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and renal function should be monitored. \u003ci\u003eHepatic impairment\u003c\/i\u003e : In patients with mild or moderate reduction of liver function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and liver function should be monitored. Momentact is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePaediatric population\u003c\/i\u003e Momentact is contraindicated in children under 12 years of age (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e Momentact can be taken on an empty stomach. In subjects with gastric tolerability problems, it is preferable to take the medicine on a full stomach.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\n\u003ch3\u003e Storage Momentact 400mg 8 sachets oral suspension 10ml - How do you store Momentact 400mg 8 sachets oral suspension 10ml?\u003c\/h3\u003e\n\n\u003cp\u003e This medicinal product does not require any special storage conditions.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\n\u003ch3\u003e Warnings Momentact 400mg 8 sachets oral suspension 10ml - About Momentact 400mg 8 sachets oral suspension 10ml it is important to know that:\u003c\/h3\u003e\n\n \u003cp\u003e• In asthmatic patients the product should be used with caution, following medical evaluation. • The use of Momentact, as of any drug inhibiting the synthesis of prostaglandins and cyclooxygenase is not recommended in women intending to become pregnant. • The administration of Momentact should be suspended in women who have fertility problems or who are undergoing investigation of fertility. • Undesirable effects can be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). • Elderly: elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see paragraph 4.2). \u003cu\u003e• Cardiovascular and cerebrovascular effects\u003c\/u\u003e Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a modest increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration should also be exercised before initiating long-term treatment in patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses (2400 mg\/day) of ibuprofen are required. Caution is advised before initiating treatment in patients with a history of hypertension and\/or heart failure since fluid retention, hypertension and oedema have been reported in association with NSAID therapy. NSAIDs may reduce the effect of diuretics, and other antihypertensive agents (see section 4.5). \u003cu\u003e• Gastrointestinal bleeding, ulceration and perforation\u003c\/u\u003e The use of Momentact should be avoided in combination with NSAIDs, including cyclooxygenase-2 (COX-2) selective inhibitors due to an increased risk of ulceration or bleeding (see section 4.5). Gastrointestinal bleeding, ulceration and perforation, which may be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest dose available. Concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant acetylsalicylic acid or other drugs likely to increase GI risk (see below and section 4.5). Patients with a history of GI toxicity, particularly when elderly, should report any unusual GI symptoms (especially GI bleeding) particularly in the initial stages of treatment. Carefully monitor patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients receiving Momentact, the treatment should be withdrawn. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). \u003cu\u003e• Renal effects\u003c\/u\u003e When initiating treatment with ibuprofen, caution should be exercised in patients with considerable dehydration. Ibuprofen may cause water and sodium, potassium retention in patients with no history of renal disease due to its effects on renal perfusion. This may cause oedema or cardiac failure or hypertension in predisposed patients. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other pathological renal changes. In general, the habitual use of analgesics, especially combinations of several analgesic active ingredients, can lead to permanent renal damage, with risk of onset of renal failure (analgesic nephropathy). Renal toxicity has been observed in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. Administration of NSAIDs in these patients may result in a dose-dependent reduction in prostaglandin formation and, as a secondary effect, renal blood flow which can rapidly lead to renal failure. Patients most at risk of these reactions are those with reduced renal function, heart failure, liver dysfunction, the elderly and all those patients taking diuretics and ACE inhibitors. Discontinuation of NSAID therapy is usually followed by recovery to the pre-treatment state. There is a risk of impaired renal function in dehydrated adolescents. In case of prolonged use, renal function should be monitored, particularly in case of diffuse lupus erythematosus. \u003cu\u003e• Dermatological effects\u003c\/u\u003e Serious skin reactions, some \u003cu\u003eof\u003c\/u\u003e them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at higher risk in the early stages of therapy: the onset of the reaction occurs in the majority of cases within the first month of treatment. Momentact should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity, as well as if visual disturbances or persistent signs of liver dysfunction occur. \u003cu\u003e• Respiratory disorders\u003c\/u\u003e Momentact should be prescribed with caution in patients with bronchial asthma, chronic rhinitis, nasal polyps, sinusitis or allergic diseases, or with a history of allergic disease, because bronchospasm, urticaria and angioedema may occur. The same applies to those subjects who have experienced bronchospasm after the use of acetylsalicylic acid or other NSAIDs. \u003cu\u003e• Hypersensitivity reactions\u003c\/u\u003e Analgesics, antipyretics, NSAIDs, can cause hypersensitivity reactions, potentially serious (anaphylactoid reactions), even in subjects not previously exposed to this type of drug. The risk of hypersensitivity reactions after taking ibuprofen is greater in subjects who have shown such reactions after the use of other analgesics, antipyretics, NSAIDs and in subjects with bronchial hyperreactivity (asthma), hay fever, nasal polyposis or chronic obstructive respiratory diseases or previous episodes of angioedema (see sections 4.3 and 4.8). Hypersensitivity reactions may present themselves in the form of asthma attacks (so-called analgesic asthma), Quincke's oedema or urticaria. Serious hypersensitivity reactions (for example anaphylactic shock) have been observed rarely. At the first signs of hypersensitivity reaction after administration of ibuprofen, treatment should be stopped. Medically assisted measures should be initiated by specialized medical personnel, in line with the symptoms. \u003cu\u003e• Reduced cardiac, renal and hepatic function\u003c\/u\u003e Particular caution should be taken in the treatment of patients with reduced cardiac, hepatic or renal function since the use of NSAIDs may cause a deterioration of renal function. The habitual concomitant use of several painkillers may further increase this risk. In patients with reduced cardiac, hepatic or renal function, it is advisable to use the lowest effective dose for the shortest period of treatment and to periodically monitor clinical and laboratory parameters, especially in case of prolonged treatment. \u003cu\u003e• Haematological effects\u003c\/u\u003e Ibuprofen, like other NSAIDs, can inhibit platelet aggregation and has been shown to prolong bleeding time in healthy subjects. Therefore, patients with coagulation defects or on anticoagulant therapy should be carefully observed. \u003cu\u003e• Aseptic meningitis\u003c\/u\u003e Symptoms of aseptic meningitis have been observed on rare occasions in patients receiving ibuprofen. Although this is more likely to occur in patients with systemic lupus erythematosus and related connective tissue diseases, it has also been observed in patients without concomitant chronic diseases (see section 4.8). • Since ocular changes have been observed in animal studies with NSAIDs, periodic ophthalmological checks are recommended in case of prolonged treatment. • Alcohol consumption should be avoided as it may intensify the side effects of NSAIDs, especially those affecting the gastrointestinal tract or the central nervous system. Ibuprofen may mask the signs or symptoms of infection (fever, pain and swelling). \u003cu\u003eImportant information about some of the excipients\u003c\/u\u003e • Momentact contains: \u003cb\u003ePropyl and methyl parahydroxybenzoate\u003c\/b\u003e : may cause allergic reactions (possibly delayed) \u003cb\u003eSucrose\u003c\/b\u003e : patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. \u003cb\u003eSodium:\u003c\/b\u003e This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium-free”.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Interactions Momentact 400mg 8 sachets oral suspension 10ml - Which medicines or foods can modify the effect of Momentact 400mg 8 sachets oral suspension 10ml?\u003c\/h3\u003e\n\n \u003cp\u003e• Ibuprofen (like other NSAIDs) should be used with caution in combination with the substances listed below.• Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4). • Anticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin or heparin (see section 4.4). In case of concomitant treatment, monitoring of the coagulation status is recommended. • \u003ci\u003eAcetylsalicylic acid:\u003c\/i\u003e concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1). • Cyclooxygenase-2 (COX-2) inhibitors and other NSAIDs: these substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). It is advisable not to combine ibuprofen with acetylsalicylic acid or other NSAIDs, including selective COX-2 inhibitors, due to the potential additive effect (see section 4.4). • Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4). • Diuretics, ACE inhibitors (such as captopril), beta blockers and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of nephrotoxicity associated with NSAIDs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Momentact concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and thereafter. • Phenytoin and lithium: concomitant administration of ibuprofen and phenytoin or lithium preparations may result in reduced elimination of these drugs with consequent increase in their plasma levels with the possibility of reaching the toxic threshold. If this combination is deemed necessary, monitoring of the plasma levels of phenytoin and lithium is recommended in order to adapt the dosage during concomitant treatment with ibuprofen. • Methotrexate: NSAIDs may inhibit the tubular secretion of methotrexate and some metabolic interactions may occur with consequent reduction in the clearance of methotrexate and increased risk of toxicity. • Moclobemide: increases the effect of ibuprofen. • Aminoglycosides: NSAIDs may decrease the excretion of aminoglycosides, \u003cu\u003eincreasing\u003c\/u\u003e their toxicity. • Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides. Monitoring of serum glycoside levels is recommended. • Cholestyramine: Concomitant administration of ibuprofen and cholestyramine may reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is unknown. • Ciclosporin: Concomitant administration of ciclosporin and some NSAIDs causes an increased risk of renal damage. This effect cannot be excluded for the combination of ciclosporin and ibuprofen. • Plant extracts: Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs. • Mifepristone: Due to the anti-prostaglandin properties of NSAIDs, their use after mifepristone administration may reduce the effect of mifepristone. Limited evidence suggests that co-administration of NSAIDs and prostaglandins on the same day does not adversely affect the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination. • Quinolone antibiotics: Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions. • Sulfonylureas: NSAIDs may enhance the hypoglycaemic effect of sulfonylureas. In case of simultaneous treatment, monitoring of blood glucose levels is recommended. • Tacrolimus: Co-administration of NSAIDs and tacrolimus may increase the risk of nephrotoxicity. • Zidovudine: There is evidence of an increased risk of haemarthrosis and haematoma in HIV-positive haemophiliac patients receiving concomitant treatment with Zidovudine and other NSAIDs. A haematological examination is recommended 1-2 weeks after starting treatment. • Ritonavir: May cause an increase in plasma concentrations of NSAIDs. • Probenecid: Slows the excretion of ibuprofen, with possible increase in its plasma concentrations. • CYP2C9 inhibitors: Concomitant administration of ibuprofen and CYP2C9 inhibitors may slow the elimination of ibuprofen (CYP2C9 substrate) resulting in increased exposure to ibuprofen. In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)ibuprofen of approximately 80% to 100% was observed. Consideration should be given to reducing the dose of ibuprofen when co-administered with strong CYP2C9 inhibitors, particularly when high doses of ibuprofen are administered with voriconazole or fluconazole. • Alcohol, bisphosphonates and oxypentifylline (pentoxifylline): may enhance gastrointestinal side effects and the risk of bleeding and ulceration. • Baclofen: high toxicity of baclofen.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Like all medicines, Momentact 400mg 8 sachets oral suspension 10ml can cause side effects - What are the side effects of Momentact 400mg 8 sachets oral suspension 10ml?\u003c\/h3\u003e\n\n\u003cp\u003e The undesirable effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and are reported below using the following convention: Very common (≥1\/10), Common (≥1\/100, \u0026lt; 1\/10), Uncommon (≥ 1\/ 1,000, \u0026lt;1\/100), Rare (≥1\/10,000, \u0026lt; 1\/1,000), Very rare (\u0026lt;1\/10,000), Not known (frequency cannot be estimated from the available data). \u003c\/p\u003e\n\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\n\u003ctbody\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e Infections and infestations\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Rhinitis*\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Aseptic meningitis* Exacerbation of infection-related inflammation (e.g. development of necrotizing fasciitis).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Pathologies of the haemolymphopoietic system\u003c\/td\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e leukopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, inhibition of platelet aggregation\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n \u003ctd rowspan=\"4\"\u003eImmune system disorders\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Hypersensitivity reactions: various types of skin rash, urticaria, pruritus, purpura, angioedema, exanthema, bronchospasm, dyspnoea, asthmatic attack (sometimes with hypotension)\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Lupus erythematosus syndrome\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Severe hypersensitivity reactions: severe asthma, facial edema, tongue edema, laryngeal edema, airway edema with bronchospasm, dyspnoea, tachycardia, anaphylaxis, exfoliative and bullous dermatitis.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Not known\u003c\/td\u003e\n\n\u003ctd\u003e nonspecific allergic reaction and anaphylaxis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Psychiatric disorders\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Insomnia, anxiety\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e\u003c\/td\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Depression, confusion, hallucinations\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"3\"\u003e Nervous system disorders\u003c\/td\u003e\n\n\u003ctd\u003e Common\u003c\/td\u003e\n\n\u003ctd\u003e Dizziness\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Paresthesia, drowsiness\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Optic neuritis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e Eye pathologies\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Visual disturbances\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Ocular alteration resulting in visual disturbances, toxic optic neuropathy\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Ear and labyrinth pathologies\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Impaired hearing, tinnitus, vertigo\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Heart disease\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n \u003ctd\u003ePalpitations, heart failure, myocardial infarction, acute pulmonary edema\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e Vascular pathologies\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Hypertension\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Not known\u003c\/td\u003e\n\n\u003ctd\u003e Stroke **\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Respiratory, thoracic and mediastinal pathologies\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Bronchospasm, dyspnea, apnea\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"4\"\u003e Gastrointestinal disorders\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Gastritis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Pancreatitis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Gastrointestinal perforation\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Not known\u003c\/td\u003e\n\n\u003ctd\u003e Peptic ulcer, gastrointestinal haemorrhage. Sensation of heaviness in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, epigastric pain, heartburn, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e Hepatobiliary pathologies\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Abnormal liver function, hepatitis, jaundice\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Liver failure\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"3\"\u003e Skin and subcutaneous tissue disorders\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Allergic skin rash (erythema) Photosensitivity reaction\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n \u003ctd\u003eBullous dermatitis including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme. Skin infection and soft tissue disorder**\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Not known\u003c\/td\u003e\n\n\u003ctd\u003e Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome)\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e Kidney and urinary disorders\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Abnormal renal function, toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Hyperazotemia\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"2\"\u003e General pathologies and conditions related to the administration site\u003c\/td\u003e\n\n\u003ctd\u003e Common\u003c\/td\u003e\n\n\u003ctd\u003e Malaise, fatigue\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Edema\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Diagnostic tests\u003c\/td\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Increased transaminases, increased alkaline phosphatase, decreased hemoglobin, decreased hematocrit, prolonged bleeding time, decreased blood calcium, increased blood uric acid\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\n\u003c\/tbody\u003e\n\n\n\u003c\/table\u003e\n\n \u003cp\u003e*Rhinitis and aseptic meningitis have been observed especially in patients with pre-existing autoimmune disorders (such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). Exacerbation of infection-related inflammation (e.g. development of necrotising fasciitis) has been described. ** Clinical studies suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a modest increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). *** Serious skin infections and soft tissue disorders may occur during varicella infection. \u003ci\u003eReporting of suspected adverse reactions\u003c\/i\u003e Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eOVERDOSE\u003c\/h2\u003e\n\n\u003ch3\u003e Overdose Momentact 400mg 8 sachets oral suspension 10ml - What are the risks of Momentact 400mg 8 sachets oral suspension 10ml in case of overdose?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003eToxicity\u003c\/u\u003e Signs and symptoms of toxicity have not generally been observed at doses below 100 mg\/kg in children or adults. However, in some cases supportive treatment may be necessary. Children have been observed to exhibit signs and symptoms of toxicity after ingestion of ibuprofen at doses of 400 mg\/kg or greater. \u003cu\u003eSymptoms\u003c\/u\u003e Most patients who have ingested significant quantities of ibuprofen will exhibit symptoms within 4 to 6 hours. The most commonly reported symptoms of overdose include nausea, vomiting, abdominal pain, lethargy and somnolence. Central nervous system (CNS) effects include headache, tinnitus, dizziness, convulsions and loss of consciousness. Nystagmus, hypothermia, renal effects, gastrointestinal bleeding, coma, apnoea, diarrhoea and CNS and respiratory depression have also been reported rarely. Disorientation, excitement, fainting and cardiovascular toxicity including hypotension, bradycardia and tachycardia have been reported. Renal failure and liver damage are possible in cases of significant overdose. In cases of severe poisoning, metabolic acidosis may occur. \u003cu\u003eTreatment\u003c\/u\u003e There is no specific antidote for ibuprofen overdose. Symptomatic and supportive treatment is indicated in the event of overdose. Particular attention should be paid to monitoring blood pressure, acid-base balance and gastrointestinal bleeding. Administration of activated charcoal should be considered within one hour of ingestion of a potentially toxic amount. Alternatively, gastric lavage should be considered within one hour of ingestion of a potentially life-threatening overdose in adults. Adequate diuresis should be ensured and renal and hepatic function should be closely monitored. The patient should remain under observation for at least four hours following ingestion of a potentially toxic amount. If frequent or prolonged convulsions occur, they should be treated with intravenous diazepam. Other supportive measures may be necessary depending on the patient's clinical condition. Contact your local poison control center for more information.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Momentact 400mg 8 sachets oral suspension 10ml\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or the embryo-foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-foetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, Momentact should not be administered unless clearly necessary. If Momentact is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. \u003cb\u003e\u003cu\u003eDuring the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to\u003c\/u\u003e :\u003c\/b\u003e - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; \u003cb\u003e\u003cu\u003eAt the end of pregnancy, all prostaglandin synthesis inhibitors may expose the mother and the neonate to:\u003c\/u\u003e\u003c\/b\u003e - possible prolongation of bleeding time, and anti-aggregating effect which may occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, Momentact is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e Ibuprofen is excreted in breast milk, but at therapeutic doses during short-term treatment, the risk of influence on the neonate seems unlikely. If, however, treatment is longer term, early weaning should be considered. NSAIDs should be avoided during breastfeeding. \u003cu\u003eFertility\u003c\/u\u003e The use of Ibuprofen may impair female fertility and is not recommended in women attempting to conceive. This effect is reversible upon discontinuation of treatment. In women who have difficulties conceiving or who are undergoing investigation of infertility, discontinuation of ibuprofen treatment should be considered.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\n\u003ch3\u003e Taking Momentact 400mg 8 sachets oral suspension 10ml before driving or using machines - Does Momentact 400mg 8 sachets oral suspension 10ml affect driving or using machines?\u003c\/h3\u003e\n\n\u003cp\u003e The use of ibuprofen does not usually affect the ability to drive or use machines. However, those patients whose activities require alertness should exercise caution if they experience drowsiness, dizziness or depression during therapy with ibuprofen.\u003c\/p\u003e","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51131297661255,"sku":"035618077","price":10.23,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-momentact-400mg-8-bustine-sospensione-orale-10ml-farmacia-dottor-tili-1213792184.jpg?v=1767127109"},{"product_id":"momendol-10-gel-50g","title":"Momendol 10% gel 50g","description":"\u003cp\u003eMomendol 10% gel 50g is a topical treatment formulated to relieve \u003cstrong\u003emuscle and joint pain\u003c\/strong\u003e . It contains 10% w\/w \u003cstrong\u003enaproxen\u003c\/strong\u003e , an active ingredient known for its anti-inflammatory and analgesic properties. This gel is particularly indicated for conditions such as \u003cstrong\u003emyalgia, lumbago, stiff neck, bursitis, tendonitis, tenosynovitis, periarthritis, muscle strains, bruises and hematomas\u003c\/strong\u003e . Its formulation is enriched with a \u003cstrong\u003eD-Limonene aroma\u003c\/strong\u003e , which contributes to a more pleasant application. Momendol 10% gel is an ideal adjuvant in orthopedic and rehabilitation therapies, offering targeted and localized relief. Its application is simple and the gel is quickly absorbed, allowing an effective action directly on the affected area.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Active ingredients contained in Momendol 10% gel 50g - What is the active ingredient of Momendol 10% gel 50g?\u003c\/h3\u003e\n\n \u003cp\u003e1 g contains: Active ingredient: 100 mg naproxen (10% w\/w). Excipients with known effect: D-Limonene flavour. For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Composition of Momendol 10% gel 50g - What does Momendol 10% gel 50g contain?\u003c\/h3\u003e\n\n\u003cp\u003e Isopropyl alcohol, Trolamine, Glycerol, Hydroxyethylcellulose, Sodium hydroxide, Perfume containing menthol and eucalyptol, Purified water.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Therapeutic indications Momendol 10% gel 50g - Why is Momendol 10% gel 50g used? What is it used for?\u003c\/h3\u003e\n\n\u003cp\u003e Momendol 10% gel is indicated in adults and children over 12 years of age for the local treatment of pain in muscular and joint conditions such as myalgia, lumbago, stiff neck, bursitis, tendonitis, tenosynovitis, periarthritis, muscle strains, contusions, hematomas. Adjuvant to orthopedic and rehabilitation therapies.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Contraindications Momendol 10% gel 50g - When should Momendol 10% gel 50g not be used?\u003c\/h3\u003e\n\n \u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in section 6.1. Third trimester of pregnancy.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\n\u003ch3\u003e Quantity and method of taking Momendol 10% gel 50g - How to take Momendol 10% gel 50g?\u003c\/h3\u003e\n\n\u003cp\u003e \u003cu\u003eDosage\u003c\/u\u003e : Spread Momendol 10% gel on the site of pain 2 times a day. The duration of treatment should not exceed 7 days. \u003ci\u003ePaediatric population\u003c\/i\u003e : Momendol 10% gel is contraindicated in children under 12 years of age. The safety and efficacy of Momendol 10% gel in children under 12 years of age have not yet been established. No data are available. \u003cu\u003eMethod of administration\u003c\/u\u003e : \u003cu\u003eSpread Momendol 10% gel on the site of pain and massage lightly until completely absorbed.\u003c\/u\u003e\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONSERVATION\u003c\/h2\u003e\n\n\u003ch3\u003e Storage Momendol 10% gel 50g - How is Momendol 10% gel 50g stored?\u003c\/h3\u003e\n\n \u003cp\u003eThis medicine does not require any special temperature storage. Store in the original package with the cap closed in order to protect from light and evaporation.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\n\u003ch3\u003e Warnings Momendol 10% gel 50g - About Momendol 10% gel 50g it is important to know that:\u003c\/h3\u003e\n\n \u003cp\u003eAvoid using the gel on eyes, mucous membranes, wounds and\/or skin lesions. The amount of active ingredient absorbed through the skin does not reach blood concentrations that expose to the risk of side effects or that make the warnings relating to systemic administration of the drug applicable. However, the use of Momendol 10% gel is not recommended for patients in whom acetylsalicylic acid and\/or other NSAIDs induce allergic reactions and furthermore it is not recommended for use in patients with current allergic manifestations or a positive history. To prevent any hypersensitivity or photosensitivity phenomena, avoid exposure to direct sunlight, including solarium, during treatment and in the two weeks following. Discontinue treatment if skin rashes or irritation occur. This medicine contains a fragrance with D-Limonene. D-Limonene may cause allergic reactions.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e INTERACTIONS\u003c\/h2\u003e\n\n \u003ch3\u003eInteractions Momendol 10% gel 50g - Which medicines or foods can modify the effect of Momendol 10% gel 50g?\u003c\/h3\u003e\n\n\u003cp\u003e No \u003cb\u003einteraction\u003c\/b\u003e studies have been performed. The product is poorly absorbed systemically, therefore interactions with other drugs are unlikely, although they cannot be excluded.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e SIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Like all medicines, Momendol 10% gel 50g can cause side effects - What are the side effects of Momendol 10% gel 50g?\u003c\/h3\u003e\n\n\u003cp\u003e The following adverse reactions are listed below, organised according to MedDRA System Organ Class. Frequency is defined as follows: very common (≥1\/10), common (≥1\/100 to \u0026lt;1\/10), uncommon (≥1\/1,000 to \u0026lt;1\/100), rare (≥1\/10,000 to \u0026lt;1\/1,000), very rare (\u0026lt;1\/10,000), not known (frequency cannot be estimated from the available data). \u003c\/p\u003e\n\n\u003ctable border=\"\" cellspacing=\"\" cellpadding=\"\"\u003e\n\n\u003ctbody\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eMedDRA System Organ Class\/Frequency\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e \u003cb\u003eSIDE EFFECT\u003c\/b\u003e\n\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd colspan=\"\"\u003e \n\u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e \u003csup\u003e(1)\u003c\/sup\u003e\n\n\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Erythema, Pruritus, Skin irritation, Burning sensation of the skin, Contact dermatitis, Bullous eruption, Photosensitivity reaction\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd colspan=\"\"\u003e \u003cb\u003eImmune system disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Awareness \u003csup\u003e(2)\u003c\/sup\u003e\n\n\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd colspan=\"\"\u003e \u003cb\u003eSystemic disorders and conditions related to the administration site\u003c\/b\u003e\n\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Feeling of heat\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\n\u003c\/tbody\u003e\n\n\n\u003c\/table\u003e\n\n \u003cp\u003e\u003csup\u003e1)\u003c\/sup\u003e Adverse skin reactions have been reported with some non-steroidal anti-inflammatory drugs for cutaneous or transdermal use, derivatives of propionic acid. \u003csup\u003e2)\u003c\/sup\u003e The use, especially if prolonged, of products for topical use may give rise to sensitization phenomena. In this case, suspend treatment and adopt appropriate therapeutic measures. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\n\u003ch3\u003e Momendol 10% gel 50g Overdose - What are the risks of Momendol 10% gel 50g in case of overdose?\u003c\/h3\u003e\n\n\u003cp\u003e No case of overdose has been reported.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Momendol 10% gel 50g.\u003c\/h3\u003e\n\n\u003cp\u003e The risk of harmful effects on the fetus and\/or child is not excluded. Therefore, during pregnancy and\/or breastfeeding Momendol gel should be used at the discretion of the doctor and when strictly necessary. Momendol gel should not be used in the third trimester of pregnancy.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\n\u003ch3\u003e Take Momendol 10% gel 50g before driving or using machines - Does Momendol 10% gel 50g affect driving or using machines?\u003c\/h3\u003e\n\n\u003cp\u003e Momendol 10% gel does not alter the ability to drive vehicles or use machinery.\u003c\/p\u003e","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51131323023687,"sku":"025829197","price":11.07,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-momendol-10-gel-50g-farmacia-dottor-tili-1213792096.jpg?v=1767136332"},{"product_id":"stilla-decongestionante-0-05-collirio-8ml","title":"Decongestant Drop 0.05% Eye Drops 8ml","description":"Stilla decongestant 0.05% eye drops 8ml is an \u003cstrong\u003eeye drop\u003c\/strong\u003e formulated to relieve symptoms such as \u003cstrong\u003eirritation\u003c\/strong\u003e , \u003cstrong\u003eburning\u003c\/strong\u003e , \u003cstrong\u003eredness\u003c\/strong\u003e and \u003cstrong\u003eitching\u003c\/strong\u003e of the eyes, often caused by allergic or physical factors. This product contains the active ingredient \u003cstrong\u003eTetrizoline hydrochloride\u003c\/strong\u003e , known for its decongestant properties. It is particularly useful in situations of excessive exposure to \u003cstrong\u003esolar rays\u003c\/strong\u003e , \u003cstrong\u003esnow glare\u003c\/strong\u003e , \u003cstrong\u003edazzling headlights\u003c\/strong\u003e during night travel or \u003cstrong\u003edust\u003c\/strong\u003e in work environments. Stilla decongestant is available in a practical 8 ml bottle, ideal for frequent and targeted use. Thanks to its formulation, it offers rapid relief from eye discomfort, improving visual comfort.\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e  \u003ch3\u003eActive ingredients contained in Stilla decongestant 0.05% eye drops 8ml - What is the active ingredient in Stilla decongestant 0.05% eye drops 8ml?\u003c\/h3\u003e 100 ml contain: Active ingredient: Tetryzoline hydrochloride 0.05 g.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Stilla decongestant 0.05% eye drops 8ml - What does Stilla decongestant 0.05% eye drops 8ml contain?\u003c\/h3\u003e Eye drops bottle: boric acid 1.415 g - sodium tetraborate 0.05 g - sodium chloride 0.25 g - benzalkonium chloride 0.01 g - methylene blue 0.0015 g - water for injections qs. up to 100 ml. Eye drops single-dose containers: glycerol 1 g - boric acid 1.1 g - sodium borate 0.035 g - polysorbate 80 g 0.010 - water for injections qs. up to 100 ml.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Stilla decongestant 0.05% eye drops 8ml - Why is Stilla decongestant 0.05% eye drops 8ml used? What is it for? \u003c\/h3\u003eIrritation, burning, redness, itching of the eye due to allergic or physical causes (excessive exposure to solar rays or glare from snow or dazzling headlights when driving at night or dust in the workplace, etc.).\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Stilla decongestant 0.05% eye drops 8ml - When should Stilla decongestant 0.05% eye drops 8ml not be used?\u003c\/h3\u003e Hypersensitivity to the components or to other closely related substances from a chemical point of view. It should not be used in subjects with glaucoma or other serious eye diseases and in children under three years of age.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Stilla decongestant 0.05% eye drops 8ml - How do you take Stilla decongestant 0.05% eye drops 8ml? \u003c\/h3\u003eInstill 1 or 2 drops in each eye, 2–3 times a day. The product should not be used for more than 4 consecutive days. Do not exceed the recommended doses. In children under 12 years of age (and over 3 years of age), use the medicine only on the advice of a doctor.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Stilla decongestant 0.05% eye drops 8ml - How do you store Stilla decongestant 0.05% eye drops 8ml?\u003c\/h3\u003e \u003cu\u003e5 ml bottle and 8 ml bottle\u003c\/u\u003e : store at a temperature not exceeding 25°C. After first opening: store for a maximum of 28 days at a temperature not exceeding 25°C. \u003cu\u003e0.3 ml single-dose container\u003c\/u\u003e : no special precautions for storage. After opening the aluminum pouch, the product must be consumed within 30 days.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Stilla decongestant 0.05% eye drops 8ml - About Stilla decongestant 0.05% eye drops 8ml it is important to know that: \u003c\/h3\u003eThe product, although having poor systemic absorption, should be used with caution in patients with hypertension, hyperthyroidism, cardiac disorders, diabetes and in patients being treated with anti-MAO drugs (Tranylcypromine, Phenelzine, Pargilline). Infections, pus, foreign bodies in the eye, mechanical, chemical, heat damage require medical attention. If the symptoms, after a short period of treatment, persist or worsen, consult your doctor. Keep the product out of the reach of children as accidental ingestion may cause marked sedation. Stilla Decongestant single-dose eye drops are presented in single sterile doses, each of which contains the quantity of eye drops sufficient for one application to both eyes. The single-dose package protects the eye drops from any contamination and ensures their sterility and stability without the need for preservatives, therefore they can also be used by contact lens wearers. Allow 5 minutes to pass between using the eye drops and applying contact lenses.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Stilla decongestant 0.05% eye drops 8ml - Which medicines or foods can modify the effect of Stilla decongestant 0.05% eye drops 8ml?\u003c\/h3\u003e There are no notes.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Stilla decongestant 0.05% eye drops 8ml can cause side effects - What are the side effects of Stilla decongestant 0.05% eye drops 8ml?\u003c\/h3\u003e The use of the product can sometimes cause pupil dilation, increased intraocular pressure, nausea, headache. Hypersensitivity phenomena may rarely occur. Only with very high doses can hypertension, cardiac disorders or hyperglycemia occur. In these cases, treatment should be stopped and the doctor should be consulted so that, if necessary, appropriate therapy can be instituted.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Stilla decongestant 0.05% eye drops 8ml - What are the risks of Stilla decongestant 0.05% eye drops 8ml in case of overdose? \u003c\/h3\u003eThe product, if used for a long period at excessive doses, can cause toxic phenomena. In children, if accidentally ingested, the preparation can cause drowsiness, even deep and hypotonia. Notify your doctor immediately or go to the nearby hospital.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e PREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Stilla decongestant 0.05% eye drops 8ml.\u003c\/h3\u003e During pregnancy, breastfeeding and in children, use only if strictly necessary, after consulting your doctor.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\u003ch3\u003e Taking Stilla decongestant 0.05% eye drops 8ml before driving or using machinery - Does Stilla decongestant 0.05% eye drops 8ml affect driving or using machinery?\u003c\/h3\u003e With topical applications of tetryzoline no effects of any kind on the ability to drive vehicles or use other machinery have been reported.","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51131338031431,"sku":"015001023","price":8.09,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-stilla-decongestionante-0-05-collirio-8ml-farmacia-dottor-tili-1213792036.jpg?v=1767148668"},{"product_id":"gelenterum-20-bustine-bambini","title":"Gelenterum 20 sachets children","description":"\u003cp\u003e\u003cstrong\u003eGelenterum 20 sachets for children\u003c\/strong\u003e is a class III medical device, specifically formulated to support the physiological functions of the intestinal walls in children. This product is particularly indicated for the \u003cstrong\u003econtrol and reduction of symptoms related to diarrheal manifestations\u003c\/strong\u003e of various origins, such as abdominal tension and frequent stool emissions. Thanks to its formulation based on \u003cstrong\u003egelatin tannate\u003c\/strong\u003e , Gelenterum acts quickly, usually within 12 hours, offering effective and safe relief for the little ones.\u003c\/p\u003e\n\n \u003cp\u003eGelenterum sachets are designed for \u003cstrong\u003epediatric use\u003c\/strong\u003e , making them ideal for children aged 0 to 14 years. Their targeted action helps protect the intestinal mucosa, helping to restore normal intestinal balance and improve the child's general well-being. This product is a valuable ally for parents looking for a reliable and fast solution to deal with the symptoms of diarrhea in their children.\u003c\/p\u003e\n\n\u003cp\u003e Produced by Angelini, Gelenterum is available in packs of 20 sachets, ensuring an adequate supply to effectively address episodes of diarrhoea.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003e Dosage and method of use\u003c\/h2\u003e\n\n\u003ch3\u003e How do I use Gelenterum 20 sachets children?\u003c\/h3\u003e\n\n \u003cp\u003eAdults: It is recommended to take 1 or 2 capsules every 4-6 hours until the symptoms disappear. The dosage can be increased as needed and always after consulting your doctor. Children under 3 years: The recommended dose is 1 sachet every 6 hours until the symptoms disappear. Children from 3 to 14 years: The recommended dose is 1 or 2 sachets every 6 hours until the symptoms disappear.\u003c\/p\u003e\n\n\u003ch2\u003e Ingredients Gelenterum 20 sachets children\u003c\/h2\u003e\n\n\u003ch3\u003e What ingredients does Gelenterum 20 sachets for children contain?\u003c\/h3\u003e\n\n\u003cp\u003e Tannate of gelatin.\u003c\/p\u003e\n\n\u003ch2\u003e Gelenterum format 20 sachets children\u003c\/h2\u003e\n\n\u003cp\u003e • GelENTERUM sachets 250 mg, in packs of 20 (paediatric use). • GelENTERUM capsules 500 mg, in packs of 15.\u003c\/p\u003e","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51131338621255,"sku":"931147918","price":15.44,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-gelenterum-20-bustine-bambini-farmacia-dottor-tili-1213792030.jpg?v=1767148779"},{"product_id":"momenxsin-200mg-30mg-12-compresse-rivestite","title":"Momenxsin 200mg\/30mg 12 coated tablets","description":"\u003cp\u003eMomenxsin 200mg\/30mg 12 coated tablets is a combination medicine that combines the properties of \u003cstrong\u003eibuprofen\u003c\/strong\u003e and \u003cstrong\u003epseudoephedrine hydrochloride\u003c\/strong\u003e . Each coated tablet contains \u003cstrong\u003e200 mg of ibuprofen\u003c\/strong\u003e , a well-known nonsteroidal anti-inflammatory drug (NSAID) that helps reduce pain and inflammation, and \u003cstrong\u003e30 mg of pseudoephedrine hydrochloride\u003c\/strong\u003e , a decongestant that relieves nasal congestion. This product is indicated for the symptomatic treatment of \u003cstrong\u003enasal congestion\u003c\/strong\u003e associated with \u003cstrong\u003eacute rhinosinusitis\u003c\/strong\u003e of suspected viral origin, accompanied by \u003cstrong\u003eheadache\u003c\/strong\u003e and\/or \u003cstrong\u003efever\u003c\/strong\u003e . Momenxsin is intended for use in adults and adolescents aged 15 years and older. The tablets are coated to facilitate swallowing and improve gastrointestinal tolerability.\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\n \u003ch3\u003eActive ingredients contained in Momenxsin 200mg\/30mg 12 coated tablets - What is the active ingredient of Momenxsin 200mg\/30mg 12 coated tablets?\u003c\/h3\u003e\n\n\u003cp\u003e Each film-coated tablet contains 200 mg ibuprofen and 30 mg pseudoephedrine hydrochloride. \u003cu\u003eExcipient with known effect:\u003c\/u\u003e sodium. For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Composition of Momenxsin 200mg\/30mg 12 coated tablets - What does Momenxsin 200mg\/30mg 12 coated tablets contain?\u003c\/h3\u003e\n\n\u003cp\u003e \u003cu\u003eTablet core:\u003c\/u\u003e Microcrystalline cellulose; Calcium hydrogen phosphate anhydrous; Croscarmellose sodium \u003cb\u003e;\u003c\/b\u003e Maize starch; Colloidal anhydrous silica; Magnesium stearate. \u003cu\u003eTablet coating:\u003c\/u\u003e Hypromellose; Macrogol 400; Talc; Titanium dioxide (E171); Yellow iron oxide (E172).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Therapeutic indications Momenxsin 200mg\/30mg 12 coated tablets - Why is Momenxsin 200mg\/30mg 12 coated tablets used? What is it used for?\u003c\/h3\u003e\n\n \u003cp\u003eSymptomatic treatment of nasal congestion associated with acute rhinosinusitis of suspected viral origin with headache and\/or fever. Momenxsin is indicated in adults and adolescents aged 15 years and older.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Contraindications Momenxsin 200mg\/30mg 12 coated tablets - When should Momenxsin 200mg\/30mg 12 coated tablets not be used?\u003c\/h3\u003e\n\n \u003cp\u003e• Hypersensitivity to ibuprofen, pseudoephedrine hydrochloride or to any of the excipients listed in section 6.1; • Patients under 15 years of age; • Women in the third trimester of pregnancy (see section 4.6); • Breast-feeding women (see section 4.6); • Patients with a history of hypersensitivity reactions (e.g. bronchospasm, asthma, rhinitis, angioedema or urticaria) associated with acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs (NSAIDs); • History of gastrointestinal bleeding or perforation associated with previous NSAID therapy; • Current or history of recurrent peptic ulcer\/haemorrhage (at least two distinct episodes of proven ulceration or bleeding); • Cerebrovascular or other bleeding; • Haematopoietic abnormalities of unknown origin; • Severe hepatic insufficiency; • Severe renal insufficiency; • Severe cardiac insufficiency; • Severe cardiovascular disorders, coronary heart disease (heart disease, hypertension, angina pectoris), tachycardia, hyperthyroidism, diabetes, pheochromocytoma; • History of stroke or presence of risk factors for stroke (due to the α-–sympathomimetic activity of pseudoephedrine hydrochloride); • Risk of narrow-angle glaucoma; • Risk of urinary retention related to urethroprostatic disorders; • History of myocardial infarction; • History of seizures; • Systemic lupus erythematosus; • Concomitant use of other vasoconstrictors such as nasal decongestants, administered orally or nasally (e.g. phenylpropanolamine, phenylephrine and ephedrine), and methylphenidate (see section 4.5); • Concomitant use of non-selective monoamine oxidase inhibitors (MAOIs) (iproniazid) (see section 4.5) or use of monoamine oxidase inhibitors within the last two weeks.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\n\u003ch3\u003e Quantity and method of taking Momenxsin 200mg\/30mg 12 coated tablets - How to take Momenxsin 200mg\/30mg 12 coated tablets?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003eDosage.\u003c\/u\u003e \u003ci\u003eAdults and adolescents aged 15 years and over\u003c\/i\u003e : 1 tablet (equivalent to 200 mg ibuprofen and 30 mg pseudoephedrine hydrochloride) every 6 hours if necessary. In case of more intense symptoms, 2 tablets (equivalent to 400 mg ibuprofen and 60 mg pseudoephedrine hydrochloride) every 6 hours if necessary, up to a maximum total daily dose of 6 tablets (equivalent to 1200 mg ibuprofen and 180 mg pseudoephedrine hydrochloride). Do not exceed the maximum total daily dose of 6 tablets (equivalent to 1200 mg ibuprofen and 180 mg pseudoephedrine hydrochloride). For short-term use. \u003cb\u003eIf symptoms worsen, consult a doctor. The maximum duration of treatment is 4 days for adults and 3 days for adolescents aged 15 years and over.\u003c\/b\u003e In cases where the symptoms consist predominantly of pain\/fever or nasal congestion, the administration of a product containing a single active ingredient is preferable. \u003ci\u003eUndesirable effects can be limited by using the lowest effective dose for the shortest time necessary to control the symptoms (see section 4.4).\u003c\/i\u003e \u003ci\u003ePaediatric population\u003c\/i\u003e : Momenxsin is contraindicated in paediatric patients under 15 years of age (see section 4.3). \u003cu\u003eMethod of administration:\u003c\/u\u003e For oral use. The tablets should be swallowed whole and not chewed, with a glass of water, preferably during meals.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\n\u003ch3\u003e Storage Momenxsin 200mg\/30mg 12 coated tablets - How to store Momenxsin 200mg\/30mg 12 coated tablets?\u003c\/h3\u003e\n\n\u003cp\u003e Do not store above 30°C.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\n\u003ch3\u003e Warnings Momenxsin 200mg\/30mg 12 coated tablets - About Momenxsin 200mg\/30mg 12 coated tablets it is important to know that:\u003c\/h3\u003e\n\n \u003cp\u003eConcomitant use of Momenxsin and other NSAIDs, including selective cyclooxygenase (COX)-2 inhibitors, should be avoided. Undesirable effects may be minimised by using the lowest effective dose necessary to control symptoms for the shortest duration possible (see sections \"Gastrointestinal effects\" and \"Cardiovascular and cerebrovascular effects\" below). If symptoms persist beyond the maximum recommended duration of treatment with this medicinal product (4 days for adults and 3 days for adolescents), the measures to be implemented, in particular the possible usefulness of antibiotic treatment, should be reassessed. Acute rhinosinusitis of suspected viral origin is defined as a series of bilateral rhinological symptoms of moderate intensity, dominated by nasal congestion with severe or purulent rhinorrhoea, occurring in an epidemic context. The purulent aspect of rhinorrhoea is common and does not systematically correspond to bacterial superinfection. Sinus pain in the first few days of the disease is associated with congestion of the sinus mucosa (acute congestive rhinosinusitis) and resolves spontaneously in most cases. In case of acute bacterial sinusitis, antibiotic therapy is justified. \u003cb\u003e\u003ci\u003eSpecial warnings related to pseudoephedrine hydrochloride\u003c\/i\u003e :\u003c\/b\u003e • The dosage, the maximum recommended duration of treatment (4 days for adults and 3 days for adolescents) and contraindications must be strictly respected (see section 4.8); • Patients should be informed that treatment must be discontinued if hypertension, tachycardia, palpitations, cardiac arrhythmias, nausea or any neurological signs, such as the onset or worsening of headache, appear; • Ischemic colitis Some cases of ischemic colitis have been reported with pseudoephedrine. If sudden abdominal pain, rectal bleeding or other symptoms of ischemic colitis develop, pseudoephedrine should be discontinued and a doctor should be consulted. \u003ci\u003eSerious skin reactions:\u003c\/i\u003e Serious skin reactions such as acute generalized exanthematous pustulosis (AGEP) may occur with products containing pseudoephedrine. This acute pustular eruption may occur within the first 2 days of treatment, with fever and numerous, small, mostly non-follicular pustules arising from a widespread edematous erythema and located mainly on the skin folds, trunk and upper limbs. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema or numerous small pustules are observed, administration of Momenxsin should be discontinued and appropriate measures taken if necessary. Before using this medicine, patients should consult their doctor in case of: • hypertension, heart disease, hyperthyroidism, psychosis or diabetes; • concomitant use of antimigraine drugs, in particular vasoconstrictors based on ergot alkaloids (due to the α-sympathomimetic activity of pseudoephedrine); • mixed connective tissue disease: increased risk of aseptic meningitis (see section 4.8); • neurological symptoms such as seizures, hallucinations, behavioral disturbances, agitation and insomnia have been described following the administration of systemic vasoconstrictors, especially during febrile episodes or in case of overdose. These symptoms have been reported more commonly in the pediatric population. Therefore, it is advisable to: • avoid the administration of Momenxsin in association with drugs that can lower the epileptogenic threshold, such as terpene derivatives, clobutinol, atropine-like substances and local anaesthetics, or in the presence of a history of seizures; • strictly adhere, in all cases, to the recommended dosage and inform patients about the risks of overdose if Momenxsin is taken concomitantly with other medicinal products containing vasoconstrictors. Patients with urethroprostatic disorders are more likely to develop symptoms such as dysuria and urinary retention. Elderly patients may be more sensitive to the effects on the central nervous system (CNS). \u003cb\u003e\u003ci\u003ePrecautions for use relating to pseudoephedrine hydrochloride\u003c\/i\u003e :\u003c\/b\u003e • In patients who are to undergo scheduled surgery in which volatile halogenated anaesthetics are to be used, it is preferable to discontinue treatment with Momenxsin several days before the operation, in view of the risk of acute hypertension (see section 4.5); • Athletes should be informed that treatment with pseudoephedrine hydrochloride may result in positive anti-doping tests. \u003cu\u003eInterference with serological tests:\u003c\/u\u003e Pseudoephedrine may potentially reduce the uptake of iobenguane i-131 in neuroendocrine tumors, thus interfering with scintigraphy. \u003cb\u003e\u003ci\u003eSpecial warnings relating to ibuprofen\u003c\/i\u003e :\u003c\/b\u003e In patients suffering from bronchial asthma or allergic diseases or with a history of such diseases, bronchospasm may occur. In case of asthma, the product should not be taken without first consulting a doctor (see section 4.3). Patients with asthma associated with chronic rhinitis, chronic sinusitis and\/or nasal polyposis are at increased risk of allergic reactions when taking acetylsalicylic acid and\/or NSAIDs. Administration of Momenxsin may trigger an acute asthma attack, particularly in some patients allergic to acetylsalicylic acid or an NSAID (see section 4.3). Prolonged use of any type of painkiller for headache may cause worsening of the headache. If this situation is observed or suspected, medical advice should be sought and treatment discontinued. The diagnosis of medication-overuse headache (MOH) should be suspected in patients who experience frequent or daily headaches despite (or because of) the regular use of headache medications. Patients with blood clotting disorders should consult their doctor before using this medicine. \u003ci\u003e\u003cu\u003eGastrointestinal effects:\u003c\/u\u003e\u003c\/i\u003e Gastrointestinal bleeding, ulceration or perforation, sometimes fatal, have been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of GI events. The risk of gastrointestinal bleeding, ulceration or perforation, sometimes fatal, is increased with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with bleeding or perforation (see section 4.3), and in the elderly. These patients should start treatment on the lowest dose available. Combination therapy with gastroprotective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients and for those taking concomitant low dose acetylsalicylic acid or other medicinal products likely to increase gastrointestinal risk (see below and section 4.5). Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual abdominal symptoms (particularly gastrointestinal bleeding), particularly in the initial stages of treatment. Particular caution is advised in patients receiving concomitant treatment with drugs which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors (SSRIs) or anti-platelet agents such as acetylsalicylic acid (see section 4.5). Treatment with Momenxsin should be discontinued immediately if gastrointestinal bleeding or ulceration occurs. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). In case of concomitant intake of alcohol, the use of NSAIDs may increase the undesirable effects related to the active substance, in particular those involving the gastrointestinal tract or the central nervous system. \u003ci\u003e\u003cu\u003eCardiovascular and cerebrovascular effects:\u003c\/u\u003e\u003c\/i\u003e The following conditions are contraindicated due to the presence of pseudoephedrine hydrochloride (see section 4.3): severe cardiovascular disorders, coronary heart disease (heart disease, hypertension, angina pectoris), tachycardia, hyperthyroidism, diabetes, pheochromocytoma, history of stroke or presence of risk factors for stroke, history of myocardial infarction. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low-dose ibuprofen (e.g. ≤ 1200 mg\/day) is associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration should also be given before patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) undertake long-term treatment, particularly if high doses of ibuprofen (2400 mg\/day) are required. \u003ci\u003e\u003cu\u003eSevere skin reactions:\u003c\/u\u003e\u003c\/i\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk for these reactions in the early stages of therapy: the onset of the reaction occurs in most cases within the first month of treatment. Severe skin reactions, such as acute generalized exanthematous pustulosis (AGEP), may occur with medicinal products containing ibuprofen and pseudoephedrine. This acute pustular eruption may occur within the first 2 days of treatment, with fever and numerous, small, mostly non-follicular pustules, arising from a widespread edematous erythema and localized mainly in the skin folds, trunk and upper limbs. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema or numerous small pustules, as well as the appearance of a skin rash, mucosal lesions or any other sign of hypersensitivity are observed, the administration of Momenxsin should be discontinued and appropriate measures taken if necessary. \u003ci\u003eMasking of symptoms of underlying infections:\u003c\/i\u003e Momenxsin may mask the symptoms of infection, which may delay initiation of adequate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When Momenxsin is administered for the relief of infection-related fever or pain, monitoring for infection is advised. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. \u003cb\u003e\u003ci\u003ePrecautions for use related to ibuprofen:\u003c\/i\u003e\u003c\/b\u003e • Elderly: The pharmacokinetics of ibuprofen are not affected by age, therefore no dosage adjustment is necessary in the elderly. However, elderly patients should be carefully monitored, as they are more sensitive to adverse reactions related to NSAIDs, in particular gastrointestinal bleeding and perforation, which may be fatal; • Caution and special monitoring are required when ibuprofen is administered to patients with a history of gastrointestinal disease (such as peptic ulcer, hiatus hernia or gastrointestinal bleeding); • In the initial stages of treatment, careful monitoring of diuresis and renal function is necessary in patients with heart failure, in patients with chronic renal or hepatic impairment, in patients taking diuretics, in patients who are hypovolaemic due to major surgery and, in particular, in elderly patients. Dehydrated adolescents are at risk of renal damage; • If vision changes during treatment, the patient should undergo a complete ophthalmological examination. \u003ci\u003e\u003cu\u003eImportant information about some of the excipients.\u003c\/u\u003e\u003c\/i\u003e Momenxsin contains: - \u003cb\u003eSodium:\u003c\/b\u003e this medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially 'sodium-free'.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Interactions Momenxsin 200mg\/30mg 12 coated tablets - Which medicines or foods can modify the effect of Momenxsin 200mg\/30mg 12 coated tablets? \u003c\/h3\u003e\n\n\u003ctable border=\"\" cellspacing=\"\" cellpadding=\"\"\u003e\n\n\u003ctbody\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eAssociation of pseudoephedrine with:\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e \u003cb\u003ePossible reaction\u003c\/b\u003e\n\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Non-selective MAOIs (iproniazid)\u003c\/td\u003e\n\n\u003ctd\u003e Paroxysmal hypertension and hyperthermia, which may be fatal. Due to the long duration of action of MAOIs, this interaction may occur up to 15 days after discontinuation of the MAOI.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Other sympathomimetics or indirectly acting vasoconstrictors administered orally or nasally, α-sympathomimetic drugs, phenylpropanolamine, phenylephrine, ephedrine, methylphenidate\u003c\/td\u003e\n\n\u003ctd\u003e Risk of vasoconstriction and\/or hypertensive crisis.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Reversible inhibitors of monoamine oxidase A (RIMA), linezolid, dopaminergic ergot alkaloids, vasoconstrictor ergot alkaloids\u003c\/td\u003e\n\n\u003ctd\u003e Risk of vasoconstriction and\/or hypertensive crisis.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Volatile halogenated anesthetics\u003c\/td\u003e\n\n \u003ctd\u003eAcute perioperative hypertension. In case of scheduled surgery, stop taking Momenxsin several days in advance.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Guanethidine, reserpine and methyldopa\u003c\/td\u003e\n\n\u003ctd\u003e The effect of pseudoephedrine may be attenuated.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Tricyclic antidepressants\u003c\/td\u003e\n\n\u003ctd\u003e The effect of pseudoephedrine may be attenuated or enhanced.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Digitalis, quinidine or tricyclic antidepressants\u003c\/td\u003e\n\n\u003ctd\u003e Increased frequency of arrhythmias. \u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\n\u003c\/tbody\u003e\n\n\n\u003c\/table\u003e\n\n\u003ctable border=\"\" cellspacing=\"\" cellpadding=\"\"\u003e\n\n\u003ctbody\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eConcomitant use of ibuprofen with:\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e \u003cb\u003ePossible reaction\u003c\/b\u003e\n\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Other NSAIDs, including salicylates and selective COX-2 inhibitors\u003c\/td\u003e\n\n\u003ctd\u003e Concomitant administration of several NSAIDs may increase the risk of bleeding and gastrointestinal ulcers due to a synergistic effect. Therefore, concomitant use of ibuprofen with other NSAIDs should be avoided (see section 4.4).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Digoxin\u003c\/td\u003e\n\n \u003ctd\u003eConcomitant use of Momenxsin with digoxin preparations may increase the serum levels of the latter. With correct use (maximum 4 days), a control of serum digoxin levels is generally not necessary.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Corticosteroids\u003c\/td\u003e\n\n\u003ctd\u003e Corticosteroids may increase the risk of adverse reactions, particularly affecting the gastrointestinal tract (gastrointestinal bleeding or ulceration) (see section 4.3).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Anti-platelet agents\u003c\/td\u003e\n\n\u003ctd\u003e Increased risk of gastrointestinal bleeding (see section 4.4).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Acetylsalicylic acid\u003c\/td\u003e\n\n \u003ctd\u003eConcomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may cause competitive inhibition of the effect of low-dose acetylsalicylic acid on platelet aggregation when the two medicinal products are administered concomitantly. Although there are doubts as to the applicability of these data to clinical situations, the possibility that long-term regular use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Anticoagulants (e.g. warfarin, ticlopidine, clopidogrel, Tirofiban, eptifibatide, abciximab, iloprost)\u003c\/td\u003e\n\n\u003ctd\u003e NSAIDs such as ibuprofen may enhance the effects of anticoagulants (see section 4.4).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n \u003ctd\u003ePhenytoin\u003c\/td\u003e\n\n\u003ctd\u003e Concomitant use of Momenxsin with phenytoin preparations may increase the serum levels of the latter. With correct use (maximum 4 days), a control of phenytoin serum levels is generally not necessary.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Selective serotonin reuptake inhibitors (SSRIs)\u003c\/td\u003e\n\n\u003ctd\u003e Increased risk of gastrointestinal bleeding (see section 4.4).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Lithium\u003c\/td\u003e\n\n\u003ctd\u003e Concomitant use of Momenxsin with lithium preparations may increase the serum levels of the latter. With correct use (maximum 4 days), a control of serum lithium levels is generally not necessary.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Probenecid and sulfinpyrazone\u003c\/td\u003e\n\n\u003ctd\u003e Medicines containing probenecid or sulfinpyrazone may delay the excretion of ibuprofen.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Diuretics, ACE inhibitors, beta-blockers and angiotensin II antagonists\u003c\/td\u003e\n\n \u003ctd\u003eNSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function), the concomitant administration of ACE inhibitors, beta-blockers or angiotensin II antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, this combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and periodically thereafter.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Potassium-sparing diuretics\u003c\/td\u003e\n\n \u003ctd\u003eConcomitant administration of Momenxsin and potassium-sparing diuretics may cause hyperkalemia (monitoring of serum potassium levels is recommended).\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Methotrexate\u003c\/td\u003e\n\n\u003ctd\u003e Administration of Momenxsin within 24 hours before or after taking methotrexate may increase its concentrations and toxic effects.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Cyclosporine\u003c\/td\u003e\n\n\u003ctd\u003e The risk of renal damage induced by ciclosporin is increased by the concomitant use of some nonsteroidal anti-inflammatory drugs. This effect cannot be excluded even in the case of concomitant intake of ciclosporin and ibuprofen.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Tacrolimus\u003c\/td\u003e\n\n\u003ctd\u003e The risk of nephrotoxicity increases if the two drugs are administered concomitantly.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Zidovudine\u003c\/td\u003e\n\n\u003ctd\u003e There is evidence of an increased risk of haemarthrosis and haematoma in HIV (+) haemophiliac patients receiving concomitant treatment with zidovudine and ibuprofen.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Sulfonylureas\u003c\/td\u003e\n\n \u003ctd\u003eClinical studies have demonstrated the existence of interactions between nonsteroidal anti-inflammatory drugs and antidiabetic drugs (sulfonylureas). Although no interactions between ibuprofen and sulfonylureas have been described so far, when these two drugs are taken at the same time, it is advisable, as a precaution, to monitor blood sugar levels.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Quinolone antibiotics\u003c\/td\u003e\n\n\u003ctd\u003e Animal studies indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may be at increased risk of seizures.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Heparin; \u003ci\u003egingko biloba\u003c\/i\u003e\n\n\u003c\/td\u003e\n\n\u003ctd\u003e Increased risk of bleeding.\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\n\u003c\/tbody\u003e\n\n\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e SIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Like all medicines, Momenxsin 200mg\/30mg 12 coated tablets can cause side effects - What are the side effects of Momenxsin 200mg\/30mg 12 coated tablets?\u003c\/h3\u003e\n\n \u003cp\u003eThe most commonly observed adverse reactions related to ibuprofen are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal bleeding, even fatal, particularly in the elderly, may occur (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease have been reported following its administration (see section 4.4 Special warnings and precautions for use). Gastritis has been observed less frequently. In general, the risk of experiencing adverse reactions (particularly serious gastrointestinal complications) increases with increasing dose and duration of treatment. Hypersensitivity reactions have been reported following treatment with ibuprofen, which may include: (a) non-specific allergic reactions and anaphylaxis; (b) respiratory tract reactivity, including asthma, aggravated asthma, bronchospasm or dyspnoea; (c) various skin disorders, including rashes of various types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatoses (including epidermal necrolysis and erythema multiforme). In patients with active autoimmune disorders (such as systemic lupus erythematosus or mixed connective tissue disease), isolated cases of symptoms of aseptic meningitis, such as stiff neck, headache, nausea, vomiting, fever or disorientation, have been observed during treatment with ibuprofen. Oedema, hypertension and cardiac failure have been reported in association with the use of NSAIDs. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). The list of adverse reactions reported below refers to reactions seen with over-the-counter doses of ibuprofen and pseudoephedrine hydrochloride for short-term use. In the treatment of chronic conditions, additional adverse reactions may occur during long-term treatment. Patients should be advised to stop taking Momenxsin immediately and seek medical advice in the event of a serious adverse drug reaction. very common (≥1\/10); common (≥1\/100, \u0026lt;1\/10); uncommon (≥1\/1,000, \u0026lt;1\/100); rare (≥1\/10,000, \u0026lt;1\/1,000); very rare (\u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\n\u003ctable border=\"\" cellspacing=\"\" cellpadding=\"\"\u003e\n\n\u003ctbody\u003e\n\n\u003ctr\u003e\n\n \u003ctd\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/td\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Exacerbation of infectious inflammation (e.g. necrotizing fasciitis), aseptic meningitis (stiff neck, headache, nausea, vomiting, fever or disorientation) in patients with pre-existing autoimmune diseases (systemic lupus erythematosus (SLE), mixed connective tissue disease)\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003ePathologies of the haemolymphopoietic system\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Hematopoietic disorders (anemia, leukopenia, thrombocytopenia, pancytopenia, agranulocytosis)\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"\"\u003e \u003cb\u003eImmune system disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Hypersensitivity reactions with urticaria, itching and asthma attacks (with drop in blood pressure)\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Ibuprofen and Pseudoephedrine hydrochloride\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Severe generalized hypersensitivity reactions, the signs of which may be facial edema, angioedema, dyspnoea, tachycardia, reduction in blood pressure, anaphylactic shock\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"\"\u003e \u003cb\u003ePsychiatric disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Psychotic reactions, depression\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Pseudoephedrine hydrochloride\u003c\/td\u003e\n\n \u003ctd\u003eNot known\u003c\/td\u003e\n\n\u003ctd\u003e Agitation, hallucinations, anxiety, abnormal behavior, insomnia\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"\"\u003e \u003cb\u003eNervous system disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Central nervous system disorders, such as headache, dizziness, insomnia, agitation, irritability or tiredness\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Pseudoephedrine hydrochloride\u003c\/td\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Insomnia, nervousness, anxiety, restlessness, tremors, hallucinations\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Pseudoephedrine hydrochloride\u003c\/td\u003e\n\n\u003ctd\u003e Not known\u003c\/td\u003e\n\n\u003ctd\u003e Hemorrhagic stroke, ischemic stroke, seizures, headache\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eEye pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Vision problems\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eEar and labyrinth pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Tinnitus\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"\"\u003e \u003cb\u003eHeart disease\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Palpitations, heart failure, myocardial infarction\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Pseudoephedrine hydrochloride\u003c\/td\u003e\n\n\u003ctd\u003e Not known\u003c\/td\u003e\n\n\u003ctd\u003e Palpitations, tachycardia, chest pain, arrhythmia\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"\"\u003e \u003cb\u003eVascular pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e High blood pressure\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Pseudoephedrine hydrochloride\u003c\/td\u003e\n\n\u003ctd\u003e Not known\u003c\/td\u003e\n\n\u003ctd\u003e Hypertension\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eRespiratory, thoracic and mediastinal pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Pseudoephedrine hydrochloride\u003c\/td\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Exacerbation of asthma or hypersensitivity reaction with bronchospasm\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n \u003ctd rowspan=\"\"\u003e\u003cb\u003eGastrointestinal disorders\u003c\/b\u003e\u003c\/td\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Common\u003c\/td\u003e\n\n\u003ctd\u003e Gastrointestinal discomfort, dyspepsia, abdominal pain, nausea, vomiting, flatulence, diarrhoea, constipation, mild gastrointestinal bleeding which in rare cases leads to anaemia\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Gastrointestinal ulcers in some cases associated with bleeding and\/or perforation, gastritis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4)\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Esophagitis, pancreatitis, diaphragm-like intestinal stenosis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Pseudoephedrine hydrochloride\u003c\/td\u003e\n\n\u003ctd\u003e Not known\u003c\/td\u003e\n\n\u003ctd\u003e Dry mouth, thirst, nausea, vomiting, ischemic colitis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e \u003cb\u003eHepatobiliary pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Liver dysfunction, liver damage, especially in case of prolonged therapy, liver failure, acute hepatitis\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"\"\u003e \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Uncommon\u003c\/td\u003e\n\n\u003ctd\u003e Various skin rashes\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n \u003ctd\u003eBullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome), alopecia, severe skin infections and soft tissue complications in chickenpox infection\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Not known\u003c\/td\u003e\n\n\u003ctd\u003e Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome) Acute Generalized Exanthematous Pustulosis (AGEP)\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Pseudoephedrine hydrochloride\u003c\/td\u003e\n\n\u003ctd\u003e Not known\u003c\/td\u003e\n\n\u003ctd\u003e Rash, urticaria, pruritus, hyperhidrosis, severe skin reactions including acute generalized exanthematous pustulosis (AGEP)\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd rowspan=\"\"\u003e \u003cb\u003eKidney and urinary disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Rare\u003c\/td\u003e\n\n\u003ctd\u003e Damage to kidney tissue (papillary necrosis) and high concentrations of uric acid in the blood\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Ibuprofen\u003c\/td\u003e\n\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\n\u003ctd\u003e Increased serum creatinine, edema (particularly in patients with arterial hypertension or renal insufficiency), nephrotic syndrome, interstitial nephritis, acute renal failure\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003ctd\u003e Pseudoephedrine hydrochloride\u003c\/td\u003e\n\n\u003ctd\u003e Not known\u003c\/td\u003e\n\n\u003ctd\u003e Difficulty in urination\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\n\u003c\/tbody\u003e\n\n\n\u003c\/table\u003e\n\n \u003cp\u003e\u003ci\u003e\u003cu\u003eReporting of suspected adverse reactions:\u003c\/u\u003e\u003c\/i\u003e Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\n\u003ch3\u003e Overdose Momenxsin 200mg\/30mg 12 coated tablets - What are the risks of Momenxsin 200mg\/30mg 12 coated tablets in case of overdose?\u003c\/h3\u003e\n\n \u003cp\u003eThe clinical effects of overdose are most likely due to the presence of pseudoephedrine hydrochloride in this product, rather than ibuprofen. The effects are not clearly related to the dose taken because of the different sensitivity of different individuals to the sympathomimetic properties. \u003ci\u003eSymptoms due to the sympathomimetic effect\u003c\/i\u003e CNS depression: e.g. sedation, apnea, cyanosis, coma. CNS stimulation (more likely in children): e.g. insomnia, hallucinations, convulsions, tremors. In addition to the symptoms already mentioned as adverse effects, the following symptoms may occur: hypertensive crisis, cardiac arrhythmias, muscle weakness and tension, euphoria, excitement, thirst, chest pain, dizziness, tinnitus, ataxia, blurred vision, hypotension. \u003ci\u003eSymptoms related to ibuprofen (in addition to the gastrointestinal and neurological symptoms already mentioned as adverse effects)\u003c\/i\u003e Drowsiness, nystagmus, tinnitus, hypotension, loss of consciousness. In severe poisoning, metabolic acidosis may occur. \u003ci\u003eTherapeutic measures\u003c\/i\u003e There are no specific antidotes. If the patient presents within one hour of ingestion of a potentially toxic amount of the drug, oral activated charcoal may be considered. Monitoring of electrolytes and performing an ECG are also necessary. In case of cardiovascular instability and\/or symptomatic electrolyte imbalance, symptomatic treatment should be initiated.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Momenxsin 200mg\/30mg 12 coated tablets.\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003ePregnancy.\u003c\/u\u003e \u003ci\u003ePseudoephedrine hydrochloride:\u003c\/i\u003e Studies in animals have shown reproductive toxicity (see section 5.3). The use of pseudoephedrine hydrochloride reduces maternal uterine blood flow, but clinical data on the effects on pregnancy are insufficient. \u003ci\u003eIbuprofen\u003c\/i\u003e : Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or the embryonic\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage, cardiac malformation and gastroschisis following the use of prostaglandin synthesis inhibitors in early pregnancy. The risk is believed to increase proportionally with the dose and duration of therapy. Administration of a prostaglandin synthesis inhibitor to animals has been shown to result in increased pre- and post-implantation loss and embryonic\/foetal lethality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period. During the first and second trimesters of pregnancy, ibuprofen should not be given unless clearly necessary. If a woman attempting to conceive or who is in the first or second trimester of pregnancy must take ibuprofen, the dose and duration of treatment should be kept as low as possible. \u003cu\u003eDuring the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to:\u003c\/u\u003e - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which may progress to renal failure with oligohydramnios; \u003cu\u003ethe mother and child, at the end of pregnancy:\u003c\/u\u003e - possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, this medicinal product is: contraindicated in the third trimester of pregnancy and should be administered only when strictly necessary in the first and second trimester. \u003cu\u003eBreastfeeding:\u003c\/u\u003e The need to take measures during breastfeeding arises from the presence of pseudoephedrine hydrochloride in the formulation of the medicinal product: pseudoephedrine hydrochloride is excreted in breast milk. Taking into account the potential cardiovascular and neurological effects of vasoconstrictors, the use of this medicinal product is contraindicated during breastfeeding. \u003cu\u003eFertility:\u003c\/u\u003e There is evidence that cyclooxygenase\/prostaglandin synthesis inhibitors may impair female fertility by affecting ovulation. The effect is reversible upon discontinuation of treatment.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\n\u003ch3\u003e Taking Momenxsin 200mg\/30mg 12 coated tablets before driving or using machines - Does Momenxsin 200mg\/30mg 12 coated tablets affect driving or using machines?\u003c\/h3\u003e\n\n\u003cp\u003e Momenxsin slightly or moderately affects the ability to drive or use machines. Patients who experience dizziness, hallucinations, unusual headaches, and vision or hearing disturbances should avoid driving or using machines. Generally, a single administration or the use of this medicine for short periods does not require the adoption of any special precautions.\u003c\/p\u003e","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51131350778183,"sku":"043682020","price":9.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-momenxsin-200mg-30mg-12-compresse-rivestite-farmacia-dottor-tili-1213791971.jpg?v=1767149890"},{"product_id":"alaxa-5mg-20-compresse-gastroresistenti","title":"Alaxa 5mg 20 gastro-resistant tablets","description":"Alaxa 5mg 20 gastro-resistant tablets is a medicine indicated for the \u003cstrong\u003eshort-term treatment of occasional constipation\u003c\/strong\u003e . Each tablet contains \u003cstrong\u003ebisacodyl 5 mg\u003c\/strong\u003e as the active ingredient, known for its effectiveness in promoting intestinal transit. The tablets are designed to be \u003cstrong\u003egastro-resistant\u003c\/strong\u003e , ensuring that the active ingredient is released into the intestine, where it is most effective. This medicine is formulated with excipients such as \u003cstrong\u003elactose monohydrate\u003c\/strong\u003e and \u003cstrong\u003esucrose\u003c\/strong\u003e , which contribute to its stability and absorption. Alaxa is a targeted solution for those looking for an effective remedy against constipation, with a rapid and targeted action.\n\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e  \u003ch3\u003eActive ingredients contained in Alaxa 5mg 20 gastro-resistant tablets - What is the active ingredient of Alaxa 5mg 20 gastro-resistant tablets?\u003c\/h3\u003e Each gastro-resistant tablet contains: Active substance: bisacodyl 5 mg; Excipients with known effect: lactose monohydrate, sucrose, \u003cb\u003esodium\u003c\/b\u003e carboxymethylcellulose. For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Alaxa 5mg 20 gastro-resistant tablets - What does Alaxa 5mg 20 gastro-resistant tablets contain?\u003c\/h3\u003e \u003ci\u003eTablet core\u003c\/i\u003e : \u003cb\u003elactose monohydrate\u003c\/b\u003e , maize starch, magnesium stearate, gelatin. \u003ci\u003eGastro-resistant film coating\u003c\/i\u003e : diethyl phthalate, cellulose acetophthalate, talc. \u003ci\u003eSugar coating\u003c\/i\u003e : acacia, \u003cb\u003esucrose\u003c\/b\u003e , \u003cb\u003esodium\u003c\/b\u003e carboxymethylcellulose, macrogol 6000, titanium dioxide, calcium carbonate, talc.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Alaxa 5mg 20 gastro-resistant tablets - Why is Alaxa 5mg 20 gastro-resistant tablets used? What is it used for? \u003c\/h3\u003eShort-term treatment of occasional constipation.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Alaxa 5mg 20 gastro-resistant tablets - When should Alaxa 5mg 20 gastro-resistant tablets not be used?\u003c\/h3\u003e - Hypersensitivity to the active substance or to other chemically related substances or to any of the excipients listed in section 6.1. - Children under 3 years of age. - Generally contraindicated during pregnancy and breastfeeding (see section 4.6). - Subjects with acute or unknown origin abdominal pain, nausea or vomiting, intestinal obstruction or stenosis, rectal bleeding of unknown origin, severe dehydration, acute surgical abdomen, appendicitis, gastroenteritis.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Alaxa 5mg 20 gastro-resistant tablets - How to take Alaxa 5mg 20 gastro-resistant tablets? \u003c\/h3\u003e\n\u003cu\u003eDosage\u003c\/u\u003e : 2 tablets per day; in particularly stubborn cases, 3 tablets. \u003ci\u003ePaediatric population\u003c\/i\u003e . \u003cu\u003eChildren aged between 3 and 12 years\u003c\/u\u003e : 1-2 tablets per day (0.3 mg\/kg) under direct medical supervision. The correct dose is the minimum sufficient to produce easy evacuation of soft stools. It is advisable to initially use the minimum doses indicated. When necessary, the dose can then be increased, but without ever exceeding the maximum indicated. Laxatives should be used as infrequently as possible and for no more than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. \u003cu\u003eMethod of administration\u003c\/u\u003e : The tablets should be swallowed whole, without chewing, together with an adequate quantity of water (a large glass). A diet rich in liquids promotes the effect of the medicine. The tablets should preferably be administered after the evening meal, so that the effect of the laxative, which occurs after 10-12 hours, does not disturb sleep. If taken on an empty stomach, the laxative effect occurs within approximately 5 hours. Take ALAXA at ​​least 1 hour after taking milk or antacids and at least two hours after taking other oral medications.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Alaxa 5mg 20 gastro-resistant tablets - How to store Alaxa 5mg 20 gastro-resistant tablets?\u003c\/h3\u003e This medicine does not require any special temperature storage conditions. Store in the original package in order to protect from moisture.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Alaxa 5mg 20 gastro-resistant tablets - About Alaxa 5mg 20 gastro-resistant tablets it is important to know that: \u003c\/h3\u003eAbuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutrients. In the most serious cases, dehydration or hypokalemia may occur, which can cause cardiac or neuromuscular dysfunction, especially in the case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. Abuse of laxatives, especially contact laxatives (stimulant laxatives), can also cause dependence (and therefore, possible need to gradually increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). Frequent or prolonged use of the medicine should be avoided as it can cause addiction and atonic colitis. Treatment of chronic or recurrent constipation always requires medical intervention for diagnosis, prescription of drugs and monitoring during therapy. Caution is recommended if the need for a laxative arises from a sudden change in previous bowel habits (frequency and characteristics of bowel movements) that lasts for more than two weeks; when rectal bleeding is present; when the use of a laxative fails to produce effects or when the patient suffers from diabetes mellitus, hypertension or heart disease. It is also advisable for elderly or unhealthy subjects to consult their doctor before using the medicine. \u003ci\u003ePaediatric population\u003c\/i\u003e : In children under 12 years of age, the medicine can only be used after consulting your doctor. \u003cu\u003eImportant information about some of the excipients:\u003c\/u\u003e ALAXA contains: - lactose monohydrate: patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine; - sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. - sodium: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Alaxa 5mg 20 gastro-resistant tablets - Which medicines or foods can modify the effect of Alaxa 5mg 20 gastro-resistant tablets?\u003c\/h3\u003e Milk or antacids may alter the effect of the medicine; leave an interval of at least one hour before taking the laxative. Concomitant use of diuretics, cardiac glycosides or adrenocorticosteroids may promote electrolyte imbalance. Laxatives may reduce the time spent in the intestine, and therefore the absorption, of other drugs administered simultaneously orally. Therefore, avoid taking laxatives and other drugs at the same time: after taking a medicine, leave an interval of at least 2 hours before taking the laxative.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Alaxa 5mg 20 gastro-resistant tablets can cause side effects - What are the side effects of Alaxa 5mg 20 gastro-resistant tablets? \u003c\/h3\u003eOccasionally: isolated cramping pain or abdominal colic. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Alaxa 5mg 20 gastro-resistant tablets - What are the risks of Alaxa 5mg 20 gastro-resistant tablets in case of overdose? \u003c\/h3\u003eExcessive doses may cause abdominal pain and diarrhea; the resulting fluid and electrolyte losses must be replaced. Muscle weakness and weight loss may occur. In case of accidental overdose, gastric lavage is indicated. See also paragraph 4.4 regarding laxative abuse.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e PREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Alaxa 5mg 20 gastro-resistant tablets.\u003c\/h3\u003e There are no adequate and well-controlled studies on the use of the medicinal product during pregnancy or breastfeeding. Therefore, the medicinal product should be used only when necessary, under the direct supervision of a doctor, after evaluating the expected benefit for the mother in relation to the possible risk for the fetus or the infant.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e  \u003ch3\u003eTaking Alaxa 5mg 20 gastro-resistant tablets before driving or using machines - Does Alaxa 5mg 20 gastro-resistant tablets affect driving or using machines?\u003c\/h3\u003e There are no restrictions. However, those who perform an activity that requires vigilance should exercise caution.","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51131368341831,"sku":"009262015","price":7.51,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-alaxa-5mg-20-compresse-gastroresistenti-farmacia-dottor-tili-1213791893.jpg?v=1767150208"},{"product_id":"moment-200mg-10-capsule-molli","title":"Moment 200mg 10 softgels","description":"\u003cp\u003e\u003cstrong\u003eMoment 200mg 10 soft capsules\u003c\/strong\u003e is a drug based on \u003cstrong\u003eibuprofen\u003c\/strong\u003e , an active ingredient belonging to the class of nonsteroidal anti-inflammatory drugs (NSAIDs). It is indicated for the treatment of \u003cstrong\u003epain of various origins and nature\u003c\/strong\u003e , such as headache, toothache, neuralgia, osteoarticular and muscular pain, as well as menstrual pain. Furthermore, Moment is an adjuvant in the symptomatic treatment of feverish and flu states. Each capsule contains 200 mg of ibuprofen, formulated for rapid absorption and effective analgesic and anti-inflammatory action. The soft capsules are designed to facilitate swallowing and improve the bioavailability of the active ingredient.\u003cbr\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Active ingredients contained in Moment 200mg 10 soft capsules - What is the active ingredient in Moment 200mg 10 soft capsules?\u003c\/h3\u003e\n\n\u003cp\u003e Each capsule contains: \u003cu\u003eActive substance\u003c\/u\u003e : ibuprofen 200 mg. For a full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\n \u003ch3\u003eComposition of Moment 200mg 10 soft capsules - What does Moment 200mg 10 soft capsules contain?\u003c\/h3\u003e\n\n\u003cp\u003e Macrogol 600, potassium hydroxide, gelatin, partially dehydrated liquid sorbitol, purified water, Ponceau 4R (E124), lecithin, fractionated coconut oil.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Therapeutic indications Moment 200mg 10 soft capsules - Why is Moment 200mg 10 soft capsules used? What is it used for?\u003c\/h3\u003e\n\n\u003cp\u003e Pain of various origins and nature (headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain). Adjuvant in the symptomatic treatment of feverish and flu states.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Contraindications Moment 200mg 10 soft capsules - When should Moment 200mg 10 soft capsules not be used?\u003c\/h3\u003e\n\n \u003cp\u003e• Do not administer to children under 12 years of age. • Pregnancy and breastfeeding. • Hypersensitivity to the active substance, to other antirheumatics (acetylsalicylic acid, etc.) or to any of the excipients. • Active or severe gastroduodenal ulcer or other gastropathies. • History of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). • Severe hepatic or renal insufficiency. • Severe cardiac insufficiency.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\n\u003ch3\u003e Quantity and method of taking Moment 200mg 10 soft capsules - How to take Moment 200mg 10 soft capsules?\u003c\/h3\u003e\n\n \u003cp\u003eAdults and adolescents over 12 years: 1–2 capsules, 2–3 times a day. Do not exceed the dose of 6 capsules per day. If the use of the medicine is necessary for more than 3 days in adolescents, or in case of worsening of symptoms, a doctor should be consulted. Do not exceed the recommended doses; in particular, elderly patients should stick to the minimum dosages indicated above. Take the product on a full stomach.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONSERVATION\u003c\/h2\u003e\n\n\u003ch3\u003e Storage Moment 200mg 10 soft capsules - How to store Moment 200mg 10 soft capsules?\u003c\/h3\u003e\n\n\u003cp\u003e Store below 25°C.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\n\u003ch3\u003e Warnings Moment 200mg 10 soft capsules - About Moment 200mg 10 soft capsules it is important to know that:\u003c\/h3\u003e\n\n \u003cp\u003e• In asthmatic patients the product should be used with caution, after consulting a doctor. • Patients whose activity requires alertness should be cautious if they notice drowsiness, dizziness or depression during therapy with ibuprofen. • The use of Moment, as with any drug inhibiting the synthesis of prostaglandins and cyclooxygenase, is not recommended in women intending to become pregnant. • The administration of Moment should be suspended in women who have fertility problems or who are undergoing investigation of fertility. • The use of Moment should be avoided in conjunction with NSAIDs, including selective COX-2 inhibitors. • Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). • Cardiovascular and cerebrovascular effects: Clinical trial and epidemiological data suggest that use of ibuprofen, particularly at high doses (2400 mg\/day) and in long term treatment, may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low dose ibuprofen (e.g. ≤ 1200 mg\/day) is associated with an increased risk of myocardial infarction. • There is a risk of impaired renal function in dehydrated adolescents. • Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2). • Gastrointestinal bleeding, ulceration and perforation: Gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. • The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest dose available. Concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients taking low dose aspirin or other drugs likely to increase GI risk (see below and section 4.5). • Patients with a history of GI toxicity, particularly when elderly, should report any unusual GI symptoms (especially GI bleeding) particularly in the initial stages of treatment. • Carefully monitor patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as aspirin (see section 4.5). • If gastrointestinal bleeding or ulceration occurs in patients receiving Moment, the treatment should be withdrawn. • NSAIDs should be given with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). • Caution is advised before initiating treatment in patients with a history of hypertension and\/or heart failure as fluid retention, hypertension and oedema have been reported in association with NSAID therapy. • Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens–Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk early in the course of therapy: the onset of the reaction occurs in the majority of cases within the first month of treatment. Moment should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. • MOMENT capsules contain: – sorbitol: patients with rare hereditary problems of fructose intolerance should not take this medicine; – Ponceau 4R (E124): may cause allergic reactions.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Interactions Moment 200mg 10 soft capsules - Which medicines or foods can modify the effect of Moment 200mg 10 soft capsules?\u003c\/h3\u003e\n\n \u003cp\u003e• Possible interactions with coumarin-type anticoagulants should be taken into account: patients undergoing treatment with such drugs should consult their doctor before taking the product. It is also advisable to seek medical advice in the case of any concomitant therapy before administering the product. • Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4). • Anticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin (see section 4.4). • Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4). • Diuretics, ACE inhibitors and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Moment concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. • Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy. • Experimental data indicate that ibuprofen may inhibit the effects of low-dose acetylsalicylic acid on platelet aggregation when the drugs are administered concomitantly. However, the limited data and the uncertainties regarding their application to the clinical situation do not allow definitive conclusions to be drawn for the continuous use of ibuprofen; there appears to be no clinically relevant effect from occasional use of ibuprofen (see section 5.1).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Like all medicines, Moment 200mg 10 soft capsules can cause side effects - What are the side effects of Moment 200mg 10 soft capsules?\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003eSkin effects\u003c\/u\u003e Allergic skin rashes (erythema, pruritus, urticaria) may occasionally occur. Bullous reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (very rarely). \u003cu\u003eGastrointestinal effects\u003c\/u\u003e The most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal haemorrhage, sometimes fatal, particularly in the elderly, may occur (see section 4.4). The following have been reported following administration of Moment: feeling of heaviness in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Less frequently, gastritis has been observed. \u003cu\u003eCardiovascular effects\u003c\/u\u003e Oedema, hypertension and cardiac failure have been reported in association with treatment with NSAIDs. Clinical trial and epidemiological data suggest that use of ibuprofen (particularly at high doses 2400 mg\/day) and in long-term treatment may be associated with a modest increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). These phenomena rapidly regress upon discontinuation of treatment.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eOVERDOSE\u003c\/h2\u003e\n\n\u003ch3\u003e Overdose Moment 200mg 10 softgels - What are the risks of Moment 200mg 10 softgels in case of overdose?\u003c\/h3\u003e\n\n\u003cp\u003e In case of overdose, gastric lavage and correction of blood electrolytes are indicated. There is no specific antidote for ibuprofen.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e PREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Moment 200mg 10 soft capsules.\u003c\/h3\u003e\n\n \u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or the embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose: \u003cu\u003ethe fetus to\u003c\/u\u003e : – cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); – renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; \u003cu\u003ethe mother and the neonate, at the end of pregnancy, to\u003c\/u\u003e : – possible prolongation of bleeding time, and anti-aggregating effect which may occur even at very low doses; – inhibition of uterine contractions resulting in delayed or prolonged labor.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\n\u003ch3\u003e Take Moment 200mg 10 softgels before driving or using machines - Does Moment 200mg 10 softgels affect driving or using machines?\u003c\/h3\u003e\n\n\u003cp\u003e The use of ibuprofen does not usually affect the ability to drive or use other machines. However, those patients whose activities require alertness should exercise caution if they experience drowsiness, dizziness or depression during therapy with ibuprofen.\u003c\/p\u003e","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51131368538439,"sku":"025669197","price":7.25,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-moment-200mg-10-capsule-molli-farmacia-dottor-tili-1213791896.jpg?v=1767150270"},{"product_id":"ginetantum-500mg-10-bustine-granulato-per-soluzione-cutanea-per-genitali-esterni","title":"Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia","description":"\u003cp\u003eGinetantum 500mg 10 sachets granules for cutaneous solution for external genitalia is a product specifically formulated for the treatment of \u003cstrong\u003evulvovaginitis\u003c\/strong\u003e of any origin and nature, with a prevalent vulvar component. This granules, containing \u003cstrong\u003ebenzydamine hydrochloride\u003c\/strong\u003e as an active ingredient, is indicated to relieve symptoms such as small vaginal discharge, itching, irritation, burning and vulvar pain. It is particularly useful for \u003cstrong\u003eintimate hygiene during the puerperium\u003c\/strong\u003e . Each sachet is designed to be dissolved in water, creating an effective cutaneous solution for washing the external genitalia. The formulation also includes a base rose scent, which contributes to a more pleasant experience of use. Ginetantum is a targeted option for those seeking relief from vulvar discomfort, ensuring a localized and specific action.\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\n \u003ch3\u003eActive ingredients contained in Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia - What is the active ingredient of Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia?\u003c\/h3\u003e\n\n\u003cp\u003e Each sachet contains: active ingredient: benzydamine hydrochloride 500 mg. Each vial contains: active ingredient: benzydamine hydrochloride 500 mg. Excipients with known effect: rose fragrance base (Benzyl alcohol, Benzyl benzoate, Benzyl cinnamate, Benzyl salicylate, Citral, Citronellol, Eugenol, Farnesol, Geraniol, Limonene Linanool) For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\n\u003ch3\u003e Composition of Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia - What does Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia contain?\u003c\/h3\u003e\n\n \u003cp\u003eGranules for cutaneous solution: trimethylcetylammonium-p-toluenesulfonate, sodium chloride, povidone. Concentrate for cutaneous solution: trimethylcetylammonium-p-toluenesulfonate, \u003cb\u003erose fragrance base\u003c\/b\u003e , purified water.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Therapeutic indications Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia - Why is Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia used? What is it used for?\u003c\/h3\u003e\n\n\u003cp\u003e Vulvovaginitis of any origin and nature with a prevalent vulvar component, characterized by small vaginal discharge, itching, irritation, burning and vulvar pain. Intimate hygiene during puerperium.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Contraindications Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia - When should Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia not be used?\u003c\/h3\u003e\n\n\u003cp\u003e Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\n \u003ch3\u003eQuantity and method of taking Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia - How do you take Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia?\u003c\/h3\u003e\n\n\u003cp\u003e \u003cu\u003eDosage\u003c\/u\u003e Use to wash the external genitals once or twice a day for up to 7 days. \u003cu\u003eMethod of administration\u003c\/u\u003e Dissolve the contents of 1-2 sachets or 1-2 vials in 1 litre of water.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e CONSERVATION\u003c\/h2\u003e\n\n\u003ch3\u003e Storage Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia - How do you store Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia?\u003c\/h3\u003e\n\n\u003cp\u003e This medicinal product does not require any special storage conditions.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\n\u003ch3\u003e Warnings Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia - About Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia it is important to know that:\u003c\/h3\u003e\n\n \u003cp\u003eGinetantum must be used locally for washing the external genitalia. It should not be ingested. Use of the product, especially if prolonged, could give rise to sensitization phenomena. In this case, treatment must be suspended and appropriate therapeutic measures must be adopted. Instruct the patient to contact the doctor before use in case of vaginal bleeding and\/or leucorrhoea.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e INTERACTIONS\u003c\/h2\u003e\n\n\u003ch3\u003e Interactions Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia - Which medicines or foods can modify the effect of Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia?\u003c\/h3\u003e\n\n\u003cp\u003e Not known\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e SIDE EFFECTS\u003c\/h2\u003e\n\n\u003ch3\u003e Like all medicines, Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia can cause side effects - What are the side effects of Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia?\u003c\/h3\u003e\n\n \u003cp\u003eOccasionally, especially with prolonged use of the product, skin irritation may occur. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important, as it allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/u\u003e .\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\n\u003ch3\u003e Overdose Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia - What are the risks of Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia in case of overdose?\u003c\/h3\u003e\n\n \u003cp\u003eIntoxication is expected only in case of accidental ingestion of large quantities of benzydamine (\u0026gt;300 mg). Symptoms associated with overdose by ingestion of benzydamine are mainly gastrointestinal and central nervous system symptoms. The most frequent gastrointestinal symptoms are nausea, vomiting, abdominal pain and esophageal irritation. Central nervous system symptoms include dizziness, hallucinations, agitation, anxiety and irritability. In case of acute overdose, only symptomatic treatment is possible. Patients should be kept under close observation, and should receive supportive treatment. Adequate hydration should be maintained.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e PREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia.\u003c\/h3\u003e\n\n \u003cp\u003eThere are no contraindications to the topical use of benzydamine during pregnancy or breastfeeding.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\n\u003ch3\u003e Taking Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia before driving or using machines - Does Ginetantum 500mg 10 sachets granules for cutaneous solution for external genitalia affect driving or using machines?\u003c\/h3\u003e\n\n\u003cp\u003e Ginetantum does not alter the ability to drive vehicles or use\u003c\/p\u003e","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51131371749703,"sku":"023399013","price":9.58,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-ginetantum-500mg-10-bustine-granulato-per-soluzione-cutanea-per-genitali-esterni-farmacia-dottor-tili-1213791856.jpg?v=1767137531"},{"product_id":"tantum-verde-0-30-spray-15ml","title":"Tantum Verde 0.30% spray 15ml","description":"Tantum Verde 0.30% spray 15ml is a topical treatment indicated for the \u003cstrong\u003esymptomatic treatment of irritative-inflammatory conditions\u003c\/strong\u003e of the oropharyngeal cavity, such as \u003cstrong\u003egingivitis, stomatitis and pharyngitis\u003c\/strong\u003e . This spray is also particularly useful following conservative or extractive dental therapies. The active ingredient, \u003cstrong\u003ebenzydamine hydrochloride\u003c\/strong\u003e , is present in a concentration of 0.30 g per 100 ml, equivalent to 0.268 g of benzydamine, and acts locally to relieve pain and reduce inflammation. The formulation also includes excipients such as \u003cstrong\u003emethyl parahydroxybenzoate\u003c\/strong\u003e and \u003cstrong\u003ehydrogenated polyoxydated castor oil 40\u003c\/strong\u003e , which contribute to the stability and efficacy of the product. Tantum Verde 0.30% spray 15ml is a practical and targeted solution for the rapid relief of oropharyngeal symptoms.\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e  \u003ch3\u003eActive ingredients contained in Tantum Verde 0.30% spray 15ml - What is the active ingredient in Tantum Verde 0.30% spray 15ml?\u003c\/h3\u003e 100 ml contain: active ingredient: benzydamine hydrochloride 0.30 g (equivalent to 0.268 g of benzydamine). Excipients: methyl parahydroxybenzoate, hydrogenated polyoxyl 40 castor oil. For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tantum Verde 0.30% spray 15ml - What does Tantum Verde 0.30% spray 15ml contain?\u003c\/h3\u003e Glycerol, Ethanol (96 percent), Sodium saccharin, Methyl parahydroxybenzoate, Mint flavor, Hydrogenated castor oil 40 polyoxyl, Purified water.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Tantum Verde 0.30% spray 15ml - Why is Tantum Verde 0.30% spray 15ml used? What is it for?\u003c\/h3\u003e Symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e  \u003ch3\u003eContraindications Tantum Verde 0.30% spray 15ml - When should Tantum Verde 0.30% spray 15ml not be used?\u003c\/h3\u003e Hypersensitivity to benzydamine or to any of the excipients.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Tantum Verde 0.30% spray 15ml - How to take Tantum Verde 0.30% spray 15ml?\u003c\/h3\u003e Adults: 2–4 sprays 2–6 times daily (each spray is equivalent to 0.17 ml of solution). Do not exceed the recommended dose.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Tantum Verde 0.30% spray 15ml - How is Tantum Verde 0.30% spray 15ml stored?\u003c\/h3\u003e This medicinal product does not require any special storage conditions.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tantum Verde 0.30% spray 15ml - About Tantum Verde 0.30% spray 15ml it is important to know that: \u003c\/h3\u003eThe use of the product, especially if prolonged, may give rise to sensitization phenomena. In this case, stop treatment and consult your doctor to establish appropriate therapy. In a limited number of patients, oropharyngeal ulcerations may be a sign of more serious pathologies. Therefore, if the symptoms persist for more than three days, the patient should contact their doctor or dentist as needed. The use of benzydamine is not recommended in patients with hypersensitivity to acetylsalicylic acid or other NSAIDs. Tantum Verde oral mucosa solution should be administered with caution in subjects who have had episodes of bronchial asthma in the past, as bronchospasm phenomena may occur in this type of patient. Tantum Verde contains parahydroxybenzoates that may cause allergic reactions (even delayed). For those who play sports: the use of medicines containing ethyl alcohol may cause positive results in anti-doping tests in relation to the limits of blood alcohol concentration indicated by some sports federations.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Tantum Verde 0.30% spray 15ml Interactions - Which medicines or foods can modify the effect of Tantum Verde 0.30% spray 15ml?\u003c\/h3\u003e No interaction studies with other drugs have been conducted.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tantum Verde 0.30% spray 15ml can cause side effects - What are the side effects of Tantum Verde 0.30% spray 15ml? \u003c\/h3\u003eWithin each frequency grouping, undesirable effects are presented in decreasing order of seriousness. The following scales of values ​​have been used: very common (≥1\/10); common (≥1\/100, \u0026lt;1\/10); uncommon (≥1\/1,000, \u0026lt;1\/100); rare ≥1\/10,000, \u0026lt;1\/1,000); very rare (\u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data). \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e – \u003ci\u003eRare\u003c\/i\u003e : burning and dry mouth. \u003cu\u003eImmune system disorders\u003c\/u\u003e – \u003ci\u003eRare\u003c\/i\u003e : hypersensitivity reactions – \u003ci\u003eNot known\u003c\/i\u003e : anaphylactic reactions. \u003cu\u003eRespiratory, thoracic, mediastinal disorders\u003c\/u\u003e – \u003ci\u003eVery rare\u003c\/i\u003e : laryngospasm. \u003cu\u003eSkin and subcutaneous tissue disorders\u003c\/u\u003e – \u003ci\u003eUncommon\u003c\/i\u003e : photosensitivity – \u003ci\u003eVery rare\u003c\/i\u003e : angioedema.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Tantum Verde 0.30% spray 15ml - What are the risks of Tantum Verde 0.30% spray 15ml in case of overdose? \u003c\/h3\u003eSymptoms of overdose in children, such as excitation, convulsions, sweating, ataxia, tremor and vomiting, have been reported very rarely after oral administration of benzydamine at a dosage approximately 100 times that of the 3 mg tablets. In the event of acute overdose, only symptomatic treatment is possible; empty the stomach by inducing vomiting or by gastric lavage and keep the patient under observation by giving supportive treatment and maintaining adequate hydration.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e PREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tantum Verde 0.30% spray 15ml. \u003c\/h3\u003eThere are no data on the use of benzydamine during pregnancy or breastfeeding. The excretion of the product in breast milk has not been studied. Studies conducted in animals with reference to the effects on pregnancy and breastfeeding are insufficient (see paragraph 5.3) and therefore the potential risk for humans cannot be evaluated. During pregnancy and breastfeeding Tantum Verde should not be used.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\u003ch3\u003e Taking Tantum Verde 0.30% spray 15ml before driving or using machines - Does Tantum Verde 0.30% spray 15ml affect driving or using machines?\u003c\/h3\u003e It does not interfere with the ability to drive or use machines.","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51131382530375,"sku":"022088088","price":10.97,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-tantum-verde-0-30-spray-15ml-farmacia-dottor-tili-1213791705.jpg?v=1767144310"},{"product_id":"tachipirina-adulti-1000mg-10-supposte","title":"Tachipirina adults 1000mg 10 suppositories","description":"\u003cstrong\u003eTachipirina adults 1000mg 10 suppositories\u003c\/strong\u003e is a drug based on \u003cstrong\u003eparacetamol\u003c\/strong\u003e , an active ingredient known for its \u003cstrong\u003eantipyretic\u003c\/strong\u003e and \u003cstrong\u003eanalgesic\u003c\/strong\u003e properties. This product is indicated for the symptomatic treatment of febrile conditions such as influenza and exanthematous diseases, as well as for the relief of moderate pain such as headaches, neuralgia and myalgia. The 1000 mg suppositories are particularly suitable for adults, offering an alternative administration option for those who prefer to avoid oral formulations. Thanks to its effectiveness in reducing fever and relieving pain, Tachipirina adults 1000mg 10 suppositories represents a versatile choice for the treatment of common symptoms associated with various medical conditions.\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Tachipirina adults 1000mg 10 suppositories - What is the active ingredient of Tachipirina adults 1000mg 10 suppositories? \u003c\/h3\u003e\n\u003ci\u003eTACHIPIRINA 500 mg tablets.\u003c\/i\u003e Each tablet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 500 mg effervescent granules.\u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 12.3 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 125 mg effervescent granules.\u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 3.07 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Neonati 62.5 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains. \u003cu\u003eactive ingredient: paracetamol 62.5 mg\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Prima Infanzia 125 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Children 250 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 250 mg.\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Children 500 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Adults 1000 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 1000 mg.\u003c\/u\u003e For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eEXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tachipirina adults 1000mg 10 suppositories - What does Tachipirina adults 1000mg 10 suppositories contain?\u003c\/h3\u003e • \u003cu\u003eTablets:\u003c\/u\u003e microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, croscarmellose sodium. • \u003cu\u003eEffervescent granules\u003c\/u\u003e : maltitol, mannitol, sodium bicarbonate, anhydrous citric acid, citrus flavouring, aspartame, sodium docusate. • \u003cu\u003eSuppositories\u003c\/u\u003e : solid semi-synthetic glycerides.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Tachipirina adults 1000mg 10 suppositories - Why is Tachipirina adults 1000mg 10 suppositories used? What is it used for?\u003c\/h3\u003e As an antipyretic: symptomatic treatment of febrile conditions such as influenza, exanthematous diseases, acute respiratory tract conditions, etc. As an analgesic: headaches, neuralgia, myalgia and other moderately severe painful conditions of various origins.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Tachipirina adults 1000mg 10 suppositories - When should Tachipirina adults 1000mg 10 suppositories not be used? \u003c\/h3\u003e• Hypersensitivity to paracetamol or to any of the excipients listed in paragraph 6.1. • Patients suffering from severe haemolytic anaemia (this contraindication does not apply to the 500 mg oral formulations). • Severe hepatocellular insufficiency (this contraindication does not apply to the 500 mg oral formulations).\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Tachipirina adults 1000mg 10 suppositories - How do you take Tachipirina adults 1000mg 10 suppositories? \u003c\/h3\u003eFor children, it is essential to respect the dosage defined according to their body weight, and therefore choose the appropriate formulation. The approximate ages according to body weight are given for information purposes only. In adults, the maximum oral dosage is 3000 mg and rectal dosage is 4000 mg of paracetamol per day (see section 4.9). The doctor must evaluate the need for treatments for more than 3 consecutive days. The dosage schedule of Tachipirina in relation to body weight and administration route is as follows: \u003cb\u003e500 mg tablets.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): ½ tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day (3 tablets). • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately 8 and 11 years): 1 tablet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately 12 and 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e : 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In case of severe pain or high fever, 2 tablets of 500 mg to be repeated if necessary after not less than 4 hours. \u003cb\u003eEffervescent granules of 500 mg in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately 8 to 11 years): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately 12 to 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e : 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 sachets of 500 mg to be repeated if necessary after not less than 4 hours. \u003cb\u003e125 mg effervescent granules in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003eNewborn Suppositories 62.5 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 3.2 and 5 kg\u003c\/u\u003e (approximately between birth and 2 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eEarly Childhood Suppositories 125 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 6 and 7 kg\u003c\/u\u003e (approximately between 3 and 5 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 suppository at a time, to be repeated if necessary after 4 - 6 hours, without exceeding 5 administrations per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003eSuppositories Children 250 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Children 500 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately between 8 and 11 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Adults 1000 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately 12 and 15 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e : 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003ci\u003e\u003cu\u003eRenal insufficiency.\u003c\/u\u003e\u003c\/i\u003e In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Tachipirina adults 1000mg 10 suppositories - How is Tachipirina adults 1000mg 10 suppositories stored?\u003c\/h3\u003e \u003cu\u003eTablets and effervescent granules\u003c\/u\u003e : no special precautions for storage. \u003cu\u003eSuppositories:\u003c\/u\u003e store at a temperature not exceeding 25°C.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tachipirina adults 1000mg 10 suppositories - About Tachipirina adults 1000mg 10 suppositories it is important to know that: \u003c\/h3\u003eIn rare cases of allergic reactions, administration should be suspended and appropriate treatment should be instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u0026gt;9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause alterations to the kidney and blood, even serious, therefore administration to subjects with renal insufficiency should be carried out only if really necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and renal function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other medicine. See also section 4.5. \u003cb\u003e\u003cu\u003eImportant information about some of the excipients.\u003c\/u\u003e\u003c\/b\u003e \u003cu\u003eTachipirina 125 mg effervescent granules contains\u003c\/u\u003e \u003cu\u003e:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e , is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e : use with caution in patients with rare hereditary problems of fructose intolerance. 70.6 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 3.53% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult: to be taken into consideration by people with reduced kidney function or who follow a low-sodium diet. \u003cu\u003eTachipirina 500 mg effervescent granules contains:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e , is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e : use with caution in patients with rare hereditary problems of fructose intolerance. - 283 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 14.1% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. The maximum dose for this product is equivalent to 84.6% of the WHO recommended maximum daily sodium intake.: to be taken into consideration by people with reduced kidney function or on a low-sodium diet.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Tachipirina adults 1000mg 10 suppositories - Which medicines or foods can modify the effect of Tachipirina adults 1000mg 10 suppositories? \u003c\/h3\u003eOral absorption of paracetamol depends on the rate of gastric emptying. Therefore, concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may lead to a decrease or increase in the bioavailability of the product, respectively. Concomitant administration of cholestyramine reduces the absorption of paracetamol. Concomitant intake of paracetamol and chloramphenicol may lead to an increase in the half-life of chloramphenicol, with the risk of increasing its toxicity. Concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants may lead to slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its discontinuation. Use with extreme caution and under close monitoring during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol can interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tachipirina adulti 1000mg 10 suppositories can cause side effects - What are the side effects of Tachipirina adulti 1000mg 10 suppositories?\u003c\/h3\u003e The following are the adverse reactions of paracetamol organized according to the MedDRA system organ classification. There are insufficient data to establish the frequency of the individual effects listed.\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003ePathologies of the haemolymphopoietic system\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Thrombocytopenia, leukopenia, anemia, agranulocytosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eImmune system disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eNervous system disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Dizziness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eGastrointestinal disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Gastrointestinal reaction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eHepatobiliary pathologies\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Abnormal liver function, hepatitis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eSkin and subcutaneous tissue disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e  \u003ctd\u003eErythema multiforme, Stevens Johnson syndrome, Epidermal necrolysis, Skin rash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eKidney and urinary disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Acute renal failure, interstitial nephritis, hematuria, anuria\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e Very rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Tachipirina adults 1000mg 10 suppositories - What are the risks of Tachipirina adults 1000mg 10 suppositories in case of overdose? \u003c\/h3\u003e\n\u003cu\u003eThere is a risk of intoxication, especially in patients with liver disease, in cases of chronic alcoholism, in patients with chronic malnutrition, and in patients receiving enzyme inducers. In these cases, overdose can be fatal.\u003c\/u\u003e \u003cu\u003eSymptoms\u003c\/u\u003e In case of accidental ingestion of very high doses of paracetamol, acute intoxication manifests itself with anorexia, nausea and vomiting followed by a profound deterioration of general conditions; these symptoms generally appear within the first 24 hours. In case of overdose, paracetamol can cause hepatic cytolysis which can evolve into massive and irreversible necrosis, with consequent hepatocellular insufficiency, metabolic acidosis and encephalopathy, which can lead to coma and death. Simultaneously, an increase in the levels of hepatic transaminases, lactate dehydrogenase, and bilirubinemia, and a reduction in prothrombin levels are observed, which may occur within 12-48 hours of ingestion. \u003cu\u003eTreatment\u003c\/u\u003e The measures to be taken consist of early gastric emptying and hospitalization for appropriate treatment, by administering, as early as possible, N-acetylcysteine ​​as an antidote: the dosage is 150 mg\/kg iv in glucose solution over 15 minutes, then 50 mg\/kg over the next 4 hours and 100 mg\/kg over the next 16 hours, for a total of 300 mg\/kg over 20 hours.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina adults 1000mg 10 suppositories.\u003c\/h3\u003e Pregnancy: A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to administer the product only in cases of real need and under the direct supervision of a doctor.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e  \u003ch3\u003eTaking Tachipirina adulti 1000mg 10 suppositories before driving or using machinery - Does Tachipirina adulti 1000mg 10 suppositories affect driving or using machinery?\u003c\/h3\u003e Tachipirina does not alter the ability to drive vehicles or use machinery.","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51131394720071,"sku":"012745067","price":7.22,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-tachipirina-adulti-1000mg-10-supposte-farmacia-dottor-tili-1213791661.jpg?v=1767145245"},{"product_id":"tantum-rosa-detergente-intimo-lenitivo-200ml","title":"Tantum Rosa soothing intimate cleanser 200ml","description":"\u003cp\u003e\u003cstrong\u003eTantum Rosa soothing intimate cleanser 200ml\u003c\/strong\u003e is a product specifically formulated to ensure delicate \u003cstrong\u003edaily intimate hygiene\u003c\/strong\u003e that respects the natural physiology of the intimate parts. Thanks to its formulation enriched with \u003cstrong\u003enatural substances\u003c\/strong\u003e with a soothing, hydrating and emollient action, this cleanser offers a sensation of \u003cstrong\u003efreshness\u003c\/strong\u003e and \u003cstrong\u003erelief\u003c\/strong\u003e , helping to prevent small intimate discomforts and maintain the well-being of the intimate areas.\u003c\/p\u003e\n\n\n \u003cp\u003eThe cleanser is \u003cstrong\u003egynecologically and dermatologically tested\u003c\/strong\u003e , ensuring high tolerability even for the most sensitive skin. Its formula is enriched with \u003cstrong\u003eCalendula extract\u003c\/strong\u003e , known for its soothing properties, and \u003cstrong\u003eEvening Primrose oil\u003c\/strong\u003e , which offers an anti-itch action. These natural ingredients are combined to preserve the skin's \u003cstrong\u003ehydrolipidic layer\u003c\/strong\u003e without altering its natural defenses.\u003c\/p\u003e\n\n\n\u003cp\u003e The product is equipped with a practical measuring cap, designed to dispense the right amount of detergent needed for effective washing. With a \u003cstrong\u003epH of 4.5\u003c\/strong\u003e , it is ideal for daily use, helping to maintain the natural balance of the intimate parts. Furthermore, it is \u003cstrong\u003eSLES-free\u003c\/strong\u003e and \u003cstrong\u003enickel tested\u003c\/strong\u003e , ensuring additional protection against allergic reactions.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e Dosage and method of use\u003c\/h2\u003e\n\n\u003ch3\u003e How do I use Tantum Rosa soothing intimate cleanser?\u003c\/h3\u003e\n\n \u003cp\u003eShake the bottle before use. Dispense 1 puff of product into the palm of your hand and apply to intimate areas. Rinse as usual. External use.\u003c\/p\u003e\n\n\n\u003ch2\u003e Ingredients Tantum Rosa soothing intimate cleanser\u003c\/h2\u003e\n\n\u003ch3\u003e What ingredients does Tantum Rosa Soothing Intimate Cleanser contain?\u003c\/h3\u003e\n\n\u003cp\u003e Aqua, Sodium Laureth-11 Carboxylate, Decyl Glucoside, Glyceryl Stearate, Parfum, Glycerin, Sodium Chloride, Oleyl Alcohol, Lecithin, Potassium Chloride, Tocopherol, Ascorbyl Palmitate, Citric Acid, Sodium Benzoate, Potassium Sorbate, Phenoxyethanol.\u003c\/p\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings for Tantum Rosa soothing intimate cleanser?\u003c\/h3\u003e\n\n\u003cp\u003e Store in a cool place away from heat sources.\u003c\/p\u003e\n\n\n\u003ch2\u003e Format Tantum Rosa soothing intimate cleanser\u003c\/h2\u003e\n\n\u003cp\u003e 200ml bottle\u003c\/p\u003e","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51694324449607,"sku":"975597117","price":9.25,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-tantum-rosa-detergente-intimo-lenitivo-200ml-farmacia-dottor-tili-1213791516.jpg?v=1767153070"},{"product_id":"tachipirina-bambini-500-mg-10-supposte","title":"Tachipirina children 500 mg 10 suppositories","description":"\u003cp\u003e\n \u003cstrong\u003eTachipirina bambini 500 mg 10 suppositories\u003c\/strong\u003e is a \u003cstrong\u003eparacetamol-based medicine\u003c\/strong\u003e , specifically formulated for the symptomatic treatment of \u003cstrong\u003efever in children\u003c\/strong\u003e and for the relief of \u003cstrong\u003emedium-level pain\u003c\/strong\u003e . Thanks to its \u003cstrong\u003eantipyretic and analgesic action\u003c\/strong\u003e , it is indicated in the case of \u003cstrong\u003efebrile conditions\u003c\/strong\u003e such as \u003cstrong\u003einfluenza, exanthematous diseases\u003c\/strong\u003e and \u003cstrong\u003eacute respiratory tract conditions\u003c\/strong\u003e . The \u003cstrong\u003e500 mg suppository\u003c\/strong\u003e formulation is particularly suitable for children \u003cstrong\u003eweighing between 21 and 40 kg\u003c\/strong\u003e (approximate age: \u003cstrong\u003e6-10 years\u003c\/strong\u003e ), offering an effective solution even when oral administration is not possible.\n\u003c\/p\u003e\n\n\u003cp\u003e \n\u003cstrong\u003eTachipirina children's suppositories\u003c\/strong\u003e guarantee \u003cstrong\u003erapid and safe absorption\u003c\/strong\u003e of the active ingredient, making them ideal for the \u003cstrong\u003etreatment of fever and pain in children\u003c\/strong\u003e who require \u003cstrong\u003erectal administration\u003c\/strong\u003e . Paracetamol, the active ingredient in Tachipirina, is widely recognized for its efficacy and tolerability in pediatrics, making this product a reliable choice for \u003cstrong\u003econtrolling body temperature\u003c\/strong\u003e and \u003cstrong\u003etreating pain\u003c\/strong\u003e associated with various conditions.\n\u003c\/p\u003e\n\n\u003cp\u003e \n\u003cstrong\u003eTachipirina bambini 500 mg suppositories\u003c\/strong\u003e is a reference \u003cstrong\u003eantipyretic and analgesic\u003c\/strong\u003e for \u003cstrong\u003epediatric use\u003c\/strong\u003e , particularly indicated when you want a \u003cstrong\u003epractical and fast treatment\u003c\/strong\u003e in case of \u003cstrong\u003ehigh fever\u003c\/strong\u003e or \u003cstrong\u003eacute pain\u003c\/strong\u003e in children. The package contains \u003cstrong\u003e10 suppositories\u003c\/strong\u003e , ideal for covering multiple episodes of fever or pain, always ensuring maximum practicality and safety of use.\n\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Tachipirina bambini 500 mg 10 suppositories - What is the active ingredient of Tachipirina bambini 500 mg 10 suppositories? \u003c\/h3\u003e\n\u003ci\u003eTACHIPIRINA 500 mg tablets.\u003c\/i\u003e Each tablet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 500 mg effervescent granules.\u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 12.3 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 125 mg effervescent granules.\u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 3.07 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Neonati 62.5 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains. \u003cu\u003eactive ingredient: paracetamol 62.5 mg\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Prima Infanzia 125 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Children 250 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 250 mg.\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Children 500 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Adults 1000 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 1000 mg.\u003c\/u\u003e For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eEXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tachipirina children 500 mg 10 suppositories - What does Tachipirina children 500 mg 10 suppositories contain?\u003c\/h3\u003e • \u003cu\u003eTablets:\u003c\/u\u003e microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, croscarmellose sodium. • \u003cu\u003eEffervescent granules\u003c\/u\u003e : maltitol, mannitol, sodium bicarbonate, anhydrous citric acid, citrus flavouring, aspartame, sodium docusate. • \u003cu\u003eSuppositories\u003c\/u\u003e : solid semi-synthetic glycerides.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Tachipirina children 500 mg 10 suppositories - Why is Tachipirina children 500 mg 10 suppositories used? What is it used for?\u003c\/h3\u003e As an antipyretic: symptomatic treatment of febrile conditions such as influenza, exanthematous diseases, acute respiratory tract conditions, etc. As an analgesic: headaches, neuralgia, myalgia and other moderately severe painful conditions of various origins.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e  \u003ch3\u003eContraindications Tachipirina children 500 mg 10 suppositories - When should Tachipirina children 500 mg 10 suppositories not be used?\u003c\/h3\u003e • Hypersensitivity to paracetamol or to any of the excipients listed in paragraph 6.1. • Patients with severe haemolytic anaemia (this contraindication does not apply to the 500 mg oral formulations). • Severe hepatocellular insufficiency (this contraindication does not apply to the 500 mg oral formulations).\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Tachipirina bambini 500 mg 10 suppositories - How do you take Tachipirina bambini 500 mg 10 suppositories? \u003c\/h3\u003eFor children, it is essential to respect the dosage defined according to their body weight, and therefore choose the appropriate formulation. The approximate ages according to body weight are given for information purposes only. In adults, the maximum oral dosage is 3000 mg and rectal dosage is 4000 mg of paracetamol per day (see section 4.9). The doctor must evaluate the need for treatments for more than 3 consecutive days. The dosage schedule of Tachipirina in relation to body weight and administration route is as follows: \u003cb\u003e500 mg tablets.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): ½ tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day (3 tablets). • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately 8 and 11 years): 1 tablet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately 12 and 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e : 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In case of severe pain or high fever, 2 tablets of 500 mg to be repeated if necessary after not less than 4 hours. \u003cb\u003eEffervescent granules of 500 mg in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately 8 to 11 years): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately 12 to 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e : 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 sachets of 500 mg to be repeated if necessary after not less than 4 hours. \u003cb\u003e125 mg effervescent granules in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003eNewborn Suppositories 62.5 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 3.2 and 5 kg\u003c\/u\u003e (approximately between birth and 2 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eEarly Childhood Suppositories 125 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 6 and 7 kg\u003c\/u\u003e (approximately between 3 and 5 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 suppository at a time, to be repeated if necessary after 4 - 6 hours, without exceeding 5 administrations per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003eSuppositories Children 250 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Children 500 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately between 8 and 11 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Adults 1000 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately 12 and 15 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e : 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003ci\u003e\u003cu\u003eRenal insufficiency.\u003c\/u\u003e\u003c\/i\u003e In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Tachipirina children 500 mg 10 suppositories - How is Tachipirina children 500 mg 10 suppositories stored?\u003c\/h3\u003e \u003cu\u003eTablets and effervescent granules\u003c\/u\u003e : no special precautions for storage. \u003cu\u003eSuppositories:\u003c\/u\u003e store at a temperature not exceeding 25°C.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tachipirina children 500 mg 10 suppositories - About Tachipirina children 500 mg 10 suppositories it is important to know that: \u003c\/h3\u003eIn rare cases of allergic reactions, administration should be suspended and appropriate treatment should be instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u0026gt;9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause even serious alterations to the kidney and blood, therefore administration to subjects with renal insufficiency should be carried out only if really necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and renal function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other medicine. See also section 4.5. \u003cb\u003e\u003cu\u003eImportant information about some of the excipients.\u003c\/u\u003e\u003c\/b\u003e \u003cu\u003eTachipirina 125 mg effervescent granules contains\u003c\/u\u003e \u003cu\u003e:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e , is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e : use with caution in patients with rare hereditary problems of fructose intolerance. 70.6 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 3.53% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult: to be taken into consideration by people with reduced kidney function or who follow a low-sodium diet. \u003cu\u003eTachipirina 500 mg effervescent granules contains:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e , is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e : use with caution in patients with rare hereditary problems of fructose intolerance. - 283 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 14.1% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. The maximum dose for this product is equivalent to 84.6% of the WHO recommended maximum daily sodium intake.: to be taken into consideration by people with reduced kidney function or on a low-sodium diet.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Tachipirina children 500 mg 10 suppositories - Which medicines or foods can modify the effect of Tachipirina children 500 mg 10 suppositories? \u003c\/h3\u003eOral absorption of paracetamol depends on the rate of gastric emptying. Therefore, concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may lead to a decrease or increase in the bioavailability of the product, respectively. Concomitant administration of cholestyramine reduces the absorption of paracetamol. Concomitant intake of paracetamol and chloramphenicol may lead to an increase in the half-life of chloramphenicol, with the risk of increasing its toxicity. Concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants may lead to slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its discontinuation. Use with extreme caution and under close monitoring during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol can interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tachipirina bambini 500 mg 10 suppositories can cause side effects - What are the side effects of Tachipirina bambini 500 mg 10 suppositories?\u003c\/h3\u003e The following are the adverse reactions of paracetamol organized according to the MedDRA system organ classification. There are insufficient data to establish the frequency of the individual effects listed.\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003ePathologies of the haemolymphopoietic system\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Thrombocytopenia, leukopenia, anemia, agranulocytosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eImmune system disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eNervous system disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Dizziness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eGastrointestinal disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Gastrointestinal reaction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eHepatobiliary pathologies\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Abnormal liver function, hepatitis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eSkin and subcutaneous tissue disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e  \u003ctd\u003eErythema multiforme, Stevens Johnson syndrome, Epidermal necrolysis, Skin rash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eKidney and urinary disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Acute renal failure, interstitial nephritis, hematuria, anuria\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e Very rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Tachipirina children 500 mg 10 suppositories - What are the risks of Tachipirina children 500 mg 10 suppositories in case of overdose? \u003c\/h3\u003e\n\u003cu\u003eThere is a risk of intoxication, especially in patients with liver disease, in chronic alcoholism, in patients with chronic malnutrition, and in patients receiving enzyme inducers. In these cases, overdose can be fatal.\u003c\/u\u003e \u003cu\u003eSymptoms\u003c\/u\u003e In case of accidental ingestion of very high doses of paracetamol, acute intoxication manifests itself with anorexia, nausea and vomiting followed by a profound deterioration of general conditions; these symptoms generally appear within the first 24 hours. In case of overdose, paracetamol can cause hepatic cytolysis that can evolve into massive and irreversible necrosis, with consequent hepatocellular insufficiency, metabolic acidosis and encephalopathy, which can lead to coma and death. Simultaneously, an increase in the levels of hepatic transaminases, lactate dehydrogenase, and bilirubinemia, and a reduction in prothrombin levels are observed, which may occur within 12-48 hours after ingestion. \u003cu\u003eTreatment\u003c\/u\u003e The measures to be taken consist of early gastric emptying and hospitalization for appropriate treatment, by administering, as early as possible, N-acetylcysteine ​​as an antidote: the dosage is 150 mg\/kg iv in glucose solution over 15 minutes, then 50 mg\/kg over the next 4 hours and 100 mg\/kg over the next 16 hours, for a total of 300 mg\/kg over 20 hours.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina bambini 500 mg 10 suppositories.\u003c\/h3\u003e Pregnancy: A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to administer the product only in cases of real need and under the direct supervision of a doctor.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e  \u003ch3\u003eTaking Tachipirina bambini 500 mg 10 suppositories before driving or using machinery - Does Tachipirina bambini 500 mg 10 suppositories affect driving and using machinery?\u003c\/h3\u003e Tachipirina does not alter the ability to drive vehicles or use machinery.","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51730202984775,"sku":"012745055","price":6.56,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-tachipirina-bambini-500-mg-10-supposte-farmacia-dottor-tili-1213791437.jpg?v=1767138407"},{"product_id":"tachipirina-100-mg-ml-30-ml-gocce-orali-soluzione","title":"Tachipirina 100 mg\/ml 30 ml oral drops solution","description":"\u003cp\u003e \n\u003cstrong\u003eTachipirina 100 mg\/ml 30 ml oral drops solution\u003c\/strong\u003e is an \u003cstrong\u003eover-the-counter drug\u003c\/strong\u003e based on \u003cstrong\u003eparacetamol\u003c\/strong\u003e , indicated for the \u003cstrong\u003esymptomatic treatment of fever\u003c\/strong\u003e and \u003cstrong\u003epain\u003c\/strong\u003e in children. Thanks to its formulation in \u003cstrong\u003eoral drops solution\u003c\/strong\u003e , it is particularly suitable for the little ones, ensuring precise dosing and simple administration. The product is effective as \u003cstrong\u003ean antipyretic\u003c\/strong\u003e to lower body temperature in case of \u003cstrong\u003einfluenza\u003c\/strong\u003e , \u003cstrong\u003eexanthematous diseases\u003c\/strong\u003e and \u003cstrong\u003erespiratory tract infections\u003c\/strong\u003e , as well as being a valid \u003cstrong\u003eanalgesic\u003c\/strong\u003e to relieve \u003cstrong\u003eheadaches, neuralgia, myalgia\u003c\/strong\u003e and other medium-level pain.\n\u003c\/p\u003e\n\n\u003cp\u003e \nThe \u003cstrong\u003e30 ml pack\u003c\/strong\u003e of Tachipirina drops allows for practical and safe use, with the possibility of adapting the dosage based on the child's weight. Each ml of solution contains \u003cstrong\u003e100 mg of paracetamol\u003c\/strong\u003e , ensuring rapid and targeted action. The selected excipients, such as \u003cstrong\u003esorbitol\u003c\/strong\u003e and \u003cstrong\u003epropylene glycol\u003c\/strong\u003e , ensure good tolerability and pleasant administration. Ideal for the \u003cstrong\u003esymptomatic treatment\u003c\/strong\u003e of feverish and painful conditions, Tachipirina drops is a reliable ally for the well-being of the little ones, offering relief in a safe and controlled way.\n\u003c\/p\u003e\n\n\u003cp\u003e\n \u003cstrong\u003eTachipirina 100 mg\/ml oral drops solution\u003c\/strong\u003e is a choice recommended by pediatricians for its effectiveness and practicality. Its rapid action and ease of dosing make it indispensable in the home pharmacy, especially during periods of greater incidence of \u003cstrong\u003einfluenza\u003c\/strong\u003e and \u003cstrong\u003eseasonal diseases\u003c\/strong\u003e .\n\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e  \u003ch2\u003eACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Tachipirina 100 mg\/ml 30 ml oral drops solution - What is the active ingredient of Tachipirina 100 mg\/ml 30 ml oral drops solution?\u003c\/h3\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA 120mg\/5 ml syrup\u003c\/u\u003e\u003c\/i\u003e 5 ml of syrup contain \u003cu\u003eactive ingredient: paracetamol 120 mg\u003c\/u\u003e excipients with known effects: sucrose, methyl parahydroxybenzoate, sodium. \u003ci\u003e\u003cu\u003eTACHIPIRINA 100mg\/ ml oral drops, solution\u003c\/u\u003e\u003c\/i\u003e 1 ml of solution contains \u003cu\u003eactive ingredient: paracetamol 100 mg\u003c\/u\u003e excipients with known effects: sorbitol, propylene glycol For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tachipirina 100 mg\/ml 30 ml oral drops solution - What does Tachipirina 100 mg\/ml 30 ml oral drops solution contain? \u003c\/h3\u003e• \u003cu\u003eSyrup\u003c\/u\u003e : sucrose, sodium citrate, sodium saccharin, methyl parahydroxybenzoate, potassium sorbate, Macrogol 6000, citric acid monohydrate, strawberry flavouring, mandarin flavouring, purified water. • \u003cu\u003eOral drops\u003c\/u\u003e : propylene glycol, Macrogol 6000, sorbitol, sodium saccharin, citrus vanilla flavouring, propyl gallate, caramel (E150a), sodium edetate, purified water.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Tachipirina 100 mg\/ml 30 ml oral drops solution - Why is Tachipirina 100 mg\/ml 30 ml oral drops solution used? What is it used for?\u003c\/h3\u003e As an antipyretic: symptomatic treatment of febrile conditions such as influenza, exanthematous diseases, acute respiratory tract conditions, etc. As an analgesic: headaches, neuralgia, myalgia and other moderately severe painful conditions of various origins.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Tachipirina 100 mg\/ml 30 ml oral drops solution - When should Tachipirina 100 mg\/ml 30 ml oral drops solution not be used? \u003c\/h3\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • Patients suffering from severe haemolytic anaemia (this contraindication does not apply to the 500 mg oral formulations). • Severe hepatocellular insufficiency (this contraindication does not apply to the 500 mg oral formulations).\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Tachipirina 100 mg\/ml 30 ml oral drops solution - How is Tachipirina 100 mg\/ml 30 ml oral drops solution taken? \u003c\/h3\u003eIn children up to 10 years of age, it is essential to respect the dosage defined based on body weight and not based on age, which is approximate and indicated for information purposes only. If the age of the child does not correspond to the weight shown in the table, always refer to body weight when choosing the dosage. In children weighing up to 7.2 kg, it is recommended to use the formulation in drops, between 7.2 and 11 kg it is possible to use the drops or the syrup as the dosage for each weight range is identical, between 12 and 32 kg it is recommended to use the syrup. The dosage schedule for Tachipirina drops is as follows.\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\u003ctd colspan=\"4\"\u003e \u003cb\u003eTACHIPIRINA DROPS\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eWeight\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eAge\u003c\/b\u003e (approximate)\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eSingle dose\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eDaily dose\u003c\/b\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 3.2 kg\u003c\/td\u003e\n\u003ctd\u003e 0-30 days\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e8 drops\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 4.3 kg\u003c\/td\u003e\n\u003ctd\u003e 1 month\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e10 drops\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 5.3 kg\u003c\/td\u003e\n\u003ctd\u003e 2 months\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e13 drops\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 6.1 kg\u003c\/td\u003e\n\u003ctd\u003e 3 months\u003c\/td\u003e  \u003ctd\u003e\u003cb\u003e22 drops\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 6.7 kg\u003c\/td\u003e\n\u003ctd\u003e 4 months\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e25 drops\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 7.2 kg\u003c\/td\u003e\n\u003ctd\u003e 5-6 months\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e27 drops\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 8 kg\u003c\/td\u003e\n\u003ctd\u003e 7-10 months\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e30 drops\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 9 kg\u003c\/td\u003e\n\u003ctd\u003e 11-14 months\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e33 drops\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 10 kg\u003c\/td\u003e\n\u003ctd\u003e 15-19 months\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e36 drops\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 11 kg\u003c\/td\u003e\n\u003ctd\u003e 20-23 months\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e39 drops\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e The dosage schedule for Tachipirina syrup is as follows.\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\u003ctd colspan=\"4\"\u003e \u003cb\u003eTACHIPIRINA SYRUP\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eWeight\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eAge\u003c\/b\u003e (approximate)\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eSingle dose\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eDaily dose\u003c\/b\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 7.2 kg\u003c\/td\u003e\n\u003ctd\u003e 5-6 months\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e4.5 ml\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 8 kg\u003c\/td\u003e\n\u003ctd\u003e 7-10 months\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e5 ml\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 9 kg\u003c\/td\u003e\n\u003ctd\u003e 11-14 months\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e5.5 ml\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 10 kg\u003c\/td\u003e\n\u003ctd\u003e 15-19 months\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e6 ml\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 11 kg\u003c\/td\u003e\n\u003ctd\u003e 20-23 months\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e6.5 ml\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 12 kg\u003c\/td\u003e\n\u003ctd\u003e 2 years\u003c\/td\u003e  \u003ctd\u003e\u003cb\u003e7.5 ml\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 14 kg\u003c\/td\u003e\n\u003ctd\u003e 3 years\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e8.5 ml\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 16 kg\u003c\/td\u003e\n\u003ctd\u003e 4 years\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e10 ml\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 18 kg\u003c\/td\u003e\n\u003ctd\u003e 5 years\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e11ml\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 20 kg\u003c\/td\u003e\n\u003ctd\u003e 6 years\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e12.5 ml\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 22 kg\u003c\/td\u003e\n\u003ctd\u003e 7 years\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e13.5 ml\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 25 kg\u003c\/td\u003e\n\u003ctd\u003e 8 years old\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e15.5 ml\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 28 kg\u003c\/td\u003e\n\u003ctd\u003e 9 years old\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e17.5 ml\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 31 kg up to 32 kg\u003c\/td\u003e\n\u003ctd\u003e 10 years\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e19 ml\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e  \u003c\/table\u003eIn case of jaundice in children under three months, it is advisable to reduce the single dose. In children over 10 years of age, the relationship between weight and age becomes no longer homogeneous due to pubertal development which, at the same age, has a different impact on body weight depending on the sex and individual characteristics of the child. Therefore, over 10 years of age, the dosage of the syrup is indicated in terms of weight and age ranges, as reported below. Children weighing between 33 and 40 kg (over 10 years and under 12 years): 20 ml of syrup at a time (corresponding to 480 mg), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Adolescents weighing more than 40 kg (aged 12 years or over) and adults: 20 ml of syrup at a time (corresponding to 480 mg), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. The doctor must evaluate the need for treatments for more than 3 consecutive days. \u003cu\u003eMethod of administration\u003c\/u\u003e The package contains a dosing syringe with level marks corresponding to 1 ml, 2 ml, 3 ml, 4 ml, 4.5 ml and 5 ml and a measuring cup with level marks corresponding to 5.5 ml, 6 ml, 6.5 ml, 7.5 ml, 8.5 ml, 10 ml, 11 ml, 12.5 ml, 13.5 ml, 15.5 ml, 17.5 ml, 19 ml \u003cu\u003eSyrup\u003c\/u\u003e The syrup contains 24 mg of paracetamol per ml of product. To open the bottle, push the cap down and simultaneously turn it to the left. To use the syringe, insert the tip of the syringe fully into the hole in the undercap:  \u003cimg src=\"https:\/\/www.farmadati.it\/public\/imgSkt\/l.PNG\"\u003eFor doses greater than 5 ml, take the required amount with the syringe and pour the contents into the cup. Repeat the action until the mark corresponding to the indicated dosage is reached, and administer to the child, inviting him to drink. For doses in children over 10 years of age and in adults, equal to 20 ml, use the cup by filling it twice up to the 10 ml mark. The product must be used immediately after taking it from the bottle. Any residual product in the syringe or cup must be eliminated. After use, close the bottle by screwing the cap tightly and wash the syringe and cup with hot water. Leave them to dry, keeping them out of the reach and sight of children. \u003cu\u003eDrops\u003c\/u\u003e Each drop contains 4 mg of paracetamol. Turn the bottle upside down and pour the number of drops corresponding to the dosage to be used in 25-50 ml of water, and have the child drink. \u003ci\u003e\u003cu\u003eRenal impairment\u003c\/u\u003e\u003c\/i\u003e In case of severe renal impairment (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Tachipirina 100 mg\/ml 30 ml oral drops solution - How is Tachipirina 100 mg\/ml 30 ml oral drops solution stored?\u003c\/h3\u003e This medicinal product does not require any special storage conditions.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tachipirina 100 mg\/ml 30 ml oral drops solution - About Tachipirina 100 mg\/ml 30 ml oral drops solution it is important to know that: \u003c\/h3\u003eIn rare cases of allergic reactions, administration should be suspended and appropriate treatment should be instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u0026gt;9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause even serious alterations to the kidney and blood, therefore administration to subjects with renal insufficiency should be carried out only if really necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and renal function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other medicine (see section 4.5). \u003cb\u003e\u003cu\u003eImportant information about some of the excipients\u003c\/u\u003e\u003c\/b\u003e \u003cu\u003eTachipirina drops, solution contains\u003c\/u\u003e : - sorbitol: patients with rare hereditary problems of fructose intolerance should not take this medicine. - propylene glycol: may cause symptoms similar to those caused by alcohol. - The container of \u003cu\u003eTachipirina drops, solution\u003c\/u\u003e is made of latex rubber. May cause serious allergic reactions. \u003cu\u003eTachipirina syrup contains\u003c\/u\u003e : - sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine. For the 15 ml dose this medicinal product contains 5.25 g sucrose, for the 16.5 ml dose it contains 5.78 g sucrose, for the 18.5 ml dose it contains 6.48 g sucrose and for the 20 ml dose it contains 7 g sucrose. To be taken into consideration by people with diabetes mellitus. - methyl parahydroxybenzoate: may cause allergic reactions (possibly delayed). - sodium: this medicinal product contains 1.2 mmol (or 27.6 mg) sodium per 20 ml equivalent to 1.38% of the WHO recommended maximum daily intake of 2 g sodium for an adult. To be taken into consideration by people on a controlled sodium diet.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Tachipirina 100 mg\/ml 30 ml oral drops solution - Which medicines or foods can modify the effect of Tachipirina 100 mg\/ml 30 ml oral drops solution? \u003c\/h3\u003eOral absorption of paracetamol depends on the rate of gastric emptying. Therefore, concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may lead to a decrease or increase in the bioavailability of the product, respectively. Concomitant administration of cholestyramine reduces the absorption of paracetamol. Concomitant intake of paracetamol and chloramphenicol may lead to an increase in the half-life of chloramphenicol, with the risk of increasing its toxicity. Concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants may lead to slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its discontinuation. Use with extreme caution and under close monitoring during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol can interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tachipirina 100 mg\/ml 30 ml oral drops solution can cause side effects - What are the side effects of Tachipirina 100 mg\/ml 30 ml oral drops solution?\u003c\/h3\u003e The following are the adverse reactions of paracetamol organized according to the MedDRA system organ classification. There are insufficient data to establish the frequency of the individual effects listed.\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003ePathologies of the haemolymphopoietic system\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Thrombocytopenia, leukopenia, anemia, agranulocytosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eImmune system disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eNervous system disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Dizziness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eGastrointestinal disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Gastrointestinal reaction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eHepatobiliary pathologies\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Abnormal liver function, hepatitis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eSkin and subcutaneous tissue disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e  \u003ctd\u003eErythema multiforme, Stevens Johnson syndrome, Epidermal necrolysis, Skin rash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eKidney and urinary disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Acute renal failure, interstitial nephritis, hematuria, anuria\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e Very rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Tachipirina 100 mg\/ml 30 ml oral drops solution - What are the risks of Tachipirina 100 mg\/ml 30 ml oral drops solution in case of overdose? \u003c\/h3\u003e\n\u003cu\u003eThere is a risk of intoxication, especially in patients with liver disease, in chronic alcoholism, in patients with chronic malnutrition, and in patients receiving enzyme inducers. In these cases, overdose can be fatal.\u003c\/u\u003e \u003cu\u003eSymptoms\u003c\/u\u003e In case of accidental ingestion of very high doses of paracetamol, acute intoxication manifests itself with anorexia, nausea and vomiting followed by a profound deterioration of general conditions; these symptoms generally appear within the first 24 hours. In case of overdose, paracetamol can cause hepatic cytolysis that can evolve into massive and irreversible necrosis, with consequent hepatocellular insufficiency, metabolic acidosis and encephalopathy, which can lead to coma and death. Simultaneously, an increase in the levels of hepatic transaminases, lactate dehydrogenase, and bilirubinemia, and a reduction in prothrombin levels are observed, which may occur within 12-48 hours after ingestion. \u003cu\u003eTreatment\u003c\/u\u003e The measures to be taken consist of early gastric emptying and hospitalization for appropriate treatment, by administering, as early as possible, N-acetylcysteine ​​as an antidote: the dosage is 150 mg\/kg iv in glucose solution over 15 minutes, then 50 mg\/kg over the next 4 hours and 100 mg\/kg over the next 16 hours, for a total of 300 mg\/kg over 20 hours.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina 100 mg\/ml 30 ml oral drops solution.\u003c\/h3\u003e Pregnancy: A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: it is recommended to take \/ administer this medicine only in cases of real need and under direct medical supervision.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e  \u003ch3\u003eTaking Tachipirina 100 mg\/ml 30 ml oral drops solution before driving or using machines - Does Tachipirina 100 mg\/ml 30 ml oral drops solution affect driving or using machines?\u003c\/h3\u003e Tachipirina does not alter the ability to drive vehicles or use machinery.","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51730204229959,"sku":"012745081","price":4.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-tachipirina-100-mg-ml-30-ml-gocce-orali-soluzione-farmacia-dottor-tili-1213791408.jpg?v=1767138910"},{"product_id":"tachipirina-120-mg-5-ml-120-ml-sospensione-orale-gusto-vaniglia-carammello-con-adattatore-siringa-e-bicchierino","title":"Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup","description":"\u003cp\u003e \n\u003cstrong\u003eTachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavoured oral suspension\u003c\/strong\u003e is a solution specifically formulated for the symptomatic treatment of \u003cstrong\u003efever and pain in children\u003c\/strong\u003e . Thanks to its active ingredient, \u003cstrong\u003eparacetamol\u003c\/strong\u003e , this oral suspension acts effectively as \u003cstrong\u003ean antipyretic and analgesic\u003c\/strong\u003e , making it ideal for combating feverish states due to \u003cstrong\u003einfluenza, exanthematous diseases and acute respiratory tract conditions\u003c\/strong\u003e , as well as for relieving \u003cstrong\u003eheadaches, neuralgia and myalgia\u003c\/strong\u003e of medium severity.\n\u003c\/p\u003e\n\n\u003cp\u003e \nThe \u003cstrong\u003esyrup formulation\u003c\/strong\u003e with a pleasant \u003cstrong\u003evanilla-caramel flavour\u003c\/strong\u003e makes it easy to administer even to the littlest ones, making the treatment simpler and more well-accepted. The \u003cstrong\u003e120 ml\u003c\/strong\u003e pack includes a practical \u003cstrong\u003eadapter, a measuring syringe and a measuring cup\u003c\/strong\u003e , tools that allow you to precisely measure the necessary dose based on the child's weight, thus ensuring maximum safety of use.\n\u003c\/p\u003e\n\n\u003cp\u003e \n\u003cstrong\u003eTachipirina oral suspension\u003c\/strong\u003e is particularly indicated for \u003cstrong\u003epediatric use\u003c\/strong\u003e and represents a reliable solution for the \u003cstrong\u003ereduction of fever\u003c\/strong\u003e and the \u003cstrong\u003etreatment of pain in children\u003c\/strong\u003e . The presence of selected excipients and the absence of sodium make the product also suitable for subjects with particular dietary needs. Choosing \u003cstrong\u003eTachipirina 120 mg\/5 ml\u003c\/strong\u003e means relying on a \u003cstrong\u003esafe, practical and proven effective drug\u003c\/strong\u003e for the health of the little ones.\n\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup - What is the active ingredient of Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup? \u003c\/h3\u003eEach ml of oral suspension contains 24 mg of paracetamol. 5 ml of suspension contains 120 mg of paracetamol. Excipients with known effect: 1 ml of oral suspension contains: sorbitol (90.30 mg), sucrose (500 mg), methyl parahydroxybenzoate (1.25 mg). For a full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup - What does Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup contain?\u003c\/h3\u003e Sorbitol; Sucrose; Xanthan gum; Disodium edetate (dihydrate); Methyl parahydroxybenzoate; Microcrystalline cellulose; Sodium carmellose (Avicel RC591); Sodium citrate; Sodium chloride; Potassium sorbate; Colloidal anhydrous silica; Citric acid monohydrate; Vanillin-caramel flavour; Purified water.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e  \u003ch3\u003eTherapeutic indications Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup - Why is Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup used? What is it used for?\u003c\/h3\u003e As an antipyretic: symptomatic treatment of febrile conditions such as influenza, exanthematous diseases, acute respiratory tract conditions, etc. As an analgesic: headaches, neuralgia, myalgia and other moderately severe painful conditions of various origins.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup - When should Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup not be used? \u003c\/h3\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • Patients with severe haemolytic anaemia (this contraindication does not apply to the 500 mg oral formulations). • Severe hepatocellular insufficiency (this contraindication does not apply to the 500 mg oral formulations).\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup - How do you take Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup? \u003c\/h3\u003eIn children up to 10 years of age, it is essential to respect the dosage defined based on body weight and not based on age, which is approximate and indicated for information purposes only. If the child's age does not correspond to the weight reported in the table, always refer to body weight when choosing the dosage. The dosage schedule for Tachipirina suspension is as follows.\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\u003ctd colspan=\"4\"\u003e \u003cb\u003eTACHIPIRINA SUSPENSION\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eWeight\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eAge\u003c\/b\u003e (approximate)\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eSingle dose\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eDaily dose\u003c\/b\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 7.2 kg\u003c\/td\u003e\n\u003ctd\u003e 5-6 months\u003c\/td\u003e\n\u003ctd\u003e 4.5 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 8 kg\u003c\/td\u003e\n\u003ctd\u003e 7-10 months\u003c\/td\u003e\n\u003ctd\u003e 5 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 9 kg\u003c\/td\u003e\n\u003ctd\u003e 11-14 months\u003c\/td\u003e\n\u003ctd\u003e 5.5 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 10 kg\u003c\/td\u003e\n\u003ctd\u003e 15-19 months\u003c\/td\u003e\n\u003ctd\u003e 6 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 11 kg\u003c\/td\u003e\n\u003ctd\u003e 20-23 months\u003c\/td\u003e\n\u003ctd\u003e 6.5 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 12 kg\u003c\/td\u003e\n\u003ctd\u003e 2 years\u003c\/td\u003e\n\u003ctd\u003e 7.5 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 14 kg\u003c\/td\u003e\n\u003ctd\u003e 3 years\u003c\/td\u003e\n\u003ctd\u003e 8.5 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 16 kg\u003c\/td\u003e\n\u003ctd\u003e 4 years\u003c\/td\u003e\n\u003ctd\u003e 10 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 18 kg\u003c\/td\u003e\n\u003ctd\u003e 5 years\u003c\/td\u003e  \u003ctd\u003e11 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 20 kg\u003c\/td\u003e\n\u003ctd\u003e 6 years\u003c\/td\u003e\n\u003ctd\u003e 12.5 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 22 kg\u003c\/td\u003e\n\u003ctd\u003e 7 years\u003c\/td\u003e\n\u003ctd\u003e 13.5 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 25 kg\u003c\/td\u003e\n\u003ctd\u003e 8 years old\u003c\/td\u003e\n\u003ctd\u003e 15.5 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 28 kg\u003c\/td\u003e\n\u003ctd\u003e 9 years old\u003c\/td\u003e\n\u003ctd\u003e 17.5 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e from 31 kg up to 32 kg\u003c\/td\u003e\n\u003ctd\u003e 10 years\u003c\/td\u003e\n\u003ctd\u003e 19 ml\u003c\/td\u003e\n\u003ctd\u003e Up to 4 times (every 6 hours)\u003c\/td\u003e\n\u003c\/tr\u003e  \u003c\/table\u003eIn case of jaundice in children under three months, it is advisable to reduce the single dose. In children over 10 years of age, the relationship between weight and age becomes no longer homogeneous due to pubertal development which, at the same age, has a different impact on body weight depending on the sex and individual characteristics of the child. Therefore, above 10 years of age, the dosage of the suspension is indicated in terms of weight and age ranges, as reported below. Children weighing between 33 and 40 kg (over 10 years and under 12 years): 20 ml of suspension at a time (corresponding to 480 mg), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. Adolescents weighing more than 40 kg (aged 12 years or over) and adults: 20 ml of suspension at a time (corresponding to 480 mg), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. The doctor must evaluate the need for treatments for more than 3 consecutive days. \u003cu\u003eMethod of administration\u003c\/u\u003e The package contains a dosing syringe with level marks corresponding to 1 ml, 2 ml, 3 ml, 4 ml, 4.5 ml and 5 ml and a measuring cup with level marks corresponding to 5.5 ml, 6 ml, 6.5 ml, 7.5 ml, 8.5 ml, 10 ml, 11 ml, 12.5 ml, 13.5 ml, 15.5 ml, 17.5 ml, 19 ml. \u003cu\u003eShake the bottle before use and then follow the instructions below\u003c\/u\u003e . The suspension contains 24 mg of paracetamol per ml of product. To open the bottle, push the cap down and simultaneously turn to the left. To use the syringe, insert the tip of the syringe fully into the hole in the undercap:  \u003cimg src=\"https:\/\/www.farmadati.it\/public\/imgSkt\/81209_1.png\"\u003eTurn the bottle upside down:\u003cimg src=\"https:\/\/www.farmadati.it\/public\/imgSkt\/81209_2.png\"\u003e Holding the syringe firmly, gently pull the plunger down, filling the syringe to the mark corresponding to the desired dose.\u003cimg src=\"https:\/\/www.farmadati.it\/public\/imgSkt\/81209_3.png\"\u003e Return the bottle to an upright position:\u003cimg src=\"https:\/\/www.farmadati.it\/public\/imgSkt\/81209_4.png\"\u003e Remove the syringe by gently twisting it.  \u003cimg src=\"https:\/\/www.farmadati.it\/public\/imgSkt\/81209_5.png\"\u003eInsert the tip of the syringe into the child's mouth and apply gentle pressure to the plunger to release the suspension. The product must be used immediately after taking it from the bottle. Any residual product in the syringe must be discarded. For doses greater than 5 ml, take the required amount with the syringe and pour the contents into the cup. Repeat the procedure until the mark corresponding to the indicated dosage is reached, and administer to the child, inviting him or her to drink. For doses in children over 10 years of age and in adults, equal to 20 ml, use the cup, filling it twice up to the 10 ml mark. The product must be used immediately after taking it from the bottle. Any residual product in the syringe or cup must be discarded. After use, close the bottle by screwing the cap tightly and wash the syringe and cup with hot water. Leave them to dry, keeping them out of the reach and sight of children. \u003cb\u003e\u003ci\u003e\u003cu\u003eRenal impairment\u003c\/u\u003e\u003c\/i\u003e\u003c\/b\u003e In case of severe renal impairment (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup - How is Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup stored?\u003c\/h3\u003e Do not store above 25°C.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup - It is important to know that Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup: \u003c\/h3\u003eIn rare cases of allergic reactions, administration should be suspended and appropriate treatment should be instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u0026gt;9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause even serious alterations to the kidney and blood, therefore administration to subjects with renal insufficiency should be carried out only if really necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and renal function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other medicine (see section 4.5). \u003cb\u003e\u003cu\u003eImportant information about some of the excipients\u003c\/u\u003e\u003c\/b\u003e \u003cu\u003eTachipirina suspension contains\u003c\/u\u003e : - sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. - methyl parahydroxybenzoate: may cause allergic reactions (possibly delayed). - sodium: this medicine contains less than 1 mmol (23 mg) sodium per 20 ml, i.e. essentially “sodium-free”. - sorbitol: this medicine contains 1806 mg sorbitol per 20 ml dose. The additive effect of co-administration of medicinal products containing sorbitol (or fructose) and daily dietary intake of sorbitol (or fructose) should be considered. The sorbitol content of oral medicinal products may alter the bioavailability of other concomitantly administered oral medicinal products. Patients with hereditary fructose intolerance should not be given this medicinal product.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Tachipirina 120 mg\/5 ml 120 ml oral suspension vanilla-caramel flavour with adapter, syringe and cup - Which medicines or foods can modify the effect of Tachipirina 120 mg\/5 ml 120 ml oral suspension vanilla-caramel flavour with adapter, syringe and cup? \u003c\/h3\u003eOral absorption of paracetamol depends on the rate of gastric emptying. Therefore, concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may lead to a decrease or increase in the bioavailability of the product, respectively. Concomitant administration of cholestyramine reduces the absorption of paracetamol. Concomitant intake of paracetamol and chloramphenicol may lead to an increase in the half-life of chloramphenicol, with the risk of increasing its toxicity. Concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants may lead to slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its discontinuation. Use with extreme caution and under close monitoring during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol can interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tachipirina 120 mg\/5 ml 120 ml oral suspension vanilla-caramel flavour with adapter, syringe and cup can cause side effects - What are the side effects of Tachipirina 120 mg\/5 ml 120 ml oral suspension vanilla-caramel flavour with adapter, syringe and cup?\u003c\/h3\u003e The following are the adverse reactions of paracetamol organized according to the MedDRA system organ classification. There are insufficient data to establish the frequency of the individual effects listed.\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003ePathologies of the haemolymphopoietic system\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Thrombocytopenia, leukopenia, anemia, agranulocytosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eImmune system disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eNervous system disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Dizziness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eGastrointestinal disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Gastrointestinal reaction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eHepatobiliary pathologies\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e  \u003ctd\u003eAbnormal liver function, hepatitis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eSkin and subcutaneous tissue disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Erythema multiforme, Stevens Johnson syndrome, Epidermal necrolysis, Skin rash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eKidney and urinary disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Acute renal failure, interstitial nephritis, hematuria, anuria\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e Very rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/u\u003e\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e  \u003ch3\u003eOverdose Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup - What are the risks of Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup in case of overdose? \u003c\/h3\u003e\n\u003cu\u003eThere is a risk of intoxication, especially in patients with liver disease, in chronic alcoholism, in patients with chronic malnutrition, and in patients receiving enzyme inducers. In these cases, overdose can be fatal\u003c\/u\u003e . \u003cu\u003eSymptoms\u003c\/u\u003e In case of accidental ingestion of very high doses of paracetamol, acute intoxication manifests itself with anorexia, nausea and vomiting followed by a profound deterioration of general conditions; these symptoms generally appear within the first 24 hours. In case of overdose, paracetamol can cause hepatic cytolysis which can evolve into massive and irreversible necrosis, with consequent hepatocellular insufficiency, metabolic acidosis and encephalopathy, which can lead to coma and death. Simultaneously, an increase in the levels of hepatic transaminases, lactate dehydrogenase, and bilirubinemia, and a reduction in prothrombin levels are observed, which may occur within 12-48 hours after ingestion. \u003cu\u003eTreatment\u003c\/u\u003e The measures to be taken consist of early gastric emptying and hospitalization for appropriate treatment, by administering, as early as possible, N-acetylcysteine ​​as an antidote: the dosage is 150 mg\/kg iv in glucose solution over 15 minutes, then 50 mg\/kg over the next 4 hours and 100 mg\/kg over the next 16 hours, for a total of 300 mg\/kg over 20 hours.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup.\u003c\/h3\u003e \u003cu\u003ePregnancy\u003c\/u\u003e A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. \u003cu\u003eBreastfeeding\u003c\/u\u003e It is recommended to administer the product only in cases of real need and under direct medical supervision.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e  \u003ch3\u003eTaking Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup before driving or using machines - Does Tachipirina 120 mg\/5 ml 120 ml vanilla-caramel flavour oral suspension with adapter, syringe and cup affect driving or using machines?\u003c\/h3\u003e Tachipirina does not alter the ability to drive vehicles or use machinery.","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51730204295495,"sku":"012745283","price":6.89,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-tachipirina-120-mg-5-ml-120-ml-sospensione-orale-gusto-vaniglia-carammello-con-adattatore-siringa-e-bicchierino-farmacia-dottor-tili-1213791407.jpg?v=1767139007"},{"product_id":"tachipirina-prima-infanzia-125-mg-10-supposte","title":"Tachipirina Early Childhood 125 mg 10 suppositories","description":"\u003cp\u003e \n\u003cstrong\u003eTachipirina Prima Infanzia 125 mg 10 suppositories\u003c\/strong\u003e is a \u003cstrong\u003eparacetamol\u003c\/strong\u003e -based medicine, specifically formulated for the symptomatic treatment of \u003cstrong\u003efever\u003c\/strong\u003e and \u003cstrong\u003epain in young children\u003c\/strong\u003e , starting from 3 months of age. Thanks to its \u003cstrong\u003eantipyretic and analgesic action\u003c\/strong\u003e , this product is indicated for the \u003cstrong\u003ereduction of fever\u003c\/strong\u003e associated with \u003cstrong\u003einfluenza\u003c\/strong\u003e , \u003cstrong\u003eexanthematous diseases\u003c\/strong\u003e and \u003cstrong\u003eacute respiratory tract conditions\u003c\/strong\u003e , as well as for the relief of \u003cstrong\u003emedium-level painful manifestations\u003c\/strong\u003e such as headaches, neuralgia and myalgia.\n\u003c\/p\u003e\n\n\u003cp\u003e \nThe \u003cstrong\u003e125 mg\u003c\/strong\u003e suppositories are particularly suitable for \u003cstrong\u003echildren who have difficulty taking medications orally\u003c\/strong\u003e , offering \u003cstrong\u003erapid relief\u003c\/strong\u003e thanks to rectal absorption. The package contains \u003cstrong\u003e10 suppositories\u003c\/strong\u003e , practical to use and dosed to ensure maximum safety and efficacy in the \u003cstrong\u003esymptomatic treatment of feverish and painful conditions\u003c\/strong\u003e in the little ones. The selected excipients, such as \u003cstrong\u003esolid semi-synthetic glycerides\u003c\/strong\u003e , ensure a delicate and well-tolerated administration even in the most sensitive children.\n\u003c\/p\u003e\n\n\u003cp\u003e \n\u003cstrong\u003eTachipirina Prima Infanzia 125 mg suppositories\u003c\/strong\u003e is the ideal choice for parents looking for a \u003cstrong\u003ereliable antipyretic and analgesic\u003c\/strong\u003e for the \u003cstrong\u003ewell-being of their children\u003c\/strong\u003e , ensuring \u003cstrong\u003eeffective and safe treatment\u003c\/strong\u003e in case of \u003cstrong\u003efever\u003c\/strong\u003e and \u003cstrong\u003epain\u003c\/strong\u003e of various origins. The product is widely recommended in the pediatric field for its \u003cstrong\u003eclinically proven efficacy\u003c\/strong\u003e and its \u003cstrong\u003eease of use\u003c\/strong\u003e in children from \u003cstrong\u003e3 months and up\u003c\/strong\u003e .\n\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Tachipirina Prima Infanzia 125 mg 10 suppositories - What is the active ingredient of Tachipirina Prima Infanzia 125 mg 10 suppositories? \u003c\/h3\u003e\n\u003ci\u003eTACHIPIRINA 500 mg tablets.\u003c\/i\u003e Each tablet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 500 mg effervescent granules.\u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 12.3 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 125 mg effervescent granules.\u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 3.07 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Neonati 62.5 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains. \u003cu\u003eactive ingredient: paracetamol 62.5 mg\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Prima Infanzia 125 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Children 250 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 250 mg.\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Children 500 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Adults 1000 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 1000 mg.\u003c\/u\u003e For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eEXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tachipirina Prima Infanzia 125 mg 10 suppositories - What does Tachipirina Prima Infanzia 125 mg 10 suppositories contain?\u003c\/h3\u003e • \u003cu\u003eTablets:\u003c\/u\u003e microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, croscarmellose sodium. • \u003cu\u003eEffervescent granules\u003c\/u\u003e : maltitol, mannitol, sodium bicarbonate, anhydrous citric acid, citrus flavouring, aspartame, sodium docusate. • \u003cu\u003eSuppositories\u003c\/u\u003e : solid semi-synthetic glycerides.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Tachipirina Prima Infanzia 125 mg 10 suppositories - Why is Tachipirina Prima Infanzia 125 mg 10 suppositories used? What is it used for?\u003c\/h3\u003e As an antipyretic: symptomatic treatment of febrile conditions such as influenza, exanthematous diseases, acute respiratory tract conditions, etc. As an analgesic: headaches, neuralgia, myalgia and other moderately severe painful conditions of various origins.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e  \u003ch3\u003eContraindications Tachipirina Prima Infanzia 125 mg 10 suppositories - When should Tachipirina Prima Infanzia 125 mg 10 suppositories not be used?\u003c\/h3\u003e • Hypersensitivity to paracetamol or to any of the excipients listed in paragraph 6.1. • Patients with severe haemolytic anaemia (this contraindication does not apply to the 500 mg oral formulations). • Severe hepatocellular insufficiency (this contraindication does not apply to the 500 mg oral formulations).\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Tachipirina Prima Infanzia 125 mg 10 suppositories - How do you take Tachipirina Prima Infanzia 125 mg 10 suppositories? \u003c\/h3\u003eFor children, it is essential to respect the dosage defined according to their body weight, and therefore choose the appropriate formulation. The approximate ages according to body weight are given for information purposes only. In adults, the maximum oral dosage is 3000 mg and rectal dosage is 4000 mg of paracetamol per day (see section 4.9). The doctor must evaluate the need for treatments for more than 3 consecutive days. The dosage schedule of Tachipirina in relation to body weight and administration route is as follows: \u003cb\u003e500 mg tablets.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): ½ tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day (3 tablets). • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately 8 and 11 years): 1 tablet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately 12 and 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e : 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In case of severe pain or high fever, 2 tablets of 500 mg to be repeated if necessary after not less than 4 hours. \u003cb\u003eEffervescent granules of 500 mg in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately 8 to 11 years): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately 12 to 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e : 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 sachets of 500 mg to be repeated if necessary after not less than 4 hours. \u003cb\u003e125 mg effervescent granules in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003eNewborn Suppositories 62.5 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 3.2 and 5 kg\u003c\/u\u003e (approximately between birth and 2 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eEarly Childhood Suppositories 125 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 6 and 7 kg\u003c\/u\u003e (approximately between 3 and 5 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 suppository at a time, to be repeated if necessary after 4 - 6 hours, without exceeding 5 administrations per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003eSuppositories Children 250 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Children 500 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately between 8 and 11 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Adults 1000 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately 12 and 15 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e : 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003ci\u003e\u003cu\u003eRenal insufficiency.\u003c\/u\u003e\u003c\/i\u003e In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Tachipirina Prima Infanzia 125 mg 10 suppositories - How is Tachipirina Prima Infanzia 125 mg 10 suppositories stored?\u003c\/h3\u003e \u003cu\u003eTablets and effervescent granules\u003c\/u\u003e : no special precautions for storage. \u003cu\u003eSuppositories:\u003c\/u\u003e store at a temperature not exceeding 25°C.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tachipirina Prima Infanzia 125 mg 10 suppositories - About Tachipirina Prima Infanzia 125 mg 10 suppositories it is important to know that: \u003c\/h3\u003eIn rare cases of allergic reactions, administration should be suspended and appropriate treatment should be instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u0026gt;9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause even serious alterations to the kidney and blood, therefore administration to subjects with renal insufficiency should be carried out only if really necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and renal function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other medicine. See also section 4.5. \u003cb\u003e\u003cu\u003eImportant information about some of the excipients.\u003c\/u\u003e\u003c\/b\u003e \u003cu\u003eTachipirina 125 mg effervescent granules contains\u003c\/u\u003e \u003cu\u003e:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e , is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e : use with caution in patients with rare hereditary problems of fructose intolerance. 70.6 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 3.53% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult: to be taken into consideration by people with reduced kidney function or who follow a low-sodium diet. \u003cu\u003eTachipirina 500 mg effervescent granules contains:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e , is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e : use with caution in patients with rare hereditary problems of fructose intolerance. - 283 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 14.1% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. The maximum dose for this product is equivalent to 84.6% of the WHO recommended maximum daily sodium intake.: to be taken into consideration by people with reduced kidney function or on a low-sodium diet.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Tachipirina Prima Infanzia 125 mg 10 suppositories - Which medicines or foods can modify the effect of Tachipirina Prima Infanzia 125 mg 10 suppositories? \u003c\/h3\u003eOral absorption of paracetamol depends on the rate of gastric emptying. Therefore, concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may lead to a decrease or increase in the bioavailability of the product, respectively. Concomitant administration of cholestyramine reduces the absorption of paracetamol. Concomitant intake of paracetamol and chloramphenicol may lead to an increase in the half-life of chloramphenicol, with the risk of increasing its toxicity. Concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants may lead to slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its discontinuation. Use with extreme caution and under close monitoring during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol can interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tachipirina Prima Infanzia 125 mg 10 suppositories can cause side effects - What are the side effects of Tachipirina Prima Infanzia 125 mg 10 suppositories?\u003c\/h3\u003e The following are the adverse reactions of paracetamol organized according to the MedDRA system organ classification. There are insufficient data to establish the frequency of the individual effects listed.\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003ePathologies of the haemolymphopoietic system\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Thrombocytopenia, leukopenia, anemia, agranulocytosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eImmune system disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eNervous system disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Dizziness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eGastrointestinal disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Gastrointestinal reaction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eHepatobiliary pathologies\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Abnormal liver function, hepatitis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eSkin and subcutaneous tissue disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e  \u003ctd\u003eErythema multiforme, Stevens Johnson syndrome, Epidermal necrolysis, Skin rash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eKidney and urinary disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Acute renal failure, interstitial nephritis, hematuria, anuria\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e Very rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Tachipirina Prima Infanzia 125 mg 10 suppositories - What are the risks of Tachipirina Prima Infanzia 125 mg 10 suppositories in case of overdose? \u003c\/h3\u003e\n\u003cu\u003eThere is a risk of intoxication, especially in patients with liver disease, in chronic alcoholism, in patients with chronic malnutrition, and in patients receiving enzyme inducers. In these cases, overdose can be fatal.\u003c\/u\u003e \u003cu\u003eSymptoms\u003c\/u\u003e In case of accidental ingestion of very high doses of paracetamol, acute intoxication manifests itself with anorexia, nausea and vomiting followed by a profound deterioration of general conditions; these symptoms generally appear within the first 24 hours. In case of overdose, paracetamol can cause hepatic cytolysis that can evolve into massive and irreversible necrosis, with consequent hepatocellular insufficiency, metabolic acidosis and encephalopathy, which can lead to coma and death. Simultaneously, an increase in the levels of hepatic transaminases, lactate dehydrogenase, and bilirubinemia, and a reduction in prothrombin levels are observed, which may occur within 12-48 hours after ingestion. \u003cu\u003eTreatment\u003c\/u\u003e The measures to be taken consist of early gastric emptying and hospitalization for appropriate treatment, by administering, as early as possible, N-acetylcysteine ​​as an antidote: the dosage is 150 mg\/kg iv in glucose solution over 15 minutes, then 50 mg\/kg over the next 4 hours and 100 mg\/kg over the next 16 hours, for a total of 300 mg\/kg over 20 hours.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina Prima Infanzia 125 mg 10 suppositories.\u003c\/h3\u003e Pregnancy: A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to administer the product only in cases of real need and under the direct supervision of a doctor.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e  \u003ch3\u003eTaking Tachipirina Prima Infanzia 125 mg 10 suppositories before driving or using machinery - Does Tachipirina Prima Infanzia 125 mg 10 suppositories affect driving or using machinery?\u003c\/h3\u003e Tachipirina does not alter the ability to drive vehicles or use machinery.","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51730204426567,"sku":"012745079","price":5.65,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-tachipirina-prima-infanzia-125-mg-10-supposte-farmacia-dottor-tili-1213791403.jpg?v=1767139048"},{"product_id":"tachipirina-orosolubile-250-mg-10-bustine-granulato","title":"Tachipirina orosoluble 250 mg 10 sachets granules","description":"\u003cp\u003e \n\u003cstrong\u003eTachipirina orosoluble 250 mg 10 sachets granules\u003c\/strong\u003e is an \u003cstrong\u003eanalgesic and antipyretic\u003c\/strong\u003e based on \u003cstrong\u003eparacetamol\u003c\/strong\u003e , ideal for the \u003cstrong\u003esymptomatic treatment of fever and mild to moderate pain\u003c\/strong\u003e in adults and children. The formulation in 250 mg \u003cstrong\u003eorosoluble sachets\u003c\/strong\u003e allows for a \u003cstrong\u003epractical and fast oral solution\u003c\/strong\u003e , perfect for those seeking \u003cstrong\u003erapid relief\u003c\/strong\u003e from symptoms such as \u003cstrong\u003eheadache, sore throat, toothache, muscle pain, menstrual pain\u003c\/strong\u003e and the typical discomforts of \u003cstrong\u003ea cold\u003c\/strong\u003e .\n\u003c\/p\u003e\n\n\u003cp\u003e \nThanks to its \u003cstrong\u003eeasy intake without water\u003c\/strong\u003e , Tachipirina orosoluble is particularly suitable for \u003cstrong\u003epediatric use\u003c\/strong\u003e and for those who have difficulty swallowing tablets. The granules dissolve directly on the tongue, ensuring \u003cstrong\u003erapid assimilation of the active ingredient\u003c\/strong\u003e and timely action against fever and pain. Each sachet contains 250 mg of paracetamol, a dosage designed to offer \u003cstrong\u003eefficacy and safety\u003c\/strong\u003e in both children and adults, according to the instructions of the doctor or pharmacist.\n\u003c\/p\u003e\n\n\u003cp\u003e\n The \u003cstrong\u003e10-sachet\u003c\/strong\u003e pack is convenient to carry with you and allows you to manage the administration of the drug in a simple and precise way. \u003cstrong\u003eTachipirina orosolubile 250 mg\u003c\/strong\u003e represents a modern and reliable solution for the control of flu symptoms and pain of various origins, offering \u003cstrong\u003econvenience, rapid action and tolerability\u003c\/strong\u003e even in the most sensitive subjects.\n\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e  \u003ch2\u003eACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Tachipirina orosolubile 250 mg 10 sachets granules - What is the active ingredient of Tachipirina orosolubile 250 mg 10 sachets granules?\u003c\/h3\u003e One sachet contains 250 mg of paracetamol. Excipients with known effect: One sachet contains: sorbitol (E420) 600.575 mg, sucrose 0.1 mg, propylene glycol 1.075 mg and sodium. For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tachipirina orosolubile 250 mg 10 sachets granules - What does Tachipirina orosolubile 250 mg 10 sachets granules contain? \u003c\/h3\u003eSorbitol Talc Butyl methacrylate basic copolymer Light magnesium oxide Sodium carmellose Sucralose Magnesium stearate (Ph.Eur.) Hypromellose Stearic acid Sodium lauryl sulphate Titanium dioxide (E 171) Simethicone Strawberry flavour (contains maltodextrin, gum arabic (E414), natural and\/or nature-identical flavouring substances, propylene glycol (E1520), triacetin (E1518), maltol (E636)) Vanilla flavour (contains maltodextrin, natural and\/or nature-identical flavouring substances, propylene glycol (E1520), sucrose)\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Tachipirina orosolubile 250 mg 10 sachets granules - Why is Tachipirina orosolubile 250 mg 10 sachets granules used? What is it used for?\u003c\/h3\u003e TACHIPIRINA OROSOLUBILE is indicated for the symptomatic treatment of mild to moderate pain and fever.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e  \u003ch3\u003eContraindications Tachipirina orosolubile 250 mg 10 sachets granules - When should Tachipirina orosolubile 250 mg 10 sachets granules not be used?\u003c\/h3\u003e Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with severe hepatic dysfunction (Child-Pugh \u0026gt; 9). • severe renal or hepatic insufficiency (Child-Pugh \u0026gt; 9) • acute hepatitis • concomitant treatment with medicinal products that affect liver function • glucose-6-phosphate dehydrogenase deficiency • haemolytic anaemia • alcohol abuse • severe haemolytic anaemia\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Tachipirina orosolubile 250 mg 10 sachets granules - How do you take Tachipirina orosolubile 250 mg 10 sachets granules? \u003c\/h3\u003eDoses depend on body weight and age. A single dose ranges from 10 to 15 mg\/kg of body weight up to a maximum of 60 - 75 mg\/kg for the total daily dose. The time interval between individual doses depends on the symptoms and the maximum daily dose. In any case, it must not be less than 4 hours. TACHIPIRINA OROSOLUBILE must not be used for more than three days without consulting your doctor. 250 mg sachets\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e Body weight (age)\u003c\/td\u003e\n\u003ctd\u003e Single dose [sachet]\u003c\/td\u003e\n\u003ctd\u003e Maximum daily dose [sachets]\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e 17 - 25 kg\u003c\/td\u003e\n\u003ctd rowspan=\"2\"\u003e 250 mg paracetamol (1 sachet)\u003c\/td\u003e\n\u003ctd rowspan=\"2\"\u003e 1000 mg paracetamol (4 sachets)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd\u003e (4 - 8 years)\u003c\/td\u003e\u003c\/tr\u003e  \u003c\/table\u003e\n\u003cu\u003eMethod of administration.\u003c\/u\u003e For oral use only. The granules should be taken by placing them directly on the tongue and should be swallowed without water. TACHIPIRINA OROSOLUBILE should not be taken on a full stomach. Special populations. Hepatic or renal insufficiency. In patients with hepatic or renal insufficiency or Gilbert's syndrome, the dose should be reduced or the time interval between administrations should be prolonged. Patients with renal insufficiency. In patients with severe renal insufficiency (creatinine clearance \u0026lt; 10 ml\/min.), a time interval between administrations of at least 8 hours should be respected. Chronic alcoholism. Chronic alcohol consumption can lower the toxicity threshold of paracetamol. In these patients, the time interval between two doses should be at least 8 hours. The dose of 2 g of paracetamol per day should not be exceeded. Elderly patients. In the elderly, dose adjustment is not required. For all indications: Adults, elderly and children over 12 years of age: the usual dose is 500 - 1000 mg every 4 - 6 hours up to a maximum of 3 g per day. The dose should not be repeated before four hours. Renal insufficiency. The dose should be reduced in case of renal insufficiency.  \u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlomerular filtration\u003c\/td\u003e\n\u003ctd\u003e Dose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e 10 - 50 ml\/min.\u003c\/td\u003e\n\u003ctd\u003e 500 mg every 6 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u0026lt; 10 ml\/min.\u003c\/td\u003e\n\u003ctd\u003e 500 mg every 8 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e The effective daily dose should be considered, without exceeding 60 mg\/kg\/day (without exceeding 3 g\/day), in the following situations: Adults weighing less than 50 kg. Hepatocellular insufficiency (mild to moderate). Chronic alcoholism. Dehydration. Chronic malnutrition. Hepatic or renal insufficiency. In patients with hepatic or renal insufficiency or Gilbert's syndrome, the dose should be reduced or the administration interval should be prolonged. The sachet formulation is not recommended for children under 4 years of age. Older children (4 - 12 years) can be administered 250 - 500 mg every 4 - 6 hours up to a maximum of 4 doses in 24 hours.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Tachipirina orosolubile 250 mg 10 sachets granules - How is Tachipirina orosolubile 250 mg 10 sachets granules stored? \u003c\/h3\u003eDo not store above 30°C. Store in the original package in order to protect from light and moisture.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tachipirina orosolubile 250 mg 10 sachets granules - About Tachipirina orosolubile 250 mg 10 sachets granules it is important to know that: \u003c\/h3\u003eTo avoid the risk of overdose, it is necessary to check that any other drugs taken at the same time do not contain paracetamol. Paracetamol should be administered with particular caution in the following cases: • hepatocellular insufficiency (Child-Pugh \u0026lt; 9) • chronic alcohol abuse • severe renal insufficiency (creatinine clearance \u0026lt; 10 ml\/min. [see section 4.2]) • Gilbert's syndrome (familial non-haemolytic jaundice). In the presence of high fever or signs of secondary infection or if the symptoms persist for more than 3 days, a doctor should be consulted. In general, medicines containing paracetamol can only be taken for a few days and at low doses without consulting a doctor or dentist. In case of prolonged incorrect use of analgesics at high doses, headaches may occur which should not be treated with higher doses of the drug. In general, the habitual intake of analgesics, especially a combination of several analgesic substances, can cause permanent kidney damage with risk of renal failure (analgesic nephropathy). Prolonged or frequent use is not recommended. Patients should be warned not to take other products containing paracetamol at the same time. Taking multiple daily doses in a single administration can seriously damage the liver. In this case, the patient does not lose consciousness, however, a doctor should be consulted immediately. Prolonged use without medical supervision can be harmful. In children treated with 60 mg\/kg per day of paracetamol, the combination with another antipyretic is not justified unless ineffective. Abrupt cessation of analgesic intake after a prolonged period of incorrect use, at high doses, can cause headache, fatigue, muscle pain, nervousness and autonomic symptoms. These withdrawal symptoms resolve within a few days. Until then, further intake of analgesics should be avoided and should not be resumed without consulting your doctor. Caution should be exercised when taking paracetamol in combination with inducers of cytochrome CYP3A4 or with substances that induce liver enzymes such as rifampicin, cimetidine and antiepileptics such as glutethimide, phenobarbital and carbamazepine. Caution should be exercised when administering paracetamol to patients with renal insufficiency (creatinine clearance ≤ 30 ml\/min, see section 4.2) or hepatocellular insufficiency (mild to moderate). Alcohol consumption should be avoided during treatment with paracetamol. The risks of overdose are greater in patients with non-cirrhotic alcoholic liver disease. Caution should be exercised in cases of chronic alcoholism. The dose should be reduced in patients with alcohol abuse (see section 4.2). In this case, the daily dose should not exceed 2 grams. TACHIPIRINA OROSOLUBILE contains: - \u003cb\u003esorbitol\u003c\/b\u003e : this medicine contains 600.575 mg of sorbitol per sachet. Patients with hereditary fructose intolerance should not be given this medicine; The additive effect of co-administration of medicinal products containing sorbitol (or fructose) and the daily intake of sorbitol (or fructose) with the diet should be considered. The sorbitol content in medicinal products for oral use may alter the bioavailability of other medicinal products for oral use co-administered. - \u003cb\u003esucrose\u003c\/b\u003e : patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine; - \u003cb\u003epropylene glycol:\u003c\/b\u003e this medicine contains 1.075 mg of propylene glycol per sachet. Co-administration with any substrate of alcohol dehydrogenase such as ethanol may induce serious adverse effects in neonates; - \u003cb\u003esodium\u003c\/b\u003e : this medicinal product contains less than 1 mmol sodium (23 mg) per sachet, i.e. “essentially sodium-free”. In the presence of high fever or signs of secondary infection or persistence of symptoms beyond 3 days, a review of the treatment should be performed. Doses higher than recommended carry the risk of very serious liver damage. Treatment with the antidote should be administered as soon as possible (see section 4.9). Paracetamol should be used with caution in cases of dehydration and chronic malnutrition.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Tachipirina orosolubile 250 mg 10 sachets granules - Which medicines or foods can modify the effect of Tachipirina orosolubile 250 mg 10 sachets granules? \u003c\/h3\u003eProbenecid inhibits the binding of paracetamol to glucuronic acid, resulting in a reduction in the clearance of paracetamol approximately two-fold. In patients taking probenecid concomitantly, the dose of paracetamol should be reduced. The metabolism of paracetamol is increased in patients taking enzyme-inducing drugs, such as rifampicin and some antiepileptics (carbamazepine, phenytoin, phenobarbital, primidone). Some isolated reports describe unexpected hepatotoxicity in patients taking enzyme-inducing drugs. Concomitant administration of paracetamol and AZT (zidovudine) increases the tendency to neutropenia. Therefore, co-administration of this drug with AZT should only occur on medical advice. Concomitant administration of drugs that accelerate gastric emptying, such as metoclopramide, accelerates the absorption and onset of action of paracetamol. Concomitant administration of drugs that slow gastric emptying may delay the absorption and onset of action of paracetamol. Cholestyramine reduces the absorption of paracetamol and, therefore, should not be administered within one hour of paracetamol administration. Repeated administration of paracetamol for periods exceeding one week increases the effect of anticoagulants, particularly warfarin. Therefore, long-term administration of paracetamol in patients treated with anticoagulants should only occur under medical supervision. Occasional paracetamol intake has no significant effect on bleeding tendency. Effects on laboratory tests Paracetamol may interfere with determinations of uric acid using phosphotungstic acid and with those of blood glucose using the glucose-oxidase-peroxidase reaction. Probenecid causes an almost two-fold reduction in the clearance of paracetamol by inhibiting its conjugation with glucuronic acid. A reduction in paracetamol should be considered in case of concomitant treatment with probenecid. Paracetamol increases the plasma levels of acetylsalicylic acid and chloramphenicol.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tachipirina orosolubile 250 mg 10 sachets granules can cause side effects - What are the side effects of Tachipirina orosolubile 250 mg 10 sachets granules?\u003c\/h3\u003e MedDRA system organ classification is used with the following frequencies: very common (≥ 1\/10), common (≥ 1\/100, \u0026lt; 1\/10), uncommon (≥ 1\/1,000,\u0026lt; 1\/100), rare (≥ 1\/10,000,\u0026lt; 1\/1,000), very rare (\u0026lt;1\/10,000).\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eSOC\/FREQUENCY\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eAdverse reactions\u003c\/b\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003ePathologies of the haemolymphopoietic system\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e anemia, non-hemolytic anemias and bone marrow depression, thrombocytopenia\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eVascular pathologies\u003c\/b\u003e :\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e edema\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e exocrine pancreas conditions, acute and chronic pancreatitis, gastrointestinal bleeding, abdominal pain, diarrhea, nausea, vomiting\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eHepatobiliary pathologies\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e liver failure, liver necrosis, jaundice\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e  \u003ctd colspan=\"2\"\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e allergic conditions, anaphylactic reaction, allergies to foods, food additives, drugs and other chemicals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e urticaria, pruritus, rash, sweating, purpura, angioedema\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eVery rare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Very rare cases of serious skin reactions have been reported.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eKidney and urinary disorders\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e nephropathies, nephropathies and tubular disorders\u003c\/td\u003e\n\u003c\/tr\u003e  \u003c\/table\u003eVery rare cases of severe skin reactions have been reported. Nephrotoxic effects are infrequent and have not been reported in association with therapeutic doses, except after prolonged administration. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Tachipirina orosolubile 250 mg 10 sachets granules - What are the risks of Tachipirina orosolubile 250 mg 10 sachets granules in case of overdose? \u003c\/h3\u003eThere is a risk of poisoning, especially in the elderly, young children, patients with liver disease, chronic alcoholism and patients with chronic malnutrition. Overdose can be fatal in these cases. Symptoms generally appear within the first 24 hours and include: nausea, vomiting, anorexia, pallor and abdominal pain. Overdose, i.e. administration of 10 g of paracetamol or more in a single dose in adults or administration of 150 mg\/kg of body weight in a single dose in children, causes necrosis of liver cells which may induce complete and irreversible necrosis, resulting in hepatocellular failure, metabolic acidosis and encephalopathy which may lead to coma and death. Simultaneously, increased levels of liver transaminases (AST, ALT), lactate dehydrogenase and bilirubin are observed, together with increased prothrombin levels that may appear 12 - 48 hours after administration. Emergency procedure: Immediate hospital admission Blood sampling to determine the initial plasma concentration of paracetamol Gastric lavage IV (or oral if possible) administration of the antidote N-acetylcysteine ​​as soon as possible and within 10 hours of the overdose Implement symptomatic treatment.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina orosoluble 250 mg 10 sachets granules.\u003c\/h3\u003e \u003cu\u003ePregnancy:\u003c\/u\u003e A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. \u003cu\u003eBreastfeeding:\u003c\/u\u003e After oral intake, paracetamol is excreted in breast milk in small quantities. No undesirable effects have been reported in breast-fed infants. Therapeutic doses of this medicine can be used during breastfeeding.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\u003ch3\u003e Taking Tachipirina orosolubile 250 mg 10 sachets granules before driving or using machines - Does Tachipirina orosolubile 250 mg 10 sachets granules affect driving and using machines?\u003c\/h3\u003e TACHIPIRINA OROSOLUBILE does not alter the ability to drive vehicles or use machinery. No studies on the ability to drive vehicles and use machinery have been performed.","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51730204459335,"sku":"040313013","price":6.13,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-tachipirina-orosolubile-250-mg-10-bustine-granulato-farmacia-dottor-tili-1213791402.jpg?v=1767139029"},{"product_id":"tachipirina-flashtab-250-mg-12-compresse-dispersibili","title":"Tachipirina Flashtab 250 mg 12 dispersible tablets","description":"\u003cp\u003e \u003cstrong\u003eTachipirina Flashtab 250 mg 12 dispersible tablets\u003c\/strong\u003e is a \u003cstrong\u003eparacetamol\u003c\/strong\u003e -based medicine, specifically formulated for the \u003cstrong\u003esymptomatic treatment of fever and mild to moderate pain in children\u003c\/strong\u003e . Each tablet contains 250 mg of paracetamol, an active ingredient recognized for its \u003cstrong\u003eantipyretic\u003c\/strong\u003e and \u003cstrong\u003eanalgesic\u003c\/strong\u003e properties, ideal for combating \u003cstrong\u003eheadaches\u003c\/strong\u003e , \u003cstrong\u003ecolds\u003c\/strong\u003e , \u003cstrong\u003eexanthematous diseases\u003c\/strong\u003e and other painful disorders typical of pediatric age. The \u003cstrong\u003edispersible\u003c\/strong\u003e formulation makes the product particularly suitable for children: the tablets can be easily \u003cstrong\u003edissolved in the mouth\u003c\/strong\u003e , in water or milk, ensuring simple and pleasant administration even for the little ones.\u003c\/p\u003e\n\n\n \u003cp\u003eThanks to its \u003cstrong\u003erapid action\u003c\/strong\u003e , Tachipirina Flashtab 250 mg is the ideal solution to provide \u003cstrong\u003erapid relief\u003c\/strong\u003e from the symptoms of fever and pain in children weighing between 13 and 50 kg (approximately 2 to 15 years). The \u003cstrong\u003eorosoluble tablets\u003c\/strong\u003e are banana-flavoured, making them more pleasant to take and facilitating compliance in the little ones. The product is indicated for the \u003cstrong\u003esymptomatic treatment of fever\u003c\/strong\u003e and for the \u003cstrong\u003esymptomatic treatment of pain\u003c\/strong\u003e of various origins, such as muscle pain, headache, cold pain and pain associated with exanthematous diseases.\u003c\/p\u003e\n\n\n \u003cp\u003eThe pack contains \u003cstrong\u003e12 tablets\u003c\/strong\u003e in a practical blister, ideal for home or travel use. \u003cstrong\u003eTachipirina Flashtab 250 mg\u003c\/strong\u003e is a \u003cstrong\u003emedicine for children\u003c\/strong\u003e with proven efficacy, chosen by pediatricians and parents for its safety and ease of use. Its formulation allows you to adapt the dosage based on the child's body weight, ensuring personalized and safe treatment. Choose Tachipirina Flashtab 250 mg to guarantee your children \u003cstrong\u003erapid relief from fever and pain\u003c\/strong\u003e , with maximum convenience and tolerability.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Tachipirina Flashtab 250 mg 12 dispersible tablets - What is the active ingredient of Tachipirina Flashtab 250 mg 12 dispersible tablets? \u003c\/h3\u003eEach dispersible tablet contains paracetamol 250 mg (as coated paracetamol crystals). Excipients with known effect: Each tablet also contains 30 mg aspartame (E951). For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tachipirina Flashtab 250 mg 12 dispersible tablets - What does Tachipirina Flashtab 250 mg 12 dispersible tablets contain?\u003c\/h3\u003e \u003ci\u003eCoated paracetamol crystals\u003c\/i\u003e : Basic butylated methacrylate copolymer, 30% polyacrylate dispersion, Silica, colloidal hydrophobic. \u003ci\u003eTablet\u003c\/i\u003e : Mannitol (granules, powder), Crospovidone, Aspartame (E951), Banana flavour, Magnesium stearate.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Tachipirina Flashtab 250 mg 12 dispersible tablets - Why is Tachipirina Flashtab 250 mg 12 dispersible tablets used? What is it used for?\u003c\/h3\u003e Symptomatic treatment of mild to moderate pain and\/or fever.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e  \u003ch3\u003eContraindications Tachipirina Flashtab 250 mg 12 dispersible tablets - When should Tachipirina Flashtab 250 mg 12 dispersible tablets not be used?\u003c\/h3\u003e - Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Phenylketonuria (due to the presence of aspartame). - Severe hepatocellular insufficiency.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Tachipirina Flashtab 250 mg 12 dispersible tablets - How do you take Tachipirina Flashtab 250 mg 12 dispersible tablets? \u003c\/h3\u003e\n\u003cb\u003e\u003ci\u003eDosage\u003c\/i\u003e\u003c\/b\u003e This formulation is reserved for children weighing between 13 and 50 kg (approximately 2 to 15 years). For children, it is essential \u003cb\u003eto respect the dosage defined according to their body weight\u003c\/b\u003e and therefore choose the appropriate formulation. The approximate ages according to body weight are given for information purposes only. The recommended daily dose of paracetamol is approximately 60 mg\/kg\/day, to be divided into 4 or 6 daily administrations, \u003cb\u003ei.e. approximately 15 mg\/kg every 6 hours or 10 mg\/kg at intervals of 4 hours\u003c\/b\u003e . • For children weighing \u003cb\u003ebetween 13 and 20 kg\u003c\/b\u003e (approximately 2 to 7 years): 1 tablet at a time, to be repeated if necessary after 6 hours, \u003cb\u003ewithout exceeding 4 tablets per day\u003c\/b\u003e . • For children weighing \u003cb\u003ebetween 21 and 25 kg\u003c\/b\u003e (approximately 6 to 10 years): 1 tablet at a time, to be repeated if necessary after 4 hours, \u003cb\u003ewithout exceeding 6 tablets per day\u003c\/b\u003e . • For children weighing \u003cb\u003ebetween 26 and 40 kg\u003c\/b\u003e (approximately 8 to 13 years): 2 tablets at a time, to be repeated if necessary after 6 hours, \u003cb\u003ewithout exceeding 8 tablets per day\u003c\/b\u003e . • For adolescents weighing \u003cb\u003ebetween 41 and 50 kg\u003c\/b\u003e (approximately 12 to 15 years): 2 tablets at a time, to be repeated if necessary after 4 hours, \u003cb\u003ewithout exceeding 12 tablets per day\u003c\/b\u003e . \u003cu\u003eMaximum daily dose\u003c\/u\u003e : The total dose of paracetamol must not exceed 80 mg\/kg\/day in children weighing less than 37 kg and 3 g per day in adults and adolescents weighing 38 kg or more (see section 4.9 “Overdose”). \u003cu\u003eFrequency of administration\u003c\/u\u003e In children, administration should be performed at regular intervals, \u003cb\u003eincluding during the night\u003c\/b\u003e , \u003cu\u003epreferably at intervals of 6 hours\u003c\/u\u003e , or at intervals of not less than 4 hours. \u003cu\u003eRenal insufficiency\u003c\/u\u003e In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the minimum interval between 2 administrations should be 8 hours. \u003cb\u003e\u003ci\u003eMethod of administration\u003c\/i\u003e\u003c\/b\u003e Oral route. -For children under 6 years of age, the tablets should be dissolved in a spoonful of water or milk (fruit juice may give a bitter taste) before being administered. -For children over 6 years of age, the tablets can be sucked: they dissolve very quickly in the mouth on contact with saliva.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Tachipirina Flashtab 250 mg 12 dispersible tablets - How is Tachipirina Flashtab 250 mg 12 dispersible tablets stored?\u003c\/h3\u003e This medicinal product does not require any special storage conditions.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tachipirina Flashtab 250 mg 12 dispersible tablets - About Tachipirina Flashtab 250 mg 12 dispersible tablets it is important to know that: \u003c\/h3\u003e\n\u003cb\u003eWarnings\u003c\/b\u003e Do not exceed the recommended dose. Prolonged use of the product, outside of medical supervision, may be harmful. This product should be used only if strictly necessary. Doses higher than those recommended carry a risk of very serious liver damage. Treatment with an antidote should be administered as soon as possible. See section 4.9. To avoid the risk of overdose, patients should be advised to avoid the concomitant use of other medicinal products containing paracetamol. The total dose of paracetamol should not exceed 80 mg\/kg\/day in children weighing less than 37 kg and 3 g per day in adults and children weighing 38 kg or more (see section 4.9 “Overdose”). The ingestion of undissolved tablets should be avoided in children under 6 years of age as this could lead to their inhalation. This medicinal product contains aspartame, a source of phenylalanine, equivalent to 0.15 mg per tablet and is therefore contraindicated in subjects with phenylketonuria (see section 4.3). There are no non-clinical or clinical studies available on the use of aspartame in children under 12 weeks of age. \u003cb\u003ePrecautions for use\u003c\/b\u003e Paracetamol should be used with caution in case of: - Adults weighing less than 50 kg - Mild to moderate hepatocellular insufficiency (note: paracetamol is contraindicated in cases of severe hepatocellular insufficiency) - Chronic alcoholism - Chronic malnutrition (low reserves of hepatic glutathione) - Dehydration - Severe renal insufficiency (creatinine clearance ≤ 10 ml\/min - see section 4.2). In children treated with 60 mg\/kg\/day of paracetamol, the association with another antipyretic is not justified unless the treatment is ineffective. In case of high fever, or signs of secondary infection, or if symptoms persist beyond 3 days, a review of the treatment should be performed. Caution is advised if paracetamol is administered concomitantly with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism), as well as in those using maximum daily doses of paracetamol. Careful monitoring, including measurement of urinary 5-oxoproline, is recommended.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Tachipirina Flashtab 250 mg 12 dispersible tablets - Which medicines or foods can modify the effect of Tachipirina Flashtab 250 mg 12 dispersible tablets? \u003c\/h3\u003e• Probenecid causes a reduction of at least 2-fold in the clearance of paracetamol by inhibiting its conjugation with glucuronic acid. In case of concomitant treatment with probenecid, a reduction in the dosage of paracetamol should be considered. • Salicylamide may prolong the elimination half-life of paracetamol. • Paracetamol should be used with caution in case of concomitant intake of enzyme inducers (such as carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. John's Wort or St. John's Wort) or potentially hepatotoxic substances (see section 4.9). • Metoclopramide and domperidone: accelerate the absorption of paracetamol. • Cholestyramine: reduces the absorption of paracetamol. • Concomitant use of paracetamol (4 g daily for at least 4 days) with oral anticoagulants may induce slight variations in INR values ​​with consequent increased risk of bleeding. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its discontinuation. • Caution should be exercised when paracetamol is used concomitantly with flucloxacillin since concomitant intake has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4). \u003ci\u003eInteractions with clinical tests\u003c\/i\u003e : The administration of paracetamol may alter the measurement of uric acid in the blood, obtained with the phosphotungstic acid method, and the measurement of blood glucose obtained with the glucose oxidase-peroxidase method.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tachipirina Flashtab 250 mg 12 dispersible tablets can cause side effects - What are the side effects of Tachipirina Flashtab 250 mg 12 dispersible tablets?\u003c\/h3\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eSystemic organic classification\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eRare (≥1\/10,000 to \u0026lt;1\/1,000)\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eVery rare (\u0026lt;1\/10,000), not known (frequency cannot be estimated from the available data)\u003c\/b\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eHepatobiliary pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e - increased levels of liver transaminases\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eImmune system disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e - hypersensitivity reaction (ranging from simple skin rash or urticaria to anaphylactic shock requiring discontinuation of treatment)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003ePathologies of the haemolymphopoietic system\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e - thrombocytopenia, leukopenia, neutropenia (sporadic reports)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e Very rare cases of serious skin reactions have been reported.\u003c\/td\u003e\n\u003c\/tr\u003e  \u003c\/table\u003eReporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.aifa.gov.it\/content\/ segnalazioni-reazioni-avverse.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Tachipirina Flashtab 250 mg 12 dispersible tablets - What are the risks of Tachipirina Flashtab 250 mg 12 dispersible tablets in case of overdose? \u003c\/h3\u003eThere is a risk of liver damage (including fulminant hepatitis, hepatic failure, cholestatic hepatitis, hepatic cytolysis), particularly in elderly subjects, in young children, in patients with liver disease, in chronic alcoholism, in patients with chronic malnutrition and in patients receiving enzyme inducers. In these cases, overdose may be fatal. Symptoms generally appear in the first 24 hours and include: nausea, vomiting, anorexia, pallor and abdominal pain. Overdose, 7.5 g or more of paracetamol in a single administration in adults or 140 mg\/kg of body weight in a single administration in children, causes necrosis of hepatocytes which makes it likely to induce complete and irreversible necrosis, resulting in hepatocellular failure, metabolic acidosis and encephalopathy which may lead to coma and death. Concomitantly, an increase in the levels of hepatic transaminases (AST, ALT), lactate dehydrogenase and bilirubin is observed, together with an increase in prothrombin time which may appear 12 to 48 hours after administration. Clinical symptoms of liver damage usually appear after two days and reach a maximum after 4 - 6 days. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Other non-hepatic symptoms that have been reported following paracetamol overdose include myocardial abnormalities and pancreatitis. \u003ci\u003eEmergency treatment\u003c\/i\u003e : • immediate transfer to hospital, even if there are no significant early symptoms • collection of a blood sample for initial measurement of plasma paracetamol concentration • gastric lavage • intravenous (or oral if possible) administration of the antidote N-acetylcysteine ​​if possible \u003ci\u003e\u003cu\u003ewithin\u003c\/u\u003e\u003c\/i\u003e ten hours of ingestion. N-acetylcysteine ​​can, however, provide a certain degree of protection even after 10 hours, and up to 48 hours, but in these cases prolonged treatment is performed. • symptomatic treatment must be performed • oral methionine can be used as an alternative to N-acetylcysteine ​​provided that it is administered as soon as possible after the overdose and, in any case, within 10 hours of the overdose.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina Flashtab 250 mg 12 dispersible tablets. \u003c\/h3\u003e\n\u003cb\u003e\u003ci\u003ePregnancy\u003c\/i\u003e\u003c\/b\u003e A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically needed, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. \u003cb\u003e\u003ci\u003eBreastfeeding\u003c\/i\u003e\u003c\/b\u003e After oral administration, paracetamol is excreted in breast milk in small quantities. No undesirable effects on breast-fed children have been reported. Therapeutic doses of this medicinal product can be taken during breastfeeding.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\u003ch3\u003e Taking Tachipirina Flashtab 250 mg 12 dispersible tablets before driving or using machines - Does Tachipirina Flashtab 250 mg 12 dispersible tablets affect driving or using machines? \u003c\/h3\u003eNot relevant.","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51730204524871,"sku":"034329122","price":6.84,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-tachipirina-flashtab-250-mg-12-compresse-dispersibili-farmacia-dottor-tili-1213791400.jpg?v=1767139108"},{"product_id":"tachipirina-500-mg-20-bustine-granulato-effervescente","title":"Tachipirina 500 mg 20 sachets effervescent granules","description":"\u003cp\u003e\u003cstrong\u003eTachipirina 500 mg 20 sachets effervescent granules\u003c\/strong\u003e is an \u003cstrong\u003eover-the-counter drug\u003c\/strong\u003e based on \u003cstrong\u003eparacetamol\u003c\/strong\u003e , indicated for the \u003cstrong\u003esymptomatic treatment of fever\u003c\/strong\u003e and \u003cstrong\u003emedium-level pain\u003c\/strong\u003e of various origins. Thanks to its \u003cstrong\u003eeffervescent granule\u003c\/strong\u003e formulation, it dissolves easily in water, ensuring a \u003cstrong\u003erapid antipyretic and analgesic action\u003c\/strong\u003e . It is particularly useful in cases of \u003cstrong\u003eflu\u003c\/strong\u003e , \u003cstrong\u003ecolds\u003c\/strong\u003e , \u003cstrong\u003eexanthematous diseases\u003c\/strong\u003e and \u003cstrong\u003eacute respiratory tract infections\u003c\/strong\u003e , offering effective relief from symptoms such as \u003cstrong\u003eheadache\u003c\/strong\u003e , \u003cstrong\u003eneuralgia\u003c\/strong\u003e and \u003cstrong\u003emyalgia\u003c\/strong\u003e .\u003c\/p\u003e\n\n\n \u003cp\u003eThe pack contains \u003cstrong\u003e20 single-dose sachets\u003c\/strong\u003e , each with \u003cstrong\u003e500 mg of paracetamol\u003c\/strong\u003e , suitable for both \u003cstrong\u003eadults\u003c\/strong\u003e and \u003cstrong\u003echildren\u003c\/strong\u003e aged 8 years and over (or according to body weight). The effervescent granules are citrus-flavoured, making them more pleasant to take. The product is ideal for those looking for a quick and practical solution to \u003cstrong\u003elower fever\u003c\/strong\u003e and \u003cstrong\u003erelieve pain\u003c\/strong\u003e without having to swallow tablets. \u003cstrong\u003eTachipirina 500 mg\u003c\/strong\u003e is known for its \u003cstrong\u003etolerability\u003c\/strong\u003e and its \u003cstrong\u003eweak anti-inflammatory effects\u003c\/strong\u003e , making it a safe choice for the \u003cstrong\u003esymptomatic treatment\u003c\/strong\u003e of many common conditions.\u003c\/p\u003e\n\n\n \u003cp\u003eThanks to its effectiveness and practicality, \u003cstrong\u003eTachipirina 500 mg effervescent granules\u003c\/strong\u003e is one of the most used products in Italy for the management of \u003cstrong\u003efever and pain\u003c\/strong\u003e , both at home and when traveling. The effervescent formulation allows for \u003cstrong\u003erapid absorption\u003c\/strong\u003e and timely action, ensuring immediate relief from flu and painful symptoms.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Tachipirina 500 mg 20 sachets effervescent granules - What is the active ingredient in Tachipirina 500 mg 20 sachets effervescent granules? \u003c\/h3\u003e\n\u003ci\u003eTACHIPIRINA 500 mg tablets.\u003c\/i\u003e Each tablet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 500 mg effervescent granules.\u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 12.3 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 125 mg effervescent granules.\u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 3.07 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Neonati 62.5 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains. \u003cu\u003eactive ingredient: paracetamol 62.5 mg\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Prima Infanzia 125 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Children 250 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 250 mg.\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Children 500 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003e\u003cu\u003eTACHIPIRINA Adults 1000 mg suppositories.\u003c\/u\u003e\u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 1000 mg.\u003c\/u\u003e For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eEXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tachipirina 500 mg 20 sachets effervescent granules - What does Tachipirina 500 mg 20 sachets effervescent granules contain?\u003c\/h3\u003e • \u003cu\u003eTablets:\u003c\/u\u003e microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, croscarmellose sodium. • \u003cu\u003eEffervescent granules\u003c\/u\u003e : maltitol, mannitol, sodium bicarbonate, anhydrous citric acid, citrus flavouring, aspartame, sodium docusate. • \u003cu\u003eSuppositories\u003c\/u\u003e : solid semi-synthetic glycerides.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Tachipirina 500 mg 20 sachets effervescent granules - Why is Tachipirina 500 mg 20 sachets effervescent granules used? What is it used for?\u003c\/h3\u003e As an antipyretic: symptomatic treatment of febrile conditions such as influenza, exanthematous diseases, acute respiratory tract conditions, etc. As an analgesic: headaches, neuralgia, myalgia and other moderately severe painful conditions of various origins.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e  \u003ch3\u003eContraindications Tachipirina 500 mg 20 sachets effervescent granules - When should Tachipirina 500 mg 20 sachets effervescent granules not be used?\u003c\/h3\u003e • Hypersensitivity to paracetamol or to any of the excipients listed in paragraph 6.1. • Patients with severe haemolytic anaemia (this contraindication does not apply to the 500 mg oral formulations). • Severe hepatocellular insufficiency (this contraindication does not apply to the 500 mg oral formulations).\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Tachipirina 500 mg 20 sachets effervescent granules - How do you take Tachipirina 500 mg 20 sachets effervescent granules? \u003c\/h3\u003eFor children, it is essential to respect the dosage defined according to their body weight, and therefore choose the appropriate formulation. The approximate ages according to body weight are given for information purposes only. In adults, the maximum oral dosage is 3000 mg and rectal dosage is 4000 mg of paracetamol per day (see section 4.9). The doctor must evaluate the need for treatments for more than 3 consecutive days. The dosage schedule of Tachipirina in relation to body weight and administration route is as follows: \u003cb\u003e500 mg tablets.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): ½ tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day (3 tablets). • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately 8 and 11 years): 1 tablet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately 12 and 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e : 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In case of severe pain or high fever, 2 tablets of 500 mg to be repeated if necessary after not less than 4 hours. \u003cb\u003eEffervescent granules of 500 mg in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately 8 to 11 years): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately 12 to 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e : 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In the case of severe pain or high fever, 2 sachets of 500 mg to be repeated if necessary after not less than 4 hours. \u003cb\u003e125 mg effervescent granules in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003eNewborn Suppositories 62.5 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 3.2 and 5 kg\u003c\/u\u003e (approximately between birth and 2 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eEarly Childhood Suppositories 125 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 6 and 7 kg\u003c\/u\u003e (approximately between 3 and 5 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 suppository at a time, to be repeated if necessary after 4 - 6 hours, without exceeding 5 administrations per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003eSuppositories Children 250 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Children 500 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately between 8 and 11 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Adults 1000 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately 12 and 15 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 administrations per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e : 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003ci\u003e\u003cu\u003eRenal insufficiency.\u003c\/u\u003e\u003c\/i\u003e In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Tachipirina 500 mg 20 sachets effervescent granules - How is Tachipirina 500 mg 20 sachets effervescent granules stored?\u003c\/h3\u003e \u003cu\u003eTablets and effervescent granules\u003c\/u\u003e : no special precautions for storage. \u003cu\u003eSuppositories:\u003c\/u\u003e store at a temperature not exceeding 25°C.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tachipirina 500 mg 20 sachets effervescent granules - About Tachipirina 500 mg 20 sachets effervescent granules it is important to know that: \u003c\/h3\u003eIn rare cases of allergic reactions, administration should be suspended and appropriate treatment should be instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u0026gt;9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause even serious alterations to the kidney and blood, therefore administration to subjects with renal insufficiency should be carried out only if really necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and renal function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other medicine. See also section 4.5. \u003cb\u003e\u003cu\u003eImportant information about some of the excipients.\u003c\/u\u003e\u003c\/b\u003e \u003cu\u003eTachipirina 125 mg effervescent granules contains\u003c\/u\u003e \u003cu\u003e:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e , is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e : use with caution in patients with rare hereditary problems of fructose intolerance. 70.6 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 3.53% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult: to be taken into consideration by people with reduced kidney function or who follow a low-sodium diet. \u003cu\u003eTachipirina 500 mg effervescent granules contains:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e , is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk associated with the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e : use with caution in patients with rare hereditary problems of fructose intolerance. - 283 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 14.1% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. The maximum dose for this product is equivalent to 84.6% of the WHO recommended maximum daily sodium intake.: to be taken into consideration by people with reduced kidney function or on a low-sodium diet.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Tachipirina 500 mg 20 sachets effervescent granules - Which medicines or foods can modify the effect of Tachipirina 500 mg 20 sachets effervescent granules? \u003c\/h3\u003eOral absorption of paracetamol depends on the rate of gastric emptying. Therefore, concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may lead to a decrease or increase in the bioavailability of the product, respectively. Concomitant administration of cholestyramine reduces the absorption of paracetamol. Concomitant intake of paracetamol and chloramphenicol may lead to an increase in the half-life of chloramphenicol, with the risk of increasing its toxicity. Concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants may lead to slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be performed during concomitant use and after its discontinuation. Use with extreme caution and under close monitoring during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol can interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tachipirina 500 mg 20 sachets effervescent granules can cause side effects - What are the side effects of Tachipirina 500 mg 20 sachets effervescent granules?\u003c\/h3\u003e The following are the adverse reactions of paracetamol organized according to the MedDRA system organ classification. There are insufficient data to establish the frequency of the individual effects listed.\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003ePathologies of the haemolymphopoietic system\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Thrombocytopenia, leukopenia, anemia, agranulocytosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eImmune system disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eNervous system disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Dizziness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eGastrointestinal disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Gastrointestinal reaction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eHepatobiliary pathologies\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Abnormal liver function, hepatitis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eSkin and subcutaneous tissue disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e  \u003ctd\u003eErythema multiforme, Stevens Johnson syndrome, Epidermal necrolysis, Skin rash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eKidney and urinary disorders\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Acute renal failure, interstitial nephritis, hematuria, anuria\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e Very rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Tachipirina 500 mg 20 sachets effervescent granules - What are the risks of Tachipirina 500 mg 20 sachets effervescent granules in case of overdose? \u003c\/h3\u003e\n\u003cu\u003eThere is a risk of intoxication, especially in patients with liver disease, in chronic alcoholism, in patients with chronic malnutrition, and in patients receiving enzyme inducers. In these cases, overdose can be fatal.\u003c\/u\u003e \u003cu\u003eSymptoms\u003c\/u\u003e In case of accidental ingestion of very high doses of paracetamol, acute intoxication manifests itself with anorexia, nausea and vomiting followed by a profound deterioration of general conditions; these symptoms generally appear within the first 24 hours. In case of overdose, paracetamol can cause hepatic cytolysis that can evolve into massive and irreversible necrosis, with consequent hepatocellular insufficiency, metabolic acidosis and encephalopathy, which can lead to coma and death. Simultaneously, an increase in the levels of hepatic transaminases, lactate dehydrogenase, and bilirubinemia, and a reduction in prothrombin levels are observed, which may occur within 12-48 hours after ingestion. \u003cu\u003eTreatment\u003c\/u\u003e The measures to be taken consist of early gastric emptying and hospitalization for appropriate treatment, by administering, as early as possible, N-acetylcysteine ​​as an antidote: the dosage is 150 mg\/kg iv in glucose solution over 15 minutes, then 50 mg\/kg over the next 4 hours and 100 mg\/kg over the next 16 hours, for a total of 300 mg\/kg over 20 hours.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachipirina 500 mg 20 sachets effervescent granules.\u003c\/h3\u003e Pregnancy: A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to administer the product only in cases of real need and under the direct supervision of a doctor.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e  \u003ch3\u003eTake Tachipirina 500 mg 20 sachets effervescent granules before driving or using machinery - Does Tachipirina 500 mg 20 sachets effervescent granules affect driving or using machinery?\u003c\/h3\u003e Tachipirina does not alter the ability to drive vehicles or use machinery.","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51730206064967,"sku":"012745117","price":7.51,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-tachipirina-500-mg-20-bustine-granulato-effervescente-farmacia-dottor-tili-1213791362.jpg?v=1767139907"},{"product_id":"tachifludec-gusto-limone-e-miele-16-bustine-polvere-per-soluzione-orale","title":"Tachifludec lemon and honey flavour 16 sachets powder for oral solution","description":"\u003cp\u003e \n\u003cstrong\u003eTachifludec lemon and honey flavor 16 sachets powder for oral solution\u003c\/strong\u003e is an \u003cstrong\u003eover-the-counter drug\u003c\/strong\u003e formulated for the \u003cstrong\u003esymptomatic treatment of flu and colds\u003c\/strong\u003e . Thanks to its composition based on \u003cstrong\u003eparacetamol\u003c\/strong\u003e (600 mg), \u003cstrong\u003eascorbic acid (vitamin C)\u003c\/strong\u003e (40 mg) and \u003cstrong\u003ephenylephrine hydrochloride\u003c\/strong\u003e (10 mg), this product is indicated for \u003cstrong\u003equickly relieving flu symptoms\u003c\/strong\u003e such as \u003cstrong\u003efever, headache, muscle pain and nasal congestion\u003c\/strong\u003e . The presence of \u003cstrong\u003elemon and honey\u003c\/strong\u003e gives the solution a pleasant and delicate taste, making it more pleasant to take even in moments of discomfort.\n\u003c\/p\u003e\n\n\u003cp\u003e \nEach sachet of \u003cstrong\u003eTachifludec\u003c\/strong\u003e dissolves easily in hot water, offering \u003cstrong\u003erapid relief from cold and flu symptoms\u003c\/strong\u003e . \u003cstrong\u003eParacetamol\u003c\/strong\u003e acts as an antipyretic and analgesic, reducing fever and pain, while \u003cstrong\u003ephenylephrine\u003c\/strong\u003e has a \u003cstrong\u003edecongestant\u003c\/strong\u003e action on the respiratory tract, making breathing easier. The addition of \u003cstrong\u003evitamin C\u003c\/strong\u003e helps support the immune system during feverish states. The package contains \u003cstrong\u003e16 single-dose sachets\u003c\/strong\u003e , convenient to carry with you and use as needed.\n\u003c\/p\u003e\n\n\u003cp\u003e \n\u003cstrong\u003eTachifludec lemon and honey flavor\u003c\/strong\u003e is ideal for those looking for an \u003cstrong\u003eeffective and fast treatment of flu symptoms\u003c\/strong\u003e , with the convenience of an \u003cstrong\u003eoral solution powder\u003c\/strong\u003e to prepare in a few moments. Suitable for adults and children over 12 years old, it is the perfect solution to deal with \u003cstrong\u003eseasonal ailments\u003c\/strong\u003e and quickly return to your daily activities.\n\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Tachifludec lemon and honey flavour 16 sachets powder for oral solution - What is the active ingredient of Tachifludec lemon and honey flavour 16 sachets powder for oral solution? \u003c\/h3\u003eEach sachet contains: \u003cu\u003eactive ingredients:\u003c\/u\u003e paracetamol 600 mg, ascorbic acid 40 mg and phenylephrine hydrochloride 10 mg (equivalent to phenylephrine 8.2 mg). \u003cu\u003eExcipients with known effects:\u003c\/u\u003e \u003cu\u003eTACHIFLUDEC lemon flavour contains:\u003c\/u\u003e 1.817 g of \u003cb\u003esucrose\u003c\/b\u003e , 112.86 mg of \u003cb\u003esodium\u003c\/b\u003e , 6.65 mg of \u003cb\u003eglucose\u003c\/b\u003e . \u003cu\u003eTACHIFLUDEC lemon and honey flavour contains:\u003c\/u\u003e 1.892 g of \u003cb\u003esucrose\u003c\/b\u003e , 135.79 mg of \u003cb\u003esodium\u003c\/b\u003e . For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tachifludec lemon and honey flavour 16 sachets powder for oral solution - What does Tachifludec lemon and honey flavour 16 sachets powder for oral solution contain? \u003c\/h3\u003e- TACHIFLUDEC powder for oral solution lemon flavour: \u003cb\u003esucrose\u003c\/b\u003e , anhydrous citric acid, \u003cb\u003esodium\u003c\/b\u003e citrate, corn starch, \u003cb\u003esodium\u003c\/b\u003e cyclamate, \u003cb\u003esodium\u003c\/b\u003e saccharin, anhydrous colloidal silica, lemon flavouring, curcumin (E100), dried \u003cb\u003eglucose\u003c\/b\u003e syrup. - TACHIFLUDEC powder for oral solution lemon and honey flavour: \u003cb\u003esucrose\u003c\/b\u003e , anhydrous citric acid, \u003cb\u003esodium\u003c\/b\u003e citrate, corn starch, \u003cb\u003esodium\u003c\/b\u003e cyclamate, \u003cb\u003esodium\u003c\/b\u003e saccharin, lemon flavouring, honey flavouring, caramel (E150), anhydrous colloidal silica.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Tachifludec lemon and honey flavour 16 sachets powder for oral solution - Why is Tachifludec lemon and honey flavour 16 sachets powder for oral solution used? What is it for?\u003c\/h3\u003e Short-term treatment of cold and flu symptoms, including mild to moderate pain and fever, when associated with nasal congestion.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e  \u003ch3\u003eContraindications Tachifludec lemon and honey flavour 16 sachets powder for oral solution - When should Tachifludec lemon and honey flavour 16 sachets powder for oral solution not be used? \u003c\/h3\u003e- Children under 12 years of age. - Hypersensitivity to the active substances or to any of the excipients (listed in section 6.1). - Patients taking beta-blockers. - Patients taking tricyclic antidepressants and those taking or who have taken in the last 2 weeks monoamine oxidase inhibitors. - Patients with bronchial asthma, pheochromocytoma, narrow-angle glaucoma, or who are taking other sympathomimetic medicinal products (such as decongestants, appetite suppressants and amphetamine-like psychostimulants) at the same time. - Patients with hepatic or renal insufficiency, diabetes, hyperthyroidism, hypertension and cardiovascular disease. - Paracetamol-based products are contraindicated in patients with manifest glucose-6-phosphate dehydrogenase insufficiency and in those with severe haemolytic anaemia. - Severe hepatocellular insufficiency.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e  \u003ch3\u003eQuantity and method of taking Tachifludec lemon and honey flavour 16 sachets powder for oral solution - How do you take Tachifludec lemon and honey flavour 16 sachets powder for oral solution?\u003c\/h3\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003cu\u003eAdults and children over 12 years\u003c\/u\u003e : 1 sachet every 4-6 hours and up to a maximum of 3 sachets in 24 hours. The medicine should not be used for more than 3 consecutive days without consulting your doctor. \u003ci\u003ePaediatric population\u003c\/i\u003e \u003cu\u003eChildren under 12 years:\u003c\/u\u003e TACHIFLUDEC lemon, lemon and honey flavour is contraindicated in children under 12 years of age (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e Dissolve the contents of 1 sachet in half a glass of very hot water and, if desired, dilute with cold water to cool and sweeten as desired.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Tachifludec lemon and honey flavour 16 sachets powder for oral solution - How do you store Tachifludec lemon and honey flavour 16 sachets powder for oral solution? \u003c\/h3\u003eStore below 25°C. Store in the original container in order to protect from moisture and light.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tachifludec lemon and honey flavour 16 sachets powder for oral solution - About Tachifludec lemon and honey flavour 16 sachets powder for oral solution it is important to know that: \u003c\/h3\u003ePatients should be advised not to take other paracetamol-containing medicinal products while taking TACHIFLUDEC as high doses of paracetamol may cause serious adverse reactions. Avoid alcohol consumption during treatment with TACHIFLUDEC. The risk of overdose is greater in patients with liver problems. Instruct the patient to contact the doctor before combining warfarin or any other drug (see also section 4.5). The use of the product is not recommended if the patient is being treated with anti-inflammatory drugs. Caution is advised if paracetamol is administered concomitantly with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism), as well as in those using maximum daily doses of paracetamol. Careful monitoring is recommended, including measurement of urinary 5-oxoproline. Consult your doctor before using the product in patients with enlarged prostate gland or occlusive vascular diseases (e.g. Raynaud's syndrome). Do not exceed the recommended dose and do not administer for more than 3 consecutive days. TACHIFLUDEC lemon flavor contains: - \u003cb\u003esodium\u003c\/b\u003e : this medicine contains 112.86 mg of sodium per sachet equivalent to 5.64% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult, to be taken into consideration in patients with reduced renal function or who follow a low-sodium diet. - \u003cb\u003esucrose:\u003c\/b\u003e patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Patients with diabetes should take into account the sucrose content within TACHIFLUDEC when taking more than 2 sachets per day (sucrose\u0026gt; 5g). - \u003cb\u003eglucose:\u003c\/b\u003e patients with rare glucose-galactose malabsorption problems should not take this medicine. TACHIFLUDEC lemon and honey flavour contains: - \u003cb\u003esodium:\u003c\/b\u003e 135.79 mg of sodium per sachet equivalent to 6.79% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult, to be taken into consideration in patients with reduced renal function or who follow a low-sodium diet. - \u003cb\u003esucrose:\u003c\/b\u003e patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. The sucrose content within TACHIFLUDEC should be taken into consideration in people with diabetes mellitus in case of taking more than 2 sachets per day (sucrose\u0026gt; 5g).\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Tachifludec lemon and honey flavour 16 sachets powder for oral solution - Which medicines or foods can modify the effect of Tachifludec lemon and honey flavour 16 sachets powder for oral solution? \u003c\/h3\u003e\n\u003ci\u003e\u003cu\u003eParacetamol\u003c\/u\u003e\u003c\/i\u003e The hepatotoxic effect of paracetamol may be enhanced by the intake of other drugs that act on the liver such as zidovudine and isoniazid which can produce an inhibition of the metabolism of paracetamol. The administration of probenecid before paracetamol decreases the clearance of paracetamol and the urinary elimination of paracetamol sulphate and paracetamol-glucuronide, and increases the half-life of paracetamol itself. Use with extreme caution and under strict monitoring during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). Paracetamol increases the half-life of chloramphenicol. The product taken in high doses can enhance the effect of coumarin anticoagulants (warfarin). Metoclopramide and domperidone may increase the absorption of paracetamol, while it is reduced or delayed by cholestyramine and anticholinergics, respectively. Caution should be exercised when paracetamol is used concomitantly with flucloxacillin since concomitant intake has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4). \u003ci\u003e\u003cu\u003ePhenylephrine\u003c\/u\u003e\u003c\/i\u003e Phenylephrine may antagonise the effect of beta-blocking and antihypertensive drugs (including debrisoquine, guanethidine, reserpine and methyldopa) and may potentiate the action of monoamine oxidase inhibitors (see section 4.3). Concomitant use of phenylephrine with tricyclic antidepressants or sympathomimetic amines may increase the risk of cardiovascular effects. Phenylephrine may interact with digoxin and cardiac glycosides, increasing the risk of arrhythmia or infarction, and with alkaloids (ergotamine and methylsergide), increasing the risk of ergotism. \u003ci\u003e\u003cu\u003eAscorbic Acid\u003c\/u\u003e\u003c\/i\u003e Ascorbic acid may increase the absorption of iron and estrogens. Ascorbic acid is metabolized to oxalate, and may potentially cause hyperoxaluria and kidney stones in patients through the crystallization of calcium oxalate in patients who tend to form calcium stones. \u003ci\u003e\u003cu\u003eInterference with some laboratory tests\u003c\/u\u003e\u003c\/i\u003e Paracetamol administration may interfere with the determination of uric acid (by the phosphotungstic acid method) and blood glucose (by the glucose-oxidase-peroxidase method). Ascorbic acid may interfere with the measurement of blood and urine parameters (e.g. urate, glucose, bilirubin, hemoglobin).\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tachifludec lemon and honey flavour 16 sachets powder for oral solution can cause side effects - What are the side effects of Tachifludec lemon and honey flavour 16 sachets powder for oral solution?\u003c\/h3\u003e The following adverse reactions are listed below, organised according to MedDRA System Organ Class. The frequency is defined as follows: very common (≥1\/10), common (≥1\/100 to \u0026lt;1\/10), uncommon (≥1\/1,000 to \u0026lt;1\/100), rare (≥1\/10,000 to \u0026lt;1\/1,000), very rare (\u0026lt;1\/10,000), not known (frequency cannot be estimated from the available data).\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eClassification by System Organs \/ \u003ci\u003eFrequency\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eSide effect\u003c\/b\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003ePathologies of the haemolymphopoietic system\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Agranulocytosis¹, leukopenia¹, thrombocytopenia¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Anemia¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eImmune system disorders\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e  \u003ctd\u003eAllergic reactions \u003csup\u003e1.2\u003c\/sup\u003e , hypersensitivity reactions \u003csup\u003e1.2\u003c\/sup\u003e , anaphylaxis \u003csup\u003e1.2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Anaphylactic shock \u003csup\u003e1.2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eMetabolism and nutrition disorders\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eCommon\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Anorexia²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003ePsychiatric disorders\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eVery rare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Insomnia², nervousness², anxiety², restlessness², confusion², irritability²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eNervous system disorders\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eVery rare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Tremor², dizziness², headache²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eEye pathologies\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Mydriasis², acute angle-closure glaucoma²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eHeart disease\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Tachycardia², palpitations²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eVascular pathologies\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Hypertension²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eRespiratory, thoracic and mediastinal pathologies\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Bronchospasm \u003csup\u003e1,2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Laryngeal edema¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eCommon\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Nausea², vomiting²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Diarrhea¹, gastrointestinal disease¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e  \u003ctd colspan=\"2\"\u003e\u003cb\u003eHepatobiliary pathologies\u003c\/b\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Abnormal liver function¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Liver disease¹, hepatitis¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Skin rash \u003csup\u003e1,2\u003c\/sup\u003e , angioedema²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Toxic epidermal necrolysis¹, Stevens Johnson syndrome¹, erythema multiforme or polymorphous¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eKidney and urinary disorders\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eVery rare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Tubulointerstitial nephritis (after prolonged use of paracetamol at high doses)¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Aggravated renal failure¹, hematuria¹, anuria¹ urinary retention²\u003c\/td\u003e\n\u003c\/tr\u003e  \u003c\/table\u003eVery rare cases of serious skin reactions have been reported. ¹ Side effects associated with paracetamol ² Side effects associated with phenylephrine \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cb\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/b\u003e .\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Tachifludec lemon and honey flavour 16 sachets powder for oral solution - What are the risks of Tachifludec lemon and honey flavour 16 sachets powder for oral solution in case of overdose? \u003c\/h3\u003e\n\u003ci\u003eParacetamol\u003c\/i\u003e At the recommended doses, or even if the entire pack is taken, no symptoms of paracetamol overdose should appear. However, if very high doses of paracetamol (more than 10 g) are ingested, the most common complication is liver damage, which usually occurs 12-48 hours after ingestion. \u003cu\u003eRisk factors\u003c\/u\u003e a. Long-term treatment with carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. John's Wort or other drugs that induce liver enzymes; b. Regular consumption of ethanol in quantities greater than recommended; c. Glutathione depletion (e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia). \u003cu\u003eSymptoms\u003c\/u\u003e The early symptoms of paracetamol overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, liver failure may progress to encephalopathy, haemorrhage, hypoglycemia, cerebral edema and death. Acute renal failure with acute tubular necrosis, strongly suggested by flank pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. \u003cu\u003eTreatment\u003c\/u\u003e Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant initial symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of the overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines. If overdose has occurred within 1 hour, treatment with activated charcoal should be considered. Plasma paracetamol concentrations should be measured 4 or more hours after ingestion (early concentrations are unreliable). Treatment with N-acetylcysteine ​​may be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is obtained up to 8 hours after ingestion. The efficacy of the antidote declines sharply after this period. If necessary, the patient should be given N-acetylcysteine ​​intravenously, in line with the established dose regimen. If vomiting is not a problem, oral methionine may be a suitable alternative in more remote, out-of-hospital areas. Management of patients presenting with severe liver dysfunction more than 24 hours after ingestion should be discussed with the National Poisons Control Centre or liver unit. \u003ci\u003ePhenylephrine\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e Symptoms of overdose caused by phenylephrine are irritability, headache and increased blood pressure. In severe cases, confusion, hallucinations, convulsions and arrhythmias may occur. However, the amount needed to produce serious phenylephrine toxicity would be greater than that produced by paracetamol. \u003cu\u003eTreatment\u003c\/u\u003e Treatment should be as clinically appropriate. Severe hypertension should be treated with alpha-blocking drugs such as phentolamine. \u003ci\u003eAscorbic Acid\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e High doses of ascorbic acid (\u0026gt;3000mg) may cause transient osmotic diarrhoea and gastrointestinal effects such as nausea and abdominal discomfort. The effects of ascorbic acid overdose may be obscured by the severe liver toxicity caused by paracetamol overdose. \u003cu\u003eTreatment\u003c\/u\u003e Treatment should be as clinically appropriate.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachifludec lemon and honey flavour 16 sachets powder for oral solution \u003c\/h3\u003ePREGNANCY \u003ci\u003e\u003cu\u003eParacetamol\u003c\/u\u003e\u003c\/i\u003e A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible duration and with the lowest possible frequency. Epidemiological studies in pregnant women have shown that there are no contraindications to the use of paracetamol when used in the recommended doses, but the administration of the preparation during pregnancy and breastfeeding should take place under the direct supervision of a doctor. \u003ci\u003e\u003cu\u003ePhenylephrine\u003c\/u\u003e\u003c\/i\u003e Data on the use of phenylephrine during pregnancy are limited. Vasoconstriction of the uterine vessels and reduction of blood flow to the uterus associated with the use of phenylephrine may result in fetal hypoxia. The use of phenylephrine during pregnancy should be avoided as further information is needed. \u003ci\u003e\u003cu\u003eAscorbic Acid\u003c\/u\u003e\u003c\/i\u003e There are no controlled data on use during pregnancy. The use of ascorbic acid during pregnancy is recommended only when the benefit outweighs the risk. BREASTFEEDING \u003ci\u003e\u003cu\u003eParacetamol\u003c\/u\u003e\u003c\/i\u003e Paracetamol is excreted in breast milk but in clinically insignificant quantities. Available published data do not contraindicate its use during breastfeeding. \u003ci\u003e\u003cu\u003ePhenylephrine\u003c\/u\u003e\u003c\/i\u003e There are no data on the excretion of phenylephrine in breast milk nor are there any information on the effects of phenylephrine on breast-fed children. In the absence of available data, the use of phenylephrine should be avoided during breastfeeding. \u003ci\u003e\u003cu\u003eAscorbic Acid\u003c\/u\u003e\u003c\/i\u003e Ascorbic acid is excreted in breast milk. The effects on breast-fed children are not known. In summary, the use of TACHIFLUDEC is not recommended during pregnancy and breastfeeding. FERTILITY There is no evidence in non-clinical studies to indicate an effect of paracetamol on male and female fertility at doses commonly used in clinic. The effect of phenylephrine on male and female fertility has not been studied. There is sufficient evidence to indicate the importance of ascorbic acid at different levels in the reproductive process. However, no definitive data in humans are available on the clinical potential of vitamin C.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\u003ch3\u003e Taking Tachifludec lemon and honey flavour 16 sachets powder for oral solution before driving or using machinery - Does Tachifludec lemon and honey flavour 16 sachets powder for oral solution affect driving or using machinery?\u003c\/h3\u003e TACHIFLUDEC does not alter the ability to drive or use machines. However, patients should be advised not to drive or operate machines if they feel dizzy.","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51730207473991,"sku":"034358059","price":12.18,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-tachifludec-gusto-limone-e-miele-16-bustine-polvere-per-soluzione-orale-farmacia-dottor-tili-1213791094.jpg?v=1767140291"},{"product_id":"momentact-400-mg-12-bustine-granulato-per-soluzione-orale","title":"Momentact 400 mg 12 sachets granules for oral solution","description":"\u003cp\u003e \n\u003cstrong\u003eMomentact 400 mg 12 sachets granules for oral solution\u003c\/strong\u003e is an \u003cstrong\u003eanalgesic and anti-inflammatory\u003c\/strong\u003e based on \u003cstrong\u003eibuprofen\u003c\/strong\u003e , ideal for the \u003cstrong\u003esymptomatic treatment of pain of various origins and natures\u003c\/strong\u003e . Thanks to its formulation in \u003cstrong\u003esachets of granules for oral solution\u003c\/strong\u003e , Momentact guarantees a rapid and targeted action, proving particularly effective against \u003cstrong\u003eheadaches, migraines, toothaches, neuralgia, osteo-articular pain, muscle pain and menstrual pain\u003c\/strong\u003e . The product is also indicated for the relief of \u003cstrong\u003epain associated with flu symptoms and fever\u003c\/strong\u003e , offering a practical and fast solution for adults and adolescents over 12 years.\n\u003c\/p\u003e\n\n\u003cp\u003e \nThe presence of \u003cstrong\u003eibuprofen\u003c\/strong\u003e as an active ingredient ensures an effective \u003cstrong\u003eanalgesic and anti-inflammatory\u003c\/strong\u003e action, acting directly on the processes that cause pain and inflammation. The \u003cstrong\u003esoluble granule\u003c\/strong\u003e formulation allows for easy intake and rapid assimilation, ideal for those seeking immediate relief from painful symptoms. \u003cstrong\u003eMomentact 400 mg\u003c\/strong\u003e is produced by \u003cstrong\u003eAngelini\u003c\/strong\u003e , a leading company in the pharmaceutical sector, synonymous with quality and reliability.\n\u003c\/p\u003e\n\n\u003cp\u003e\n Choosing \u003cstrong\u003eMomentact 400 mg granulated sachets for oral solution\u003c\/strong\u003e means relying on a specific product for the \u003cstrong\u003erapid and safe treatment of acute pain\u003c\/strong\u003e , with the convenience of a ready-to-use formulation and a pleasant taste. Ideal for those who need an \u003cstrong\u003eeffective pain reliever\u003c\/strong\u003e to always carry with them, to face the most demanding days with serenity.\n\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e  \u003ch3\u003eActive ingredients contained in Momentact 400 mg 12 sachets granules for oral solution - What is the active ingredient in Momentact 400 mg 12 sachets granules for oral solution?\u003c\/h3\u003e One sachet contains: \u003ci\u003eActive ingredient\u003c\/i\u003e : ibuprofen sodium salt dihydrate 512 mg (corresponding to 400 mg of ibuprofen). Excipients with known effect: 2148 mg of Sucrose, 20 mg of Aspartame, 90 mg of Potassium, 39.2 mg of Sodium For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Momentact 400 mg 12 sachets granules for oral solution - What does Momentact 400 mg 12 sachets granules for oral solution contain?\u003c\/h3\u003e \u003cb\u003eSucrose\u003c\/b\u003e , \u003cb\u003epotassium\u003c\/b\u003e bicarbonate, orange flavouring, acesulfame \u003cb\u003epotassium\u003c\/b\u003e , \u003cb\u003easpartame\u003c\/b\u003e .\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Momentact 400 mg 12 sachets granules for oral solution - Why is Momentact 400 mg 12 sachets granules for oral solution used? What is it used for? \u003c\/h3\u003eMomentact analgesic is indicated in adults and adolescents over 12 years of age. Pain of various origins and nature (headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain).\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Momentact 400 mg 12 sachets granules for oral solution - When should Momentact 400 mg 12 sachets granules for oral solution not be used? \u003c\/h3\u003e• Hypersensitivity to the active substance, to other antirheumatics (acetylsalicylic acid, etc.) or to any of the excipients listed in section 6.1. • Do not administer to children under 12 years of age. • Ibuprofen is contraindicated during the third trimester of pregnancy and during breastfeeding (see section 4.6). • Active or severe gastroduodenal ulcer or other gastropathies. • History of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). • Severe hepatic or renal insufficiency. • Severe cardiac insufficiency (NYHA class IV). • Severe dehydration (caused by vomiting, diarrhoea or insufficient fluid intake). • Subjects with phenylketonuria (see section 4.4).\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e  \u003ch3\u003eQuantity and method of taking Momentact 400 mg 12 sachets granules for oral solution - How do you take Momentact 400 mg 12 sachets granules for oral solution? \u003c\/h3\u003e\n\u003cb\u003e\u003cu\u003eDosage\u003c\/u\u003e\u003c\/b\u003e \u003cb\u003eAdults and adolescents over 12 years\u003c\/b\u003e : 1 sachet 2-3 times a day. Do not exceed 3 sachets per day. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). If the use of the medicinal product is necessary for more than 3 days in adolescents, or in case of worsening of symptoms, a doctor should be consulted. Do not exceed the recommended doses: in particular, elderly patients should adhere to the minimum dosages indicated above. \u003ci\u003eElderly:\u003c\/i\u003e NSAIDs should be used with particular caution in elderly patients who are more prone to adverse events and are at increased risk of potentially fatal gastrointestinal bleeding, ulceration or perforation (see section 4.4). If treatment is considered necessary, the lowest dose for the shortest duration necessary to control symptoms should be used (see section 4.4). \u003ci\u003eRenal impairment\u003c\/i\u003e : In patients with mild or moderate reduction of renal function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and renal function should be monitored. \u003ci\u003eHepatic impairment\u003c\/i\u003e : In patients with mild or moderate reduction of liver function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and liver function should be monitored. MOMENTACT ANALGESICO is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePaediatric population\u003c\/i\u003e Momentact analgesic is contraindicated in children under 12 years of age (see section 4.3). \u003cb\u003e\u003cu\u003eMethod of administration\u003c\/u\u003e\u003c\/b\u003e Dissolve the contents of the sachet in a glass of water, stirring with a teaspoon until dissolved and drink the solution immediately. MOMENTACT ANALGESICO can be taken on an empty stomach. In subjects with gastric tolerability problems, it is preferable to take the medicine on a full stomach.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Momentact 400 mg 12 sachets granules for oral solution - How do you store Momentact 400 mg 12 sachets granules for oral solution?\u003c\/h3\u003e This medicine does not require any special storage temperatures.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Momentact 400 mg 12 sachets granules for oral solution - About Momentact 400 mg 12 sachets granules for oral solution it is important to know that: \u003c\/h3\u003e• The use of MOMENTACT ANALGESICO, as with any drug inhibiting the synthesis of prostaglandins and cyclooxygenase, is not recommended in women who intend to become pregnant. • The administration of MOMENTACT ANALGESICO should be suspended in women who have fertility problems or who are undergoing investigation of fertility. • Undesirable effects can be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). • Elderly: elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see paragraph 4.2). • \u003ci\u003e\u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e\u003c\/i\u003e Caution is required before initiating treatment in patients with a history of hypertension and\/or heart failure since fluid retention, hypertension and oedema have been reported in association with NSAID treatment. NSAIDs may reduce the effect of diuretics, and other antihypertensive drugs (see section 4.5). Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low dose ibuprofen (e.g. ≤ 1200 mg\/day) is associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration should also be exercised before initiating long-term treatment in patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses (2400 mg\/day) of ibuprofen are required. Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration. Similar consideration should be exercised before initiating long-term treatment in patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking). • \u003ci\u003e\u003cu\u003eGastrointestinal bleeding, ulceration and perforation\u003c\/u\u003e\u003c\/i\u003e The use of MOMENTACT ANALGESICO should be avoided in combination with NSAIDs, including cyclooxygenase-2 (COX-2) selective inhibitors due to an increased risk of ulceration or bleeding (see section 4.5). In particular, gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious gastrointestinal events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest available dose. Concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose acetylsalicylic acid or other drugs likely to increase gastrointestinal risk (see below and section 4.5). Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment. Carefully monitor patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors (SSRIs) or anti-platelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients receiving MOMENTACT ANALGESICO, the treatment should be withdrawn. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). • Severe skin reactions Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Acute generalised exanthematous pustulosis (AGEP) has been reported in association with medicinal products containing ibuprofen. Ibuprofen should be discontinued at the first appearance of signs and symptoms of severe skin reactions, such as rash, mucosal lesions or any other sign of hypersensitivity as well as if visual disturbances or persistent signs of liver dysfunction occur. \u003ci\u003e\u003cu\u003eRenal effects\u003c\/u\u003e\u003c\/i\u003e When starting treatment with ibuprofen, caution should be exercised in patients with considerable dehydration. Ibuprofen may cause water, sodium and potassium retention in patients who have never suffered from renal disorders due to its effects on renal perfusion. This may cause oedema or cardiac failure or hypertension in predisposed patients. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other pathological renal changes. In general, habitual use of analgesics, especially combinations of several analgesic active ingredients, may lead to permanent renal damage, with risk of onset of renal failure (analgesic nephropathy). Renal toxicity has been observed in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. Administration of NSAIDs in these patients may result in a dose-dependent reduction in prostaglandin formation and, as a secondary effect, renal blood flow, which may rapidly lead to renal failure. Patients most at risk of these reactions are those with reduced renal function, heart failure, liver dysfunction, the elderly, and all patients taking diuretics and ACE inhibitors. Discontinuation of NSAID therapy is usually followed by recovery to the pre-treatment state. There is a risk of impaired renal function in dehydrated adolescents. In case of prolonged use, monitor renal function, particularly in cases of diffuse lupus erythematosus. • \u003ci\u003e\u003cu\u003eRespiratory disorders\u003c\/u\u003e\u003c\/i\u003e MOMENTACT ANALGESICO should be prescribed with caution in patients with bronchial asthma, chronic rhinitis, nasal polyps, sinusitis or allergic diseases in progress or in the past because bronchospasm, urticaria and angioedema may occur. The same applies to those subjects who have experienced bronchospasm after the use of acetylsalicylic acid or other NSAIDs. • \u003ci\u003e\u003cu\u003eHypersensitivity reactions\u003c\/u\u003e\u003c\/i\u003e Analgesics, antipyretics, NSAIDs, can cause hypersensitivity reactions, potentially serious (anaphylactoid reactions), even in subjects not previously exposed to this type of drug. The risk of hypersensitivity reactions after taking ibuprofen is greater in subjects who have presented such reactions after the use of other analgesics, antipyretics, NSAIDs and in subjects with bronchial hyperreactivity (asthma), hay fever, nasal polyposis or chronic obstructive respiratory diseases or previous episodes of angioedema (see sections 4.3 and 4.8). Hypersensitivity reactions may present as asthma attacks (so-called analgesic asthma), Quincke's edema or urticaria. Severe hypersensitivity reactions (e.g. anaphylactic shock) have been observed rarely. At the first signs of a hypersensitivity reaction after administration of ibuprofen, treatment should be discontinued. Medically assisted measures should be initiated by specialized medical personnel, in line with the symptoms.• \u003ci\u003e\u003cu\u003eReduced cardiac, renal and hepatic function\u003c\/u\u003e\u003c\/i\u003e Particular caution should be exercised when treating patients with reduced cardiac, hepatic or renal function since the use of NSAIDs may lead to a deterioration of renal function. The habitual concomitant use of several painkillers may further increase this risk. In patients with reduced cardiac, hepatic or renal function, it is advisable to use the lowest effective dose for the shortest period of treatment and to periodically monitor clinical and laboratory parameters, especially in the case of prolonged treatment. • \u003ci\u003e\u003cu\u003eHaematological effects\u003c\/u\u003e\u003c\/i\u003e Ibuprofen, like other NSAIDs, may inhibit platelet aggregation and has been shown to prolong bleeding time in healthy subjects. Therefore, patients with coagulation defects or on anticoagulant therapy should be carefully observed. • \u003ci\u003e\u003cu\u003eAseptic meningitis\u003c\/u\u003e\u003c\/i\u003e On rare occasions, symptoms of aseptic meningitis have been observed in patients receiving ibuprofen. Although this is more likely to occur in patients with systemic lupus erythematosus and related connective tissue diseases, it has also been observed in patients without concomitant chronic disease (see section 4.8). • Since ocular changes have been observed in animal studies with NSAIDs, periodic ophthalmological checks are recommended in case of prolonged treatment. • Alcohol consumption should be avoided as it may intensify the side effects of NSAIDs, especially those affecting the gastrointestinal tract or the central nervous system. • Masking of symptoms of underlying infections Momentact Analgesic may mask the symptoms of infection, which may delay the initiation of adequate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and in bacterial complications of chickenpox. When Momentact Analgesic is administered for the relief of infection-related pain, monitoring for infection is advised. In non-hospital settings, the patient should seek medical advice if symptoms persist or worsen. \u003ci\u003e\u003cu\u003eImportant information about some of the excipients\u003c\/u\u003e\u003c\/i\u003e MOMENTACT ANALGESIC contains: - \u003cb\u003eSucrose\u003c\/b\u003e : patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. - \u003cb\u003eSodium:\u003c\/b\u003e This medicine contains 39.2 mg sodium per sachet, per maximum daily dose of 3 sachets 117.6 mg sodium, equivalent to 5.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult. - \u003cb\u003ePotassium:\u003c\/b\u003e This medicine contains 90 mg potassium (2.3 mmol) per sachet. To be taken into consideration by patients with reduced kidney function or patients on a low potassium diet. - \u003cb\u003eAspartame:\u003c\/b\u003e This medicine contains 20 mg aspartame per sachet equivalent to 20 mg\/3000 mg. Aspartame is a source of phenylalanine. It may be harmful for patients with phenylketonuria, a rare genetic disorder in which the amount of phenylalanine builds up because the body cannot process it properly.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Momentact 400 mg 12 sachets granules for oral solution - Which medicines or foods can modify the effect of Momentact 400 mg 12 sachets granules for oral solution? \u003c\/h3\u003eIt is advisable to seek medical advice in case of any concomitant therapy before administering the product. Ibuprofen (like other NSAIDs) should be taken with caution in combination with the substances listed below. • Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4). • Anticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin or heparin (see section 4.4). In case of concomitant treatment, monitoring of the coagulation status is recommended. • Cyclooxygenase-2 (COX-2) inhibitors and other NSAIDs: these substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). Ibuprofen should not be combined with other NSAIDs, including COX-2 selective inhibitors, due to the potential for additive effects (see section 4.4). • Acetylsalicylic acid \u003ci\u003e:\u003c\/i\u003e Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1). • Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4). • Diuretics, ACE inhibitors (such as captopril), beta blockers and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of nephrotoxicity associated with NSAIDs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclooxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking MOMENTACT ANALGESICO concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and thereafter. • Phenytoin and lithium: concomitant administration of ibuprofen and phenytoin or lithium preparations may result in reduced elimination of these medicinal products with consequent increase in their plasma levels with the possibility of reaching the toxic threshold. If this combination is deemed necessary, monitoring of phenytoin and lithium plasma levels is recommended in order to adapt the appropriate dosage during concomitant treatment with ibuprofen. • Methotrexate: NSAIDs may inhibit the tubular secretion of methotrexate and some metabolic interactions may occur resulting in reduced clearance of methotrexate and consequent increase in the risk of toxicity. • Moclobemide: increases the effect of ibuprofen. • Aminoglycosides: NSAIDs may decrease the excretion of aminoglycosides, increasing their toxicity. • Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides. Monitoring of serum glycoside levels is recommended. • Cholestyramine: Concomitant administration of ibuprofen and cholestyramine may reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is unknown. • Ciclosporins: Concomitant administration of ciclosporin and some NSAIDs causes an increased risk of renal damage. This effect cannot be excluded for the combination of ciclosporin and ibuprofen. • Plant extracts: Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs. • Mifepristone: Due to the anti-prostaglandin properties of NSAIDs, their use after mifepristone administration may reduce the effect of mifepristone. Limited evidence suggests that co-administration of NSAIDs and prostaglandins on the same day does not adversely affect the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination. • Quinolone antibiotics: Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions. • Sulfonylureas: NSAIDs may enhance the hypoglycaemic effect of sulfonylureas. In case of simultaneous treatment, monitoring of blood glucose levels is recommended. • Tacrolimus: Co-administration of NSAIDs and tacrolimus may increase the risk of nephrotoxicity. • Zidovudine: There is evidence of an increased risk of haemarthrosis and haematoma in HIV-positive haemophiliac patients receiving concomitant treatment with Zidovudine and other NSAIDs. A haematological examination is recommended 1-2 weeks after starting treatment. • Ritonavir: May cause an increase in plasma concentrations of NSAIDs. • Probenecid: Slows the excretion of ibuprofen, with possible increase in plasma concentrations. • CYP2C9 inhibitors: Concomitant administration of ibuprofen and CYP2C9 inhibitors may slow the elimination of ibuprofen (CYP2C9 substrate) resulting in increased exposure to ibuprofen. In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)-ibuprofen of approximately 80% to 100% was observed. Consideration should be given to reducing the dose of ibuprofen when co-administered with strong CYP2C9 inhibitors, particularly when high doses of ibuprofen are administered with voriconazole or fluconazole. • Alcohol, bisphosphonates and oxypentifylline (pentoxifylline): may enhance gastrointestinal side effects and the risk of bleeding and ulceration. • Baclofen: high toxicity of baclofen.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Momentact 400 mg 12 sachets granules for oral solution can cause side effects - What are the side effects of Momentact 400 mg 12 sachets granules for oral solution? \u003c\/h3\u003eThe undesirable effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and are reported below using the following convention: Very common (≥1\/10); Common (≥1\/100, \u0026lt; 1\/10); Uncommon (≥ 1\/ 1,000, \u0026lt; 1\/100); Rare (≥1\/10,000, \u0026lt; 1\/1,000); Very rare (\u0026lt;1\/10,000); Not known (frequency cannot be estimated from the available data). The most commonly observed adverse events are gastrointestinal in nature. Clinical trial and epidemiological data suggest that use of ibuprofen (particularly at high doses (2400 mg\/day) and in long-term treatment may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). \u003cu\u003eGastrointestinal disorders:\u003c\/u\u003e Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Gastrointestinal perforation with ibuprofen has been observed rarely. After administration of MOMENTACT ANALGESICO the following have been reported: feeling of heaviness in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Uncommon: gastritis. Very rare: pancreatitis. \u003cu\u003eImmune system disorders\u003c\/u\u003e : The following undesirable effects have been reported following treatment with NSAIDs: non-specific allergic reaction and anaphylaxis; uncommon: hypersensitivity reactions such as skin rash of various types, urticaria, pruritus, purpura, angioedema, exanthema, respiratory tract reactions including asthma, including severe asthma, bronchospasm or dyspnoea, asthmatic attack (sometimes with hypotension); rare: lupus erythematosus syndrome; very rare: severe hypersensitivity reactions. Symptoms may include: facial oedema, tongue oedema, laryngeal oedema, airway oedema with constriction, dyspnoea, tachycardia, anaphylaxis, exfoliative and bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). \u003cu\u003eCardiac and vascular disorders:\u003c\/u\u003e Oedema, fatigue, hypertension and cardiac failure have been reported in association with treatment with NSAIDs. Clinical trial and epidemiological data suggest that use of ibuprofen, particularly at high doses (2400 mg\/day) and in long-term treatment, may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Very rare: palpitations, heart failure, myocardial infarction, acute pulmonary oedema, oedema, hypertension. These events generally tend to resolve on discontinuation of treatment. Other adverse events reported less frequently and for which causality has not necessarily been established include: \u003cu\u003eBlood and lymphatic system disorders\u003c\/u\u003e . Rare: leucopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia. \u003cu\u003ePsychiatric disorders\u003c\/u\u003e . Uncommon: insomnia, anxiety; Rare: depression, confusional state, hallucinations. \u003cu\u003eNervous system disorders\u003c\/u\u003e . Common: dizziness; Uncommon: paraesthesia, somnolence; Rare: optic neuritis. \u003cu\u003eInfections and infestations.\u003c\/u\u003e Uncommon: rhinitis; Rare: aseptic meningitis. Rhinitis and aseptic meningitis (especially in patients with pre-existing autoimmune disorders, such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). Exacerbation of infection-related inflammation (e.g. development of necrotising fasciitis) has been described. \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e . Uncommon: bronchospasm, dyspnoea, apnoea. \u003cu\u003eEye disorders.\u003c\/u\u003e Uncommon: visual disturbances; Rare: ocular impairment resulting in visual disturbances, toxic optic neuropathy. \u003cu\u003eEar and labyrinth disorders.\u003c\/u\u003e Uncommon: hearing impaired, tinnitus, vertigo. \u003cu\u003eHepatobiliary disorders.\u003c\/u\u003e Uncommon: abnormal liver function, hepatitis and jaundice; Very rare: liver failure. \u003cu\u003eSkin and subcutaneous tissue disorders.\u003c\/u\u003e Allergic skin rashes (erythema, pruritus, urticaria) may occasionally occur. Uncommon: photosensitivity reactions; Very rare: bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. In exceptional cases, serious skin infections and soft tissue disorders may occur during varicella infection (see “infections and infestations”). Not known: drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), acute generalised exanthematous pustulosis (AGEP). \u003cu\u003eRenal and urinary disorders.\u003c\/u\u003e Uncommon: renal function impairment and toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure. \u003cu\u003eGeneral disorders and administration site conditions.\u003c\/u\u003e Common: malaise, fatigue; Rare: oedema. \u003ci\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e\u003c\/i\u003e Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cb\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/b\u003e\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eOVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Momentact 400 mg 12 sachets granules for oral solution - What are the risks of Momentact 400 mg 12 sachets granules for oral solution in case of overdose? \u003c\/h3\u003e\n\u003ci\u003e\u003cu\u003eToxicity\u003c\/u\u003e\u003c\/i\u003e Signs and symptoms of toxicity have not generally been observed at doses below 100 mg\/kg in children or adults. However, in some cases supportive treatment may be necessary. Children have been observed to exhibit signs and symptoms of toxicity after ingestion of ibuprofen at doses of 400 mg\/kg or greater. \u003ci\u003e\u003cu\u003eSymptoms\u003c\/u\u003e\u003c\/i\u003e Most patients who have ingested significant quantities of ibuprofen will exhibit symptoms within 4 to 6 hours. The most commonly reported symptoms of overdose include nausea, vomiting, abdominal pain, lethargy and somnolence. Central nervous system (CNS) effects include headache, tinnitus, dizziness, convulsions and loss of consciousness. Nystagmus, hypothermia, renal effects, gastrointestinal bleeding, coma, apnoea, diarrhoea and CNS and respiratory depression have also been reported rarely. Disorientation, excitement, fainting and cardiovascular toxicity including hypotension, bradycardia and tachycardia have been reported. Renal failure and liver damage are possible in cases of significant overdose. In cases of severe poisoning, metabolic acidosis may occur. \u003ci\u003e\u003cu\u003eTreatment\u003c\/u\u003e\u003c\/i\u003e There is no specific antidote for ibuprofen overdose. Symptomatic and supportive treatment is indicated in cases of overdose. Particular attention should be paid to monitoring blood pressure, acid-base balance and gastrointestinal bleeding. Administration of activated charcoal should be considered within one hour of ingestion of a potentially toxic amount. Alternatively, gastric lavage should be considered within one hour of ingestion of a potentially life-threatening overdose in adults. Adequate diuresis should be ensured and renal and hepatic function should be closely monitored. The patient should remain under observation for at least four hours following ingestion of a potentially toxic amount. If frequent or prolonged convulsions occur, they should be treated with intravenous diazepam. Other supportive measures may be necessary depending on the patient's clinical condition. Contact your local poison control center for more information.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Momentact 400 mg 12 sachets granules for oral solution. \u003c\/h3\u003e\n\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or the embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. From the twentieth week of pregnancy onwards, the use of MOMENTACT ANALGESICO may cause oligohydramnios resulting from fetal renal dysfunction. This condition may occur shortly after the start of treatment and is usually reversible after discontinuation. In addition, cases of constriction of the ductus arteriosus have been reported following treatment in the second trimester, most of which resolved after treatment discontinuation. Therefore, during the first and second trimester of pregnancy, MOMENTACT ANALGESICO should not be administered unless clearly necessary. If MOMENTACT ANALGESICO is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. Following exposure to MOMENTACT ANALGESICO for several days from gestational week 20 onwards, prenatal monitoring for oligohydramnios and constriction of the ductus arteriosus should be considered. MOMENTACT ANALGESICO should be discontinued if oligohydramnios or constriction of the ductus arteriosus are observed. \u003cu\u003eDuring the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to:\u003c\/u\u003e - cardiopulmonary toxicity (premature constriction\/closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction (see above); \u003cu\u003eAt the end of pregnancy, all prostaglandin synthesis inhibitors may expose the mother and the neonate to\u003c\/u\u003e : - possible prolongation of bleeding time, and antiaggregant effect which may occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently MOMENTACT ANALGESICO is contraindicated during the third trimester of pregnancy (see sections 4.3 and 5.3). \u003cu\u003eBreast-feeding\u003c\/u\u003e Ibuprofen is excreted in breast milk, but at therapeutic doses during short-term treatment, the risk of influence on the neonate seems unlikely. If, however, treatment is longer term, early weaning should be considered. NSAIDs should be avoided during breastfeeding. \u003cu\u003eFertility\u003c\/u\u003e The use of Ibuprofen may impair female fertility and is not recommended in women attempting to conceive. This effect is reversible upon discontinuation of treatment. In women who have difficulties conceiving or who are undergoing investigation of infertility, discontinuation of treatment with ibuprofen should be considered.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\u003ch3\u003e Taking Momentact 400 mg 12 sachets granules for oral solution before driving or using machines - Does Momentact 400 mg 12 sachets granules for oral solution affect driving or using machines?\u003c\/h3\u003e The use of ibuprofen does not usually affect the ability to drive or use machines. However, those patients whose activities require alertness should exercise caution if they experience drowsiness, dizziness or depression during therapy with ibuprofen.","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51730207768903,"sku":"037858014","price":10.2,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-momentact-400-mg-12-bustine-granulato-per-soluzione-orale-farmacia-dottor-tili-1213791089.jpg?v=1767140429"},{"product_id":"ginetantum-0-1-5-140-ml-soluzione-vaginale","title":"Ginetantum 0.1% 5×140 ml vaginal solution","description":"\u003cp\u003e \u003cstrong\u003eGinetantum 0.1% vaginal solution\u003c\/strong\u003e is a specific treatment for \u003cstrong\u003efemale intimate care\u003c\/strong\u003e , formulated to offer rapid and targeted relief in the case of \u003cstrong\u003evulvovaginitis\u003c\/strong\u003e of any origin and nature. Each pack contains \u003cstrong\u003e5 bottles of 140 ml\u003c\/strong\u003e each, ideal for a complete cycle of vaginal washes. The solution, based on \u003cstrong\u003ebenzydamine hydrochloride\u003c\/strong\u003e , acts effectively against the most common symptoms of vaginal and vulvar inflammation, such as \u003cstrong\u003eintimate itching, irritation, burning, vulvar pain\u003c\/strong\u003e and \u003cstrong\u003esmall vaginal discharge\u003c\/strong\u003e .\u003c\/p\u003e\n\n\n \u003cp\u003eThanks to its soothing and anti-inflammatory action, \u003cstrong\u003eGinetantum 0.1%\u003c\/strong\u003e is particularly indicated for the \u003cstrong\u003elocal treatment\u003c\/strong\u003e of \u003cstrong\u003einflammation of the vulva and vagina\u003c\/strong\u003e , ensuring an immediate sensation of freshness and well-being. The presence of \u003cstrong\u003ebenzalkonium chloride\u003c\/strong\u003e and a delicate rose scent helps maintain intimate hygiene, making the product suitable even during the \u003cstrong\u003epuerperium\u003c\/strong\u003e or in all situations in which support for intimate health is necessary.\u003c\/p\u003e\n\n\n\u003cp\u003e The practical single-dose packaging facilitates the use of \u003cstrong\u003evaginal douche\u003c\/strong\u003e in a safe and hygienic way, both at home and when traveling. \u003cstrong\u003eGinetantum 0.1% vaginal solution\u003c\/strong\u003e is a reliable choice for those looking for an effective product for the \u003cstrong\u003eprevention and treatment of vaginal irritation\u003c\/strong\u003e , ensuring protection and daily comfort.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e  \u003ch3\u003eActive ingredients contained in Ginetantum 0.1% 5×140 ml vaginal solution - What is the active ingredient of Ginetantum 0.1% 5×140 ml vaginal solution?\u003c\/h3\u003e 100 ml contain: Active ingredient: benzydamine hydrochloride 100 mg (equivalent to 89.46 mg of benzydamine). Excipient with known effect: benzalkonium chloride, rose fragrance base (Benzyl alcohol, Benzyl benzoate, Benzyl cinnamate, Benzyl salicylate, Citral, Citronellol, Eugenol, Farnesol, Geraniol, Limonene, Linanool). For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Ginetantum 0.1% 5×140 ml vaginal solution - What does Ginetantum 0.1% 5×140 ml vaginal solution contain?\u003c\/h3\u003e \u003cb\u003eBenzalkonium chloride\u003c\/b\u003e , disodium edetate, rose perfume base, purified water.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Ginetantum 0.1% 5×140 ml vaginal solution - Why is Ginetantum 0.1% 5×140 ml vaginal solution used? What is it used for? \u003c\/h3\u003eVulvovaginitis of any origin and nature, characterized by small vaginal discharge, itching, irritation, burning and vulvar pain. Intimate hygiene during puerperium.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Ginetantum 0.1% 5×140 ml vaginal solution - When should Ginetantum 0.1% 5×140 ml vaginal solution not be used?\u003c\/h3\u003e Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1 or to closely chemically related substances.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Ginetantum 0.1% 5x140 ml vaginal solution - How is Ginetantum 0.1% 5x140 ml vaginal solution taken?\u003c\/h3\u003e Dosage 1-2 vaginal irrigations per day for seven consecutive days. The solution can be used at room temperature. If you want to warm it up, just expose the closed bottle to a jet of hot water for a few minutes.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONSERVATION\u003c\/h2\u003e  \u003ch3\u003eStorage Ginetantum 0.1% 5×140 ml vaginal solution - How is Ginetantum 0.1% 5×140 ml vaginal solution stored?\u003c\/h3\u003e This medicine does not require any special storage conditions. Store the bottle upright.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Ginetantum 0.1% 5×140 ml vaginal solution - It is important to know that about Ginetantum 0.1% 5×140 ml vaginal solution:\u003c\/h3\u003e The use, especially if prolonged, of topical products could give rise to sensitization phenomena, in which case it is necessary to suspend the treatment and adopt the appropriate therapeutic measures. Invite the patient to contact the doctor before use in case of vaginal bleeding and\/or leucorrhoea.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e INTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Ginetantum 0.1% 5×140 ml vaginal solution - Which medicines or foods can modify the effect of Ginetantum 0.1% 5×140 ml vaginal solution?\u003c\/h3\u003e No negative interactions with other drugs commonly used in the relevant therapy have been observed.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e SIDE EFFECTS\u003c\/h2\u003e  \u003ch3\u003eLike all medicines, Ginetantum 0.1% 5×140 ml vaginal solution can cause side effects - What are the side effects of Ginetantum 0.1% 5×140 ml vaginal solution?\u003c\/h3\u003e Occasionally, especially with prolonged use of the product, skin irritation may occur. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important, as it allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/u\u003e\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Ginetantum 0.1% 5×140 ml vaginal solution - What are the risks of Ginetantum 0.1% 5×140 ml vaginal solution in case of overdose? \u003c\/h3\u003eIntoxication is expected only in case of accidental ingestion of large quantities of benzydamine (\u0026gt;300 mg). Symptoms associated with overdose by ingestion of benzydamine are mainly gastrointestinal and central nervous system symptoms. The most frequent gastrointestinal symptoms are nausea, vomiting, abdominal pain and esophageal irritation. Central nervous system symptoms include dizziness, hallucinations, agitation, anxiety and irritability. In case of acute overdose, only symptomatic treatment is possible. Patients should be kept under close observation, and should receive supportive treatment. Adequate hydration should be maintained.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e PREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Ginetantum 0.1% 5×140 ml vaginal solution. \u003c\/h3\u003eThere are no contraindications to the topical use of benzydamine during pregnancy or breastfeeding.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\u003ch3\u003e Taking Ginetantum 0.1% 5×140 ml vaginal solution before driving or using machines - Does Ginetantum 0.1% 5×140 ml vaginal solution affect driving and using machines?\u003c\/h3\u003e Ginetantum does not alter the ability to drive vehicles or use machinery.","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51730207801671,"sku":"023399049","price":16.63,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-ginetantum-0-1-5x140-ml-soluzione-vaginale-farmacia-dottor-tili-1213791088.jpg?v=1767140410"},{"product_id":"tachiflutask-600-mg-10-mg-10-bustine-granulato-per-soluzione-orale","title":"Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution","description":"\u003cp\u003e \u003cstrong\u003eTachiflutask 600 mg + 10 mg 10 sachets granules for oral solution\u003c\/strong\u003e is an over-the-counter medicine indicated for the \u003cstrong\u003eshort-term treatment of cold and flu symptoms\u003c\/strong\u003e , such as \u003cstrong\u003emild\/moderate pain, fever and nasal congestion\u003c\/strong\u003e . Each sachet contains \u003cstrong\u003eparacetamol 600 mg\u003c\/strong\u003e and \u003cstrong\u003ephenylephrine hydrochloride 10 mg\u003c\/strong\u003e , an effective combination to \u003cstrong\u003equickly relieve pain and fever\u003c\/strong\u003e and \u003cstrong\u003ereduce nasal congestion\u003c\/strong\u003e . The granules, with a \u003cstrong\u003elemon flavour\u003c\/strong\u003e , dissolve easily in the mouth or can be dissolved in hot water, offering a practical and quick solution even away from home, without the need for water.\u003c\/p\u003e\n\n \u003cp\u003eThanks to the synergistic action of its active ingredients, \u003cstrong\u003eTachiflutask\u003c\/strong\u003e acts on multiple fronts: \u003cstrong\u003eparacetamol\u003c\/strong\u003e lowers fever and relieves pain, while \u003cstrong\u003ephenylephrine\u003c\/strong\u003e decongests the nasal passages, facilitating breathing. This makes it particularly suitable for those seeking a \u003cstrong\u003ecomplete treatment of flu and cold symptoms\u003c\/strong\u003e in a single solution. The formulation in single-dose sachets is ideal for precise dosing and simple administration, even away from home.\u003c\/p\u003e\n\n \u003cp\u003e\u003cstrong\u003eTachiflutask 600 mg + 10 mg\u003c\/strong\u003e is a \u003cstrong\u003enon-prescription drug\u003c\/strong\u003e designed for adults and children over 12 years old, perfect for those who want \u003cstrong\u003equick and targeted relief from flu and cold symptoms\u003c\/strong\u003e , with the convenience of a pleasant-tasting granule. The presence of \u003cstrong\u003eparacetamol\u003c\/strong\u003e and \u003cstrong\u003ephenylephrine\u003c\/strong\u003e guarantees effective action against \u003cstrong\u003efever, pain and nasal congestion\u003c\/strong\u003e , helping to quickly regain well-being on days of seasonal malaise.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution - What is the active ingredient of Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution? \u003c\/h3\u003eEach sachet contains: Active ingredients: paracetamol 600 mg and phenylephrine hydrochloride 10 mg (equivalent to phenylephrine 8.2 mg). Each sachet contains sorbitol (E 420) 42 mg, aspartame (E 951) 25 mg. For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution - What does Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution contain?\u003c\/h3\u003e Mannitol (E 421), Xylitab 200 (xylitol, carboxymethylcellulose), lemon flavouring, sorbitol (E 420), ascorbic acid, citric acid, colloidal hydrated silica, aspartame (E 951), sodium saccharin.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution - Why is Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution used? What is it used for?\u003c\/h3\u003e Short-term treatment of cold and flu symptoms, including mild to moderate pain and fever, when associated with nasal congestion.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution - When should Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution not be used? \u003c\/h3\u003e- Children under 12 years of age. - Hypersensitivity to the active substances or to any of the excipients (listed in section 6.1). - Patients taking beta-blockers. - Patients taking tricyclic antidepressants and those taking or who have taken in the last 2 weeks monoamine oxidase inhibitors. - Patients with bronchial asthma, pheochromocytoma, narrow-angle glaucoma, or who are taking other sympathomimetic medicinal products (such as decongestants, appetite suppressants and amphetamine-like psychostimulants) at the same time. Patients with hepatic or renal insufficiency, diabetes, hyperthyroidism, hypertension and cardiovascular disease. - Paracetamol-based products are contraindicated in patients with manifest glucose-6-phosphate dehydrogenase insufficiency and in those with severe haemolytic anaemia. - Severe hepatocellular insufficiency.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e  \u003ch3\u003eQuantity and method of taking Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution - How do you take Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution? \u003c\/h3\u003e\n\u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults and children over 12 years:\u003c\/i\u003e 1 sachet every 4-6 hours and up to a maximum of 3 sachets in 24 hours. The medicine should not be used for more than 3 consecutive days without consulting your doctor. \u003ci\u003ePaediatric population\u003c\/i\u003e \u003ci\u003eChildren under 12 years:\u003c\/i\u003e TACHIFLUTASK is contraindicated in children under 12 years of age (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e Place the granules directly on the tongue and swallow. TACHIFLUTASK dissolves in saliva: this allows it to be used without water. The contents of the sachet can also be dissolved in a glass of hot (not boiling) water, stirring with a teaspoon. If desired, dilute with cold water to cool and sweeten. Once prepared, the solution obtained should be drunk within a few minutes.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONSERVATION\u003c\/h2\u003e  \u003ch3\u003eStorage Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution - How is Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution stored?\u003c\/h3\u003e This medicine does not require any special temperature storage. Store in the original container in order to protect from moisture and light.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution - About Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution it is important to know that: \u003c\/h3\u003ePatients should be advised not to take other paracetamol-containing medicinal products while taking TACHIFLUTASK as high doses of paracetamol may cause serious adverse reactions. Avoid alcohol consumption during treatment with TACHIFLUTASK. The risk of overdose is greater in patients with liver problems. Instruct the patient to contact the doctor before combining warfarin or any other drug (see also section 4.5). The use of the product is not recommended if the patient is being treated with anti-inflammatory drugs. Caution is advised if paracetamol is administered concomitantly with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism), as well as in those using maximum daily doses of paracetamol. Careful monitoring, including measurement of urinary 5-oxoproline, is recommended. Consult your doctor before using the product in patients with enlarged prostate gland or occlusive vascular disease (e.g. Raynaud's syndrome). Do not exceed the recommended dose and do not administer for more than 3 consecutive days. TACHIFLUTASK contains aspartame: this substance may be harmful to people with phenylketonuria. TACHIFLUTASK contains less than 1 mmol (23 mg) sodium per tablet, i.e. it is essentially sodium-free.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution - Which medicines or foods can modify the effect of Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution? \u003c\/h3\u003e\n\u003ci\u003eParacetamol\u003c\/i\u003e The hepatotoxic effect of paracetamol may be enhanced by the intake of other drugs that act on the liver such as zidovudine and isoniazid which can produce an inhibition of the metabolism of paracetamol. The administration of probenecid before paracetamol decreases the clearance of paracetamol and the urinary elimination of paracetamol sulphate and paracetamol-glucuronide, and increases the half-life of paracetamol itself. Use with extreme caution and under strict monitoring during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine). Paracetamol increases the half-life of chloramphenicol. The product taken in high doses can enhance the effect of coumarin anticoagulants (warfarin). Metoclopramide and domperidone may increase the absorption of paracetamol, while it is reduced or delayed by cholestyramine and anticholinergics, respectively. Caution should be exercised when paracetamol is used concomitantly with flucloxacillin since concomitant intake has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4). \u003ci\u003ePhenylephrine\u003c\/i\u003e Phenylephrine may antagonise the effect of beta-blocking and antihypertensive drugs (including debrisoquine, guanethidine, reserpine and methyldopa) and may potentiate the action of monoamine oxidase inhibitors (see section 4.3). Concomitant use of phenylephrine with tricyclic antidepressants or sympathomimetic amines may increase the risk of cardiovascular effects. Phenylephrine may interact with digoxin and cardiac glycosides, increasing the risk of arrhythmia or heart attack, and with alkaloids (ergotamine and methylsergide), increasing the risk of ergotism. \u003ci\u003eInterference with some laboratory tests\u003c\/i\u003e The administration of paracetamol may interfere with the determination of uricemia (by the phosphotungstic acid method) and with that of glycemia (by the glucose-oxidase-peroxidase method).\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution can cause side effects - What are the side effects of Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution?\u003c\/h3\u003e The following adverse reactions are listed below, organised according to MedDRA System Organ Class. Frequency is defined as follows: very common (≥1\/10), common (≥1\/100 to \u0026lt;1\/10), uncommon (≥1\/1,000 to \u0026lt;1\/100), rare (≥1\/10,000 to \u0026lt;1\/1,000), very rare (\u0026lt;1\/10,000), not known (frequency cannot be estimated from the available data).\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eClassification by Systems and Organs \/\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003e\u003ci\u003eFrequency\u003c\/i\u003e\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eSide effect\u003c\/b\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e \u003cb\u003ePathologies of the haemolymphopoietic system\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Agranulocytosis¹, leukopenia¹, thrombocytopenia¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Anemia¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e \u003cb\u003eImmune system disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e  \u003ctd\u003eAllergic reactions \u003csup\u003e1.2\u003c\/sup\u003e , hypersensitivity reactions \u003csup\u003e1.2\u003c\/sup\u003e , anaphylaxis \u003csup\u003e1.2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Anaphylactic shock \u003csup\u003e1.2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eMetabolism and nutrition disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003eCommon\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Anorexia²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003ePsychiatric disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003eVery rare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Insomnia², nervousness², anxiety², restlessness², confusion², irritability22\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eNervous system disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003eVery rare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Tremor², dizziness², headache²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eEye pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Mydriasis², acute angle-closure glaucoma²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eHeart disease\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Tachycardia², palpitations²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eVascular pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Hypertension²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e \u003cb\u003eRespiratory, thoracic and mediastinal pathologies\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Bronchospasm \u003csup\u003e1,2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Laryngeal edema¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003eCommon\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Nausea², vomiting²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Diarrhea¹, gastrointestinal disease¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e  \u003ctd rowspan=\"2\"\u003e\u003cb\u003eHepatobiliary pathologies\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Abnormal liver function¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Liver disease¹, hepatitis¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003eRare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Skin rash \u003csup\u003e1,2\u003c\/sup\u003e , angioedema²\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Toxic epidermal necrolysis¹, Stevens Johnson syndrome¹, erythema multiforme or polymorphous¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e \u003cb\u003eKidney and urinary disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003eVery rare\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Tubulointerstitial nephritis (after prolonged use of paracetamol at high doses)¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003ci\u003eNot known\u003c\/i\u003e\n\u003c\/td\u003e\n\u003ctd\u003e Aggravated renal failure¹, hematuria¹, anuria¹ urinary retention\u003c\/td\u003e\n\u003c\/tr\u003e  \u003c\/table\u003e¹ Side effects associated with paracetamol ² Side effects associated with phenylephrine Very rare cases of serious skin reactions have been reported. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse \u003cu\u003e.\u003c\/u\u003e\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution - What are the risks of Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution in case of overdose? \u003c\/h3\u003e\n\u003ci\u003eParacetamol\u003c\/i\u003e At the recommended doses, or even if the entire pack is taken, no symptoms of paracetamol overdose should appear. However, if very high doses of paracetamol (more than 10 g) are ingested, the most common complication is liver damage, which usually occurs 12-48 hours after ingestion. \u003cu\u003eRisk factors\u003c\/u\u003e • Long-term treatment with carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. John's Wort or other drugs that induce liver enzymes; • Regular consumption of ethanol in quantities greater than recommended; • Glutathione depletion (e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia). \u003cu\u003eSymptoms\u003c\/u\u003e The early symptoms of paracetamol overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, liver failure may progress to encephalopathy, haemorrhage, hypoglycemia, cerebral edema and death. Acute renal failure with acute tubular necrosis, strongly suggested by flank pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. \u003cu\u003eTreatment\u003c\/u\u003e Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant initial symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of the overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines. If overdose has occurred within 1 hour, treatment with activated charcoal should be considered. Plasma paracetamol concentrations should be measured 4 or more hours after ingestion (early concentrations are unreliable). Treatment with N-acetylcysteine ​​may be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is obtained up to 8 hours after ingestion. The efficacy of the antidote declines sharply after this period. If necessary, the patient should be given N-acetylcysteine ​​intravenously, in line with the established dose regimen. If vomiting is not a problem, oral methionine may be a suitable alternative in more remote, out-of-hospital areas. Management of patients presenting with severe liver dysfunction more than 24 hours after ingestion should be discussed with the National Poisons Control Centre or liver unit. \u003ci\u003ePhenylephrine\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e Symptoms of overdose caused by phenylephrine are irritability, headache and increased blood pressure. In more severe cases, confusion, hallucinations, convulsions and arrhythmias may occur. However, the amount needed to produce serious phenylephrine toxicity would be greater than that produced by paracetamol. \u003cu\u003eTreatment\u003c\/u\u003e Treatment should be clinically appropriate. Severe hypertension should be treated with alpha-blocking drugs such as phentolamine.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution. \u003c\/h3\u003e\n\u003cu\u003ePregnancy\u003c\/u\u003e \u003ci\u003eParacetamol\u003c\/i\u003e A large amount of data on pregnant women indicate neither malformative nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible duration and with the lowest possible frequency. The administration of the preparation during pregnancy and breastfeeding should take place under the direct supervision of a physician. \u003ci\u003ePhenylephrine\u003c\/i\u003e Data on the use of phenylephrine during pregnancy are limited. Vasoconstriction of the uterine vessels and reduction of blood flow to the uterus associated with the use of phenylephrine may result in fetal hypoxia. The use of phenylephrine during pregnancy should be avoided as further information is needed. \u003cu\u003eBreastfeeding\u003c\/u\u003e \u003ci\u003eParacetamol\u003c\/i\u003e Paracetamol is excreted in breast milk but in clinically insignificant quantities. Available published data do not contraindicate its use during breastfeeding. \u003ci\u003ePhenylephrine\u003c\/i\u003e There are no data on the excretion of phenylephrine in human milk nor are there any reports on the effects of phenylephrine on breast-fed infants. In the absence of available data, the use of phenylephrine should be avoided during breastfeeding. \u003cu\u003eFertility\u003c\/u\u003e There is no evidence in non-clinical studies to indicate effects of paracetamol on male and female fertility at doses commonly used in clinical practice. The effect of phenylephrine on male and female fertility has not been studied.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\u003ch3\u003e Taking Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution before driving or using machines - Does Tachiflutask 600 mg + 10 mg 10 sachets granules for oral solution affect driving or using machines?\u003c\/h3\u003e TACHIFLUTASK does not alter the ability to drive or use machines. However, patients should be advised not to drive or operate machines if they feel dizzy.","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51730208194887,"sku":"047430018","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-tachiflutask-600-mg-10-mg-10-bustine-granulato-per-soluzione-orale-farmacia-dottor-tili-1213791080.jpg?v=1767154212"},{"product_id":"tantum-verde-bocca-22-5-mg-15-ml-7-5-mg-15-ml-240-ml-collutorio","title":"Tantum Verde mouth 22, 5 mg\/15 ml + 7, 5 mg\/15 ml 240 ml mouthwash","description":"\u003cp\u003e \n\u003cstrong\u003eTantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash\u003c\/strong\u003e is an \u003cstrong\u003eantiseptic, anti-inflammatory and analgesic mouthwash\u003c\/strong\u003e specifically formulated for the \u003cstrong\u003etreatment of mouth and gum irritation\u003c\/strong\u003e . Thanks to the presence of \u003cstrong\u003ebenzydamine hydrochloride\u003c\/strong\u003e and \u003cstrong\u003ecetylpyridinium chloride\u003c\/strong\u003e , this product offers a targeted action against \u003cstrong\u003egingivitis, stomatitis\u003c\/strong\u003e and other inflammatory conditions of the oral cavity, helping to reduce pain and promote \u003cstrong\u003emouth disinfection\u003c\/strong\u003e .\n\u003c\/p\u003e\n\n\u003cp\u003e\n Ideal for \u003cstrong\u003edaily oral hygiene\u003c\/strong\u003e , Tantum Verde mouth is also indicated \u003cstrong\u003ebefore and after tooth extractions\u003c\/strong\u003e , helping to keep the mouth clean and protected from infections and inflammations. Its formula, enriched with \u003cstrong\u003emint aroma\u003c\/strong\u003e , guarantees a pleasant sensation of freshness after each use.\n\u003c\/p\u003e\n\n\u003cp\u003e \nThe combined action of the active ingredients allows for \u003cstrong\u003erapid relief of oral pain\u003c\/strong\u003e and effective fight against the bacteria responsible for infections, promoting the healing of irritated mucous membranes. Tantum Verde bocca is particularly indicated for those suffering from \u003cstrong\u003einflammation of the mouth and gums\u003c\/strong\u003e , offering effective support in the \u003cstrong\u003etreatment of sensitive gums\u003c\/strong\u003e and \u003cstrong\u003egum irritation\u003c\/strong\u003e .\n\u003c\/p\u003e\n\n\u003cp\u003e\n Thanks to its ease of use, the mouthwash can be easily used throughout the day for targeted \u003cstrong\u003eoral rinses\u003c\/strong\u003e , helping to maintain optimal \u003cstrong\u003eoral hygiene\u003c\/strong\u003e and prevent discomfort and complications affecting the mouth and throat. Choose Tantum Verde mouth for \u003cstrong\u003ecomplete protection and immediate relief\u003c\/strong\u003e in case of \u003cstrong\u003epain, inflammation and oral irritation\u003c\/strong\u003e .\n\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e  \u003ch3\u003eActive ingredients contained in Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash - What is the active ingredient in Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash?\u003c\/h3\u003e 100 ml contain: \u003ci\u003eactive ingredients\u003c\/i\u003e : benzydamine hydrochloride 0.15 g (equivalent to benzydamine 0.134 g) and cetylpyridinium chloride 0.05 g (equivalent to cetylpyridinium 0.0425 g). Excipients with known effect: Hydrogenated castor oil 40 polyoxyethylene, ethanol 96%. For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tantum Verde mouthwash 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash - What does Tantum Verde mouthwash 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash contain?\u003c\/h3\u003e Glycerol, \u003cb\u003eEthanol (96%),\u003c\/b\u003e Saccharin, \u003cb\u003ePolyoxyethylene 40 hydrogenated castor oil,\u003c\/b\u003e Sodium bicarbonate, Mint flavour, Quinoline yellow (E 104), Patent blue V (E 131), Purified water\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e  \u003ch3\u003eTherapeutic indications Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash - Why is Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash used? What is it used for?\u003c\/h3\u003e Antiseptic, anti-inflammatory and analgesic treatment for mouth and gum irritation; gingivitis and stomatitis. Also indicated before and after tooth extractions.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash - When should Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash not be used?\u003c\/h3\u003e Hypersensitivity to benzydamine, cetylpyridinium or to any of the excipients listed in section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Tantum Verde bocca 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash - How do you take Tantum Verde bocca 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash? \u003c\/h3\u003eRinse with 15 ml of mouthwash, 2-3 times a day, using the appropriate measuring cup. The product can be used, if necessary, at any time of the day. Use for a maximum period of 5-7 days. For longer use, consult your doctor.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash - How do you store Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash?\u003c\/h3\u003e Store in the original package in order to protect from light and moisture.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash - About Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash it is important to know that:\u003c\/h3\u003e The use, especially if prolonged, of preparations for oropharyngeal use, could give rise to sensitization phenomena. In this case, discontinue treatment and consult your doctor to establish appropriate therapy.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e INTERACTIONS \u003c\/h2\u003e\n\u003ch3\u003eInteractions Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash - Which medicines or foods can modify the effect of Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash?\u003c\/h3\u003e No interaction studies have been performed. However, it is advisable to avoid the concomitant use of other antiseptics.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tantum Verde bocca 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash can cause side effects - What are the side effects of Tantum Verde bocca 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash? \u003c\/h3\u003eThe table below lists adverse reactions by MedDRA system organ class. Adverse reactions are listed using the following frequency scales: very common (≥1\/10); common (≥1\/100, \u0026lt; 1\/10); uncommon (≥ 1\/1,000, \u0026lt; 1\/100); rare ≥ 1\/10,000, \u0026lt; 1\/1,000); very rare (\u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data).\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eCLASSIFICATION BY SYSTEMS AND ORGANS\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eFREQUENCY: SIDE EFFECTS\u003c\/b\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003e\u003cu\u003eNot known:\u003c\/u\u003e\u003c\/i\u003e slight numbness in the mouth¹\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e \u003cb\u003eSystemic disorders and conditions related to the administration site\u003c\/b\u003e\n\u003c\/td\u003e\n\u003ctd\u003e \u003ci\u003e\u003cu\u003eNot known:\u003c\/u\u003e\u003c\/i\u003e phenomena of intolerance to the drug, which manifest themselves with slight and transitory burning or irritation at the application site²\u003c\/td\u003e\n\u003c\/tr\u003e  \u003c\/table\u003e\n\u003ci\u003e\u003csup\u003e1)\u003c\/sup\u003e associated with the local anaesthetic activity of benzydamine\u003c\/i\u003e \u003ci\u003e\u003csup\u003e2)\u003c\/sup\u003e phenomena observed with cetylpyridinium, which do not require modification of treatment\u003c\/i\u003e \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important, as it allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash - What are the risks of Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash in case of overdose? \u003c\/h3\u003eToxic manifestations of systemic benzydamine overdose include excitation, convulsions, sweating, ataxia, tremors and vomiting. Benzydamine Intoxication is expected only in the event of accidental ingestion of large quantities of benzydamine (\u0026gt;300 mg). Symptoms associated with overdose by ingestion of benzydamine are mainly gastrointestinal and central nervous system symptoms. The most frequent gastrointestinal symptoms are nausea, vomiting, abdominal pain and esophageal irritation. Central nervous system symptoms include dizziness, hallucinations, agitation, anxiety and irritability. In the event of acute overdose, only symptomatic treatment is possible. Patients should be kept under close observation and should receive supportive treatment. Adequate hydration should be maintained. Cetylpyridinium Symptoms following the ingestion of significant quantities of quaternary ammonium compounds include nausea, vomiting, dyspnea, cyanosis, asphyxia, CNS depression, hypotension and coma. However, such toxic doses of cetylpyridinium chloride cannot be reached even with the intake of more than 10 packages of the product. Treatment of cetylpyridinium overdose is symptomatic.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tantum Verde mouthwash 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml\u003c\/h3\u003e There are no contraindications to the topical use of benzydamine and cetylpyridinium during pregnancy or breastfeeding.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\u003ch3\u003e Taking Tantum Verde mouthwash 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash before driving or using machines - Does Tantum Verde mouthwash 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml affect driving or using machines?\u003c\/h3\u003e Tantum Verde Bocca, at the recommended doses, does not alter the ability to drive vehicles or use machinery.","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51730210128199,"sku":"035355015","price":10.44,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-tantum-verde-bocca-22-5-mg-15-ml-7-5-mg-15-ml-240-ml-collutorio-farmacia-dottor-tili-1213791055.jpg?v=1767154787"},{"product_id":"moment-200-mg-24-compresse-rivestite","title":"Moment 200 mg 24 coated tablets","description":"\u003cp\u003e\u003cstrong\u003eMoment 200 mg 24 coated tablets\u003c\/strong\u003e is an \u003cstrong\u003eover-the-counter medicine\u003c\/strong\u003e based on \u003cstrong\u003eibuprofen\u003c\/strong\u003e , an active ingredient known for its effectiveness as \u003cstrong\u003ean anti-inflammatory\u003c\/strong\u003e and \u003cstrong\u003eanalgesic\u003c\/strong\u003e . These coated tablets are ideal for the \u003cstrong\u003esymptomatic treatment\u003c\/strong\u003e of different types of \u003cstrong\u003epain\u003c\/strong\u003e , including \u003cstrong\u003eheadache\u003c\/strong\u003e , \u003cstrong\u003etoothache\u003c\/strong\u003e , \u003cstrong\u003emuscle pain\u003c\/strong\u003e , \u003cstrong\u003ejoint pain\u003c\/strong\u003e and \u003cstrong\u003emenstrual pain\u003c\/strong\u003e . In addition, Moment 200 mg is also indicated for the reduction of \u003cstrong\u003efever\u003c\/strong\u003e and to relieve the symptoms associated with \u003cstrong\u003eflu-like conditions\u003c\/strong\u003e .\u003c\/p\u003e\n\n\n \u003cp\u003eThe package contains \u003cstrong\u003e24 coated tablets\u003c\/strong\u003e , convenient to take orally and formulated to ensure \u003cstrong\u003erapid action\u003c\/strong\u003e and \u003cstrong\u003egradual release\u003c\/strong\u003e of the active ingredient. Thanks to its effectiveness, Moment 200 mg represents a valid \u003cstrong\u003eadjuvant\u003c\/strong\u003e for those seeking rapid and safe relief from the most common pains.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Moment 200 mg 24 coated tablets - What is the active ingredient in Moment 200 mg 24 coated tablets?\u003c\/h3\u003e Each coated tablet contains: \u003cu\u003eActive substance\u003c\/u\u003e : ibuprofen 200 mg. For a full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Moment 200 mg 24 coated tablets - What does Moment 200 mg 24 coated tablets contain?\u003c\/h3\u003e Maize starch, sodium starch glycolate, povidone, colloidal anhydrous silica, talc, hydroxypropylcellulose, gum arabic, sucrose, Macrogol 6000, light magnesium carbonate, titanium dioxide.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e  \u003ch3\u003eTherapeutic indications Moment 200 mg 24 coated tablets - Why is Moment 200 mg 24 coated tablets used? What is it used for?\u003c\/h3\u003e Pain of various origins and nature (headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain). Adjuvant in the symptomatic treatment of feverish and flu states.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Moment 200 mg 24 coated tablets - When should Moment 200 mg 24 coated tablets not be used? \u003c\/h3\u003e• Do not administer to children under 12 years of age. • Pregnancy and breastfeeding. • Hypersensitivity to the active substance, to other antirheumatics (acetylsalicylic acid, etc.) or to any of the excipients. • Active or severe gastroduodenal ulcer or other gastropathies. • History of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). • Severe hepatic or renal insufficiency. • Severe cardiac insufficiency.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Moment 200 mg 24 coated tablets - How to take Moment 200 mg 24 coated tablets? \u003c\/h3\u003eAdults and adolescents over 12 years: 1–2 tablets, 2–3 times a day. Do not exceed the dose of 6 tablets per day. If the use of the medicine is necessary for more than 3 days in adolescents, or in case of worsening of symptoms, a doctor should be consulted. Do not exceed the recommended doses; in particular, elderly patients should stick to the minimum dosages indicated above. Take the product on a full stomach.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Moment 200 mg 24 coated tablets - How to store Moment 200 mg 24 coated tablets?\u003c\/h3\u003e This medicine does not require any special storage temperatures.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Moment 200 mg 24 coated tablets - About Moment 200 mg 24 coated tablets it is important to know that: \u003c\/h3\u003e• In asthmatic patients the product should be used with caution, after consulting the doctor. • The use of Moment, as of any drug inhibiting the synthesis of prostaglandins and cyclooxygenase is not recommended in women who intend to become pregnant. • The administration of Moment should be suspended in women who have fertility problems or who are undergoing investigation of fertility. • The use of Moment should be avoided in conjunction with NSAIDs, including selective COX-2 inhibitors. • Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). • Cardiovascular and cerebrovascular effects: Clinical trial and epidemiological data suggest that use of ibuprofen, particularly at high doses (2400 mg\/day) and in long term treatment, may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low dose ibuprofen (e.g. ≤ 1200 mg\/day) is associated with an increased risk of myocardial infarction. • There is a risk of impaired renal function in dehydrated adolescents. • Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2). • Gastrointestinal bleeding, ulceration and perforation: Gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. • The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest dose available. Concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients taking low dose aspirin or other drugs likely to increase GI risk (see below and section 4.5). • Patients with a history of GI toxicity, particularly when elderly, should report any unusual GI symptoms (especially GI bleeding) particularly in the initial stages of treatment. • Carefully monitor patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as aspirin (see section 4.5). • If gastrointestinal bleeding or ulceration occurs in patients receiving Moment, the treatment should be withdrawn. • NSAIDs should be given with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). • Caution is advised before initiating treatment in patients with a history of hypertension and\/or heart failure as fluid retention, hypertension and oedema have been reported in association with NSAID therapy. • Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens–Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Moment should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. • Moment contains: – sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Moment 200 mg 24 coated tablets - Which medicines or foods can modify the effect of Moment 200 mg 24 coated tablets? \u003c\/h3\u003e• Possible interactions with coumarin-type anticoagulants should be taken into account: patients undergoing treatment with such drugs should consult their doctor before taking the product. It is also advisable to seek medical advice in the case of any concomitant therapy before administering the product. • Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4). • Anticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin (see section 4.4). • Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4). • Diuretics, ACE inhibitors and Angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Moment concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. • Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy. • Experimental data indicate that ibuprofen may inhibit the effects of low-dose acetylsalicylic acid on platelet aggregation when the drugs are administered concomitantly. However, the limited data and the uncertainties regarding their application to the clinical situation do not allow definitive conclusions to be drawn for the continuous use of ibuprofen; there appears to be no clinically relevant effect from occasional use of ibuprofen (see section 5.1).\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Moment 200 mg 24 coated tablets can cause side effects - What are the side effects of Moment 200 mg 24 coated tablets? \u003c\/h3\u003e\n\u003cu\u003eSkin effects\u003c\/u\u003e Allergic skin rashes (erythema, pruritus, urticaria) may occasionally occur. Bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (very rare). \u003cu\u003eGastrointestinal effects\u003c\/u\u003e The most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal haemorrhage, sometimes fatal, particularly in the elderly, may occur (see section 4.4). The following have been reported following administration of Moment: feeling of heaviness in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Less frequently, gastritis has been observed. \u003cu\u003eCardiovascular effects\u003c\/u\u003e Oedema, hypertension and cardiac failure have been reported in association with treatment with NSAIDs. Clinical trial and epidemiological data suggest that use of ibuprofen (particularly at high doses 2400 mg\/day) and in long-term treatment may be associated with a modest increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see Section 4.4). These phenomena rapidly regress upon discontinuation of treatment.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eOVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Moment 200 mg 24 coated tablets - What are the risks of Moment 200 mg 24 coated tablets in case of overdose?\u003c\/h3\u003e In case of overdose, gastric lavage and correction of blood electrolytes are indicated. There is no specific antidote for ibuprofen.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e PREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Moment 200 mg 24 coated tablets. \u003c\/h3\u003e\n\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or the embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose: the fetus to: – cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); – renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the neonate, at the end of pregnancy, to: – possible prolongation of bleeding time, and anti-aggregating effect which may occur even at very low doses; – inhibition of uterine contractions resulting in delayed or prolonged labor.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\u003ch3\u003e Taking Moment 200 mg 24 coated tablets before driving or using machines - Does Moment 200 mg 24 coated tablets affect driving or using machines?\u003c\/h3\u003e The use of ibuprofen does not usually affect the ability to drive or use other machines. However, those patients whose activities require alertness should exercise caution if they experience drowsiness, dizziness or depression during therapy with ibuprofen.","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51730210357575,"sku":"025669072","price":12.73,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-moment-200-mg-24-compresse-rivestite-farmacia-dottor-tili-1213791049.jpg?v=1767154908"},{"product_id":"tantum-verde-gola-250-mg-100-ml-15-ml-spray-orale","title":"Tantum Verde throat 250 mg\/100 ml 15 ml oral spray","description":"\u003cp\u003e\u003cstrong\u003eTantum Verde Gola 250 mg\/100 ml 15 ml oral spray\u003c\/strong\u003e is a specific solution for the \u003cstrong\u003esymptomatic treatment of sore throat\u003c\/strong\u003e and \u003cstrong\u003eirritation-inflammatory conditions of the oral mucosa\u003c\/strong\u003e . Thanks to the presence of \u003cstrong\u003eflurbiprofen\u003c\/strong\u003e , an active ingredient with \u003cstrong\u003eanti-inflammatory and analgesic\u003c\/strong\u003e properties, this \u003cstrong\u003eoral spray\u003c\/strong\u003e acts quickly to relieve localized \u003cstrong\u003epain and inflammation\u003c\/strong\u003e in the throat. The \u003cstrong\u003espray solution\u003c\/strong\u003e formulation allows for targeted and practical application, ideal for those looking for \u003cstrong\u003elocal and immediate use\u003c\/strong\u003e of the product.\u003c\/p\u003e\n\n\n \u003cp\u003eThe \u003cstrong\u003e15 ml\u003c\/strong\u003e format is perfect to carry with you at all times, ensuring rapid relief at any time of the day. \u003cstrong\u003eTantum Verde Gola\u003c\/strong\u003e is an \u003cstrong\u003eover-the-counter medicine\u003c\/strong\u003e widely used to combat discomfort related to a \u003cstrong\u003esore throat, pain and inflammation\u003c\/strong\u003e due to colds, pharyngitis or other inflammatory conditions of the throat. Its effectiveness is recognized for \u003cstrong\u003elocal and targeted treatment\u003c\/strong\u003e , thanks to the possibility of easily measuring the number of \u003cstrong\u003esprays\u003c\/strong\u003e needed. Choose Tantum Verde Gola for \u003cstrong\u003erapid relief from a sore throat\u003c\/strong\u003e and to take care of your oral health with a reliable and quality product\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Tantum Verde gola 250 mg\/100 ml 15 ml oral spray - What is the active ingredient of Tantum Verde gola 250 mg\/100 ml 15 ml oral spray? \u003c\/h3\u003e100 ml contain: active ingredient: flurbiprofen 250 mg. For the full list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Tantum Verde gola 250 mg\/100 ml 15 ml oral spray - What does Tantum Verde gola 250 mg\/100 ml 15 ml oral spray contain?\u003c\/h3\u003e \u003ci\u003e\u003cu\u003eMouthwash\u003c\/u\u003e\u003c\/i\u003e : glycerol, ethanol (96%), liquid crystallizable sorbitol, polyoxyethylene hydrogenated castor oil 40, sodium saccharin, potassium bicarbonate, sodium benzoate, mint flavouring, patent blue V (E 131), purified water. \u003ci\u003e\u003cu\u003eOral mucosa spray, solution\u003c\/u\u003e :\u003c\/i\u003e glycerol, ethanol (96%), liquid crystallizable sorbitol, sodium saccharin, potassium bicarbonate, sodium benzoate, mint flavouring, polysorbate 20, purified water.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Tantum Verde gola 250 mg\/100 ml 15 ml oral spray - Why is Tantum Verde gola 250 mg\/100 ml 15 ml oral spray used? What is it used for? \u003c\/h3\u003eSymptomatic treatment of irritative-inflammatory conditions, also associated with pain in the oropharyngeal cavity (e.g. pharyngitis).\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Tantum Verde gola 250 mg\/100 ml 15 ml oral spray - When should Tantum Verde gola 250 mg\/100 ml 15 ml oral spray not be used?\u003c\/h3\u003e Tantum Verde Gola is contraindicated in patients with known hypersensitivity (asthma, urticaria or allergic type) to flurbiprofen or to any of the excipients listed in paragraph 6.1 and to aspirin or other NSAIDs. In the third trimester of pregnancy. Do not use in patients who suffer from peptic ulcer or who have suffered from it in the past.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Tantum Verde gola 250 mg\/100 ml 15 ml oral spray - How do you take Tantum Verde gola 250 mg\/100 ml 15 ml oral spray? \u003c\/h3\u003eUndesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4 \u003ci\u003eSpecial warnings and precautions for use\u003c\/i\u003e ). \u003ci\u003e\u003cu\u003eMouthwash:\u003c\/u\u003e\u003c\/i\u003e The recommended dose is 2-3 gargles per day with 10 ml of mouthwash.\u003cimg src=\"https:\/\/www.farmadati.it\/public\/imgSkt\/72150.PNG\"\u003e Pour 10 ml of Tantum Verde Gola mouthwash into the measuring cup to be used in pure form, as a gargle. \u003ci\u003e\u003cu\u003eSpray for oral mucosa, solution:\u003c\/u\u003e\u003c\/i\u003e The recommended dose is 2 sprays 3 times a day directed directly at the affected area. Each spray delivers 0.2 ml of solution equivalent to 0.5 mg of active ingredient. Use the medicine when needed, at any time of the day. \u003cb\u003eBe careful not to exceed the indicated doses.\u003c\/b\u003e\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Tantum Verde gola 250 mg\/100 ml 15 ml oral spray - How is Tantum Verde gola 250 mg\/100 ml 15 ml oral spray stored? \u003c\/h3\u003eThis medicinal product does not require any special storage conditions.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Tantum Verde gola 250 mg\/100 ml 15 ml oral spray - About Tantum Verde gola 250 mg\/100 ml 15 ml oral spray it is important to know that:\u003c\/h3\u003e At the recommended doses, occasional swallowing of Tantum Verde Gola does not cause any harm to the patient as these doses are much lower than those commonly used in treatments with systemic flurbiprofen. Tantum Verde Gola should be used with caution by patients with non-allergic asthma, in fact cases of bronchospasm with flurbiprofen have been reported in patients with a history of bronchial asthma. Use of the product, especially if prolonged, may give rise to sensitization or local irritation phenomena. In such cases, treatment should be stopped and, if necessary, appropriate therapy instituted. Do not use for prolonged treatments.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e INTERACTIONS\u003c\/h2\u003e  \u003ch3\u003eInteractions Tantum Verde gola 250 mg\/100 ml 15 ml oral spray - Which medicines or foods can modify the effect of Tantum Verde gola 250 mg\/100 ml 15 ml oral spray?\u003c\/h3\u003e There are no known interactions with other drugs or other types of drugs.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Tantum Verde gola 250 mg\/100 ml 15 ml oral spray can cause side effects - What are the side effects of Tantum Verde gola 250 mg\/100 ml 15 ml oral spray?\u003c\/h3\u003e The following undesirable effects have been reported, particularly \u003cb\u003eafter administration of systemic formulations\u003c\/b\u003e , reported according to the MedDRA system organ classification. The following scales of values ​​have been used: very common (≥1\/10); common (≥1\/100, \u0026lt; 1\/10); uncommon (≥ 1\/1,000, \u0026lt; 1\/100); rare ≥ 1\/10,000, \u0026lt; 1\/1,000); very rare (\u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data).\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e  \u003ctd\u003e\u003cb\u003e\u003ci\u003eMedDRA System Organ Classification\u003c\/i\u003e\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e \u003cb\u003eFrequency not known\u003c\/b\u003e (frequency cannot be estimated from the available data)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Pathologies of the haemolymphopoietic system\u003c\/td\u003e\n\u003ctd\u003e Thrombocytopenia, aplastic anemia, agranulocytosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Immune system disorders\u003c\/td\u003e\n\u003ctd\u003e Anaphylaxis, angioedema, allergic reaction.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Psychiatric disorders\u003c\/td\u003e\n\u003ctd\u003e Depression, confusion, hallucination\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Nervous system disorders\u003c\/td\u003e\n\u003ctd\u003e Dizziness, haemorrhage and cerebrovascular accident, optic neuritis, migraine, paraesthesia, somnolence.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Eye pathologies\u003c\/td\u003e\n\u003ctd\u003e Visual disturbances\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Ear and labyrinth pathologies\u003c\/td\u003e\n\u003ctd\u003e Tinnitus, vertigo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Respiratory, thoracic and mediastinal pathologies\u003c\/td\u003e\n\u003ctd\u003e Asthma, bronchospasm, dyspnea\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Gastrointestinal disorders\u003c\/td\u003e\n\u003ctd\u003e Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage, colitis and Crohn's disease, gastritis, peptic ulcer, perforation and gastric ulcer with haemorrhage.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e  \u003ctd\u003eSkin and subcutaneous tissue disorders\u003c\/td\u003e\n\u003ctd\u003e Bullous conditions (including Stevens Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme), skin disorders including rash, pruritus, urticaria, purpura\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Kidney and urinary disorders\u003c\/td\u003e\n\u003ctd\u003e Renal failure, nephrotoxicity in various forms including interstitial nephritis and nephrotic syndrome\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Systemic disorders and conditions related to the administration site\u003c\/td\u003e\n\u003ctd\u003e Discomfort, fatigue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ewww.agenziafarmaco.gov.it\/it\/responsabili\u003c\/u\u003e .\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e  \u003ch3\u003eOverdose Tantum Verde gola 250 mg\/100 ml 15 ml oral spray - What are the risks of Tantum Verde gola 250 mg\/100 ml 15 ml oral spray in case of overdose?\u003c\/h3\u003e Considering the low content of active ingredient and its local use, it is unlikely that overdose situations may occur. \u003cu\u003eSymptoms\u003c\/u\u003e Symptoms of overdose may include nausea, vomiting and irritation of the gastrointestinal tract. \u003cu\u003eTreatment\u003c\/u\u003e In the event of such an occurrence, appropriate treatments must be adopted; gastric lavage and, if necessary, correction of any imbalances in serum electrolytes are indicated. There are no specific antidotes for flurbiprofen.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e PREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Tantum Verde gola 250 mg\/100 ml 15 ml oral spray. \u003c\/h3\u003eDuring the first and second trimester of pregnancy, Tantum Verde Gola should not be administered unless strictly necessary. Tantum Verde Gola should not be used from the third trimester of pregnancy. However, the administration of flurbiprofen is not recommended in mothers who are breastfeeding.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\u003ch3\u003e Taking Tantum Verde gola 250 mg\/100 ml 15 ml oral spray before driving or using machines - Does Tantum Verde gola 250 mg\/100 ml 15 ml oral spray affect driving or using machines?\u003c\/h3\u003e Tantum Verde Gola does not alter the ability to drive vehicles or use machinery.","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51730210455879,"sku":"034015026","price":10.97,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-tantum-verde-gola-250-mg-100-ml-15-ml-spray-orale-farmacia-dottor-tili-1213791046.jpg?v=1767154966"},{"product_id":"momentact-400mg-30-compresse","title":"Momentact 400mg 30 Tablets","description":"\u003cp\u003e \u003cstrong\u003eMomentact 30 Tablets 400mg\u003c\/strong\u003e is an over-the-counter drug based on \u003cstrong\u003eibuprofen\u003c\/strong\u003e , an active ingredient belonging to the class of NSAIDs (nonsteroidal anti-inflammatory drugs), indicated for the \u003cstrong\u003esymptomatic treatment of pain and feverish states\u003c\/strong\u003e . Its high concentration formulation (400 mg per tablet) allows for a faster and more intense action than other over-the-counter painkillers, ensuring effective relief in a short time.\u003c\/p\u003e\n\n \u003cp\u003eThanks to its high bioavailability and coated tablet technology, Momentact 400mg tablets are able to act \u003cstrong\u003ewithin 10-15 minutes of taking them\u003c\/strong\u003e , making them an ideal choice for those who need \u003cstrong\u003ea fast and powerful pain reliever\u003c\/strong\u003e . The 30-tablet pack is a convenient and affordable solution for repeated treatments or for those who suffer from recurring pain.\u003c\/p\u003e\n\n\u003cp\u003e Momentact is indicated for adults and adolescents over 12 years of age, and is used in the treatment of various types of acute pain of mild to moderate intensity, including:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eHeadaches\u003c\/strong\u003e and tension headaches\u003c\/li\u003e\n\n\u003cli\u003e \u003cstrong\u003eMenstrual cramps\u003c\/strong\u003e\n\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eMuscle and joint pain\u003c\/strong\u003e\n\u003c\/li\u003e\n\n\u003cli\u003e \u003cstrong\u003eToothache\u003c\/strong\u003e\n\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eFlu symptoms\u003c\/strong\u003e with fever and widespread aches\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n \u003cp\u003eIbuprofen works by blocking the production of prostaglandins, chemical mediators of inflammation and pain, thus allowing for a rapid reduction in inflammation, body temperature and perceived pain.\u003c\/p\u003e\n\n\u003cp\u003e The \u003cstrong\u003e30-tablet format of 400mg\u003c\/strong\u003e is ideal for both occasional and continuous use (on medical advice), ensuring effective coverage for several days of treatment. The coated tablets are easy to swallow and well tolerated, even by those with a sensitive stomach, as long as they are taken during or after meals.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e \u003cspan\u003eACTIVE INGREDIENTS\u003c\/span\u003e\n\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eActive ingredients contained in Momentact 400 mg Analgesic 30 Tablets - What is the active ingredient of Momentact 400 mg Analgesic 30 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eEach film-coated tablet contains; active substance: ibuprofen 400 mg. Excipients with known effect: lactose, sodium. For a full list of excipients, see section 6.1.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eEXCIPIENTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eComposition of Momentact 400 mg Analgesic 30 Tablets - What does Momentact 400 mg Analgesic 30 Tablets contain?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003ePregelatinized starch, sodium starch glycolate, sodium carmellose, povidone, microcrystalline cellulose, precipitated silica, talc, sodium lauryl sulphate, lactose monohydrate, hypromellose, titanium dioxide, macrogol 4000.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDIRECTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eTherapeutic indications Momentact 400 mg Analgesic 30 Tablets - Why is Momentact 400 mg Analgesic 30 Tablets used? What is it used for?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eMomentact is indicated in adults and adolescents over 12 years of age. Pain of various origins and nature (headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain). Adjuvant in the symptomatic treatment of feverish and flu states.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONTRAINDICATIONS SIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eContraindications Momentact 400 mg Analgesic 30 Tablets - When should Momentact 400 mg Analgesic 30 Tablets not be used?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eHypersensitivity to the active substance, to other antirheumatics (acetylsalicylic acid, etc.) or to any of the excipients listed in section 6.1; do not administer to children under 12 years of age; ibuprofen is contraindicated during the third trimester of pregnancy and during breastfeeding (see section 4.6); active or severe gastroduodenal ulcer or other gastropathies; history of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding); severe hepatic or renal insufficiency; severe cardiac insufficiency (NYHA class IV); severe dehydration (caused by vomiting, diarrhoea or insufficient fluid intake).\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eDOSAGE\u003c\/span\u003e\u003c\/h2\u003e\n\n \u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eQuantity and method of taking Momentact 400 mg Analgesic 30 Tablets - How to take Momentact 400 mg Analgesic 30 Tablets?\u003c\/span\u003e\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eDosage. Adults and adolescents over 12 years: 1 tablet 2-3 times a day. Do not exceed 3 tablets per day. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). If use of the medicinal product is necessary for more than 3 days in adolescents, or in case of worsening of symptoms, a doctor should be consulted. Do not exceed the recommended doses: in particular, elderly patients should adhere to the minimum dosages indicated above. Elderly: NSAIDs should be used with particular caution in elderly patients who are more prone to adverse events and are at increased risk of potentially fatal gastrointestinal bleeding, ulceration or perforation (see section 4.4). If treatment is considered necessary, the lowest dose for the shortest duration necessary to control symptoms should be used (see section 4.4). Renal impairment: In patients with mild or moderate reduction of renal function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and renal function should be monitored. Hepatic impairment: In patients with mild or moderate reduction of liver function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and liver function should be monitored. Momentact is contraindicated in patients with severe hepatic impairment (see section 4.3). Paediatric population: Momentact is contraindicated in children under 12 years of age (see section 4.3). Method of administration: Momentact can be taken on an empty stomach. In subjects with gastric tolerability problems, it is preferable to take the medicine on a full stomach.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eCONSERVATION\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eStorage Momentact 400 mg Analgesic 30 Tablets - How to store Momentact 400 mg Analgesic 30 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n\u003cp dir=\"ltr\"\u003e \u003cspan\u003eThis medicine does not require any special storage temperatures.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWARNINGS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eWarnings Momentact 400 mg Analgesic 30 Tablets - About Momentact 400 mg Analgesic 30 Tablets it is important to know that:\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe use of Moment Act, as with any drug inhibiting the synthesis of prostaglandins and cyclooxygenase, is not recommended in women attempting to conceive. The administration of Moment Act should be suspended in women who have fertility problems or who are undergoing investigation of fertility. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). Elderly: elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2). Cardiovascular and cerebrovascular effects: caution is required before initiating treatment in patients with a history of hypertension and\/or heart failure since fluid retention, hypertension and oedema have been reported in association with NSAID therapy. NSAIDs may reduce the effect of diuretics and other antihypertensive drugs (see section 4.5). Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low dose ibuprofen (e.g. \u0026lt;= 1200 mg\/day) is associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration should also be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses (2400 mg\/day) of ibuprofen are required. Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and\/or cerebrovascular disease should only be treated with ibuprofen after careful consideration. Similar consideration should be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking). Gastrointestinal bleeding, ulceration and perforation: the use of Momentact should be avoided in combination with NSAIDs, including cyclooxygenase-2 (COX-2) selective inhibitors due to the increased risk of ulceration or bleeding (see section 4.5). In particular, gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing NSAID doses, in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). These patients should start treatment on the lowest dose available. Concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant acetylsalicylic acid or other drugs likely to increase GI risk (see below and section 4.5). Patients with a history of GI toxicity, particularly when elderly, should report any unusual GI symptoms (especially GI bleeding) particularly in the initial stages of treatment. Carefully monitor patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients receiving Momentact, the treatment should be withdrawn. NSAIDs should be given with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Severe skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk early in the course of therapy: the onset of the reaction occurs in the majority of cases within the first month of treatment. Acute generalized exanthematous pustulosis (AGEP) has been reported in relation to medicinal products containing ibuprofen. Ibuprofen should be discontinued at the first appearance of signs and symptoms of severe skin reactions, such as rash, mucosal lesions or any other sign of hypersensitivity as well as if visual disturbances or persistent signs of liver dysfunction occur. Renal effects: Caution should be exercised when initiating treatment with ibuprofen in patients with considerable dehydration. Ibuprofen may cause water and sodium, potassium retention in patients with no history of renal disease due to its effects on renal perfusion. This may cause oedema or cardiac failure or hypertension in predisposed patients. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other pathological renal changes. In general, the habitual use of analgesics, especially combinations of several analgesic active ingredients, can lead to permanent renal damage, with risk of renal failure (analgesic nephropathy). Renal toxicity has been observed in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. The administration of NSAIDs in these patients may lead to a dose-dependent reduction in prostaglandin formation and, as a secondary effect, renal blood flow, which can quickly lead to renal failure.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eINTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eInteractions Momentact 400 mg Analgesic 30 Tablets - Which medicines or foods can modify the effect of Momentact 400 mg Analgesic 30 Tablets?'\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eIt is advisable to seek medical advice in case of any concomitant therapy before administering the product. Ibuprofen (like other NSAIDs) should be taken with caution in combination with the substances listed below. Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4). Anticoagulants: NSAIDs may enhance the effects of anticoagulants, such as warfarin or heparin (see section 4.4). In case of concomitant treatment, monitoring of the coagulation status is recommended. Cyclooxygenase-2 (COX-2) inhibitors and other NSAIDs: these substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). It is advisable not to combine ibuprofen with other NSAIDs, including selective COX-2 inhibitors, due to the potential additive effect (see section 4.4). Acetylsalicylic acid: Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit platelet aggregation with low dose acetylsalicylic acid when the two drugs are administered concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered likely following occasional use of ibuprofen (see section 5.1). Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4). Diuretics, ACE inhibitors (such as captopril), beta blockers and angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of neurotoxicity associated with NSAIDs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit cyclooxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Momentact concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and thereafter. Phenytoin and lithium: Concomitant administration of ibuprofen and phenytoin or lithium preparations may result in reduced elimination of these drugs with consequent increase in their plasma levels with the possibility of reaching the toxic threshold. If this combination is deemed necessary, monitoring of plasma levels of phenytoin and lithium is recommended in order to adapt the appropriate dosage during concomitant treatment with ibuprofen. Methotrexate: NSAIDs may inhibit the tubular secretion of methotrexate and some metabolic interactions may occur resulting in reduced clearance of methotrexate and consequent increase in the risk of toxicity. Moclobemide: increases ibuprofen. Aminoglycosides: NSAIDs may decrease the excretion of aminoglycosides increasing toxicity. Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides. Monitoring of serum glycoside levels is recommended. Cholestyramine: Concomitant administration of ibuprofen and cholestyramine may reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is unknown. Ciclosporin: Concomitant administration of ciclosporin and some NSAIDs causes an increased risk of renal damage. This effect cannot be excluded for the combination of ciclosporin and ibuprofen. Plant extracts: Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs. Mifepristone: Due to the anti-prostaglandin properties of NSAIDs, their use after mifepristone administration may result in a reduction of mifepristone. Limited evidence suggests that co-administration of NSAIDs and prostaglandins on the same day does not adversely affect the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination. Quinolone antibiotics: Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions. Sulfonylureas: NSAIDs may increase the hypoglycaemic effect of sulfonylureas. Monitoring of blood glucose levels is recommended in the case of simultaneous treatment. Tacrolimus: Co-administration of NSAIDs and tacrolimus may increase the risk of nephrotoxicity. Zidovudine: There is evidence of an increased risk of haemarthrosis and haematoma in HIV-positive haemophiliac patients receiving concomitant treatment with zidovudine and other NSAIDs. A blood test is recommended 1-2 weeks after starting treatment. Ritonavir: may cause an increase in plasma concentrations of NSAIDs. Probenecid: slows the excretion of ibuprofen, with possible increase in their plasma concentrations. CYP2C9 inhibitors: Concomitant administration of ibuprofen and CYP2C9 inhibitors may slow the elimination of ibuprofen (CYP2C9 substrate) resulting in increased exposure to ibuprofen. In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)-ibuprofen of approximately 80% to 100% was observed. Consideration should be given to reducing the dose of ibuprofen when co-administered with strong CYP2C9 inhibitors, particularly when high doses of ibuprofen are administered with voriconazole or fluconazole. Alcohol, bisphosphonates and oxypentifylline (pentoxifylline): may enhance gastrointestinal side effects and the risk of bleeding and ulceration. Baclofen: high toxicity of baclofen.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eLike all medicines, Momentact 400 mg Analgesic 30 Tablets can cause side effects - What are the side effects of Momentact 400 mg Analgesic 30 Tablets?\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe undesirable effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and are reported below using the following convention: very common (\u0026gt;=1\/10); common (\u0026gt;=1\/100, \u0026lt; 1\/10); uncommon (\u0026gt;= 1\/ 1,000, \u0026lt; 1\/100); rare (\u0026gt;=1\/10,000, \u0026lt; 1\/1,000); very rare (\u0026lt;1\/10,000); not known (frequency cannot be estimated from the available data). The most commonly observed adverse events are gastrointestinal in nature. Clinical trial and epidemiological data suggest that the use of ibuprofen (particularly at high doses 2400 mg\/day) and in long-term treatment may be associated with a modest increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Gastrointestinal disorders: Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Gastrointestinal perforation with the use of ibuprofen has been observed rarely. Following administration of ibuprofen, the following have been reported: feeling of heaviness in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). Uncommon: gastritis; very rare: pancreatitis. Immune system disorders. The following undesirable effects have been reported following treatment with NSAIDs: non-specific allergic reaction and anaphylaxis; uncommon: hypersensitivity reactions such as rash of various types, urticaria, pruritus, purpura, angioedema, exanthema, respiratory tract reactions including asthma, including severe asthma, bronchospasm or dyspnoea, asthmatic attack (sometimes with hypotension); rare: lupus erythematosus syndrome; very rare: severe hypersensitivity reactions. Symptoms may include: facial oedema, tongue oedema, laryngeal oedema, airway oedema with constriction, dyspnoea, tachycardia, anaphylaxis, exfoliative and bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). Cardiac and vascular disorders: oedema, fatigue, hypertension and cardiac failure have been reported in association with NSAID treatment. Clinical trials suggest that use of ibuprofen, particularly at high doses (2400 mg\/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4). Very rare: palpitations, heart failure, myocardial infarction, acute pulmonary oedema, oedema, hypertension. These phenomena generally tend to regress on discontinuation of treatment. Other adverse events reported less frequently and for which causality has not necessarily been established include: Blood and lymphatic system disorders: Rare: leucopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia. Psychiatric disorders: Uncommon: insomnia, anxiety; rare: depression, confusional state, hallucinations. Nervous system disorders: Common: dizziness; uncommon: paraesthesia, somnolence; rare: optic neuritis. Infections and infestations. Uncommon: rhinitis; rare: aseptic meningitis. Rhinitis and aseptic meningitis (especially in patients with pre-existing autoimmune disorders, such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). Exacerbation of infection-related inflammation (e.g. development of necrotising fasciitis) has been described. Respiratory, thoracic and mediastinal disorders. Uncommon: bronchospasm, dyspnoea, apnoea. Eye disorders. Uncommon: visual disturbances; rare: ocular impairment resulting in visual disturbances, toxic optic neuropathy. Ear and labyrinth disorders. Uncommon: hearing impaired, tinnitus, vertigo. Hepatobiliary disorders. Uncommon: abnormal liver function, hepatitis and jaundice; very rare: liver failure. Skin and subcutaneous tissue disorders: Allergic skin rashes (erythema, pruritus, urticaria) may occasionally occur. Uncommon: photosensitivity reactions; very rare: bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. In exceptional cases, serious skin infections and soft tissue disorders may occur during varicella infection (see \"\"infections and infestations\"\"). Not known: drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), acute generalized exanthematous pustulosis (AGEP). Renal and urinary disorders: Uncommon: renal function impairment and toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure. General disorders and administration site conditions: Common: malaise, fatigue; rare: oedema. Reporting of suspected adverse reactions Reporting of suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003ePREGNANCY AND BREASTFEEDING\u003c\/span\u003e\u003c\/h2\u003e\n\n\u003ch3 dir=\"ltr\"\u003e \u003cspan\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Momentact 400 mg Analgesic 30 Tablets.\u003c\/span\u003e\n\u003c\/h3\u003e\n\n \u003cp dir=\"ltr\"\u003e\u003cspan\u003ePregnancy: Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. From the twentieth week of pregnancy onwards, the use of Momentact may cause oligohydramnios resulting from fetal renal dysfunction. This may occur soon after initiation of treatment and is usually reversible upon discontinuation. In addition, cases of constriction of the ductus arteriosus have been reported following treatment in the second trimester, most of which resolved upon discontinuation of treatment. Therefore, during the first and second trimester of pregnancy, Momentact should not be administered unless clearly necessary. If Momentact is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. Antenatal monitoring for oligohydramnios and constriction of the ductus arteriosus should be considered following exposure to Moment Act for several days of gestational week 20 onwards. Momentact should be discontinued if oligohydramnios or constriction of the ductus arteriosus is observed. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (premature constriction\/closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction (see above); at the end of pregnancy, all prostaglandin synthesis inhibitors may expose the mother and the neonate to: possible prolongation of bleeding time, and anti-aggregating effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, Momentact is contraindicated during the third trimester of pregnancy (see sections 4.3 and 5.3). Breast-feeding: ibuprofen is excreted in breast milk, but at therapeutic doses during short-term treatment, the risk of influence on the neonate seems unlikely. If, however, treatment is longer term, early weaning should be considered. NSAIDs should be avoided during breast-feeding. Fertility: The use of Ibuprofen may impair female fertility and is not recommended in women attempting to conceive. This effect is reversible upon discontinuation of treatment. In women who have difficulties conceiving or who are undergoing investigation of infertility, discontinuation of ibuprofen should be considered.\u003c\/span\u003e\u003c\/p\u003e","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":51730210554183,"sku":"035618204","price":15.35,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-momentact-400mg-30-compresse-farmacia-dottor-tili-1213791043.jpg?v=1767154990"},{"product_id":"stilla-collirio-0-05-10-monodose-sollievo-occhi-irritati","title":"Stilla Eye Drops 0.05% 10 Single Dose Relief Irritated Eyes","description":"\u003cp\u003e\u003cstrong\u003eStilla Collirio 0.05%\u003c\/strong\u003e is a decongestant ophthalmic solution indicated for the treatment of \u003cstrong\u003eirritation, redness and eye fatigue\u003c\/strong\u003e of various origins. Formulated with naphazoline hydrochloride, an active ingredient with a strong vasoconstrictor action, Stilla is ideal for providing relief to \u003cstrong\u003ered, tired eyes or eyes exposed to irritants\u003c\/strong\u003e such as wind, smoke, dust or prolonged use of digital devices. Its presentation in practical \u003cstrong\u003e0.3 ml single-dose containers\u003c\/strong\u003e guarantees hygiene, safety and ease of use, making the product particularly suitable for those who travel or need occasional administration away from home. The package includes 10 sterile single-dose, preservative-free, for a delicate and well-tolerated treatment, even in sensitive subjects.\u003c\/p\u003e\n\n\n\u003ch2\u003e Directions\u003c\/h2\u003e\n\n\u003ch3\u003e When is Stilla Eye Drops 0.05% indicated?\u003c\/h3\u003e\n\n\u003cp\u003e Stilla Collirio is indicated for the symptomatic treatment of:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eEye redness\u003c\/strong\u003e of mechanical, physical or environmental origin\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eIrritation and burning of the eyes\u003c\/strong\u003e caused by external agents such as dust, smoke, chlorine, wind or intense light\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eTired eyes\u003c\/strong\u003e from excessive use of digital screens, studying or prolonged reading\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp\u003e Thanks to its local vasoconstrictor action, the active ingredient naphazoline reduces redness and provides immediate relief, counteracting conjunctival hyperemia and promoting a rapid sensation of well-being.\u003c\/p\u003e\n\n\n\u003ch2\u003e Dosage and method of use\u003c\/h2\u003e\n\n\u003ch3\u003e How do I take Stilla Eye Drops 0.05%?\u003c\/h3\u003e\n\n\u003cp\u003e Apply 1 or 2 drops in the affected eye up to a maximum of \u003cstrong\u003e2-3 times a day\u003c\/strong\u003e , unless otherwise indicated by your doctor. Each single-dose container is intended for a single administration and must not be reused.\u003c\/p\u003e\n\n\u003cp\u003e For correct administration:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e Wash your hands thoroughly\u003c\/li\u003e\n\n   \u003cli\u003eOpen the single-dose container and instill the eye drops into the conjunctival sac by gently lowering the lower eyelid.\u003c\/li\u003e\n\n\u003cli\u003e Avoid direct contact of the nozzle with the eye or fingers\u003c\/li\u003e\n\n\u003cli\u003e Close your eye for a few seconds to help the solution distribute.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\u003ch2\u003e Contraindications\u003c\/h2\u003e\n\n\u003ch3\u003e What are the main contraindications of Stilla Eye Drops 0.05%?\u003c\/h3\u003e\n\n\u003cp\u003e Do not use in case of:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e Known hypersensitivity to the active substance or to any of the excipients\u003c\/li\u003e\n\n\u003cli\u003e Angle-closure glaucoma\u003c\/li\u003e\n\n\u003cli\u003e Age under 12 years\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp\u003e Also contraindicated in subjects with severe cardiovascular disease, hypertension, hyperthyroidism or uncontrolled diabetes, due to the possible systemic absorption of naphazoline.\u003c\/p\u003e\n\n\n\u003ch2\u003e Side effects\u003c\/h2\u003e\n\n\u003ch3\u003e What are the side effects of Stilla Eye Drops 0.05%?\u003c\/h3\u003e\n\n\u003cp\u003e Like all medicines, Stilla Eye Drops can cause side effects, although not everybody gets them:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e Transient eye burning\u003c\/li\u003e\n\n\u003cli\u003e Blurred vision immediately after instillation\u003c\/li\u003e\n\n   \u003cli\u003eLocal allergic reactions (itching, persistent redness)\u003c\/li\u003e\n\n\u003cli\u003e Rarely: headache, nausea, palpitations\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp\u003e Prolonged use may cause \u003cstrong\u003erebound effects\u003c\/strong\u003e such as worsening redness or increased conjunctival irritability.\u003c\/p\u003e\n\n\n\u003ch2\u003e Warnings\u003c\/h2\u003e\n\n\u003ch3\u003e What are the warnings of Stilla Eye Drops 0.05%\u003c\/h3\u003e\n\n\u003cp\u003e The product is intended for \u003cstrong\u003eexternal ophthalmic use\u003c\/strong\u003e . Do not use the eye drops for more than 3-4 consecutive days without consulting your doctor. If symptoms persist or worsen, discontinue use and contact a professional.\u003c\/p\u003e\n\n\u003cp\u003e Eye drops may interfere with the ability to drive or use machinery immediately after instillation, due to possible temporary blurred vision.\u003c\/p\u003e\n\n\u003cp\u003e Do not use simultaneously with other ocular decongestants or drugs containing systemic vasoconstrictors. Avoid use during pregnancy and breastfeeding, unless advised by a doctor.\u003c\/p\u003e\n\n\n\u003ch2\u003e Expiry and storage\u003c\/h2\u003e\n\n\u003ch3\u003e What are the expiration dates and storage of Stilla Collirio 0.05%?\u003c\/h3\u003e\n\n \u003cp\u003eStore below 25°C, away from heat, light and humidity. Do not use beyond the expiry date shown on the package. Once opened, each single-dose container must be \u003cstrong\u003eused immediately\u003c\/strong\u003e and \u003cstrong\u003enot stored or reused.\u003c\/strong\u003e\n\u003c\/p\u003e","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51730213175623,"sku":"015001086","price":9.67,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-stilla-collirio-0-05-10-monodose-sollievo-occhi-irritati-farmacia-dottor-tili-1213791005.jpg?v=1767155890"},{"product_id":"verolax-3-g-6-monodose-soluzione-rettale","title":"Verolax 3 g 6 single dose rectal solution","description":"\u003cp\u003e\u003cstrong\u003eVerolax 3 g 6 single-dose rectal solution\u003c\/strong\u003e is a \u003cstrong\u003eglycerin-based laxative\u003c\/strong\u003e , specifically formulated for the \u003cstrong\u003erapid treatment of occasional and obstinate constipation\u003c\/strong\u003e . Each pack contains \u003cstrong\u003e6 single-dose containers of 3 g\u003c\/strong\u003e of rectal solution, ideal for practical and hygienic use. The product acts locally in the rectum, promoting \u003cstrong\u003enatural evacuation\u003c\/strong\u003e without being absorbed by the body, making it particularly suitable for those who need a \u003cstrong\u003etargeted and short-term treatment\u003c\/strong\u003e against constipation.\n \n\u003cstrong\u003eGlycerin\u003c\/strong\u003e , the active ingredient of Verolax, exerts an osmotic action that draws water into the intestine, softening the stool and gently stimulating intestinal peristalsis. The presence of \u003cstrong\u003efluid extracts of mallow and chamomile\u003c\/strong\u003e helps to soothe and protect the rectal mucosa, while \u003cstrong\u003ewheat starch\u003c\/strong\u003e and \u003cstrong\u003epurified water\u003c\/strong\u003e complete the formulation, ensuring an effective and well-tolerated action even in the most sensitive subjects.\n\n Verolax 3 g single-dose rectal solution is particularly suitable for \u003cstrong\u003echildren\u003c\/strong\u003e and for those looking for a practical and safe \u003cstrong\u003esingle-dose enema\u003c\/strong\u003e , thanks to the ready-to-use format that reduces the risk of contamination and facilitates administration. The product is an easily available \u003cstrong\u003eover-the-counter drug\u003c\/strong\u003e , produced by Angelini, a leading company in the pharmaceutical sector.\n \nChoosing Verolax means relying on a \u003cstrong\u003efast-acting microenema\u003c\/strong\u003e , ideal for solving \u003cstrong\u003econstipation\u003c\/strong\u003e problems and promoting intestinal well-being in a safe, delicate and immediate way. Perfect for those who want an \u003cstrong\u003eeffective treatment of constipation\u003c\/strong\u003e without resorting to systemic solutions, Verolax 3 g 6 single-dose rectal solution represents the optimal choice for \u003cstrong\u003edaily intestinal well-being\u003c\/strong\u003e .\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Verolax 3 g 6 single-dose rectal solution - What is the active ingredient of Verolax 3 g 6 single-dose rectal solution? \u003c\/h3\u003e\n\u003ci\u003eVerolax “6.75 g Adults Rectal Solution” 6 Single-Dose Containers 9 G\u003c\/i\u003e : Each 9 G single-dose container contains: \u003ci\u003eActive ingredient\u003c\/i\u003e \u003ci\u003e:\u003c\/i\u003e glycerin 6.75 g \u003ci\u003eVerolax “2.25 g Children Rectal Solution” 6 Single-Dose Containers 3 G\u003c\/i\u003e : Each 3 G single-dose container contains: Active ingredient: glycerin 2.25 g \u003ci\u003eVerolax “2.25 g Adults Suppositories” 18 Suppositories\u003c\/i\u003e : Each adult suppository contains: \u003ci\u003eActive ingredient\u003c\/i\u003e : glycerin 2.25 g \u003ci\u003eVerolax “1.375 g Children Suppositories” 18 Suppositories\u003c\/i\u003e : Each children's suppository contains: \u003ci\u003eActive\u003c\/i\u003e \u003ci\u003eingredient\u003c\/i\u003e : glycerin \u003ci\u003e1.375 g Verolax “0.675 g Infants Suppositories” 12 Suppositories\u003c\/i\u003e : Each infant ... 0.675\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Verolax 3 g 6 single-dose rectal solution - What does Verolax 3 g 6 single-dose rectal solution contain? \u003c\/h3\u003e\n\u003ci\u003eRectal solution Adults and Children:\u003c\/i\u003e Mallow fluid extract; Chamomile fluid extract; Wheat starch; Purified water. \u003ci\u003eSuppositories Adults, Children, Infants:\u003c\/i\u003e Sodium stearate, Sodium carbonate.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e\n\u003ch3\u003e Therapeutic indications Verolax 3 g 6 single-dose rectal solution - Why is Verolax 3 g 6 single-dose rectal solution used? What is it used for?\u003c\/h3\u003e Constipation.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Verolax 3 g 6 single-dose rectal solution - When should Verolax 3 g 6 single-dose rectal solution not be used?\u003c\/h3\u003e Known individual hypersensitivity to the product. Anorectal affections, hemorrhagic rectocolitis and inflammation of hemorrhoids.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Verolax 3 g 6 single-dose rectal solution - How do you take Verolax 3 g 6 single-dose rectal solution? \u003c\/h3\u003e\n\u003ci\u003eRectal solution:\u003c\/i\u003e 1 or 2 single-dose containers in 24 hours. In case of obstinate constipation, no more than 2 doses can be introduced into the rectum at the same time. \u003ci\u003eSuppositories:\u003c\/i\u003e 1 suppository as needed. Do not exceed the recommended doses.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Verolax 3 g 6 single-dose rectal solution - How is Verolax 3 g 6 single-dose rectal solution stored?\u003c\/h3\u003e No special storage precautions.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Verolax 3 g 6 single-dose rectal solution - About Verolax 3 g 6 single-dose rectal solution it is important to know that:\u003c\/h3\u003e Continuous use of laxatives can cause addiction or harm of various kinds. Do not use laxatives if you have abdominal pain, nausea and vomiting. If constipation is persistent, consult your doctor.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e INTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Verolax 3 g 6 single-dose rectal solution - Which medicines or foods can modify the effect of Verolax 3 g 6 single-dose rectal solution?\u003c\/h3\u003e No interactions with other drugs have been found.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e SIDE EFFECTS\u003c\/h2\u003e  \u003ch3\u003eLike all medicines, Verolax 3 g 6 monodose rectal solution can cause side effects - What are the side effects of Verolax 3 g 6 monodose rectal solution?\u003c\/h3\u003e The only effects that may be encountered are of an irritative nature, at the level of the rectal area. These are usually mild forms, which do not require medical intervention.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e\n\u003ch3\u003e Overdose Verolax 3 g 6 single-dose rectal solution - What are the risks of Verolax 3 g 6 single-dose rectal solution in case of overdose?\u003c\/h3\u003e There are no known symptoms of overdose.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e PREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003e If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Verolax 3 g 6 single-dose rectal solution.\u003c\/h3\u003e Based on its chemical-physical properties, rectal glycerin can be usefully used during pregnancy or the puerperium.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DRIVING AND USE OF MACHINERY\u003c\/h2\u003e  \u003ch3\u003eTake Verolax 3 g 6 single-dose rectal solution before driving or using machinery - Does Verolax 3 g 6 single-dose rectal solution affect driving or using machinery?\u003c\/h3\u003e Taking the drug does not alter the ability to drive or use machines.","brand":"ANGELINI (A.C.R.A.F.) SpA","offers":[{"title":"Default Title","offer_id":51730213273927,"sku":"026525042","price":5.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-verolax-3-g-6-monodose-soluzione-rettale-farmacia-dottor-tili-1213791002.jpg?v=1767155951"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/collections\/Angelini_Logo-372557.jpg?v=1746528456","url":"https:\/\/www.dottortili.com\/en\/collections\/angelini-products.oembed?page=2","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}